# THE LANCET

# Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Guo J, Chen X, Wu M, et al. Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial. *Lancet* 2024; published online Nov 12. https://doi.org/10.1016/S0140-6736(24)02261-X.

# **Supplementary Appendix**

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Guo J, Chen X, Wu M, et al. The traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial

.

# **Table of Contents**

Section	Title				
1	List of CHAIN study group, trial investigators, and ethics committees	4			
2	Timelines and statements of the Data and Safety Monitoring Board	8			
3	The CONSORT 2010 checklist of information to include when reporting a randomized trial				
4	Agencies providing funding for the study	13			
5	Screening procedures	13			
6	Inclusion/exclusion criteria	13			
7	Treatment drug and placebo	14			
8	Training of investigators	26			
9	Schedule of monitoring of sites	26			
10	Definitions of protocol violations and deviations	27			
11	Complete list of major and minor protocol violations	29			
12	Sample size calculations	31			
13	Terms of reference of the Data and Safety Monitoring Board (DSMB)	31			
14	Medical review procedures				
15	Per protocol (PP) analysis set				
16	Assessments of functional outcome and health-related quality of life	33			
17	Tables				
	S1. Reasons that 7352 patients with acute intracerebral haemorrhage were excluded from participating in the trial	36			
	S2. Protocol deviations (PD) / violations (PV)	37			
	S3. Additional clinical features, medical history and use of medications in patients with acute intracerebral haemorrhage	38			
	S4. Additional information on the characteristics of intracerebral haemorrhage on computerised tomographic (CT) brain imaging	39			
	S5. Characteristics of participants aged <65 years	40			
	S6. Characteristics of participants aged ≥65 years	47			
	S7. Characteristics of female participants	54			
	S8. Characteristics of male participants	62			
	S9. Adherence to study medication	70			
	S10. Details of the management of patients with acute intracerebral haemorrhage	71			
	S11. Clinical assessment of outcomes over time	75			
	S12. Haematoma volumes and presence of intraventricular haemorrhage over time	79			
	S13. Method of assessment of the 90 day outcome	80			
	S14. Descriptive analysis of EQ-5D-5L at Day 90	81			

	S15. Description of the clinical outcomes	83
	S16. Sensitivity analysis of the primary outcome and analysis of the secondary outcomes at 28, 90 and 180 days	84
	S17. Outcomes in younger participants (age <65 years)	86
	S18. Outcomes in older participants (age ≥65 years	88
	S19. Outcomes in female participants	90
	S20. Outcomes in male participants	92
	S21. Per-protocol dataset of baseline characteristics	94
	S22. Study medication in the per protocol population	102
	S23. Clinical assessment of outcomes over time in the per protocol	103
	S24. Descriptives of outcomes in the per protocol population at 28 and 90 days	109
	S25. Modelling results of the outcomes in the per protocol population 1	110
	S26. Modelling results of the outcomes in the per protocol population 2	112
	S27. Analysis for the outcomes at 180 days	114
	S28. Causes of death	115
	S29. Reported stroke-related complications by visit until 90 days	116
	S30. Adverse events by description until 90 days	120
	S31. Serious adverse events by condition until 90 days	122
	S32. Adverse Events in the per protocol population until 90 days	125
	S33. Adverse event terms in the per protocol population until 90 days	127
	S34. List of deaths by Day 180	131
	S35. List of all serious adverse events by Day 180	140
18	Figures	177
	S1. Patient flow to Day 180	178
	S2. National Institutes of Health Stroke Scale score distribution over time	179
	S3. Analysis of the treatment effect across re-classification of subgroups at 90 days	180
	S4. Analysis of the treatment effect across subgroups at 180 days	181
	S5. Analysis of the treatment effect across re-classification of subgroups at 180 days	182
19	Chinese herbal medicine (Zhongfeng Xingnao preparations) for spontaneous intracerebral hemorrhage: a systematic review and meta-analysis of randomized controlled trials	183
20	CHAIN Protocol	234
21	CHAIN Statistical Analysis Plan	271

# 1. List of CHAIN study group, trial investigators, and ethics committees

## Trial Steering Committee (TSC)

Craig Anderson (Co-Chair, Co-Principal Investigator [PI]) at The Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China; and The George Institute for Global Health, Sydney, Australia; The University of New South Wales; and the Neurology Department, Royal Prince Alfred Hospital.

Lili Song (Deputy Chair), at The Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China; and at The George Institute for Global Health, Sydney, Australia.

Jianwen Guo (Co-Chair, Co-PI), Neurology Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.

Yefeng Cai (independent member), Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China

Yang Zhao, Stroke Program, The George Institute for Global Health China, Beijing, China Xiaoying Chen, Global Brain Health, The George Institute for Global Health, Sydney, Australia Chao You (independent member), Neurosurgery Department, The West China Hospital of Sichuan University, Chengdu, China

Suyue Pan (independent member), Nanfang Hospital, Southern Medical University, Guangzhou, China

Guanghai Tang, Liaoning Thrombus Treatment Centre of Integrated Chinese and Western Medicine, Shenyang, China

Yun Lu, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

#### International Advisory Committee

Graeme J Hankey, The University of Western Australia, Perth, Australia. Rustam Al-Shahi Salman, The University of Edinburgh, Edinburgh, UK.

#### Data Safety Monitoring Board

Jiguang Wang (Chair), Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China Bruce Campbell, Royal Melbourne Hospital, Melbourne, Australia

Chris Chen, National University Hospital, Singapore

Rong Hu, Southwest Hospital of Army Medical University, Chongqing, China

#### **Statisticians**

Qiang Li, Xiaoqiu Liu, Xinwen Ren, The George Institute for Global Health, Australia Xian Li, The George Institute for Global Health, China

## Medical Review Committee

Yingfeng Wan, The George Institute for Global Health, Beijing, China

Shoujiang You, The George Institute for Global Health, Sydney, Australia

Congcong Zhang, Fourth Clinical Medical School of Guangzhou University of Chinese Medicine, Shenzhen, China

Zhong Gui, Fourth Clinical Medical School of Guangzhou University of Chinese Medicine, Shenzhen, China

# Imaging Adjudication Committee

Man Chen, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China Shuman Ouyang, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China Congcong Zhang, Fourth Clinical Medical School of Guangzhou University of Chinese Medicine, Shenzhen, China

Xin Zhao, Liaocheng People's Hospital, China Chengju Huo, Liaocheng People's Hospital, China Ru Ban, Liaocheng People's Hospital, China Jingru Wang, Liaocheng People's Hospital, China

#### Central Coordinating Center (CCC)

The George Institute for Global Health, China: Project Management - Yajie Chen (Project Manager), Lilan Zhang, Wenjing Yu; Data Management and Programming - Borui Wang, Le Dong, Yi Ning; Quality Assurance - Penggang Li

Guangdong Provincial Hospital of Chinese Medicine: Project Management - Manli Wu, Dou Wang, Yanwen Zheng, Fengyan Huang, Zhixuan Ren, Jingbei Zhang, Zhihua Zheng, Kunhong Li, Xinwei Wang, Yongqi Li, Jiamin Cao, Lili Song, Huaying Zhu, Xinning Tan, Xinhong Qiu, Zhongkang Yang, Zhenzhen Lou, Tingting Xie, Haining Zhao, Yu Tang, Dafeng Hu, Wanzhen Cui, Mingjiang Xie, Daxiu Wang, Xiaoshu Wu, Yingyi Zheng, Rui Mao, Hao Chen, Min Luo,

# Site Principal Investigators and Coordinators (centre, numbers of patients in parentheses)

Liaoning Thrombus Treatment Centre of Integrated Chinese and Western Medicine (400): Guanghai Tang, Hongtao Jiang, Hongyan Jing, Xu Zhang, Yingnan Xu, Haiguang Yan, Guang Yang, Feilong Wang, Xiaodi Lu, Li Yan; Linyi People's Hospital (209): Fengyuan Che, Zhenchuan Liu, Zhongxiang Xie, Feng He, Wanqi Liu, Ruixue Zhuang, Qi Su, Xuli Zhang; Liaocheng People's Hospital (119): Zhangyong Xia, Guangjun Xu, Xin Zhao, Ru Ban, Tuanzhi Chen; Lianjiang People's Hospital (87): Zai Liang, Qingyan Jiang, Guanli Su, Liufu Xiao, Xiaoying Zhang; Traditional Chinese Medicine Hospital of Meishan (85): Liu Shi, Wei Zheng, Yongjian Zhang, Jiao Chen, Xiang Yin; Department of Neurosurgery, Ganzhou People's Hospital (85): Qiuhua Jiang, Zhenyu Zhang, Jinqing Huang, Qianliang Huang, Honghua Guo; Panjin Central Hospital (72): Wei Meng, Bin Zhang, Yulin Zhang, Chun Dong, Jie Shi; The First Affiliated Hospital of Shaoyang University (71): Song Tian, Xiong Deng, Zhijun Liang, Haixiang Zhong, Chubao Liu; Fushun Central Hospital (60): Xiaoguang Shao, Enzhi Liu, Weigi Fu, Wei Sheng, Minghui Chen; People's Hospital of Anshun City Guizhou Province (58): Yong Xiang, Yanping Chen, Teng Long, Jie Zhang, Tinghao Chang; The Affiliated Hospital of North Sichuan Medical College (53): Xiaoping Tang, Long Zhao, Junde Wu, Yangjingtian Hu, Zheng Li; The Affiliated Hospital of Xuzhou Medical University (50): Rutong Yu, Lei Hua, Yong Wang, Yanhong Ren, Haibo Zhang; Chongqing Hospital of Traditional Chinese Medicine (46): Jun Tang, Jianzhong Shu, Chao Luo, Gaung Wang, Yueyue Guan; The Third People's Hospital of Hubei Province (37): Yue Wan, Shangsheng Ke, Dandan He, Zhenyi Wang, Chenghang Lu; The Fourth Affiliated Hospital of Guangzhou Medical University (36): Xie Li, Jianbin Zhong, Simin Zhong, Yanfang Lai, Shijun Zhang; Guangdong Provincial Hospital of Chinese Medicine (35): Jianwen Guo, Lixin Wang, Guifu Li, Lijin Huang, Jinsong You; Guangdong Provincial Hospital of Chinese Medicine, Fangcun Hospital (28): Tao Huang, Zheng Zhen, Daojin Xue, Guo Ke, Qiurong He; Chongqing Hospital of The First Affiliated Hospital of Guangzhou University of Chinese Medicine (Chongqing Beibei Hospital of Traditional Chinese Medicine) (26): Li Lei, Tie Guo, Hui Li, Yunxue Pu, Hailin Zhu; The First Hospital of Lanzhou University (24): Gang Yang, Maohua Zheng, Wei Hou, Yue Yu, Haijun Yang; Guangyuan Hospital of Traditional Chinese Medicine (22): Gang He, Yuan Ran, Xiaoli Fan, Lai Xu, Shihui Zou; Guangdong Provincial Hospital of Chinese Medicine, Higher Education Mega Center Hospital (16): Xiaoxin Bai, Jun Cai, Ruicong Chen, Yinbin Li, Huai Tu; Inner Mongolia Hospital of Traditional Chinese Medicine (10): Guohua Ren, Jiye Zhao, Yunna Wang, Jianhui Shi, Yafeng Bai; Traditional Chinese Medica Hospital of Xinjiang Uygur Autonomous Region (9): Lin Lin, Dazhi Li, Ning Cai, Yonghui Zhang, Xiaochen Yu; Department of Neurology, Ganzhou People's Hospital (6): Zonghua Jiang, Cong Wang, Dehai He, Jiahe Lai, Xujuan Yuan; Guangdong Provincial Hospital of Chinese Medicine, Zhuhai Hospital (4): Zeshun Zhang, Minqing Zhao, Defang Qin, Yonglin Huo, Bangxiang Wang; Hospital of Chengdu University of Traditional Chinese Medicine (3): Yun Lu, Shaohong Chen, Xu Jiao, Mingfei Li, Hao Chen.

## Ethics Committee approval

*Central:* Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (Vice-chairperson Jun Liu). Approved protocol version 4.0 on 24 September 2021 (No. BF2020-174-04), used at Yuanhang Law Firm, Guangzhou; Yingke Law Firm, Guangzhou; People's sub-district office Guangzhou, China

Site: Liaoning Thrombus Treatment Centre of Integrated Chinese and Western Medicine, Shenyang; Linyi People's Hospital, Linyi; Liaocheng People's Hospital, Liaocheng; Lianjiang People's Hospital, Lianjiang; Traditional Chinese Medicine Hospital of Meishan, Meishan; Ganzhou People's Hospital, Ganzhou; Panjin Central Hospital, Panjin; The First Affiliated Hospital of Shaoyang University, Shaoyang; Fushun Central Hospital, Fushun; People's Hospital of Anshun City Guizhou Province, Anshun; The Affiliated Hospital of North Sichuan Medical College, Nanchong; The Affiliated Hospital of Xuzhou Medical University, Xuzhou; Chongqing Hospital of Traditional Chinese Medicine, Chongqing; The Third People's Hospital of Hubei Province, Wuhan; The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou; Guangdong Provincial Hospital of Chinese Medicine, Guangzhou; Guangdong Provincial Hospital of Chinese Medicine, Fangcun Hospital-Guangdong Provincial Hospital of Chinese Medicine, Guangzhou; Chongqing Hospital of The First Affiliated Hospital of Guangzhou University of Chinese Medicine (Chongqing Beibei Hospital of Traditional Chinese Medicine), Chongqing; The First Hospital of Lanzhou University, Lanzhou; Guangyuan Hospital of Traditional Chinese Medicine, Guangyuan; Guangdong Provincial Hospital of Chinese Medicine, Higher Education Mega Center Hospital- Guangdong Provincial Hospital of Chinese Medicine, Guangzhou; Inner Mongolia Hospital of Traditional Chinese Medicine, Hohhot; Traditional Chinese Medica Hospital of Xinjiang Uygur Autonomous Region, Urumqi; Ganzhou People's Hospital Neurology Department, Ganzhou; Guangdong Provincial Hospital of Chinese Medicine, Zhuhai Hospital-Guangdong Provincial Hospital of Chinese Medicine, Guangzhou; and Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.

# Central ethics committee approval document

AP/03-07.0/10.0 伦理事查查是通知 广东省中医院伦理委员会 Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine 关于中风醒脑方治疗中重型脑出血急性期的安全性和疗效性评价的 多中心、双盲随机安慰剂对照试验的伦理审查意见通知 Notification of IEC Review Decision 意见号: BF2020-174-04 审查日期: 2021年09月24日 审查地点:广东省中医院研修模20模2005-2005(长形会议室) **审查项目**:中风醒脑方治疗中重型移出血急性期的安全性和疗效性评价的多中心、双盲随 机安型剂对扭试验 审查文件: 1. 维正案申查申请表 修正的临床研究方案(版本号/日期: V004/20210923) 3. 修正的知情同意书(版本号/日期: V004/20210923) 4. 新增的招募材料(版本号/日期: V1.0/20210923) 修正的病例报告表(版本号/日期: V004/20210923) 申办者/任务下达单位:广东省科学技术厅 临床研究单位:广东省中医院(大院神经一科) 主要研究者: 何建文 审查委员。程兰、丘小惠、魏琳、贵籍、罗维妮、紫伯健、刘孝、李立思、冯吴禧 模据国家食品药品监督管理局《药物临床试验质量管理规范》、《医疗器械临床试验 质量管理规范》、《药物临床试验伦理中查工作指导原则》,卫计委《涉及人的生物医学 研究伦理审查办法》、《干细测值床研究管理办法(试行)》,国家中医药管理局《中医 药临床研究伦理审查平台建设规范》,以及世界医学会《研尔辛基宣言》和国际医学科学 组织委员会《涉及人的健康相关研究国际伦思准则》的伦理原则,本伦理委员会对项目中 风架敞方治疗中重型酸出血急性期的安全性和疗效性评价的多中心、双盲随机安胜剂对照 试验 (受理号, HF2020-174) 进行了申查,结论; 同意方案修正。 阅露审查频率(減调整后):12个月。下次跟踪审查截止日期。2022年08月21日。 操件有效期。2020年08月21日至2022年08月21日。 接审查意见修改后的文件或对审查章见不同观点的陈述。请提交"复审申请"至伦理 委员会审查,经批准后方可执行。如有疑问,请及时与伦理委员会联系。 方案、知情同意书或招募材料的修改需变更版本号和版本日期,并以下划线方式标注 分来、 如用电影见为"修正后同意",请在1个月内提交复审; 如审查意见为"修正后 重审",请在3个月内提交复审,香则将视为自动放弃修改权利,须终止研究或重新申请伦 理审查。 联系电话: 伦理委员会办公室: 020-81887233-35943 伦理委员会主任: 刘平 81887233-30908 (办), 13602708155 (手机子 主任/副主任委员签字: 广东省中医院伦理委 第1页,共1页

会议签到表 AF/02-07/0/23/0 广东省中医院伦理委员会 Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine 会议签到表 Sign-in Sheet of Full IEC Meeting 日期: 2021年09月24日 审议项目,中风醒脑方治疗中重型脑出血急性期的安全性和疗效性评价的多中心、 双盲随机安慰剂对瓶试验 伦理委员会到会委员签名: 姓名 签名 职务 性别 专业情况 刘军 主任委员 中医骨伤学、伦理学、管理学 请假 男 曾早 请假 副主任委员 女 [期临床、分子生物学、伦理学 请假 刘旭生 副主任委员 男 中医内科学 程兰 委员 中医妇科学 女 中药制剂学 丘小惠 委员 女 中医内科学、循证与临床研究与 男 温泽淮 委员 方法学 4 护理学 委员 独琳 中医儿科学 男 黄鹂 委员 中新学 女 委员 罗懿妮 男 中医骨伤科 委员 陈伯健 药学研究 男 委员 刘博 法律代表(非医药学) 男 委员 李立凯 社区代表(非医药学) 33 委员 冯昊禧 中西医结合临床肾病学 男 清假 委员/主审委 划立語 法律代表(非医药学) 请假 委员 黄秋燕

第1页 共1页

# 2. Timelines, meetings, and modifications to the protocol

Date	Name of document / event	Brief summary of changes / notes
8 May 2021	CHAIN Protocol V1.0	Original
17 May 2021	Steering Committee Meeting 1st	Kick-off meeting
		Review of the first draft of protocol
7 June 2021	CHAIN Protocol V1.1	Adding previous clinical trials and underlying mechanisms of Chinese herbal medicine for ICH
	Amendment 1	treatment.
26 June 2021	CHAIN Protocol V2.0	Inclusion criteria for item 1) changed from "Age ≥18 years and Age <90 years" to "Age ≥18 years";
	Amendment 2	Added health economic evaluation.
14 July 2021	CHAIN Protocol V3.0	Revision of "heavy burden of ICH" in the background section and "sample size calculation"
	Amendment 3	Inclusion criteria for item 3) changed from "Presentation within 24 hours of symptom onset (or last seen well)" to "Presentation within 48 hours of symptom onset (or last seen well)";
		Time to initiation of intervention changed from '6 hours after randomisation' to 'the intervention
		after the randomisation should be performed as soon as possible'.
23 September 2021	CHAIN Protocol V4.0	Inclusion criteria for item 3) changed from "Presentation within 24 hours of symptom onset (or last
	Amendment 4	seen well)" to "Presentation within 48 hours of symptom onset (or last seen well)";
		Updated inclusion criteria for item 4) Meet any of the following criteria: a) NIHSS ≥8, or b) GCS 7-14;
		Added 'secondary to antiplatelet treatment' into the exclusion criteria;
		Added the UW-mRS scores at 180 days as secondary outcome;
		Added the Barthel Index at 28 days, 90 days, and 180 days as secondary outcomes;
		Added the mRS/ EQ-5D/5L at 28 days and 180 days as secondary outcomes;
		Kept the follow up at the onset of SAP, 3 days and 7 days after the occurrence of SAP and deleted "at 14 days";
		Kept three stratification factors, including site, neurological severity (NIHSS <15 vs≥15), and
		haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle);
		Updated the randomisation to 'double-blinded randomisation will commence within 48 hours';
		Added "the intervention after the randomisation should be performed as soon as possible" for the time to initiation of Chinese herbal medicine FYTF-919 or placebo;
		Estimated sample size changed from 1500 to 1504;
		Clarified the assessment time for key outcomes: changed from "XXX days after the occurrence of ICH" into "XXX days after starting the treatment";

		Added the number of clinical trial registration for CHAIN study "NCT05066620".		
24 September 2021	DSMB Meeting 1st	Kick-off meeting		
		Protocol overview		
		DSMB charter review and finalisation		
		DSMB mock table review		
24 November 2021	Recruitment	First participant randomised at Guangdong Provincial Hospital of Chinese Medicine, China		
1 November 2022	DSMB Meeting 2nd	DSMB reviewed available data and had no concerns for the safety of participants		
		Further meeting in line with the schedule in the charter		
19 April 2023	DSMB Meeting 3rd	Reviewed both blinded and unblinded reports and recommended the trial continue as planned.		
26 September 2023	DSMB Meeting 4th	Reviewed both blinded and unblinded reports, and interim analysis report		
		DSMB recommended the trial continue as planned		
28 December 2023	Recruitment completed	Last patient recruited into study		
02 April 2024	Patient follow-up	Last 90-day outcome assessment for participants		
17 April 2024	Data lock			
26 April 2024	Unblinding of data to key members of Steering Committee			

# 3. The CONSORT 2010 checklist of information to include when reporting a randomised trial

	Item		Reported
Section/Topic	No	Checklist item	on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
Introduction			
Background and	2a	Scientific background and explanation of rationale	2-3
objectives	2b	Specific objectives or hypotheses	3
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	3
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with	Section 2
		reasons	Suppl.
			appendix
Participants	4a	Eligibility criteria for participants	3; section 6,
	4h	Cattings and locations where the data were callected	appendix
	4b	Settings and locations where the data were collected	3; section 1 appendix
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and	3-4; section 7
into i vontiono	O	when they were actually administered	suppl
		mistration and distration and an arrangement of the state	appendix
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how	4-6; section
		and when they were assessed	16 of suppl
			appendix
	6b	Any changes to trial outcomes after the trial commenced, with reasons	Section 1 of
			suppl
Comple cize	70	How comple size was determined	appendix
Sample size	7a	How sample size was determined	6; and Section 12 of
			suppl
			appendix
			<u> </u>

	7b	When applicable, explanation of any interim analyses and stopping guidelines	Section 13 appendix
Randomisation:	90	Method used to generate the random allocation sequence	2
Sequence generation	8a 8b	Type of randomisation; details of any restriction (such as blocking and block size)	3 3
Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially	3
concealment mechanism	3	numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	3
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	3
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care	Section 7 of
		providers, those assessing outcomes) and how	suppl.
			appendix
	11b	If relevant, description of the similarity of interventions	Section 7 of
			suppl.
Statistical methods	120	Statistical matheds used to compare groups for primary and accordant outcomes	appendix
Statistical methods	12a 12b	Statistical methods used to compare groups for primary and secondary outcomes  Methods for additional analyses, such as subgroup analyses and adjusted analyses	13
	120	Methods for additional analyses, such as subgroup analyses and adjusted analyses	
Results			
Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended	6
diagram is strongly	4.01	treatment, and were analysed for the primary outcome	
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	6
Recruitment	14a	Dates defining the periods of recruitment and follow-up	6
Dogolina data	14b	Why the trial ended or was stopped	6 5
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	5
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	5
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	5, and
			appendix
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	7
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	5, 7-8

<b>Discussion</b> Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	8-9
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	9
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	8-9
Other information			
Registration	23	Registration number and name of trial registry	1
Protocol	24	Where the full trial protocol can be accessed, if available	website
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	1; and
-			section 4 of
			the suppl
			appendix

# 4. Agencies providing funding for the study

This study received funding from the following grants in China: Key-Area Research and Development Program of Guangdong Province (No.2020B1111100009), Guangzhou Municipal Science and Technology Bureau (No.SL2023B01J00017); Guangdong Provincial Key Laboratory of Research on Emergency in TCM (2023B1212060062). Craig Anderson is supported to undertake stroke research by grants from the National Health and Medical Research Council (NHMRC) of Australia (APP1149987).

# 5. Screening procedures

Investigators at participating hospital sites were required to fill in a screening log for all potentially eligible patients with acute intracerebral haemorrhage (ICH) confirmed by brain imaging. Patients who failed to be randomised would have the reason recorded as a screening failure. The patients who met the screening criteria would be entered with the stratification factors into the randomised system and be assigned a random number and drug number.

#### 6. Inclusion/exclusion criteria

Inclusion criteria: Patients must meet all following criteria:

- Age ≥18 years
- Diagnosis of spontaneous ICH, confirmed by brain imaging
- Presentation within 48 hours of symptom onset (or last seen well)
- Meet any of the following criteria: a) NIHSS score ≥8, or b) GCS score ≤14
- Provide written informed consent by patient (or approved surrogate)

Exclusion criteria: Patients will NOT be eligible if there is one or more of the following:

- ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischaemic stroke), or secondary to cerebral amyloid angiopathy, or secondary to reperfusion treatment for ischaemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment
- Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment
- Other medical illness that will interfere with outcome assessments and follow-up (e.g. known significant pre-stroke disability [modified Rankin scale {mRS} scores 3-5], advanced cancer and severe renal failure)
- Known definite contraindication to the Chinese herbal medicine
- Women who are known to be pregnant or lactating
- Currently participating in another trial which would interfere with outcome assessments

# 7. Treatment drug and placebo

## 7.1 Active agent

Name of treatment drug: FYTF-919 (Zhong Feng Xing Nao [ZFXN] prescription)

Ingredients: FYTF-919 comprises four Chinese herbs – Renshen (Panax ginseng), Dahuang (Radix et Rhizoma Rhei), Sanqi (Radix Notoginseng), and Chuanxiong (Rhizoma Ligustici Chuanxiong), with sorbic acid and polysorbate 80 as auxiliary materials. The compounds in FYTF-919 were identified by information regarding molecular formula, molecular weight, peak time and secondary fragment ions with reference substances, from databases and related literatures. A total of 30 components were identified or tentatively identified (**Table 7.1**), including 15 triterpenoid saponins (ginsenosides), 9 organic acids and 6 anthraquinones. The representative compounds contained Ginsenoside Re, Ginsenoside Rg1, Ginsenoside Rb1, Notoginsenoside R1, Emodin-8-O-β-D-glucoside, Aloe-emodin, Rhein, Emodin and Ferulic Acid, and other constituents.

Quality control and stability assessment: An ultra-high performance liquid chromatography coupled with Q Exactive hybrid quadrupole-Orbitrap mass spectrometry (UHPLC-Q Exactive-Orbitrap MS) system was employed to assess the quality and stability of the drug. A total of 30 chemical profiles were detected in different batches of FYTF-919 and the similarity between different batches exceeded 0.95 (**Fig 7.1**). Similarity analysis for fingerprints of the three batches are provided in **Table 7.2**. The relative standard deviations (RSDs %) of 10 representative compounds, including notoginsenoside R1, ginsenoside Re, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rd, ferulic acid, emodin-8-O-glucoside, aloe-emodin, rhein and emodin, were all below 15%, as outlined in **Table 7.3**.

Dose and usage: The study medication was prepared as a brown-yellow liquid specifically in a 100 ml per bottle (**Fig 7.2**). The method and frequency of delivery in patients is determined by their level of consciousness and ability to swallow. Patients who are awake and have a normal swallow, take warm FYTF-919 orally, at a dose of 33 ml from 30 min after a meal. For patients with swallowing dysfunction, insufficient oral intake, unconsciousness, or are in a critical condition, a dose of 25 ml every 6 h is usually given via a nasogastric tube. For this study, patients were to take FYTF-919 immediately after randomisation and until 28 days.

*Manufacturer:* FYTF-919 was manufactoured at the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.

Table 7.1 Compounds identified in FYTF-919

No.	T <sub>R</sub> /min	[M-H] <sup>-</sup> /[M- HCOO] <sup>-</sup>	Fragment ion (MS <sup>2</sup> )	Formula	Identification compound	
1	1.78	169.0132	125.02	$C_7H_6O_5$	Gallic acid *	
2	3.73	353.0878	191.06, 179.03, 134.04	$C_{16}H_{18}O_{9}$	Neochlorogenic acid *	
3	7.45	353.0881	191.06	$C_{16}H_{18}O_{9}$	Chlorogenic acid *	
4	8.72	353.0879	173.04, 179.03, 191.06,	$C_{16}H_{18}O_{9}$	Cryptochlorogenic acid *	
4	0.72	333.0679	135.04	C161118O9	Cryptochiologenic acid	
5	9.56	515.1185	179.03, 191.05, 353.09,	$C_{25}H_{24}O_{12}$	Isochlorogenic acid C (4,5)	
3	9.30	313.1163	135.04, 335.07	C <sub>25</sub> H <sub>24</sub> O <sub>12</sub>	isocinologenic acid C (4,3)	
6	10.29	515.1192	173.04, 179.03, 191.05,	$C_{25}H_{24}O_{12}$	Isochlorogenic acid B	
O	10.29	313.1192	353.09, 135.04	C <sub>25</sub> Π <sub>24</sub> O <sub>12</sub>	Isocinologenic acid b	
7	10.30	193.0498	134.04, 178.03, 149.06,	$C_{10}H_{10}O_4$	Ferulic acid *	
1	10.30	193.0496	137.02	C <sub>10</sub> H <sub>10</sub> O <sub>4</sub>	refulic acid "	
8	10.38	515.1193	191.06, 179.03, 135.04	$C_{25}H_{24}O_{12}$	Isochlorogenic acid A	
9	10.45	977.5324	931.53, 799.48, 637.43,	$C_{47}H_{80}O_{18}$	Notoginsenoside R <sub>1</sub> *	
7	10.43	911.3324	475.38		rotognisenosiue K	
10	10.54	515.1190	173.04, 179.03, 191.05,	$C_{25}H_{24}O_{12}$	Isochlorogenic acid C	
10	10.54	313.1190	135.04	C251124O12	isocmorogome uota e	
			945.54, 799.48, 783.49,			
11	10.64	10.64	991.5484	637.43, 475.38, 765.48,	$C_{48}H_{82}O_{18} \\$	Ginsenoside Re *
			619.42, 391.29			
12	10.70	845.4899	637.43, 799.48, 475.38,	$C_{42}H_{72}O_{14}$	Ginsenoside Rg <sub>1</sub> *	
12	10.70	043.4033	619.42	C421172O14	Omsenoside Kg	
13	12.39	431.0989	269.05, 240.04, 225.04	$C_{21}H_{20}O_{10}$	Emodin-8-O-β-D-glucoside *	
14	14.09	4.08 845.4905 799.48, 475.38, 637.43, 391.29 C <sub>42</sub> H <sub>72</sub> O <sub>14</sub>	СЦО	Ginsenoside Rf		
14	14.06		391.29	C <sub>42</sub> Π <sub>72</sub> O <sub>14</sub>	Giliselloside Ki	
15	14.30	945 4004	799.48, 323.10, 475.38,	$C_{42}H_{72}O_{14}$	Pseudoginsenoside F <sub>11</sub>	
13	14.30	845.4904	637.43	C <sub>42</sub> H <sub>72</sub> O <sub>14</sub>	r seudognisenoside 1/11	
16	14.74	445.1143	283.06, 240.04	$C_{22}H_{22}O_{10}$	Physcion-8-O-β-D-glucoside *	

17	17 16.66	829.4959	783.49, 637.43, 475.38,	$C_{42}H_{72}O_{13}$	Ginsenoside F <sub>2</sub>	
			391.28, 619.42, 459.35			
18	17.29	829.4958	783.49, 475.38, 637.43,	$C_{42}H_{72}O_{13}$	Ginsenoside Rg <sub>2</sub>	
			391.29, 619.42	- 12 72 - 13	2	
19	17.44	1153.6000	1107.59, 945.54, 783.49,	$C_{54}H_{92}O_{23}$	Ginsenoside Rb <sub>1</sub> *	
1)	17.11	1123.0000	621.44, 459.38	C341192O23	Sinsenosiae Ro <sub>1</sub>	
20	19.50	955.4908	793.47, 569.38, 523.38,	C48H76O19	Ginsenoside Ro	
20	19.30	933.4900	613.37	C4811/6O19	Giliselloside Ko	
21	19.72	1123.5903	1077.58, 945.54, 783.49,	$C_{53}H_{90}O_{22}$	Ginsenoside Rc	
21	21 19.72	1123.3703	621.44, 459.38, 375.29	C531190O22	Omsenssiae re	
22	21.44	269.0444	253.05, 240.04	$C_{15}H_{10}O_5$	Aloe-emodin *	
23	23 22.71	1123.5903	1077.58, 945.54, 783.49,	$C_{53}H_{90}O_{22}$	Ginsenoside Rb2	
23	22.71	1123.3903	621.43, 459.38	C531190O22	Gillochoolde Roz	
24	23.52	1123.5903	1077.58, 945.54, 783.49,	$C_{53}H_{90}O_{22}$	Ginsenoside Rb3	
24	23.32	1123.3703	621.44, 459.38, 375.29	C531190O22	Ginschoside Ros	
25	24.05	283.0259	257.05, 239.03	$C_{15}H_8O_6$	Rhein *	
26	24.26	991.5485	945.54, 783.49, 621.44,	$C_{48}H_{82}O_{18}$	Ginsenoside Rd*	
20	24.20	991.9 <del>4</del> 03	459.38, 765.48	C481182O18	Ginsenoside Ru	
27	30.50	269.0441	225.05	$C_{15}H_{10}O_5$	Emodin *	
28	30.42	829.4959	783.49, 621.44, 459.38	$C_{42}H_{72}O_{13}$	(S)-Ginsenoside Rg <sub>3</sub>	
29	30.67	829.4959	783.49, 621.44, 459.38	$C_{42}H_{72}O_{13}$	(R)-Ginsenoside Rg <sub>3</sub>	
30	32.27	253.0502	225.05	$C_{15}H_{10}O_4$	Chrysophanol *	

<sup>\*</sup> Compared to reference substances

Figure 7.1 MS chromatographic fingerprints for three batches of FYTF-919

Table 7.2 Similarity analysis for fingerprints of the three batches

	<b>S</b> 1	S2	S3
<b>S</b> 1	1	0.984	0.978
<b>S</b> 2	0.984	1	0.98
<b>S</b> 3	0.978	0.98	1

Table 7.3 Similarity analysis for 10 representative compounds from 3 batches of FYTF-919

Compounds		C(	ug/mL)		
Compounds	No. 202109.6	No. 20211208	No. 20220419	Mean±SD	RSD%*
Notoginsenoside R1	$2135.65 \pm 27.14$	$2459.68 \pm 61.83$	$2379.76 \pm 32.62$	$2325.03 \pm 168.81$	7.26
Ginsenoside Re	$1102.94 \pm 19.83$	$1380.48 \pm 19.48$	$1360.30 \pm 31.04$	$1281.24 \pm 154.74$	12.08
Ginsenoside Rg <sub>1</sub>	$7338.03 \pm 139.94$	$9269.25 \pm 250.37$	$9081.81 \pm 271.27$	$8563.03 \pm 1065.01$	12.44
Ginsenoside Rb <sub>1</sub>	$7801.56 \pm 61.02$	$9300.57 \pm 91.54$	$9096.19 \pm 47.17$	$8732.77 \pm 812.90$	9.31
Ginsenoside Rd	$1665.45 \pm 12.37$	$2146.67 \pm 15.97$	$2088.02 \pm 7.41$	$1966.71 \pm 262.54$	13.35
ferulic acid	$103.84 \pm 2.11$	$86.72\pm0.56$	$79.64 \pm 1.66$	$90.07 \pm 12.44$	13.81
aloe-emodin	$6.07 \pm 0.1$	$7.21 \pm 0.04$	$7.04 \pm 0.12$	$6.77 \pm 0.62$	9.08
rhein	$29.95 \pm 0.66$	$33.95 \pm 0.18$	$33.05 \pm 0.54$	$32.32 \pm 2.10$	6.49
emodin	$8.17 \pm 0.38$	$9.47 \pm 0.26$	$9.39 \pm 0.5$	$9.01 \pm 0.73$	8.09
emodin-8-O-glucoside	28.35±0.33	33.43±0.24	33.08±0.88	$31.60 \pm 2.87$	9.07

<sup>\*</sup>Relative standard deviation

## 7.2 Placebo

Manufacturer: The placebo was developed and manufactured by Guangdong Huixiangyuan Biotechnology Co., Ltd. Invention patents based on placebos were published by the State Intellectual Property Office of China (application number 202211384394.6).


Features: The appearance and internal laws of flavour level structure, colour and gloss, texture, basic flavour, main flavour, and volatile aroma of FYTF-919 were imitated in the placebo, which was composed of food-grade and medicinal-valueless materials, such as soy protein


powder, vital wheat gluten, and brown sugar syrup, as outlined in **Table 7.4**. The appearances of active drug and placebo are shown in **Fig 7.2**.

Table 7.4 Features of FYTF-919 and imitated ingredients of placebo.

Items	Features of FYTF-919	Imitated ingredients of placebo
Colour and gloss	Dark black	Dark black
Texture	Slightly viscous	Maltodextrin
	Homogeneous	Vital wheat gluten
Basic flavour	Sweet	Brown sugar syrup, stevioside
	Bitter	Soy protein powder
	Sour	DL-malic acid
Main flavour	Neem wood	Food essence
Volatile aroma	Aroma of rotting wood	Food essence
	Earthy smell	Soy protein powder, maltodextrin


Fig 7.2 Pictures for FYTF-919 and placebo








The representative compounds of FYTF-919 were virtually absent in the placebo group, as shown in **Fig. 7.3**. The compounds tested in (B) depend on the herbs contained in FYTF-919, of which Notoginsenoside R1, Ginsenoside Re, Ginsenoside Rg1, and Ginsenoside Rb1 were attributed to Panax ginseng and Radix Notoginseng; Ferulic acid was attributed to Rhizoma Ligustici Chuanxiong, Emodin, Aloe-emodin, and Rhein;and Emodin-8-O-β-D glucoside was attributed to Radix et Rhizoma Rhei. In comparison with the standard ion chromatograms of graph (B), graph (C) appears to have the same exacted ion peak as well as peak retention time, and exhibits high ion intensity. Conversely, graph (D) shows no matching exacted ion peak and peak retention time as shown in graph (B) and has lower ion intensity. These results indicate that FYTF-919 represented by graph (C) contains the above 8 compounds, while the placebo represented by graph (D) does not contain any of the 8 compounds.

Figure 7.3. Extracted ion chromatograms for blank, placebo and FYTF-919 sssamples. (Black: blank solution; Blue: placebo; Red: FYTF-919; D: )









## 7.3 Comparison between treatment drug and placebo

We designed and conducted a small sample, randomised double-blind study to assess the effectiveness of the blinding of the study medication, and the physical similarity of the placebo of raw food material compared with FYTF-919 that were used in the study. The evaluation indicators of placebo effect include consistency evaluation and simulation of the actual situation in clinical trials. The test drug and placebo were blinded, and multiple evaluators were invited to evaluate the appearance, smell, sweetness, bitterness, and overall taste of the blinded trial drug and placebo simultaneously.



**Figure 7.4.** Sample 1 was test FYTF-919 drug, sample 2 was placebo.

Consistency test between placebo and trial drug. Researchers blinded the trial drug and the evaluators assessed the blinded trial drug and placebo, including the appearance and taste of the liquid. The results are shown in Tables 7.5-7.6 below:

Table 7.5. Assessment of conformity between FYTF-919 and placebo on appearance

F 1 4	Result, n (%)				
Evaluation content	Completely consistent	Relatively consistent	Half of each	Relatively inconsistent	Inconsistent
Liquid color	6 (60%)	4 (40%)	0 (0%)	0 (0%)	0 (0%)
Clarity	7 (70%)	3 (30%)	0 (0%)	0 (0%)	0 (0%)

Table 7.6. Assessment of conformity between FYTF-919 and placebo on taste

Evaluation	Result, n (%)				
content	Completely consistent	Relatively consistent	Half of each	Relatively inconsistent	Inconsistent
Smell	0 (0%)	3 (30%)	2 (20%)	0 (0%)	5 (50%)
Sweetness	1 (10%)	1 (10%)	0 (0%)	4 (40%)	4 (40%)
Bitterness	0 (0%)	1 (10%)	1 (10%)	2 (20%)	6 (60%)
Overall taste	1 (10%)	1 (10%)	1 (10%)	4 (40%)	3 (30%)

Actual situation of the simulation experiment. There were 14 clear plastic cups prepared, 7 of which were filled with FYTF-919 and 7 with placebo. A syringe was used to ensure an equal amount of FYTF-919 and placebo were poured into each cup. Participants were allowed to choose the selection of cups for tasting. They were asked whether the cup contained the test drug or placebo. The results in Table 7.7 show that participants were able to correctly distinguish the placebo with an accuracy of 0% (0 vs 7).

Table 7.7. The test results of the simulation experiment

Evaluation content	Correct	Incorrect	Indistinct	Sum up
FYTF-919	6	0	1	7
Placebo	0	5	2	7

As tested by reviewers, FYTF-919 and placebo were relatively consistent in colour and clarity. In terms of taste, there was a discrepancy between sweetness, aroma, and overall taste, but the bitterness was relatively consistent. The placebo tasted slightly sweet, while FYTF-919 tasted slightly bitter; and FYTF-919 hasda stronger fragrant taste. When the evaluator independently tasted the drug, the evaluator of the test drug was generally able to confirm that it was the test drug, while the evaluator could not adequately distinguish it from the placebo. The conclusion was that the placebo-making method was successful.

## 8. Training of investigators

All CHAIN investigators were trained in the protocol, Good Clinical Practice (GCP) procedures, and use of the National Institute for Health Stroke Scale (NIHSS), modified Rankin scale (mRS) and EQ-5D-5L, if they had no recent certification. Drs Yingfeng Wan and Tingting Xie recieved training and were on-line certified in use of mRS and NIHSS. They provided training and certification to any site assessor who had not received similar online training and certification. All such assessors received mRS training via in-person meetings or on-line during the study period. After each training session, the assessors receive an examination ensure that he/she was suitably qualified. Details of the content, frequency and evaluation of assessors are available upon request.

# 9. Schedule for monitoring of sites

Project management team undertook quality control activities necessary for the conduct of the trial in accordance with the protocol, applicable guidelines, and regulations. The first monitoring visit was within 1 week after the site had randomised the first patient following initiation and activation of the site. The second monitoring visit took place after every 10-20 patients had been randomised at each site or every 3 months. Subsequent monitoring visits were arranged every 6 months, and the frequency of monitoring can be adjusted appropriately according to the recruitment of subjects in sites, the collection of original data, the input of EDC, the progress of questioning and answering, and the problems found in the monitoring process.

All sites were monitored at least twice per year. Any significant deviation from the planned monitoring timelines was explained and documented in the monitoring visit report, and the monitoring plan was amended if appropriate.

The monitoring visit served to obtain 100% source data verification of the following data for all randomised patients: patient consent forms (patient consent forms were reviewed for compliance with GCP/ICH GCP); patient existence; inclusion & exclusion criteria; all outcome data; treatment allocation; and all serious adverse event forms to source verification.

The project manager selected 30% key sites to conduct co-monitoring visits according to the needs, found the risks in the process of the trial, corrected them in time, and controlled the quality of the data.

The CHAIN study was affected by the COVID-19 pandemic. Because of the requirement for epidemic prevention policies to be enacted in many participating hospitals, project staff were unable to undertake monitoring activities directly at sites during certain months in 2021 and 2022. To ensure integrity and authenticity of key data, the project team with data management undertook risk-based monitoring of the data on the participants. The sponsor assigned multiple regional coordination locations to manage recruitment and data collection at the centre. After on-site monitoring was allowed in 2022, the CRAs verified all data that required source data verification.

At the end of the study, 26 sites had received at least 50 on-site monitoring visits.

#### 10. Definitions of protocol violations and deviations

Protocol deviation / violations were any unapproved changes, or departures from the study design or procedures of the CHAIN protocol, that were under the investigator's control and had not been reviewed and approved by the Central Coordinating Centre (CCC) or IRB/EC. Protocol deviation / violations had two categories: 'major (reportable) violations', and 'minor (non-reportable) violations' which were also called 'Protocol Deviations'.

#### Major (reportable) protocol violations

Major protocol violations were any unapproved changes in the research study design and/or procedures that were within the investigator's control, and not in accordance with the approved protocol, that may have affected the participant's rights, safety or well-being, or the completeness, accuracy, and reliability of the study data. All major violations were required to be reported to the IRB/EC, regulatory authority and/or sponsor, in keeping with relevant national guidance and conforming to national timelines for reporting. The CCC criteria for defining major violations included any of the following violation events:

- There was harm, or posed a significant or substantive risk of harm, to the participant;
- It had resulted in a change to the participant's clinical or emotional condition or status;
- There was damage to the scientific completeness or soundness of the study data;
- There was evidence of willful or knowing misconduct on the part of the investigator(s);
- There was serious or continuing noncompliance with federal, state, or local regulations.

Examples of major protocol violations included, but were not limited to:

- a) enrolment of a participant who did not meet the eligibility criteria;
- b) failure to obtain informed consent prior to any study-specific tests/procedures;
- c) failure to follow protocol procedures that specifically related to intervention and the primary safety or efficacy endpoints of the study;
- d) failure to follow study medication management requirements;
- e) failure to follow randomisation, blinding and unblinding procedures.

#### Minor (non-reportable) protocol violations (also called protocol deviations)

Minor protocol violations were any unapproved changes in the research study design and/or procedures that are within the investigator's control and not in accordance with the approved protocol that do not have a major impact on either the participant's rights, safety or well-being, or the completeness, accuracy, and reliability of the study data. Minor protocol violations were not necessarily reportable to the IRB/EC. CCC criteria for minor violations and included all of the following:

- the violation did not harm or pose a significant risk of substantive harm to the research participant, and
- the violation did not result in a change to the participant's clinical or emotional condition or status, and

- the violation did not damage the completeness, accuracy, and reliability of the data collected for the study, and
- the violation did not result from willful or knowing misconduct on the part of the investigator(s), and
- the violation did not involve serious or continuing noncompliance with federal, state, or local regulations.

Examples of minor protocol violations included, but are not limited to:

- a) patient being unable to complete the self-administered quality of life questionnaire when they were capable of doing so;
- b) follow-up visits / assessments performed outside of defined time points or window.

# Participant took a contraindicated Traditional Chinese Medicine

- If 1 overlapping component of FYTF-919 was used for <14 days or 2 overlapping components were used for <7 days, it is considered a minor PV.
- If 1 overlapping component of FYTF-919 was used ≥14 days or 2 overlapping components were used ≥7 days (including 7 days), it is considered a major PV.

# 11. Complete list of protocol violations identified through monitoring\*

Code	Major / Minor	Description 1	Description 2	<b>FYTF-919</b>	Placebo	Total
1	Major	Consent form	Signed the wrongly version of Consent Form, but re-signed the new version.	27/817 (3.30%)	28/831 (3.37%)	55
2.1	Major	Inclusion criteria	Not me Inclusion Criteria 2: Presentation over 48 hours of symptom onset (or last seen well).	4/817 (0.49%)	4/831 (0.48%)	8
2.2	Major	Exclusion criteria	Satisfy Exclusion Criteria 1: ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischaemic stroke), or secondary to cerebral amyloid angiopathy, or secondary to reperfusion treatment for ischaemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment.	2/817 (0.24%)	4/831 (0.48%)	6
2.2	Major	Exclusion criteria	Satisfy Exclusion Criteria 2: Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment.	2/817 (0.24%)	6/831 (0.72%)	8
2.2	Major	Exclusion criteria	Satisfy Exclusion Criteria 3: Other medical illness that will interfere with outcome assessments and follow-up (e.g. known significant pre-stroke disability [modified Rankin scale {mRS} scores 3-5], advanced cancer and severe renal failure).	5/817 (0.61%)	4/831 (0.48%)	9
5	Minor	Medication management	The medication was stored over the temperature requirement, but the quality was not affected.	0/817 (0.00%)	4/831 (0.48%)	4
5	Major	Medication management	Patients were dispensed medication from other sites of the same city due to 1) insufficient stock in sites; 2) lack of random numbers.	5/817 (0.61%)	7/831 (0.84%)	12
5	Major	Medication management	Patients were given wrong medication due to an investigator's negligence.	3/817 (0.37%)	3/831 (0.36%)	6
5	Major	Medication management	Patients were not given medication due to 1) an investigator's negligence; 2) insufficient stock in site.	3/817 (0.37%)	3/831 (0.36%)	6
5	Major	Medication management	Patients were given only 32% of the medication due to an investigator's negligence.	0/817 (0.00%)	1/831 (0.12%)	1

6	Major	Taking contraindicated TCM	One overlapping component of FYTF-919 was used over 14 days or two overlapping components were used over 7 days.	18/817 (2.20%)	16/831 (1.93%)	34
6	Minor	Taking contraindicated TCM One overlapping component of FYTF-919 was used less than 14 days or two overlapping components were used less than 7 days.		29/817 (3.55%)	43/831 (5.17%)	72
7	Major	Trail endpoint-Primary outcome of D90	Not collected or Patient lost to follow up	15/817 (1.84%)	10/831 (1.20%)	25
10	Minor	Others	The wrong Stratification factor was chosen.	23/817 (2.82%)	23/831 (2.77%)	46
10	Major	Others	Patients took wrong medication due to wrong packaging.	2/817 (0.24%)	1/831 (0.12%)	3
10	Major	Others	Researchers dispensed drugs to patients on their own, rather than following the principle of randomized allocation.	0/817 (0.00%)	1/831 (0.12%)	1

# 12. Sample size calculations

The sample of 1504 patients are estimated to provide 90% power ( $\alpha$  0.05) to detect a difference in average scores for better outcome between the active and placebo groups of  $\geq$ 20% (i.e., 0.65 vs. 0.59; SD = 0.32), assuming equal group participations, 6% non-adherence rate, and 10% lost to follow-up. The calculation was based on data from the second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2) where the mean UW-mRS was estimated as 0.59 in control 'less intensive BP control' group. The protocol of CHAIN trial including the sample size estimation has been published on Cerebrovascular Diseases (https://doi.org/10.1159/000534761).

## 13. Terms of reference of the DSMB

The DSMB was responsible for: safeguarding the interests of trial participants; reviewing the research protocols and plans for data and safety monitoring; reviewing data monitoring reports provided by the study statistician; reviewing the progress of the study and monitoring adherence to the protocol, participant recruitment, outcomes, data quality, complications, and other issues related to participant safety; monitoring the assumptions underlying sample size calculations for the study (Trial Steering Committee [TSC] and Trial Operations Committee [TOC] should be kept blinded) and alert the investigators if they see substantial departures as the data accumulate; ensuring the confidentiality of the study data and the results of monitoring; assessing the safety and efficacy of the interventions during the trial; monitoring the overall conduct of the clinical trial; providing recommendations about stopping or continuing the trial to the trial Steering Committee; contributing to enhancing the integrity of the trial; formulating recommendations in relation to the selection, recruitment, or retention of participants, or their management, or to improving their adherence to protocol-specified regimens and retention of participants, and the procedures for data management and quality control.

The DSMB was advisory to the Steering Committee. The Steering Committee was responsible for promptly reviewing the DSMB recommendations, to decide as to whether to continue or terminate the trial, and to determine whether amendments to the protocol or changes in study conduct were required.

The DSMB conducted both periodical safety reviews, and a formal interim analysis, by teleconference as follows:

- The first analysis meeting of the DSMB was planned within 6 months from the first patient enrolment of the study to review initial safety data and finalize the format of reports.
- Subsequent safety review meetings were conducted approximately every six months in the initial stages of the trial. Depending on trial progress, the meeting interval was to vary; safety reviews were to concentrate on safety assessment and did include formal testing of the efficacy data.
- One 'Formal Interim Analysis' meeting was planned and undertaken. The purpose was to review data relating to treatment efficacy, patient safety and quality of trial conduct in conjunction with the following scheduled safety review meetings.
- The DSMB will allowed to respond to specific requests made by the CHAIN TSC.

The trial Principal Investigator and other members of the TOC based at The George Institute attended open sessions at the beginning of meetings and were available at the end of meetings

to answer any urgent questions. The date of each DSMB meeting was made available to the unblinded statisticians with at least 6 weeks notice. The unblinded statisticians prepared the DSMB reports and attended the whole meeting to assist with interpretation of the results.

For each DSMB meeting, both safety reviews and the interim analysis; open and closed reports were provided. Open reports, available to all who attended the DSMB meeting, included data on recruitment; study accrual by month and by site, including an assessment of whether recruitment targets are being met; pooled data on eligibility violations; major protocol changes; baseline characteristics (pooled by treatment regimen); completeness of follow-up and compliance; initial brain imaging summary; serious adverse events (including death) summary and detailed list; pooled analysis of primary outcome; details of the number of pending and missing case report forms (including the number of seriously overdue follow-ups), and the number with outstanding data items; any other relevant information (such as updated Cochrane reviews). Closed reports, available only to those attending the closed sessions of the DSMB meeting, included analyses of primary and secondary efficacy endpoints (for interim reviews), subgroup and adjusted analyses, analyses of serious adverse events, and open report analyses that are displayed by intervention group. The reports for the safety reviews were a subset of the reports prepared for the formal interim analysis.

The unblinded statistician(s) from The George Institute for Global Health prepared both the open and closed reports. The open and closed reports provided information that was accurate, with follow-up that was complete to within approximately one month of the date of the DSMB meeting. The Reports were provided to DSMB members 1-2 weeks prior to the date of meetings.

During the period of recruitment into the study, interim analyses of the proportion of patients alive and independent, or dead (at hospital discharge and at 3 months), or with other major outcome events were supplied, in strictest confidence, to all members of the DSMB, along with any other analyses that the DSMB may have requested.

A recommendation to discontinue CHAIN prematurely was to be based upon there being clear evidence that the treatment provides protection or caused harm for an important clinical outcome. The final recommendation to the TSC was at the discretion of the DSMB but based upon agreed standards for the interpretation of interim analysis in clinical trials. The TSC had responsibility for evaluating and implementing the recommendations provided by the DSMB.

A recommendation to modify CHAIN was accompanied by the maximum possible information that the DSMB could provide to the TSC without affecting the integrity of the trial. Once again, the TSC was responsibility for evaluating and implementing any recommendations as they considered appropriate.

The decision to stop the trial temporarily or indefinitely was considered in hand with ensuring safety for the trial participants and the impact premature termination will have on clinical practice. The Haybittle-Peto rule was used as a guide for 'proof beyond reasonable doubt' in the monitoring of both efficacy and safety information in the trial.

The DSMB worked on the principle that a difference of at least 3 standard deviations in an interim analysis of a major outcome event (e.g. shift in death and disability according to full range scores on mRS in stroke patients at 90 days) between patients allocated to the active or placebo groups, was a justification for recommending the halting, or modifying, the study before the planned completion of recruitment. This criterion (Peto rule) has the practical

advantage that the exact number of interim analyses is of less importance, and so no fixed schedule was proposed.

Following each DSMB meeting, a recommendation was made to the TSC with the following options in the DSMB statement:

- modification of the study;
- termination of the study early
  - o clear and substantial evidence of benefit
  - o data suggests the risk of adverse events substantially outweighs the potential benefits;
- continue the study unchanged;
- additional expert review after which a recommendation will be made;
- additional analyses by the Statistics Group after which a recommendation will be made.

#### 14. Medical review procedures

During the trial, two skilled clinical doctors conducted the medical review. Investigators were required to submit the electronic case report forms (eCRF) within one week after enrolling a patient and within 90 days of follow-up. Medical reviewers then checked the data for completeness, accuracy, and logic. The main verification points included patient eligibility criteria, the consistency of clinical symptoms with NIHSS and GCS scores, intervention and blood pressure levels, the consistency of the mRS score and mRS score at the 90-day follow-up, the consistency of the mRS score and EQ-5D-5L score, and every data point of SAE forms. If any queries were found, the medical reviewers used a secure, password-protected internet-based electronic data capture (EDC) system to send queries and request site investigators to review original data and respond to queries. Before locking the database, all medical review related data must be completed, and all queries must be answered and closed.

## 15. Per-protocol (PP) analysis set

Patients who have one or more of the following protocol violations will be excluded from the per-protocol (PP) population:

- Age <18 years
- Randomized >48 hours after stroke onset
- NIHSS <2 and GCS 15
- Final diagnosis was not spontaneous ICH
- Patients who were found later in the trial to have received incorrect treatment or incorrect dose of the allocated study drug after confirmation by local investigators.
- Other major protocol violations which have been adjudicated, for example concomitant TCM contains same components of FYTF-919.

## 16. Assessments of functional outcome and health-related quality of life

The primary outcome was the mean score for disability on the UW-mRS at 90 days. To determine the utility-weighted score, the score on the mRS is weighted according to average values calculated from patient-centered and clinician-centered studies. Based on the algorithm of utility weighing for ICH patients, the following weights are assigned to scores 0 through 6

on the mRS: 0.96, 0.88, 0.74, 0.56, 0.25, -0.11, and 0, respectively. For assessment of health-related quality of life (HRQoL), the EQ-5D-5L questionnaire was used, as assessed directly by a patient or by a proxy-responder. The descriptive system of the EQ-5D defines the state of general health across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with three levels (no problems, some/moderate problems, and severe problems). The EQ-5D-5L utility score integrates the ratings of the 5 dimensions into a single score, calculated by using population-based preference weights for each subscale. In the present analysis, we used the weights obtained from the Chinese population. Utility scores express HRQoL quantitatively as a fraction of perfect health, with a score of 1 representing perfect health, a score of 0 representing death. When patients were not able to answer the questionnaire themselves, proxy-responders, such as their caregiver or doctor, were asked to rate the patient's HRQoL. The protocol did not stipulate specifically the process of proxy-responder selection; the decision was opportunistic that arose during a telephone or face-to-face interview between the responsible neurologically competent person (blinded to treatment arm) and the patient or caregiver at the scheduled time of follow-up.

# 17. Tables

Table S1. Reasons that 7352 patients with acute intracerebral haemorrhage were excluded from participating in the trial\*

Reason	N	%
Inclusion criteria		
Refusal	2935	39.9
Diagnosis of intracerebral haemorrhage not confirmed on brain imaging	1447	19.7
Did not meet clinical severity thresholds	935	12.7
Presentation outside the 48 hour time window from last known well	650	8.8
Age <18 years	18	0.2
Exclusion criteria		
Unlikely to potentially benefit from treatment	933	12.7
Other major medical condition	339	4.6
Likely structural cause of the intracerebral haemorrhage	131	1.8
Currently participating in another clinical trial	7	0.1
Women who are know to be pregnant or lactating	6	0.1
Known contraindication to traditional Chinese medicine	4	0.1

<sup>\*</sup>These items are not mutually exclusive. Patients could have been excluded for multiple reasons.

.

Table S2. Protocol deviations (PD) / violations (PV) \*

	FYTF-919	Placebo	Overall
Variable	(N = 815)	(N = 826)	(N = 1641)
Protocol deviation/violation	141# 124/815 (15.2)	164 <sup>#</sup> 143/826 (17.3)	305# 267/1641 (16.3)
Major protocol violation	83# 73/124 (58.9)	85# 77/143 (53.8)	168# 150/267 (56.2)
Major PV			
Using consent form without regulatory approval	20/83 (24.1)	25/85 (29.4)	45/168 (26.8)
Participants have taken contraindicated Chinese medicine	22/83 (26.5)	21/85 (24.7)	43/168 (25.6)
Inclusion / exclusion criteria not met	13/83 (15.7)	17/85 (20.0)	30/168 (17.9)
Missing data for primary efficacy outcome, including 90-day mRS and EQ-5D-5L (surviving subjects)	15/83 (18.1)	10/85 (11.8)	25/168 (14.9)
Investigator did not follow the protocol for study medication or did not use study medication	5/83 (6.0)	7/85 (8.2)	12/168 (7.1)
The participant was not asked to re-sign the updated consent form after ethics committee approval	5/83 (6.0)	1/85 (1.2)	6/168 (3.6)
All other deviations that may have an impact on the main outcome of the trial, blinding or subject safety shall be analysed on a case-by-case basis	2/83 (2.4)	2/85 (2.4)	4/168 (2.4)
Using consent form without ethics committee approval	1/83 (1.2)	2/85 (2.4)	3/168 (1.8)
Minor protocol deviation	58# 57/124 (46.0)	79# 76/143 (53.1)	137# 133/267 (49.8)
Minor PD			
Participants have taken Contraindicative Chinese medicine	29/58 (50.0)	45/79 (57.0)	74/137 (54.0)
Other	23/58 (39.7)	27/79 (34.2)	50/137 (36.5)
Study medication	6/58 (10.3)	7/79 (8.9)	13/137 (9.5)

Data are not mutually exclusive and presented as n (%). EQ-5D-5L=EuroQol health-related quality of life questionnaire, mRS=modified Rankin scale. \*There were 95 patients excluded from the per protocol dataset for reasons of major PV: (i) taken a contraindicated Chinese medicine; (ii) inclusion/exclusion criteria not met, and/or (iii) the investigator did not follow the protocol in the use of the study medication. Participants were also excluded from per protocol dataset if they did not take any study medication at all (0 bottles used).

 $Table \ S3. \ Additional \ clinical \ features, medical \ history \ and \ use \ of \ medications \ in patients \ with \ acute \ intracerebral \ haemorrhage*$ 

Variable	FYTF-919 (N=815)	Placebo (N=826)
Mean total TCM assessment score (1-5)	1.1 (1.3)	1.1 (1.3)
Individual components of TMC score		
Anxiety	96/780 (12.3)	92/788 (11.7)
Red face / temperature >37.5°	156/780 (20.0)	162/787 (20.6)
Dry mouth / bad breath	188/755 (24.3)	197/783 (25.2)
Yellow tongue coating	169/760 (22.2)	179/773 (23.2)
Red tongue coating	264/760 (34.7)	265/772 (34.3)
No stool in last 48 hours	237/781 (30.3)	269/785 (34.3)
Height, cm	166 (8)	166 (8)
Weight, kg	66 (13)	68 (12)
MBI, kg/m <sup>2</sup>	24 (4)	24 (3)
Heart rate	80 (15)	81 (15)
Respiratory rate	19 (4)	19 (4)
Medical history- n (%)		
Atrial fibrillation	1 (0.1)	6 (0.7)
History of hyperlipidaemia	10/815 (1.2)	9/826 (1.1)
Current smoker	69 (17)	73 (18)
Antihypertension drugs used in those with hypertension	508/539 (94.2)	540/572 (94.4)
Type of antihypertension -		
ACE-I or ARB	37/508 (7.3)	51/540 (9.4)
Diuretic	2/508 (0.4)	5/540 (0.9)
Calcium channel blocker	85/508 (16.7)	98/540 (18.1)
Beta-blocker	12/508 (2.4)	13/540 (2.4)
Reserpine Co	5/386 (1.3)	4/395 (1.0)
Other	386/508 (76.0)	395/540 (73.1)
Unknown	381/386 (98.7)	391/395 (99.0)
Type of antiplatelet agent		
Aspirin	31/35 (88.6)	25/29 (86.2)
Clopidogrel	8/35 (22.6)	6/299 (20.7)
Cilostazol	1/35 (2.9)	3/29 (10.3)
Blood glucose lowering agents used	24/69 (34.8)	35/73 (47.9)
Insulin	1/24 (4.2)	0/35 (0)

Data are n (%)

<sup>\*</sup>ACE-I indicates angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, TMC traditional Chinese medicine

Table S4. Additional information on the characteristics of intracerebral haemorrhage on computerised tomographic (CT) brain imaging

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N = 1641)
Hour from onset to CT scan			
n	769	780	1549
Mean (SD)	5.9 (7.5)	5.7 (6.8)	5.8 (7.1)
Median (Q1; Q3)	3.2 (1.8; 6.1)	3.2 (1.8; 6.1)	3.2 (1.8; 6.1)
min max	0 55	0 44	0 55
Haematoma volume, ml			
n	775	792	1567
Mean (SD)	24.6 (22.8)	23.2 (21.9)	23.9 (22.3)
Median (Q1; Q3)	18.0 (8.0; 35.0)	16.9 (8.1; 30.0)	17.6 (8.0; 32.0)
min max	0 182	0 181	0 182
Haematoma location			
Left	428/810 (52.8)	399/821 (48.6)	827/1631 (50.7)
Right	358/810 (44.2)	400/821 (48.7)	758/1631 (46.5)
Median	24/810 (3.0)	22/821 (2.7)	46/1631 (2.8)

Data are n (%), mean (SD) or median (IQR)

Table S5. Characteristics of participants aged <65 years

	FYTF-919	Placebo	Overall
Characteristics	(N=451)	(N=494)	(N = 945)
Age (Years)			
n	451	494	945
Mean (SD)	53.5 (7.62)	53.4 (7.78)	53.4 (7.70)
Median (Q1; Q3)	55.0 (49.0; 59.0)	55.0 (49.0; 59.0)	55.0 (49.0; 59.0)
min max	29 64	18 64	18 64
Sex			
Male	307/451 (68.1%)	355/494 (71.9%)	662/945 (70.1%)
Female	144/451 (31.9%)	139/494 (28.1%)	283/945 (29.9%)
Ethnicity			
Han	436/451 (96.7%)	479/494 (97.0%)	915/945 (96.8%)
Non-Han Minorities	15/451 (3.3%)	15/494 (3.0%)	30/945 (3.2%)
Height (cm)			
n	373	416	789
Mean (SD)	166.6 (7.52)	168.1 (7.25)	167.4 (7.41)
Median (Q1; Q3)	169.0 (160.0; 172.0)	170.0 (163.0; 174.0)	170.0 (160.0; 173.0)
min max	145 183	140 183	140 183
Weight (Kg)			
n	321	368	689
Mean (SD)	69.8 (12.50)	70.7 (11.36)	70.3 (11.91)
Median (Q1; Q3)	70.0 (60.0; 80.0)	70.0 (62.5; 79.5)	70.0 (60.5; 80.0)
min max	40 120	40 115	40 120

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N=451)	(N = 494)	(N = 945)
BMI (Kg/m2)			
n	320	367	687
Mean (SD)	24.9 (3.73)	24.9 (3.22)	24.9 (3.46)
Median (Q1; Q3)	24.8 (22.5; 26.8)	24.6 (22.8; 26.8)	24.7 (22.6; 26.8)
min max	17 46	17 36	17 46
Current smoking			
No	318/451 (70.5%)	347/493 (70.4%)	665/944 (70.4%)
Yes	133/451 (29.5%)	146/493 (29.6%)	279/944 (29.6%)
Current drinking			
No	313/451 (69.4%)	343/493 (69.6%)	656/944 (69.5%)
Yes	138/451 (30.6%)	150/493 (30.4%)	288/944 (30.5%)
SBP on arrival			
n	449	492	941
Mean (SD)	170.7 (28.79)	171.9 (28.99)	171.4 (28.88)
Median (Q1; Q3)	170.0 (150.0; 190.0)	173.0 (149.0; 191.0)	171.0 (150.0; 191.0
min max	107 265	102 245	102 265
DBP on arrival			
n	449	492	941
Mean (SD)	100.6 (18.77)	102.5 (20.70)	101.6 (19.81)
Median (Q1; Q3)	100.0 (89.0; 111.0)	101.0 (88.0; 115.0)	100.0 (89.0; 113.0)
min max	44 167	11 197	11 197

	FYTF-919	Placebo	Overall
Characteristics	(N=451)	$(\mathbf{N} = 494)$	(N=945)
Heart rate on arrival			
n	450	493	943
Mean (SD)	80.4 (15.32)	82.0 (15.84)	81.3 (15.60)
Median (Q1; Q3)	80.0 (70.0; 88.0)	80.0 (72.0; 90.0)	80.0 (70.0; 90.0)
min max	47 208	20 150	20 208
Respiratory rate on arrival			
n	441	481	922
Mean (SD)	18.9 (2.66)	19.1 (3.51)	19.0 (3.13)
Median (Q1; Q3)	19.0 (18.0; 20.0)	19.0 (18.0; 20.0)	19.0 (18.0; 20.0)
min max	10 35	10 76	10 76
Body temperature on arrival			
n	451	492	943
Mean (SD)	36.58 (0.371)	36.61 (0.368)	36.60 (0.370)
Median (Q1; Q3)	36.50 (36.30; 36.80)	36.60 (36.50; 36.80)	36.60 (36.50; 36.80)
min max	35.7 39.8	35.0 39.2	35.0 39.8
first GCS on arrival			
n	429	475	904
Mean (SD)	11.6 (2.84)	11.6 (2.95)	11.6 (2.90)
Median (Q1; Q3)	12.0 (10.0; 14.0)	12.0 (10.0; 14.0)	12.0 (10.0; 14.0)
min max	3 15	3 15	3 15

first NIHSS on arrival

	FYTF-919	Placebo	Overall (N. 1945)
Characteristics	(N = 451)	(N = 494)	(N = 945)
n	447	488	935
Mean (SD)	16.6 (8.43)	16.1 (8.00)	16.3 (8.20)
Median (Q1; Q3)	15.0 (11.0; 21.0)	15.0 (10.0; 20.0)	15.0 (10.0; 21.0)
min max	0 41	1 42	0 42
NIHSS category			
NIHSS >=15	243/447 (54.4%)	265/488 (54.3%)	508/935 (54.3%)
NIHSS < 15	204/447 (45.6%)	223/488 (45.7%)	427/935 (45.7%)
First IMP method			
Oral admission (awake, 33ml/time, tid)	205/441 (46.5%)	241/491 (49.1%)	446/932 (47.9%)
Nasogastric tube (coma, 25ml/time,	236/441 (53.5%)	250/491 (50.9%)	486/932 (52.1%)
q6h)			
Previous Hypertension	301/451 (66.7%)	335/491 (68.2%)	636/942 (67.5%)
Antihypertensive medication	278/301 (92.4%)	314/335 (93.7%)	592/636 (93.1%)
ACEI ARB	17/278 (6.1%)	29/314 (9.2%)	46/592 (7.8%)
Beta blocker	7/278 (2.5%)	9/314 (2.9%)	16/592 (2.7%)
Ca antagonist	31/278 (11.2%)	63/314 (20.1%)	94/592 (15.9%)
Diuretics	1/278 (0.4%)	2/314 (0.6%)	3/592 (0.5%)

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N=451)	$(\mathbf{N} = 494)$	(N = 945)
Other antihypertensives	227/278 (81.7%)	225/314 (71.7%)	452/592 (76.4%)
Reserpine Co	1/227 (0.4%)	0/225 (0.0%)	1/452 (0.2%)
Unknown	226/227 (99.6%)	225/225 (100.0%)	451/452 (99.8%)
Previous Diabetes	32/451 (7.1%)	46/494 (9.3%)	78/945 (8.3%)
Antidiabetic medication	10/32 (31.3%)	25/46 (54.3%)	35/78 (44.9%)
Insulin	0/10 (0.0%)	0/25 (0.0%)	0/35 (0.0%)
Biguanide	1/10 (10.0%)	1/25 (4.0%)	2/35 (5.7%)
Sulfonylurea	0/10 (0.0%)	0/25 (0.0%)	0/35 (0.0%)
Glycosidase inhibitor	1/10 (10.0%)	0/25 (0.0%)	1/35 (2.9%)
Other	8/10 (80.0%)	24/25 (96.0%)	32/35 (91.4%)
Euphridine	1/8 (12.5%)	0/24 (0.0%)	1/32 (3.1%)
Liraglutide	0/8 (0.0%)	1/24 (4.2%)	1/32 (3.1%)
Repaglinide	1/8 (12.5%)	0/24 (0.0%)	1/32 (3.1%)
Unknown	6/8 (75.0%)	23/24 (95.8%)	29/32 (90.6%)
Previous Hyperlipidemia	4/451 (0.9%)	5/494 (1.0%)	9/945 (1.0%)

	FYTF-919	Placebo	Overall
Characteristics	(N=451)	$(\mathbf{N} = 494)$	(N = 945)
Lipid lowering agent	3/4 (75.0%)	3/5 (60.0%)	6/9 (66.7%)
Statin	3/3 (100.0%)	0/3 (0.0%)	3/6 (50.0%)
Cholesterol absorption inhibitor	0/3 (0.0%)	0/3 (0.0%)	0/6 (0.0%)
PCSK9 inhibitor	0/3 (0.0%)	0/3 (0.0%)	0/6 (0.0%)
Other (All unknown)	0/3 (0.0%)	3/3 (100.0%)	3/6 (50.0%)
Previous Coronary Heart Disease	13/451 (2.9%)	11/494 (2.2%)	24/945 (2.5%)
Previous Atrial Fibrillation	0/451 (0.0%)	1/494 (0.2%)	1/945 (0.1%)
Any anticoagulant treatment	1/451 (0.2%)	1/494 (0.2%)	2/945 (0.2%)
Any antiplatelet treatment	14/451 (3.1%)	13/494 (2.6%)	27/945 (2.9%)
Aspirin	14/14 (100.0%)	12/13 (92.3%)	26/27 (96.3%)
Clopidogrel	1/14 (7.1%)	4/13 (30.8%)	5/27 (18.5%)
Other	0/14 (0.0%)	1/13 (7.7%)	1/27 (3.7%)
Total TCM score (TCM 1-5)			
n	426	466	892

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	$(\mathbf{N} = 451)$	(N=494)	(N=945)
Mean (SD)	1.1 (1.28)	1.1 (1.26)	1.1 (1.27)
Median (Q1; Q3)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)
min max	0 5	0 5	0 5
Anxiety	62/425 (14.6%)	57/466 (12.2%)	119/891 (13.4%)
Red face/T>37.5	87/425 (20.5%)	98/465 (21.1%)	185/890 (20.8%)
Dry mouth/Bad breath	108/420 (25.7%)	116/463 (25.1%)	224/883 (25.4%)
Yellow tongue coating	97/410 (23.7%)	108/456 (23.7%)	205/866 (23.7%)
Red tongue coating	132/410 (32.2%)	151/456 (33.1%)	283/866 (32.7%)
No Stool in the last 48h	131/427 (30.7%)	175/466 (37.6%)	306/893 (34.3%)

**Table S6. Characteristics of participants aged ≥65 years** 

	FYTF-919	Placebo	Overall
Characteristics	$(\mathbf{N} = 364)$	(N=332)	$(\mathbf{N} = 696)$
Age (Years)			
n	364	332	696
Mean (SD)	72.9 (6.27)	73.0 (5.88)	73.0 (6.09)
Median (Q1; Q3)	72.0 (68.0; 76.5)	72.0 (68.0; 77.0)	72.0 (68.0; 77.0)
min max	65 97	65 94	65 97
Sex			
Male	221/364 (60.7%)	196/332 (59.0%)	417/696 (59.9%)
Female	143/364 (39.3%)	136/332 (41.0%)	279/696 (40.1%)
Ethnicity			
Han	354/364 (97.3%)	318/332 (95.8%)	672/696 (96.6%)
Non-Han Minorities	10/364 (2.7%)	14/332 (4.2%)	24/696 (3.4%)
Height (cm)			
n	321	299	620
Mean (SD)	164.5 (8.24)	164.0 (8.10)	164.2 (8.17)
Median (Q1; Q3)	165.0 (158.0; 170.0)	165.0 (158.0; 170.0)	165.0 (158.0; 170.0)
min max	140 182	145 180	140 182
Weight (Kg)			
n	296	273	569
Mean (SD)	62.7 (11.62)	63.1 (11.44)	62.9 (11.53)
Median (Q1; Q3)	61.2 (55.0; 70.0)	62.0 (55.0; 70.0)	62.0 (55.0; 70.0)

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N=364)	(N=332)	(N = 696)
min max	33 90	30 95	30 95
BMI (Kg/m2)			
n	295	273	568
Mean (SD)	23.0 (3.24)	23.4 (3.41)	23.2 (3.33)
Median (Q1; Q3)	23.0 (20.8; 25.2)	23.4 (21.0; 25.5)	23.1 (20.8; 25.4)
min max	15 33	13 35	13 35
Current smoking			
No	286/364 (78.6%)	253/332 (76.2%)	539/696 (77.4%)
Yes	78/364 (21.4%)	79/332 (23.8%)	157/696 (22.6%)
Current drinking			
No	295/363 (81.3%)	266/332 (80.1%)	561/695 (80.7%)
Yes	68/363 (18.7%)	66/332 (19.9%)	134/695 (19.3%)
SBP on arrival			
n	363	332	695
Mean (SD)	172.8 (30.07)	171.7 (28.97)	172.2 (29.53)
Median (Q1; Q3)	171.0 (153.0; 191.0)	170.0 (150.0; 192.0)	170.0 (151.0; 192.0)
min max	82 257	91 261	82 261
DBP on arrival			
n	363	332	695
Mean (SD)	95.5 (18.81)	93.1 (16.59)	94.4 (17.81)
Median (Q1; Q3)	95.0 (82.0; 107.0)	92.0 (80.0; 104.0)	94.0 (81.0; 105.0)

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N=364)	(N=332)	(N = 696)
min max	42 160	54 179	42 179
Heart rate on arrival			
n	363	332	695
Mean (SD)	78.4 (14.53)	78.4 (14.29)	78.4 (14.41)
Median (Q1; Q3)	79.0 (68.0; 87.0)	79.0 (68.0; 86.0)	79.0 (68.0; 87.0)
min max	46 134	20 140	20 140
Respiratory rate on arrival			
n	358	324	682
Mean (SD)	19.6 (4.78)	19.7 (3.69)	19.6 (4.30)
Median (Q1; Q3)	20.0 (18.0; 20.0)	20.0 (18.0; 20.0)	20.0 (18.0; 20.0)
min max	12 98	12 71	12 98
Body temperature on arrival			
n	364	332	696
Mean (SD)	36.60 (0.374)	36.62 (0.444)	36.61 (0.408)
Median (Q1; Q3)	36.50 (36.40; 36.80)	36.50 (36.40; 36.80)	36.50 (36.40; 36.80)
min max	35.7 39.1	35.5 39.8	35.5 39.8
first GCS on arrival			
n	355	316	671
Mean (SD)	11.6 (2.76)	11.6 (2.95)	11.6 (2.85)
Median (Q1; Q3)	12.0 (10.0; 14.0)	12.0 (9.5; 14.0)	12.0 (10.0; 14.0)
min max	3 15	3 15	3 15

	FYTF-919	Placebo	Overall
Characteristics	(N=364)	(N=332)	$(\mathbf{N} = 696)$
first NIHSS on arrival			
n	364	330	694
Mean (SD)	15.9 (7.53)	16.5 (8.26)	16.2 (7.89)
Median (Q1; Q3)	15.5 (10.0; 20.0)	15.0 (10.0; 21.0)	15.0 (10.0; 20.0)
min max	0 42	1 40	0 42
NIHSS category			
NIHSS >=15	198/364 (54.4%)	177/330 (53.6%)	375/694 (54.0%)
NIHSS < 15	166/364 (45.6%)	153/330 (46.4%)	319/694 (46.0%)
First IMP method			
Oral admission (awake, 33ml/time, tid)	195/362 (53.9%)	162/330 (49.1%)	357/692 (51.6%)
Nasogastric tube (coma, 25ml/time,	167/362 (46.1%)	168/330 (50.9%)	335/692 (48.4%)
q6h)			
Previous Hypertension	238/362 (65.7%)	237/332 (71.4%)	475/694 (68.4%)
Antihypertensive medication	230/238 (96.6%)	226/237 (95.4%)	456/475 (96.0%)
ACEI ARB	20/230 (8.7%)	22/226 (9.7%)	42/456 (9.2%)
Beta blocker	5/230 (2.2%)	4/226 (1.8%)	9/456 (2.0%)
Ca antagonist	54/230 (23.5%)	35/226 (15.5%)	89/456 (19.5%)
Diuretics	1/230 (0.4%)	3/226 (1.3%)	4/456 (0.9%)

	FYTF-919 (N = 364)	Placebo	Overall
Characteristics		(N=332)	$(\mathbf{N} = 696)$
Other antihypertensives	159/230 (69.1%)	170/226 (75.2%)	329/456 (72.1%)
Reserpine Co	4/159 (2.5%)	4/170 (2.4%)	8/329 (2.4%)
Unknown	155/159 (97.5%)	166/170 (97.6%)	321/329 (97.6%)
Previous Diabetes	37/364 (10.2%)	27/331 (8.2%)	64/695 (9.2%)
Antidiabetic medication	14/37 (37.8%)	10/27 (37.0%)	24/64 (37.5%)
Insulin	1/14 (7.1%)	0/10 (0.0%)	1/24 (4.2%)
Biguanide	2/14 (14.3%)	1/10 (10.0%)	3/24 (12.5%)
Sulfonylurea	1/14 (7.1%)	0/10 (0.0%)	1/24 (4.2%)
Glycosidase inhibitor	1/14 (7.1%)	0/10 (0.0%)	1/24 (4.2%)
Other	12/14 (85.7%)	9/10 (90.0%)	21/24 (87.5%)
Unknown	12/12 (100.0%)	9/9 (100.0%)	21/21 (100.0%)
Previous Hyperlipidemia	6/364 (1.6%)	4/332 (1.2%)	10/696 (1.4%)
Lipid lowering agent	5/6 (83.3%)	4/4 (100.0%)	9/10 (90.0%)

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N = 364)	(N=332)	(N = 696)
Statin	2/5 (40.0%)	3/4 (75.0%)	5/9 (55.6%)
Cholesterol absorption inhibitor	0/5 (0.0%)	0/4 (0.0%)	0/9 (0.0%)
PCSK9 inhibitor	0/5 (0.0%)	0/4 (0.0%)	0/9 (0.0%)
Other (All unknown)	3/5 (60.0%)	1/4 (25.0%)	4/9 (44.4%)
Previous Coronary Heart Disease	30/364 (8.2%)	19/332 (5.7%)	49/696 (7.0%)
Previous Atrial Fibrillation	1/364 (0.3%)	5/332 (1.5%)	6/696 (0.9%)
Any anticoagular treatment	0/364 (0.0%)	2/332 (0.6%)	2/696 (0.3%)
Any antiplatelet treatment	21/364 (5.8%)	16/332 (4.8%)	37/696 (5.3%)
Aspirin	17/21 (81.0%)	13/16 (81.3%)	30/37 (81.1%)
Clopidogrel	7/21 (33.3%)	2/16 (12.5%)	9/37 (24.3%)
Other	1/21 (4.8%)	2/16 (12.5%)	3/37 (8.1%)
Total TCM score (TCM 1-5)			
n	355	322	677
Mean (SD)	1.1 (1.21)	1.1 (1.27)	1.1 (1.24)
Median (Q1; Q3)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)

FYTF-919 (N = 364)	Placebo (N - 332)	Overall (N = 696)
0 5	0 5	0 5
34/355 (9.6%)	35/322 (10.9%)	69/677 (10.2%)
69/355 (19.4%)	64/322 (19.9%)	133/677 (19.6%)
80/355 (22.5%)	81/320 (25.3%)	161/675 (23.9%)
72/350 (20.6%)	71/317 (22.4%)	143/667 (21.4%)
132/350 (37.7%)	114/316 (36.1%)	246/666 (36.9%)
106/354 (29.9%)	94/319 (29.5%)	200/673 (29.7%)
	(N = 364) 0 5 34/355 (9.6%) 69/355 (19.4%) 80/355 (22.5%) 72/350 (20.6%) 132/350 (37.7%)	(N = 364) (N = 332) 0 5 0 5 34/355 (9.6%) 35/322 (10.9%) 69/355 (19.4%) 64/322 (19.9%) 80/355 (22.5%) 81/320 (25.3%) 72/350 (20.6%) 71/317 (22.4%) 132/350 (37.7%) 114/316 (36.1%)

**Table S7. Characteristics of female participants** 

Characteristics	FYTF-919 (N = 287)	Placebo	Overall
	(N=287)	(N=275)	(N = 562)
Age (Years)	207	277	5.60
n	287	275	562
Mean (SD)	64.0 (11.35)	64.5 (11.04)	64.3 (11.19)
Median (Q1; Q3)	64.0 (56.0; 73.0)	64.0 (56.0; 72.0)	64.0 (56.0; 72.0)
min max	29 97	36 94	29 97
Ethnicity			
Han	284/287 (99.0%)	270/275 (98.2%)	554/562 (98.6%)
Non-Han Minorities	3/287 (1.0%)	5/275 (1.8%)	8/562 (1.4%)
Height (cm)			
n	241	223	464
Mean (SD)	157.9 (4.95)	158.0 (5.24)	158.0 (5.09)
Median (Q1; Q3)	158.0 (155.0; 160.0)	158.0 (155.0; 162.0)	158.0 (155.0; 160.0)
min max	140 175	145 171	140 175
Weight (Kg)			
n	210	198	408
Mean (SD)	58.4 (10.69)	60.5 (10.05)	59.4 (10.43)
Median (Q1; Q3)	57.5 (50.0; 65.0)	60.0 (55.0; 65.0)	60.0 (52.0; 65.0)
min max	33 110	30 95	30 110
BMI (Kg/m2)			
n	209	198	407
Mean (SD)	23.4 (3.99)	24.1 (3.55)	23.8 (3.80)
, ,	• /	* *	, ,

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	$(\mathbf{N}=287)$	(N=275)	(N = 562)
Median (Q1; Q3)	22.9 (20.5; 25.4)	23.9 (22.0; 26.2)	23.5 (21.2; 25.9)
min max	15 46	13 35	13 46
Current smoking			
No	278/287 (96.9%)	265/275 (96.4%)	543/562 (96.6%)
Yes	9/287 (3.1%)	10/275 (3.6%)	19/562 (3.4%)
Current drinking			
No	282/286 (98.6%)	267/275 (97.1%)	549/561 (97.9%)
Yes	4/286 (1.4%)	8/275 (2.9%)	12/561 (2.1%)
SBP on arrival			
n	287	275	562
Mean (SD)	171.1 (29.06)	171.1 (29.69)	171.1 (29.34)
Median (Q1; Q3)	171.0 (150.0; 191.0)	171.0 (150.0; 189.0)	171.0 (150.0; 190.0)
min max	82 265	91 261	82 265
DBP on arrival			
n	287	275	562
Mean (SD)	95.0 (17.53)	95.4 (18.69)	95.2 (18.09)
Median (Q1; Q3)	95.0 (84.0; 105.0)	95.0 (82.0; 106.0)	95.0 (83.0; 105.0)
min max	42 153	60 197	42 197
Heart rate on arrival			
n	287	275	562
Mean (SD)	79.3 (15.40)	81.2 (14.84)	80.2 (15.14)

	FYTF-919	Placebo	Overall
Characteristics	$(\mathbf{N}=287)$	(N=275)	(N = 562)
Median (Q1; Q3)	80.0 (69.0; 86.0)	80.0 (72.0; 89.0)	80.0 (70.0; 88.0)
min max	48 208	20 150	20 208
Respiratory rate on arrival			
n	279	271	550
Mean (SD)	18.9 (2.34)	19.6 (5.31)	19.3 (4.09)
Median (Q1; Q3)	19.0 (18.0; 20.0)	19.0 (18.0; 20.0)	19.0 (18.0; 20.0)
min max	12 28	11 76	11 76
Body temperature on arrival			
n	287	275	562
Mean (SD)	36.56 (0.402)	36.64 (0.462)	36.60 (0.433)
Median (Q1; Q3)	36.50 (36.30; 36.80)	36.60 (36.50; 36.80)	36.50 (36.40; 36.80)
min max	35.7 39.8	35.8 39.8	35.7 39.8
first GCS on arrival			
n	276	258	534
Mean (SD)	11.3 (3.04)	11.4 (3.04)	11.4 (3.04)
Median (Q1; Q3)	12.0 (9.0; 14.0)	12.0 (9.0; 14.0)	12.0 (9.0; 14.0)
min max	3 15	3 15	3 15
first NIHSS on arrival			
n	284	272	556
Mean (SD)	16.5 (8.29)	16.8 (8.68)	16.6 (8.48)
Median (Q1; Q3)	15.0 (10.0; 21.0)	15.0 (10.0; 21.0)	15.0 (10.0; 21.0)
min max	1 41	1 38	1 41

	FYTF-919	Placebo	Overall
Characteristics	(N=287)	(N=275)	(N=562)
NIHSS category			
NIHSS >=15	149/284 (52.5%)	147/272 (54.0%)	296/556 (53.2%)
NIHSS < 15	135/284 (47.5%)	125/272 (46.0%)	260/556 (46.8%)
Time from onset to arrival (hour)			
n	287	275	562
Mean (SD)	5.5 (7.00)	5.1 (5.98)	5.3 (6.52)
Median (Q1; Q3)	3.0 (1.9; 6.0)	3.1 (1.7; 5.6)	3.0 (1.9; 5.9)
min max	0 45	0 37	0 45
Time from onset to randomization (hour)			
n	287	275	562
Mean (SD)	18.3 (12.98)	17.4 (11.74)	17.9 (12.39)
Median (Q1; Q3)	15.3 (7.0; 26.8)	15.5 (7.1; 25.5)	15.4 (7.0; 26.2)
min max	2 56	1 57	1 57
Time from onset to first medicine given			
(hour)			
n	285	272	557
Mean (SD)	22.7 (14.35)	22.1 (13.45)	22.4 (13.91)
Median (Q1; Q3)	20.0 (11.0; 31.6)	20.2 (10.6; 29.8)	20.0 (10.9; 31.0)
min max	3 89	2 75	2 89
First IMP method			
Oral admission (awake, 33ml/time, tid)	139/285 (48.8%)	124/273 (45.4%)	263/558 (47.1%)

	FYTF-919	Placebo	Overall
Characteristics	$(\mathbf{N}=287)$	(N=275)	(N = 562)
Nasogastric tube (coma, 25ml/time, q6h)	146/285 (51.2%)	149/273 (54.6%)	295/558 (52.9%)
Previous Hypertension	197/287 (68.6%)	209/273 (76.6%)	406/560 (72.5%)
Antihypertensive medication	187/197 (94.9%)	197/209 (94.3%)	384/406 (94.6%)
ACEI ARB	16/187 (8.6%)	24/197 (12.2%)	40/384 (10.4%)
Beta blocker	4/187 (2.1%)	4/197 (2.0%)	8/384 (2.1%)
Ca antagonist	34/187 (18.2%)	35/197 (17.8%)	69/384 (18.0%)
Diuretics	1/187 (0.5%)	2/197 (1.0%)	3/384 (0.8%)
Other antihypertensives	140/187 (74.9%)	141/197 (71.6%)	281/384 (73.2%)
Reserpine Co	3/140 (2.1%)	2/141 (1.4%)	5/281 (1.8%)
Unknown	137/140 (97.9%)	139/141 (98.6%)	276/281 (98.2%)
Previous Diabetes	26/287 (9.1%)	29/275 (10.5%)	55/562 (9.8%)
Antidiabetic medication	10/26 (38.5%)	14/29 (48.3%)	24/55 (43.6%)
Insulin	0/10 (0.0%)	0/14 (0.0%)	0/24 (0.0%)

	FYTF-919	Placebo	Overall
Characteristics	(N = 287)	(N=275)	(N = 562)
Biguanide	1/10 (10.0%)	1/14 (7.1%)	2/24 (8.3%)
Sulfonylurea	1/10 (10.0%)	0/14 (0.0%)	1/24 (4.2%)
Glycosidase inhibitor	1/10 (10.0%)	0/14 (0.0%)	1/24 (4.2%)
Other	8/10 (80.0%)	13/14 (92.9%)	21/24 (87.5%)
Liraglutide	0/8 (0.0%)	1/13 (7.7%)	1/21 (4.8%)
Repaglinide	1/8 (12.5%)	0/13 (0.0%)	1/21 (4.8%)
Unknown	7/8 (87.5%)	12/13 (92.3%)	19/21 (90.5%)
Previous Hyperlipidemia	0/287 (0.0%)	3/275 (1.1%)	3/562 (0.5%)
Lipid lowering agent	0/0 (0.0%)	3/3 (100.0%)	3/3 (100.0%)
Statin	0/0 (0.0%)	2/3 (66.7%)	2/3 (66.7%)
Cholesterol absorption inhibitor	0/0 (0.0%)	0/3 (0.0%)	0/3 (0.0%)
PCSK9 inhibitor	0/0 (0.0%)	0/3 (0.0%)	0/3 (0.0%)
Other (All unknown)	0/0 (0.0%)	1/3 (33.3%)	1/3 (33.3%)
Previous Coronary Heart Disease	20/287 (7.0%)	20/275 (7.3%)	40/562 (7.1%)

	FYTF-919	Placebo	Overall	
Characteristics	(N=287)	(N = 275)	$(\mathbf{N} = 562)$	
Previous Atrial Fibrillation	0/287 (0.0%)	3/275 (1.1%)	3/562 (0.5%)	
Any anticoagular treatment	0/287 (0.0%)	2/275 (0.7%)	2/562 (0.4%)	
Any antiplatelet treatment	12/287 (4.2%)	11/275 (4.0%)	23/562 (4.1%)	
Aspirin	11/12 (91.7%)	9/11 (81.8%)	20/23 (87.0%)	
Clopidogrel	3/12 (25.0%)	1/11 (9.1%)	4/23 (17.4%)	
Other	0/12 (0.0%)	2/11 (18.2%)	2/23 (8.7%)	
Total TCM score (TCM 1-5)				
n	273	260	533	
Mean (SD)	0.9 (1.15)	1.0 (1.21)	1.0 (1.18)	
Median (Q1; Q3)	0.0 (0.0; 2.0)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)	
min max	0 5	0 5	0 5	
Anxiety	23/273 (8.4%)	26/260 (10.0%)	49/533 (9.2%)	
Red face/T>37.5	46/273 (16.8%)	51/260 (19.6%)	97/533 (18.2%)	
Dry mouth/Bad breath	64/273 (23.4%)	59/259 (22.8%)	123/532 (23.1%)	
Yellow tongue coating	40/265 (15.1%)	46/256 (18.0%)	86/521 (16.5%)	

Characteristics	FYTF-919 (N = 287)	Placebo (N = 275)	Overall (N = 562)
Red tongue coating	82/265 (30.9%)	81/256 (31.6%)	163/521 (31.3%)
No Stool in the last 48h	76/272 (27.9%)	88/258 (34.1%)	164/530 (30.9%)

Table S8. Characteristics of male participants

	<b>FYTF-919</b>	Placebo		
Characteristics	(N=528)	(N=551)		
Age (Years)				
n	528	551	1079	
Mean (SD)	61.2 (12.19)	59.6 (12.06)	60.4 (12.14)	
Median (Q1; Q3)	61.0 (53.5; 70.0)	59.0 (52.0; 68.0)	60.0 (53.0; 69.0)	
min max	29 97	18 90	18 97	
Ethnicity				
Han	506/528 (95.8%)	527/551 (95.6%)	1033/1079 (95.7%)	
Non-Han Minorities	22/528 (4.2%)	24/551 (4.4%)	46/1079 (4.3%)	
Height (cm)				
n	453	492	945	
Mean (SD)	169.8 (5.85)	170.1 (5.66)	170.0 (5.75)	
Median (Q1; Q3)	170.0 (167.0; 175.0)	170.0 (167.0; 175.0)	170.0 (167.0; 175.0)	
min max	145 183	140 183	140 183	
Weight (Kg)				
n	407	443	850	
Mean (SD)	70.6 (11.45)	70.6 (11.46)	70.6 (11.45)	
Median (Q1; Q3)	70.0 (62.0; 80.0)	70.0 (62.5; 80.0)	70.0 (62.0; 80.0)	
min max	40 120	35 115	35 120	
BMI (Kg/m2)				
n	406	442	848	
Mean (SD)	24.3 (3.39)	24.4 (3.31)	24.3 (3.34)	

	<b>FYTF-919</b>	Placebo	Overall	
Characteristics	(N=528)	(N=551)	(N = 1079)	
Median (Q1; Q3)	24.2 (22.1; 26.1)	24.2 (22.1; 26.4)	24.2 (22.1; 26.2)	
min max	17 42	13 36	13 42	
Current smoking				
No	326/528 (61.7%)	335/550 (60.9%)	661/1078 (61.3%)	
Yes	202/528 (38.3%)	215/550 (39.1%)	417/1078 (38.7%)	
Current drinking				
No	326/528 (61.7%)	342/550 (62.2%)	668/1078 (62.0%)	
Yes	202/528 (38.3%)	208/550 (37.8%)	410/1078 (38.0%)	
SBP on arrival				
n	525	549	1074	
Mean (SD)	172.0 (29.55)	172.2 (28.61)	172.1 (29.06)	
Median (Q1; Q3)	170.0 (150.0; 190.0)	171.0 (150.0; 192.0)	170.5 (150.0; 192.0)	
min max	106 257	102 246	102 257	
DBP on arrival				
n	525	549	1074	
Mean (SD)	100.2 (19.44)	100.3 (19.98)	100.3 (19.71)	
Median (Q1; Q3)	99.0 (88.0; 112.0)	99.0 (86.0; 112.0)	99.0 (87.0; 112.0)	
min max	44 167	11 179	11 179	
Heart rate on arrival				
n	526	550	1076	
Mean (SD)	79.6 (14.78)	80.3 (15.57)	80.0 (15.19)	

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	$(\mathbf{N}=528)$	(N=551)	(N = 1079)
Median (Q1; Q3)	80.0 (69.0; 88.0)	79.0 (70.0; 89.0)	80.0 (70.0; 88.0)
min max	46 134	40 149	40 149
Respiratory rate on arrival			
n	520	534	1054
Mean (SD)	19.3 (4.35)	19.2 (2.26)	19.3 (3.45)
Median (Q1; Q3)	19.0 (18.0; 20.0)	19.0 (18.0; 20.0)	19.0 (18.0; 20.0)
min max	10 98	10 30	10 98
Body temperature on arrival			
n	528	549	1077
Mean (SD)	36.61 (0.355)	36.61 (0.365)	36.61 (0.360)
Median (Q1; Q3)	36.60 (36.40; 36.80)	36.60 (36.50; 36.80)	36.60 (36.50; 36.80
min max	35.7 39.1	35.0 38.6	35.0 39.1
first GCS on arrival			
n	508	533	1041
Mean (SD)	11.7 (2.66)	11.7 (2.90)	11.7 (2.78)
Median (Q1; Q3)	12.0 (10.0; 14.0)	13.0 (10.0; 14.0)	12.0 (10.0; 14.0)
min max	3 15	3 15	3 15
first NIHSS on arrival			
n	527	546	1073
Mean (SD)	16.1 (7.90)	16.0 (7.79)	16.1 (7.84)
Median (Q1; Q3)	15.0 (10.0; 21.0)	15.0 (10.0; 20.0)	15.0 (10.0; 20.0)
min max	0 42	1 42	0 42

	FYTF-919	Placebo	Overall	
Characteristics	(N = 528)	(N=551)	(N = 1079)	
NIHSS category				
NIHSS >=15	292/527 (55.4%)	295/546 (54.0%)	587/1073 (54.7%)	
NIHSS < 15	235/527 (44.6%)	251/546 (46.0%)	486/1073 (45.3%)	
Time from onset to arrival (hour)				
n	528	551	1079	
Mean (SD)	5.5 (6.95)	5.0 (6.08)	5.3 (6.52)	
Median (Q1; Q3)	3.1 (2.0; 5.7)	3.0 (1.9; 5.2)	3.0 (1.9; 5.4)	
min max	0 55	0 46	0 55	
Time from onset to randomization (hour)				
n	528	551	1079	
Mean (SD)	18.2 (13.06)	18.0 (12.17)	18.1 (12.61)	
Median (Q1; Q3)	14.9 (7.5; 25.7)	15.5 (7.7; 25.5)	15.2 (7.6; 25.6)	
min max	2 81	1 69	1 81	
Time from onset to first medicine given				
(hour)				
n	520	548	1068	
Mean (SD)	23.0 (14.55)	22.3 (13.31)	22.6 (13.93)	
Median (Q1; Q3)	20.0 (11.5; 31.0)	19.9 (12.0; 29.2)	20.0 (11.8; 30.3)	
min max	2 109	2 84	2 109	
First IMP method				
Oral admission (awake, 33ml/time, tid)	261/518 (50.4%)	279/548 (50.9%)	540/1066 (50.7%)	

Characteristics	FYTF-919	Placebo	Overall (N. 1070)	
Characteristics Nasogastric tube (coma, 25ml/time, q6h)	(N = <b>528</b> ) 257/518 (49.6%)	(N = 551) 269/548 (49.1%)	(N = 1079) 526/1066 (49.3%)	
Previous Hypertension	342/526 (65.0%)	363/550 (66.0%)	705/1076 (65.5%)	
Antihypertensive medication	321/342 (93.9%)	343/363 (94.5%)	664/705 (94.2%)	
ACEI ARB	21/321 (6.5%)	27/343 (7.9%)	48/664 (7.2%)	
Beta blocker	8/321 (2.5%)	9/343 (2.6%)	17/664 (2.6%)	
Ca antagonist	51/321 (15.9%)	63/343 (18.4%)	114/664 (17.2%)	
Diuretics	1/321 (0.3%)	3/343 (0.9%)	4/664 (0.6%)	
Other antihypertensives	246/321 (76.6%)	254/343 (74.1%)	500/664 (75.3%)	
Reserpine Co Unknown	2/246 (0.8%) 244/246 (99.2%)	2/254 (0.8%) 252/254 (99.2%)	4/500 (0.8%) 496/500 (99.2%)	
Previous Diabetes	43/528 (8.1%)	44/550 (8.0%)	87/1078 (8.1%)	
Antidiabetic medication	14/43 (32.6%)	21/44 (47.7%)	35/87 (40.2%)	
Insulin	1/14 (7.1%)	0/21 (0.0%)	1/35 (2.9%)	

	FYTF-919	Placebo	Overall	
Characteristics	(N = 528)	(N = 551)	(N = 1079)	
Biguanide	2/14 (14.3%)	1/21 (4.8%)	3/35 (8.6%)	
Sulfonylurea	0/14 (0.0%)	0/21 (0.0%)	0/35 (0.0%)	
Glycosidase inhibitor	1/14 (7.1%)	0/21 (0.0%)	1/35 (2.9%)	
Other	12/14 (85.7%)	20/21 (95.2%)	32/35 (91.4%)	
Euphridine	1/12 (8.3%)	0/20 (0.0%)	1/32 (3.1%)	
Unknown	11/12 (91.7%)	20/20 (100.0%)	31/32 (96.9%)	
Previous Hyperlipidemia	10/528 (1.9%)	6/551 (1.1%)	16/1079 (1.5%)	
Lipid lowering agent	8/10 (80.0%)	4/6 (66.7%)	12/16 (75.0%)	
Statin	5/8 (62.5%)	1/4 (25.0%)	6/12 (50.0%)	
Cholesterol absorption inhibitor	0/8 (0.0%)	0/4 (0.0%) 0/12		
PCSK9 inhibitor	0/8 (0.0%)	0/4 (0.0%)	0/12 (0.0%)	
Other (All unknown)	3/8 (37.5%)	3/4 (75.0%)	6/12 (50.0%)	
Previous Coronary Heart Disease	23/528 (4.4%)	10/551 (1.8%)	33/1079 (3.1%)	
Previous Atrial Fibrillation	1/528 (0.2%)	3/551 (0.5%)	4/1079 (0.4%)	

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N = 528)	(N=551)	(N = 1079)
Any anticoagular treatment	1/528 (0.2%)	1/551 (0.2%)	2/1079 (0.2%)
Any antiplatelet treatment	23/528 (4.4%)	18/551 (3.3%)	41/1079 (3.8%)
Aspirin	20/23 (87.0%)	16/18 (88.9%)	36/41 (87.8%)
Clopidogrel	5/23 (21.7%)	5/18 (27.8%)	10/41 (24.4%)
Other	1/23 (4.3%)	1/18 (5.6%)	2/41 (4.9%)
Total TCM score (TCM 1-5)			
n	508	528	1036
Mean (SD)	1.2 (1.29)	1.2 (1.28)	1.2 (1.29)
Median (Q1; Q3)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)
min max	0 5	0 5	0 5
Anxiety	73/507 (14.4%)	66/528 (12.5%)	139/1035 (13.4%
Red face/T>37.5	110/507 (21.7%)	111/527 (21.1%)	221/1034 (21.4%
Dry mouth/Bad breath	124/502 (24.7%)	138/524 (26.3%)	262/1026 (25.5%
Yellow tongue coating	129/495 (26.1%)	133/517 (25.7%)	262/1012 (25.9%
Red tongue coating	182/495 (36.8%)	184/516 (35.7%)	366/1011 (36.2%)

Characteristics	FYTF-919 (N = 528)	Placebo (N = 551)	Overall (N = 1079)
No Stool in the last 48h	161/509 (31.6%)	181/527 (34.3%)	342/1036 (33.0%)

Table S9. Adherence to study medication

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N = 1641)
Median time to first does of study medication	20.0 (11.3-31.5)	20.0 (11.5-29.4)	20.0 (11.4-30.5)
Route of administration of first dose of study medication			
Oral	400/803 (49.8)	403/821 (49.1)	803/1624 (49.4)
Nasogastric tube	403/803 (50.2)	418/821 (50.9)	821/1624 (50.6)
<b>Duration of study treatment, days</b>			
n	804	821	1625
Mean (SD)	24.9 (10.2)	25.3 (9.2)	25.1 (9.7)
Median (Q1; Q3)	29.0 (26.0; 29.0)	29.0 (27.0; 29.0)	29.0 (27.0; 29.0)
min max	1 108	1 103	1 108
<b>Duration of study treatment by category</b>			
1 - 7 days	76/804 (9.5)	68/821 (8.3)	144/1625 (8.9)
8 - 14 days	70/804 (8.7)	56/821 (6.8)	126/1625 (7.7)
15 - 21 days	31/804 (3.9)	42/821 (5.1)	73/1625 (4.5)
22 - 28 days	177/804 (22.0)	169/821 (20.6)	346/1625 (21.3)
29 - 40 days	445/804 (55.3)	475/821 (57.9)	920/1625 (56.6)
40+ days	5/804 (0.6)	11/821 (1.3)	16/1625 (1.0)
Bottles completed			
Mean (SD)	22.8 (9.1)	23.5 (8.5)	23.2 (8.8)
Median (Q1; Q3)	28.0 (21.3; 28.0)	28.0 (25.0; 28.0)	28.0 (24.0; 28.0)
min max	0 28	0 28	0 28
Complete ≥80% of medication in all participants*	608/815 (74.6)	634/826 (76.8)	1242/1641 (75.7)
Completed study medication according to protocol in all participants†	491/815 (60.2)	503/826 (60.9)	994/1641 (60.6)
Complete ≥80% of medication in survivors	605/742 (81.5)	630/756 (83.3)	1235/1498 (82.4)

Data are n (%), mean (SD) or median (IQR), \*Finished all study medication, †Finished 28 bottles in 28 days

Table S10. Details of the management of patients with acute intracerebral haemorrhage

	<b>FYTF-919</b>	Placebo	Overall
Characteristic	(N=815)	(N=826)	(N = 1641)
ICU care			
Baseline	562/815 (69.0)	574/825 (69.6)	1136/1640 (69.3)
Follow up 1 - $24h(\pm 3h)$	470/813 (57.8)	489/825 (59.3)	959/1638 (58.5)
Follow up 2 - D7±D1	243/801 (30.3)	300/812 (36.9)	543/1613 (33.7)
Follow up 3 - D14±D2	116/749 (15.5)	147/775 (19.0)	263/1524 (17.3)
Follow up 4 - D28±D3	55/711 (7.7)	64/725 (8.8)	119/1436 (8.3)
Surgery			
Baseline	288/815 (35.3)	276/825 (33.5)	564/1640 (34.4)
Follow up 1 - $24h(\pm 3h)$	103/813 (12.7)	109/825 (13.2)	212/1638 (12.9)
Follow up 2 - D7±D1	27/801 (3.4)	25/812 (3.1)	52/1613 (3.2)
Follow up 3 - D14±D2	4/749 (0.5)	2/775 (0.3)	6/1524 (0.4)
Follow up 4 - D28±D3	2/711 (0.3)	4/725 (0.6)	6/1436 (0.4)
Tracheal intubation ± track	heotomy		
Baseline	139/815 (17.1)	150/825 (18.2)	289/1640 (17.6)
Follow up 1 - $24h(\pm 3h)$	157/813 (19.3)	166/825 (20.1)	323/1638 (19.7)
Follow up 2 - D7±D1	133/801 (16.6)	170/812 (20.9)	303/1613 (18.8)
Follow up 3 - D14±D2	73/748 (9.8)	102/775 (13.2)	175/1523 (11.5)
Follow up 4 - D28±D3	37/711 (5.2)	67/724 (9.3)	104/1435 (7.2)
Mechanical ventilation			
Baseline	125/815 (15.3)	141/825 (17.1)	266/1640 (16.2)
Follow up 1 - $24h(\pm 3h)$	131/813 (16.1)	139/825 (16.8)	270/1638 (16.5)
Follow up 2 - D7±D1	104/801 (13.0)	121/812 (14.9)	225/1613 (13.9)
Follow up 3 - D14±D2	46/748 (6.1)	61/775 (7.9)	107/1523 (7.0)
Follow up 4 - D28±D3	15/711 (2.1)	26/724 (3.6)	41/1435 (2.9)
Physical or drug hypothern	nia		
Baseline	111/815 (13.6)	109/825 (13.2)	220/1640 (13.4)
Follow up 1 - $24h(\pm 3h)$	154/813 (18.9)	175/825 (21.2)	329/1638 (20.1)
Follow up 2 - D7±D1	182/801 (22.7)	216/812 (26.6)	398/1613 (24.7)
Follow up 3 - D14±D2	101/749 (13.5)	126/775 (16.3)	227/1524 (14.9)
Follow up 4 - D28±D3	29/711 (4.1)	43/724 (5.9)	72/1435 (5.0)
Nasogastric feeding			
Baseline	396/815 (48.6)	418/825 (50.7)	814/1640 (49.6)
Follow up 1 - $24h(\pm 3h)$	439/813 (54.0)	448/825 (54.3)	887/1638 (54.2)
Follow up 2 - D7±D1	393/801 (49.1)	410/812 (50.5)	803/1613 (49.8)
Follow up 3 - D14±D2	288/749 (38.5)	310/775 (40.0)	598/1524 (39.2)
Follow up 4 - D28±D3	158/711 (22.2)	175/724 (24.2)	333/1435 (23.2)

	FYTF-919	Placebo	Overall
Characteristic	(N=815)	(N=826)	(N = 1641)
Urinary catheterisation	(14-015)	(11–020)	(11 – 1041)
Baseline	543/815 (66.6)	560/825 (67.9)	1103/1640 (67.3)
Follow up 1 - $24h(\pm 3h)$	539/813 (66.3)	554/825 (67.2)	1093/1638 (66.7)
Follow up 2 - D7±D1	463/801 (57.8)	473/812 (58.3)	936/1613 (58.0)
Follow up 3 - D14±D2	292/749 (39.0)	316/775 (40.8)	608/1524 (39.9)
Follow up 4 - D28±D3	142/711 (20.0)	163/724 (22.5)	305/1435 (21.3)
Other invasive treatment			
Baseline	80/815 (9.8)	93/825 (11.3)	173/1640 (10.5)
Follow up 1 - $24h(\pm 3h)$	77/813 (9.5)	84/825 (10.2)	161/1638 (9.8)
Follow up 2 - D7±D1	165/801 (20.6)	176/812 (21.7)	341/1613 (21.1)
Follow up 3 - D14±D2	89/749 (11.9)	119/775 (15.4)	208/1524 (13.6)
Follow up 4 - D28±D3	31/711 (4.4)	37/724 (5.1)	68/1435 (4.7)
Physical or drug hypothern	nia		
Baseline	111/815 (13.6)	109/825 (13.2)	220/1640 (13.4)
Follow up 1 - $24h(\pm 3h)$	154/813 (18.9)	175/825 (21.2)	329/1638 (20.1)
Follow up 2 - D7±D1	182/801 (22.7)	216/812 (26.6)	398/1613 (24.7)
Follow up 3 - D14±D2	101/749 (13.5)	126/775 (16.3)	227/1524 (14.9)
Follow up 4 - D28±D3	29/711 (4.1)	43/724 (5.9)	72/1435 (5.0)
Analgesia and sedation			
Baseline	317/814 (38.9)	338/824 (41.0)	655/1638 (40.0)
Follow up 1 - $24h(\pm 3h)$	299/812 (36.8)	331/825 (40.1)	630/1637 (38.5)
Follow up 2 - D7±D1	225/800 (28.1)	257/811 (31.7)	482/1611 (29.9)
Follow up 3 - D14±D2	110/748 (14.7)	131/775 (16.9)	241/1523 (15.8)
Follow up 4 - D28±D3	48/710 (6.8)	47/724 (6.5)	95/1434 (6.6)
Proton pump inhibitor use			
Baseline	594/815 (72.9)	612/825 (74.2)	1206/1640 (73.5)
Follow up 1 - $24h(\pm 3h)$	577/813 (71.0)	597/825 (72.4)	1174/1638 (71.7)
Follow up 2 - D7±D1	486/801 (60.7)	485/812 (59.7)	971/1613 (60.2)
Follow up 3 - D14±D2	279/749 (37.2)	276/775 (35.6)	555/1524 (36.4)
Follow up 4 - D28±D3	122/710 (17.2)	113/724 (15.6)	235/1434 (16.4)
Diuretic use			
Baseline	105/815 (12.9)	90/825 (10.9)	195/1640 (11.9)
Follow up 1 - $24h(\pm 3h)$	116/813 (14.3)	123/825 (14.9)	239/1638 (14.6)
Follow up 2 - D7±D1	153/801 (19.1)	176/812 (21.7)	329/1613 (20.4)
Follow up 3 - D14±D2	104/749 (13.9)	113/775 (14.6)	217/1524 (14.2)
Follow up 4 - D28±D3	32/710 (4.5)	61/724 (8.4)	93/1434 (6.5)

## Anti-epilepsy drug use

Characteristic	FYTF-919 (N=815)	Placebo (N=826)	Overall (N = 1641)
Baseline	169/815 (20.7)	170/825 (20.6)	339/1640 (20.7)
	155/813 (19.1)	, ,	· · · ·
Follow up 1 - 24h(±3h)	` '	171/825 (20.7)	326/1638 (19.9)
Follow up 2 - D7±D1	130/801 (16.2)	149/812 (18.3)	279/1613 (17.3)
Follow up 3 - D14±D2	88/749 (11.7)	100/775 (12.9)	188/1524 (12.3)
Follow up 4 - D28±D3	39/710 (5.5)	56/724 (7.7)	95/1434 (6.6)
<b>Dehydration therapy</b>			
Baseline	531/815 (65.2)	563/825 (68.2)	1094/1640 (66.7)
Follow up 1 - $24h(\pm 3h)$	547/813 (67.3)	585/825 (70.9)	1132/1638 (69.1)
Follow up 2 - D7±D1	561/801 (70.0)	565/812 (69.6)	1126/1613 (69.8)
Follow up 3 - D14±D2	379/749 (50.6)	374/775 (48.3)	753/1524 (49.4)
Follow up 4 - D28±D3	97/710 (13.7)	96/724 (13.3)	193/1434 (13.5)
BP control			
Baseline	746/815 (91.5)	737/825 (89.3)	1483/1640 (90.4)
Follow up 1 - $24h(\pm 3h)$	732/813 (90.0)	718/825 (87.0)	1450/1638 (88.5)
Follow up 2 - D7±D1	730/801 (91.1)	724/812 (89.2)	1454/1613 (90.1)
Follow up 3 - D14±D2	643/749 (85.8)	652/775 (84.1)	1295/1524 (85.0)
Follow up 4 - D28±D3	548/711 (77.1)	550/724 (76.0)	1098/1435 (76.5)
Glucose control			
Baseline	74/815 (9.1)	85/825 (10.3)	159/1640 (9.7)
Follow up 1 - 24h(±3h)	90/813 (11.1)	105/825 (12.7)	195/1638 (11.9)
Follow up 2 - D7±D1	106/801 (13.2)	114/812 (14.0)	220/1613 (13.6)
Follow up 3 - D14±D2	78/749 (10.4)	99/775 (12.8)	177/1524 (11.6)
Follow up 4 - D28±D3	65/710 (9.2)	70/724 (9.7)	135/1434 (9.4)
Use of drugs to increase BP			
Baseline	7/815 (0.9)	6/825 (0.7)	13/1640 (0.8)
Follow up 1 - 24h(±3h)	11/813 (1.4)	9/825 (1.1)	20/1638 (1.2)
Follow up 2 - D7±D1	10/801 (1.2)	10/812 (1.2)	20/1613 (1.2)
Follow up 3 - D14±D2	9/749 (1.2)	6/775 (0.8)	15/1524 (1.0)
Follow up 4 - D28±D3	3/710 (0.4)	5/725 (0.7)	8/1435 (0.6)
Antique gulation mayangal			
Anticoagulation reversal Baseline	22/915 (4.0)	21/925 (2.9)	64/1640 (2.0)
	33/815 (4.0)	31/825 (3.8)	64/1640 (3.9)
Follow up 1 - 24h(±3h)	15/813 (1.8)	18/825 (2.2)	33/1638 (2.0)
Follow up 2 - D7±D1	11/801 (1.4)	6/812 (0.7)	17/1613 (1.1)
Follow up 3 - D14±D2	8/749 (1.1)	7/775 (0.9)	15/1524 (1.0)
Follow up 4 - D28±D3	2/710 (0.3)	2/724 (0.3)	4/1434 (0.3)
Rehabilitation			
Baseline	189/815 (23.2)	196/825 (23.8)	385/1640 (23.5)

	FYTF-919	Placebo	Overall
Characteristic	(N=815)	(N=826)	(N = 1641)
Follow up 1 - 24h(±3h)	235/813 (28.9)	262/825 (31.8)	497/1638 (30.3)
Follow up 2 - D7±D1	372/801 (46.4)	390/813 (48.0)	762/1614 (47.2)
Follow up 3 - D14±D2	355/749 (47.4)	383/775 (49.4)	738/1524 (48.4)
Follow up 4 - D28±D3	251/711 (35.3)	275/725 (37.9)	526/1436 (36.6)
Acupuncture			
Baseline	72/815 (8.8)	79/825 (9.6)	151/1640 (9.2)
Follow up 1 - $24h(\pm 3h)$	105/813 (12.9)	124/825 (15.0)	229/1638 (14.0)
Follow up 2 - D7±D1	307/801 (38.3)	303/813 (37.3)	610/1614 (37.8)
Follow up 3 - D14±D2	334/749 (44.6)	332/775 (42.8)	666/1524 (43.7)
Follow up 4 - D28±D3	196/711 (27.6)	218/725 (30.1)	414/1436 (28.8)

Data are n (%)

BP denotes blood pressure, D day, ICU intensive care unit

Table S11. Clinical assessment of outcomes over time

Characteristics	FYTF-919 (N=815)	Placebo (N=826)	Overall (N=1641)
NIHSS			
Baseline			
n	811	818	1629
Mean (SD)	16.2 (8.0)	16.3 (8.1)	16.3 (8.1)
Median (Q1; Q3)	15 (10-21)	15 (10-20)	15 (10-20)
min max	0 42	1 42	0 42
Follow up 1 - 24h(±3h)			
n	778	796	1574
Mean (SD)	16.1 (8.3)	16.4 (8.6)	16.3 (8.4)
Median (Q1; Q3)	15.0 (1021)	15.0 (10-21)	15.0 (10-21)
min max	0 42	0 41	0 42
Follow up 2 - D7±D1			
n	767	776	1543
Mean (SD)	13.3 (8.3)	13.8 (8.6)	13.6 (8.5)
Median (Q1; Q3)	12 (8-18)	12 (7-19)	12 (8-18)
min max	0 42	0 40	0 42
Follow up 3 - D14±D2			
n	684	704	1388
Mean (SD)	10.9 (7.7)	11.6 (8.1)	11.3 (7.9)
Median (Q1; Q3)	10 (5-15)	10.0 (6-15)	10.0 (6-15)
min max	0 42	0 41	0 42
Follow up 4 - D28±D3			
n	544	555	1099
Mean (SD)	8.3 (7.2)	9.0 (7.5)	8.7 (7.4)
Median (Q1; Q3)	7 (3-12)	7 (4-12)	7 (3-12)
min max	0 42	0 42	0 42
GCS			
Baseline			
n	784	791	1575
Mean (SD)	11.6 (2.8)	11.6 (3.0)	11.6 (2.9)
Median (Q1; Q3)	12 (10-14)	12 (10-14)	12 (10-14)
min max	3 15	3 15	3 15
Follow up 1 - 24h(±3h)			
n	758	761	1519

Characteristics	FYTF-919 (N=815)	Placebo (N=826)	Overall (N=1641)
Mean (SD)	11.6 (3.0)	11.6 (3.1)	11.6 (3.0)
Median (Q1; Q3)	12 (10-14)	13 (9-14)	12 (10-14)
min max	2 15	3 15	2 15
Follow up 2 - D7±D1			
n	735	729	1464
Mean (SD)	12.8 (2.7)	12.7 (2.9)	12.7 (2.8)
Median (Q1; Q3)	14 (11-15)	14 (11-15)	14 (11-15)
min max	3 15	3 15	3 15
Follow up 3 - D14±D2			
n	680	686	1366
Mean (SD)	13.5 (2.3)	13.3 (2.6)	13.4 (2.5)
Median (Q1; Q3)	15 (12-15)	15 (12-15)	15 (12-15)
min max	3 15	2 15	2 15
Follow up 4 - D28±D3			
n	598	611	1209
Mean (SD)	14.1 (1.8)	14.0 (2.1)	14.1 (2.0)
Median (Q1; Q3)	15 (14-15)	15 (14-15)	15 (1415)
min max	5 15	3 15	3 15
mRS			
<b>Baseline</b> (before stroke onset)			
0: No symptoms	738/814 (90.7)	747/826 (90.4)	1485/1640 (90.5)
1: No significant disability	47/814 (5.8)	43/826 (5.2)	90/1640 (5.5)
2: Slight disability	29/814 (3.6)	36/826 (4.4)	65/1640 (4.0)
3: Moderate disability	0/814 (0.0)	0/826 (0.0)	0/1640 (0.0)
4: Moderately severe disability	0/814 (0.0)	0/826 (0.0)	0/1640 (0.0)
5: Severe disability	0/814 (0.0)	0/826 (0.0)	0/1640 (0.0)
6: Death	0/814 (0.0)	0/826 (0.0)	0/1640 (0.0)
Follow up 4 - D28±D3			
0: No symptoms	28/787 (3.6)	33/800 (4.1)	61/1587 (3.8)
1: No significant disability	126/787 (16.0)	106/800 (13.3)	232/1587 (14.6)
2: Slight disability	96/787 (12.2)	97/800 (12.1)	193/1587 (12.2)
3: Moderate disability	104/787 (13.2)	116/800 (14.5)	220/1587 (13.9)
4: Moderately severe disability	294/787 (37.4)	283/800 (35.4)	577/1587 (36.4)
5: Severe disability	66/787 (8.4)	95/800 (11.9)	161/1587 (10.1)
6: Death	73/787 (9.3%)	70/800 (8.8%)	143/1587 (9.0%)
Follow up 5 - D90±D7			
0: No symptoms	61/801 (7.6)	60/818 (7.3)	121/1619 (7.5)

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
1: No significant disability	159/801 (19.9)	158/818 (19.3)	317/1619 (19.6)
2: Slight disability	122/801 (15.2)	127/818 (15.5)	249/1619 (15.4)
3: Moderate disability	153/801 (19.1)	162/818 (19.8)	315/1619 (19.5)
4: Moderately severe disability	178/801 (22.2)	169/818 (20.7)	347/1619 (21.4)
5: Severe disability	30/801 (3.7)	49/818 (6.0)	79/1619 (4.9)
6: Death	98/801 (12.2)	93/818 (11.4)	191/1619 (11.8)
Barthel index			
Follow up 4 - D28±D3			
n	711	729	1440
Mean (SD)	56.1 (32.5)	54.1 (33.0)	55.1 (32.8)
Median (Q1; Q3)	55 (25-90)	55 (25-85)	55 (25-88)
min max	0 100	0 100	0 100
Follow up 5 - D90±D7			
n	704	728	1432
Mean (SD)	71.2 (29.2)	69.7 (29.8)	70.4 (29.5)
Median (Q1; Q3)	80 (50-100)	80.(50-95)	80 (50-100)
min max	0 100	0 100	0 100
EQ-5D-5L VAS			
Follow up 4 - D28±D3			
n	702	723	1425
Mean (SD)	63.0 (24.4)	62.4 (24.9)	62.7 (24.7)
Median (Q1; Q3)	67 (50-80)	65 (50-80)	65 (50-80)
min max	0 100	0 100	0 100
Follow up 5 - D90±D7			
n	704	728	1432
Mean (SD)	71.9 (22.3)	71.3 (22.3)	71.6 (22.3)
Median (Q1; Q3)	79 (60-90)	80 (60-90)	80 (60-90)
min max	0 100	0 100	0 100
EQ-5D-5L Utility score in survivors			
Follow up 4 - D28±D3			
n	703	721	1424
Mean (SD)	0.42 (0.42)	0.41 (0.41)	0.41 (0.41)
Median (Q1; Q3)	0.38 (0.06; 0.83)	0.36 (0.06; 0.79)	0.36 (0.06; 0.81)
min max	-0.39 1.00	-0.39 1.00	-0.39 1.00
Follow up 5 - D90±D7			
n	703	725	1428

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
Mean (SD)	0.58 (0.40)	0.58 (0.38)	0.58 (0.39)
Median (Q1; Q3)	0.73 (0.22; 0.94)	0.72 (0.22; 0.93)	0.73 (0.22; 0.93)
min max	-0.39 1.00	-0.39 1.00	-0.39 1.00
EQ-5D-5L Utility score imputing Death as zero Follow up 4 - D28±D3			
n	776	791	1567
Mean (SD)	0.38 (0.41)	0.374 (0.41)	0.38 (0.41)
Median (Q1; Q3)	0.22 (0.00; 0.78)	0.23 (0.00; 0.78)	0.22 (0.00; 0.78)
min max	-0.39 1.00	-0.39 1.00	-0.39 1.00
Follow up 5 - D90±D7			
n	801	818	1619

0.51 (0.42)

-0.39 1.00

0.52 (0.40)

 $0.62\ (0.10;\ 0.89)\quad 0.58\ (0.12;\ 0.89)\quad 0.62\ (0.11;\ 0.89)$ -0.39 1.00

0.51 (0.41)

-0.39 1.00

Data are n (%), mean (SD) or median (IQR)

Mean (SD)

min max

Median (Q1; Q3)

 $\label{eq:sigma} \textbf{Table S12. Haematoma volumes and presence of intraventricular haemorrhage over time}$ 

	FYTF-919 (N=815)	Placebo (N=826)	Overall (N = 1641)
Haematoma, ml	( )	( /	
Baseline			
n	775	792	1567
Mean (SD)	24.6 (22.76)	23.2 (21.85)	23.9 (22.31)
Median (Q1; Q3)	18.0 (8.0; 35.0)	16.9 (8.1; 30.0)	17.6 (8.0; 32.0)
min max	0 182	0 181	0 182
24 h			
n	491	513	1004
Mean (SD)	17.5 (17.19)	17.0 (15.44)	17.3 (16.31)
Median (Q1; Q3)	11.8 (5.9; 23.9)	12.0 (6.6; 22.5)	12.0 (6.1; 23.2)
min max	0 110	0 99	0 110
Day 7			
n	494	507	1001
Mean (SD)	10.8 (11.19)	10.2 (10.00)	10.5 (10.60)
Median (Q1; Q3)	7.3 (3.6; 14.5)	7.3 (4.0; 13.0)	7.3 (4.0; 13.8)
min max	0 78	0 78	0 78
Day 14			
n	297	313	610
Mean (SD)	7.0 (13.62)	5.6 (6.75)	6.3 (10.68)
Median (Q1; Q3)	4.0 (1.5; 8.3)	3.0 (1.2; 7.4)	3.5 (1.4; 7.9)
min max	0 191	0 41	0 191
Intraventricular haemorrhage			
Baseline			
No	450/809 (55.6)	489/821 (59.6)	939/1630 (57.6)
Yes	359/809 (44.4)	332/821 (40.4)	691/1630 (42.4)
24 h			
No	320/625 (51.2)	369/645 (57.2)	689/1270 (54.3)
Yes	305/625 (48.8)	276/645 (42.8)	581/1270 (45.7)
Day 7			
No	413/695 (59.4)	442/704 (62.8)	855/1399 (61.1)
Yes	282/695 (40.6)	262/704 (37.2)	544/1399 (38.9)
Day14			
No	358/499 (71.7)	392/527 (74.4)	750/1026 (73.1)
Yes	141/499 (28.3)	135/527 (25.6)	276/1026 (26.9)

Data are n (%), mean (SD) or median (IQR)

Table S13. Method of assessment of the 90 day outcome

	FYTF-919	Placebo	Overall
Method	(N=815)	(N=826)	(N = 1641)
Outpatient clinic	40/724 (5.5)	29/742 (3.9)	69/1466 (4.7)
Home visit	10/724 (1.4)	9/742 (1.2)	19/1466 (1.3)
Remote	666/724 (92.0)	688/742 (92.7)	1354/1466 (92.4)
Other	8/724 (1.1)	16/742 (2.2)	24/1466 (1.6)

Table S14. Descriptive analysis of EQ-5D-5L at Day 90

	<b>FYTF-919</b>	Placebo	Overall
Outcome	(N=815)	(N=826)	(N=1641)
Mobility			
1: I have no problems with walking about	237/704 (33.7)	244/729 (33.5)	481/1433 (33.6)
2: I have slight problems with walking about	158/704 (22.4)	167/729 (22.9)	325/1433 (22.7)
3: I have moderate problems with walking about	96/704 (13.6)	108/729 (14.8)	204/1433 (14.2)
4: I have severe problems with walking about	66/704 (9.4)	65/729 (8.9)	131/1433 (9.1)
5: I am unable to walk about	147/704 (20.9)	145/729 (19.9)	292/1433 (20.4)
Self care			
1: I have no problems with washing or dressing myself	230/704 (32.7)	238/729 (32.6)	468/1433 (32.7)
2: I have slight problems with washing or dressing myself	147/704 (20.9)	134/729 (18.4)	281/1433 (19.6)
3: I have moderate problems with washing or dressing myself	101/704 (14.3)	113/729 (15.5)	214/1433 (14.9)
4: I have severe problems with washing or dressing myself	79/704 (11.2)	83/729 (11.4)	162/1433 (11.3)
5: I am unable to wash or dress myself	147/704 (20.9)	161/729 (22.1)	308/1433 (21.5)
Usual activities			
1: I have no problems doing my usual activities	214/704 (30.4)	222/729 (30.5)	436/1433 (30.4)
2: I have slight problems doing my usual activities	174/704 (24.7)	158/729 (21.7)	332/1433 (23.2)
3: I have moderate problems doing my usual activities	110/704 (15.6)	131/729 (18.0)	241/1433 (16.8)
4: I have severe problems doing my usual activities	95/704 (13.5)	102/729 (14.0)	197/1433 (13.7)
5: I am unable to do my usual activities	111/704 (15.8)	116/729 (15.9)	227/1433 (15.8)
Pain / discomfort			
1: I have no pain of discomfort	375/704 (53.3)	393/729 (53.9)	768/1433 (53.6)
2: I have slight pain of discomfort	231/704 (32.8)	240/729 (32.9)	471/1433 (32.9)

	FYTF-919	Placebo	Overall
Outcome	(N=815)	(N=826)	(N=1641)
3: I have moderate pain of discomfort	62/704 (8.8)	52/729 (7.1)	114/1433 (8.0)
4: I have severe pain of discomfort	13/704 (1.8)	26/729 (3.6)	39/1433 (2.7)
5: I am extreme pain of discomfort	23/704 (3.3)	18/729 (2.5)	41/1433 (2.9)
Anxiety / depression			
1: I am not anxious or depressed	339/704 (48.2)	355/729 (48.7)	694/1433 (48.4)
2: I am slightly anxious or depressed	245/704 (34.8)	242/729 (33.2)	487/1433 (34.0)
3: I am moderately anxious or depressed	74/704 (10.5)	93/729 (12.8)	167/1433 (11.7)
4: I am severely anxious or depressed	23/704 (3.3)	24/729 (3.3)	47/1433 (3.3)
5: I am extremely anxious or depressed	23/704 (3.3)	15/729 (2.1)	38/1433 (2.7)
VAS 0-100*			
n	704	728	1432
Mean (SD)	71.9 (22.31)	71.3 (22.28)	71.6 (22.29)
Median (Q1; Q3)	79.0 (60.0; 90.0)	80.0 (60.0; 90.0)	80.0 (60.0; 90.0)
min max	0 100	0 100	0 100

Data are n (%), mean (SD) or median (IQR)

<sup>\*</sup>VAS denotes visual analogue scale

Table S15. Description of the clinical outcomes at 28 and 90 days  $\!\!\!^*$ 

	FYTF-919	Placebo	Overall
	(N=815)	(N=826)	(N=1641)
Utility weighted mRS at Day 90			
n	801	818	1619
Mean (SD)	0.50 (0.35)	0.50 (0.36)	0.50 (0.36)
Median (Q1; Q3)	0.55 (0.20; 0.88)	0.55 (0.20; 0.88)	0.55 (0.20; 0.88)
min max	-0.19 0.97	-0.19 0.97	-0.19 0.97
Death or disability (mRS 4-6) at Day 28	433/787 (55.0)	448/800 (56.0)	881/1587 (55.5)
Death or disability (mRS 4-6) at Day 90	306/801 (38.2)	311/818 (38.0)	617/1619 (38.1)
Death at Day 28	73/815 (9.0)	70/825 (8.5)	143/1640 (8.7)
Death at Day 90	98/815 (12.0)	93/826 (11.3)	191/1641 (11.6)
Disability (mRS 4-5) at Day 28	360/787 (45.7)	378/800 (47.3)	738/1587 (46.5)
Disability (mRS 4-5) at Day 90	208/801 (26.0)	218/818 (26.7)	426/1619 (26.3)
Stroke associated pneumonia (SAP)	31/764 (4.1)	30/779 (3.9)	61/1543 (4.0)
Hospital discharge by Day 28	610/751 (81.2)	627/775 (8039)	1237/1526 (81.1)
Hospital discharge alive by Day 28 and remain alive within 7 days	607/748 (81.1)	624/772 (80.8)	1231/1520 (81.0)

Data are n (%), mean (SD) or median (IQR) mRS indicates modified Rankin scale

Table S16. Sensitivity analysis of the primary outcome and analysis of the secondary outcomes at 28, 90 and 180 days

		Primary model (1)			Adjusted model (2)	
Outcome	<b>N</b> *	OR/MD (95%CI)**	p value	N*	OR/MD (95%CI)**	p value
Primary Outcome						
uwMRS Day 90	1577	0.008 (-0.02, 0.04)	0.63	1576	0.015 (-0.02, 0.04)	0.33
uwMRS Day 90 - sensitivity 1	1577	0.004 (-0.03, 0.04)	0.80			
uwMRS Day 90 - sensitivity 2	1397	0.005 (-0.03, 0.04)	0.78			
uwMRS Day 90 - sensitivity 3	1577	0.004 (-0.03, 0.04)	0.80			
Secondary Outcomes						
uwMRS Day 180	1596	-0.003 (-0.03, 0.03)	0.88	1595	0.005 (-0.03, 0.04)	0.75
Ordinal mRS Day 28**	1551	0.89 (0.74, 1.06)	0.20	1550	0.86 (0.72, 1.03)	0.10
Ordinal mRS Day 90**	1577	1.00 (0.84, 1.20)	0.97	1576	0.97 (0.81, 1.15)	0.71
Ordinal mRS Day 180**	1596	1.01 (0.85, 1.20)	0.91	1595	0.98 (0.82, 1.16)	0.78
Death or disability - mRS [4-6] Day 28**	1551	0.94 (0.74, 1.19)	0.61	1550	0.91 (0.72, 1.15)	0.44
Death or disability - mRS [4-6] Day 90**	1577	1.01 (0.80, 1.26)	0.97	1576	0.94 (0.75, 1.19)	0.63
Death or disability – mRS [4-6] Day 180**	1596	1.04 (0.83, 1.31)	0.73	1595	0.97 (0.76, 1.24)	0.80
Death Day 28**	1597	1.03 (0.71, 1.48)	0.88	1596	0.95 (0.65, 1.39)	0.80
Death Day 90**	1597	1.06 (0.77, 1.46)	0.74	1596	0.98 (0.70, 1.38)	0.91
Death Day 180**	1597	1.02 (0.76, 1.38)	0.89	1596	0.95 (0.69, 1.30)	0.75
Disability - mRS [4-5] Day 28**	1551	0.93 (0.74, 1.16)	0.51	1550	0.92 (0.74, 1.16)	0.49
Disability - mRS [4-5] Day 90**	1577	0.97 (0.76, 1.23)	0.78	1576	0.95 (0.75, 1.21)	0.69
Disability – mRS [4-5] Day 180**	1596	1.03 (0.79, 1.35)	0.81	1595	1.01 (0.77, 1.33)	0.93
NIHSS Day 1	1541	-0.26 (-0.83, 0.31)	0.37	1540	-0.28 (-0.85, 0.29)	0.34

		Primary model (1)			Adjusted model (2)	)
Outcome	<b>N</b> *	OR/MD (95%CI)**	p value	N*	OR/MD (95%CI)**	p value
NIHSS Day 7	1509	-0.54 (-1.21, 0.14)	0.12	1508	-0.59 (-1.26, 0.09)	0.09
Barthel Index Day 28	1411	1.74 (-0.17, 4.66)	0.24	1410	2.11 (-0.80, 5.01)	0.15
Barthel Index Day 90	1396	0.76 (-2.01, 3.53)	0.59	1395	1.28 (-1.43, 4.00)	0.35
Bathel Index Day 180	1382	-0.33 (-2.91, 2.26)	0.80	1381	0.21 (-2.28, 2.70)	0.87
EQ-5D-5L VAS in survivors Day 28	1321	0.15 (-2.10, 2.41)	0.89	1320	0.32 (-1.93, 2.58)	0.78
EQ-5D-5L VAS in survivors Day 90	1363	-0.55 (-2.60, 1.51)	0.60	1362	-0.34 (-2.39, 1.71)	0.75
EQ5D5L VAS in survivors Day 180	1378	-0.91 (-2.96, 1.15)	0.39	1377	-0.70 (-2.74, 1.34)	0.50
EQ-5D-5L Utility score in survivors Day 28	1323	0.00 (-0.03, 0.04)	0.88	1322	0.01 (-0.03, 0.04)	0.77
EQ-5D-5L Utility score in survivors Day 90	1363	-0.01 (-0.05, 0.02)	0.46	1362	-0.01 (-0.04, 0.03)	0.67
EQ5D5L Utility score in survivors Day 180	1378	-0.02 (-0.05, 0.02)	0.38	1377	-0.01 (-0.04, 0.02)	0.57
EQ-5D-5L VAS Day 28 (impute death = 0)	1532	0.22 (-2.40, 2.84)	0.87	1531	0.61 (-1.99, 3.20)	0.65
EQ-5D-5L VAS Day 90 (impute death = $0$ )	1576	-0.39 (-3.17, 2.38)	0.78	1575	0.13 (-2.57, 2.83)	0.93
EQ5D5L VAS Day 180 (impute death = 0)	1596	-0.59 (-3.52, 2.33)	0.69	1595	-0.06 (-2.88, 2.77)	0.97
EQ-5D-5L Utility score Day 28 (impute death = 0)	1536	0.01 (-0.03, 0.04)	0.68	1535	0.01 (-0.02, 0.05)	0.54
EQ-5D-5L Utility score Day 90 (impute death = 0)	1577	-0.00 (-0.04, 0.03)	0.71	1576	0.00 (-0.03, 0.04)	0.98
EQ5D5L Utility score Day 180 (impute death = 0)	1596	-0.01 (-0.05, 0.03)	0.59	1595	-0.00 (-0.04, 0.03)	0.91
Any pneumonia	1500	1.04 (0.560 1.80)	0.90	1500	1.02 (0.58, 1.78)	0.95

EQ-5D-5L denoted EuroQol health-related quality of life questionnaire, mRS modified Rankin scale, NIHSS National Institutes of Health Stroke Scale, uw-mRS utility weighted modified Rankin scale, VAS visual analogue scale

Table S17. Outcomes in younger participants (age <65 years)

### a. Adherence to study medication

	FYTF-919	Placebo	Overall
Characteristics	(N=451)	$(\mathbf{N} = 494)$	(N = 945)
Duration of study treatment (Days)			
n	443	491	934
Mean (SD)	26.0 (10.11)	25.6 (8.35)	25.8 (9.23)
Median (Q1; Q3)	29.0 (28.0; 29.0)	29.0 (28.0; 29.0)	29.0 (28.0; 29.0)
min max	1 108	1 58	1 108
Duration of study treatment by category			
1 - 7 days	32/443 (7.2%)	34/491 (6.9%)	66/934 (7.1%)
8 - 14 days	29/443 (6.5%)	33/491 (6.7%)	62/934 (6.6%)
15 - 21 days	16/443 (3.6%)	23/491 (4.7%)	39/934 (4.2%)
22 - 28 days	104/443 (23.5%)	106/491 (21.6%)	210/934 (22.5%)
29 - 40 days	258/443 (58.2%)	290/491 (59.1%)	548/934 (58.7%)
40+ days	4/443 (0.9%)	5/491 (1.0%)	9/934 (1.0%)
Bottles completed			
n	451	494	945
Mean (SD)	23.7 (8.55)	23.9 (8.17)	23.8 (8.35)
Median (Q1; Q3)	28.0 (26.3; 28.0)	28.0 (27.0; 28.0)	28.0 (27.0; 28.0)
min max	0 28	0 28	0 28
Complete ≥80% of medication	355/451 (78.7%)	392/494 (79.4%)	747/945 (79.0%)
Complete study medication following protocol <sup>1</sup>	281/451 (62.3%)	315/494 (63.8%)	596/945 (63.1%)

	FYTF-919	Placebo	Overall
Characteristics	(N = 451)	(N = 494)	(N = 945)

### **b.** Clinical outcomes

FYTF-919 (N - 451)	<b>Placebo</b> (N - 494)	Overall (N = 945)
(14 – 431)	(11 – 424)	(11 – 743)
440	489	929
0.554 (0.3344)	0.561 (0.3343)	0.558 (0.3342)
0.550 (0.200; 0.880)	0.550 (0.200; 0.880)	0.550 (0.200; 0.880)
-0.19 0.97	-0.19 0.97	-0.19 0.97
240/433 (55.4%)	242/475 (50.9%)	482/908 (53.1%)
141/440 (32.0%)	148/489 (30.3%)	289/929 (31.1%)
29/451 (6.4%)	24/494 (4.9%)	53/945 (5.6%)
34/451 (7.5%)	28/494 (5.7%)	62/945 (6.6%)
211/433 (48.7%)	218/475 (45.9%)	429/908 (47.2%)
107/440 (24.3%)	120/489 (24.5%)	227/929 (24.4%)
18/429 (4.2%)	20/476 (4.2%)	38/905 (4.2%)
360/418 (86.1%)	393/470 (83.6%)	753/888 (84.8%)
	(N = 451)  440 0.554 (0.3344) 0.550 (0.200; 0.880) -0.19 0.97  240/433 (55.4%) 141/440 (32.0%)  29/451 (6.4%) 34/451 (7.5%)  211/433 (48.7%) 107/440 (24.3%)  18/429 (4.2%)	(N = 451)       (N = 494)         440       489         0.554 (0.3344)       0.561 (0.3343)         0.550 (0.200; 0.880)       0.550 (0.200; 0.880)         -0.19 0.97       -0.19 0.97         240/433 (55.4%)       242/475 (50.9%)         141/440 (32.0%)       148/489 (30.3%)         29/451 (6.4%)       24/494 (4.9%)         34/451 (7.5%)       28/494 (5.7%)         211/433 (48.7%)       218/475 (45.9%)         107/440 (24.3%)       120/489 (24.5%)         18/429 (4.2%)       20/476 (4.2%)

Table S18. Outcomes in older participants (age ≥65 years)

	FYTF-919	Placebo	Overall
Characteristics	(N=364)	(N=332)	(N = 696)
<b>Duration of study treatment (Days)</b>			
n	361	330	491
Mean (SD)	23.5 (10.07)	24.9 (10.39)	24.1 (10.24)
Median (Q1; Q3)	29.0 (17.0; 29.0)	29.0 (25.0; 29.0)	29.0 (21.0; 29.0)
min max	1 80	1 103	1 103
Duration of study treatment by category			
1 - 7 days	44/361 (12.2%)	34/330 (10.3%)	79/691 (11.3%)
8 - 14 days	41/361 (11.4%)	23/330 (7.0%)	64/691 (9.3%)
15 - 21 days	15/361 (4.2%)	19/330 (5.8%)	34/691 (4.9%)
22 - 28 days	73/361 (20.2%)	63/330 (19.1%)	136/691 (19.7%)
29 - 40 days	187/361 (51.8%)	185/330 (56.1%)	372/691 (53.8%)
40+ days	1/361 (0.3%)	6/330 (1.8%)	7/691 (1.0%)
Bottles completed			
n	364	332	696
Mean (SD)	21.8 (9.64)	22.8 (8.96)	22.3 (9.33)
Median (Q1; Q3)	28.0 (14.0; 28.0)	28.0 (20.6; 28.0)	28.0 (17.0; 28.0)
min max	0 28	0 28	0 28
Complete ≥80% of medication	253/364 (69.5%)	242/332 (72.9%)	495/696 (71.1%)
Complete study medication following protocol <sup>1</sup>	210/364 (57.7%)	188/332 (56.6%)	398/696 (57.2%)

#### c. Clinical outcome

<b>FYTF-919</b>	Placebo	Overall
(N=364)	(N=332)	(N = 696)
361	329	690
0.442 (0.3614)	0.396 (0.3731)	0.420 (0.3675)
0.550 (0.200; 0.740)	0.550 (0.000; 0.740)	0.550 (0.000; 0.740)
-0.19 0.97	-0.19 0.97	-0.19 0.97
193/354 (54.5%)	206/325 (63.4%)	399/679 (58.8%)
165/361 (45.7%)	163/329 (49.5%)	328/690 (47.5%)
44/364 (12.1%)	46/332 (13.9%)	90/696 (12.9%)
64/364 (17.6%)	65/332 (19.6%)	129/696 (18.5%)
149/354 (42.1%)	160/325 (49.2%)	309/679 (45.5%)
101/361 (28.0%)	98/329 (29.8%)	199/690 (28.8%)
13/335 (3.9%)	10/303 (3.3%)	23/638 (3.6%)
250/333 (75.1%)	234/305 (76.7%)	484/638 (75.9%)
	361 0.442 (0.3614) 0.550 (0.200; 0.740) -0.19 0.97 193/354 (54.5%) 165/361 (45.7%) 44/364 (12.1%) 64/364 (17.6%) 149/354 (42.1%) 101/361 (28.0%) 13/335 (3.9%)	(N = 364)       (N = 332)         361       329         0.442 (0.3614)       0.396 (0.3731)         0.550 (0.200; 0.740)       0.550 (0.000; 0.740)         -0.19 0.97       -0.19 0.97         193/354 (54.5%)       206/325 (63.4%)         165/361 (45.7%)       163/329 (49.5%)         44/364 (12.1%)       46/332 (13.9%)         64/364 (17.6%)       65/332 (19.6%)         149/354 (42.1%)       160/325 (49.2%)         101/361 (28.0%)       98/329 (29.8%)         13/335 (3.9%)       10/303 (3.3%)

 $\ \, \textbf{Table S19. Outcomes in female participants} \\$ 

# A Adherence to study medication

Characteristics	FYTF-919	Placebo	Overall (N. 562)	
	(N=287)	(N=275)	(N = 562)	
Duration of study treatment (Days)	20.4	272	5.50	
n	284	273	557	
Mean (SD)	25.8 (9.86)	24.9 (9.24)	25.4 (9.56)	
Median (Q1; Q3)	29.0 (28.0; 29.0)	29.0 (27.0; 29.0)	29.0 (28.0; 29.0)	
min max	1 100	1 50	1 100	
Duration of study treatment by category				
1 - 7 days	21/284 (7.4%)	25/273 (9.2%)	46/557 (8.3%)	
8 - 14 days	21/284 (7.4%)	22/273 (8.1%)	43/557 (7.7%)	
15 - 21 days	8/284 (2.8%)	14/273 (5.1%)	22/557 (3.9%)	
22 - 28 days	60/284 (21.1%)	52/273 (19.0%)	112/557 (20.1%)	
29 - 40 days	172/284 (60.6%)	156/273 (57.1%)	328/557 (58.9%)	
40+ days	2/284 (0.7%)	4/273 (1.5%)	6/557 (1.1%)	
Bottles completed				
n	287	275	562	
Mean (SD)	23.7 (8.31)	23.0 (8.98)	23.4 (8.65)	
Median (Q1; Q3)	28.0 (26.0; 28.0)	28.0 (21.7; 28.0)	28.0 (25.0; 28.0)	
min max	0 28	0 28	0 28	
Complete ≥80% of medication	224/287 (78.0%)	205/275 (74.5%)	429/562 (76.3%)	
Complete study medication following protocol <sup>1</sup>	189/287 (65.9%)	170/275 (61.8%)	359/562 (63.9%)	

	FYTF-919	Placebo	Overall
Characteristics	(N = 287)	(N = 275)	(N=562)

#### d. Clinical outcomes

	FYTF-919	Placebo	Overall
	(N=287)	(N=275)	(N=562)
Utility weighted mRS at Day 90			
n	283	273	556
Mean (SD)	0.479 (0.3575)	0.457 (0.3637)	0.468 (0.3604)
Median (Q1; Q3)	0.550 (0.200; 0.880)	0.550 (0.200; 0.740)	0.550 (0.200; 0.810)
min max	-0.19 0.97	-0.19 0.97	-0.19 0.97
Death or disability (mRS 4-6) at Day 28	160/277 (57.8%)	154/264 (58.3%)	314/541 (58.0%)
Death or disability (mRS 4-6) at Day 90	120/283 (42.4%)	115/273 (42.1%)	235/556 (42.3%)
Death at Day 28	22/287 (7.7%)	24/275 (8.7%)	46/562 (8.2%)
Death at Day 90	33/287 (11.5%)	32/275 (11.6%)	65/562 (11.6%)
Disability (mRS 4-5) at Day 28	138/277 (49.8%)	130/264 (49.2%)	268/541 (49.5%)
Disability (mRS 4-5) at Day 90	87/283 (30.7%)	83/273 (30.4%)	170/556 (30.6%)
Stroke associated pneumonia (SAP)	7/266 (2.6%)	7/266 (2.6%)	14/532 (2.6%)
Hospital discharge by Day 28	210/269 (78.1%)	211/259 (81.5%)	421/528 (79.7%)

Table S20. Outcomes in male participants

## **b.** Adherence to study medication

	FYTF-919	Placebo	Overall	
Characteristics	(N=528)	(N=551)	(N = 1079)	
Duration of study treatment (Days)				
n	520	548	1068	
Mean (SD)	24.3 (10.30)	25.5 (9.22)	24.9 (9.78)	
Median (Q1; Q3)	29.0 (22.5; 29.0)	29.0 (28.0; 29.0)	29.0 (26.5; 29.0)	
min max	1 108	1 103	1 108	
Duration of study treatment by category				
1 - 7 days	55/520 (10.6%)	43/548 (7.8%)	98/1068 (9.2%)	
8 - 14 days	49/520 (9.4%)	34/548 (6.2%)	83/1068 (7.8%)	
15 - 21 days	23/520 (4.4%)	28/548 (5.1%)	51/1068 (4.8%)	
22 - 28 days	117/520 (22.5%)	117/548 (21.4%)	234/1068 (21.9%)	
29 - 40 days	273/520 (52.5%)	319/548 (58.2%)	592/1068 (55.4%)	
40+ days	3/520 (0.6%)	7/548 (1.3%)	10/1068 (0.9%)	
Bottles completed				
n	528	551	1079	
Mean (SD)	22.3 (9.46)	23.7 (8.26)	23.0 (8.89)	
Median (Q1; Q3)	28.0 (18.0; 28.0)	28.0 (26.0; 28.0)	28.0 (23.0; 28.0)	
min max	0 28	0 28	0 28	
Complete ≥80% of medication	384/528 (72.7%)	429/551 (77.9%)	813/1079 (75.3%)	
Complete study medication following protocol <sup>1</sup>	302/528 (57.2%)	333/551 (60.4%)	635/1079 (58.9%)	

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N = 528)	(N = 551)	(N = 1079)

#### **b.** Clinical outcomes

	<b>FYTF-919</b>	Placebo	Overall
	(N=528)	(N=551)	(N = 1079)
Utility weighted mRS at Day 90			
n	518	545	1063
Mean (SD)	0.517 (0.3472)	0.514 (0.3561)	0.515 (0.3516)
Median (Q1; Q3)	0.550 (0.200; 0.880)	0.550 (0.200; 0.880)	0.550 (0.200; 0.880)
min max	-0.19 0.97	-0.19 0.97	-0.19 0.97
Death or disability (mRS 4-6) at Day 28	273/510 (53.5%)	294/536 (54.9%)	567/1046 (54.2%)
Death or disability (mRS 4-6) at Day 90	186/518 (35.9%)	196/545 (36.0%)	382/1063 (35.9%)
Death at Day 28	51/528 (9.7%)	46/550 (8.4%)	97/1078 (9.0%)
Death at Day 90	65/528 (12.3%)	61/551 (11.1%)	126/1079 (11.7%)
Disability (mRS 4-5) at Day 28	222/510 (43.5%)	248/536 (46.3%)	470/1046 (44.9%)
Disability (mRS 4-5) at Day 90	121/518 (23.4%)	135/545 (24.8%)	256/1063 (24.1%)
Stroke associated pneumonia (SAP)	24/498 (4.8%)	23/513 (4.5%)	47/1011 (4.6%)
Hospital discharge by Day 28	400/482 (83.0%)	415/515 (80.6%)	815/997 (81.7%)

Table S21. Per-protocol dataset of baseline characteristics

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
Age (Years)			
n	769	777	1546
Mean (SD)	62.3 (11.95)	61.4 (11.86)	61.8 (11.91)
Median (Q1; Q3)	62.0 (54.0; 71.0)	61.0 (53.0; 70.0)	62.0 (54.0; 71.0)
min max	29 97	18 94	18 97
Sex			
Male	495/769 (64.4%)	519/777 (66.8%)	1014/1546 (65.6%)
Female	274/769 (35.6%)	258/777 (33.2%)	532/1546 (34.4%)
Ethnicity			
Han	744/769 (96.7%)	748/777 (96.3%)	1492/1546 (96.5%)
Non-Han Minorities	25/769 (3.3%)	29/777 (3.7%)	54/1546 (3.5%)
Height (cm)			
n	657	668	1325
Mean (SD)	165.6 (7.94)	166.4 (7.86)	166.0 (7.91)
Median (Q1; Q3)	167.0 (160.0; 172.0)	168.0 (160.0; 172.0)	168.0 (160.0; 172.0)
min max	140 183	140 183	140 183
Weight (Kg)			
n	585	603	1188
Mean (SD)	66.5 (12.63)	67.4 (12.03)	66.9 (12.33)
Median (Q1; Q3)	65.0 (58.0; 75.0)	66.0 (60.0; 75.0)	65.0 (60.0; 75.0)
	` ' '	, , ,	` ' '

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
min max	33 120	30 115	30 120
BMI (Kg/m2)			
n	583	602	1185
Mean (SD)	24.0 (3.64)	24.2 (3.39)	24.1 (3.51)
Median (Q1; Q3)	24.0 (21.5; 26.0)	24.2 (22.0; 26.3)	24.1 (21.7; 26.1)
min max	15 46	13 36	13 46
Current smoking			
No	569/769 (74.0%)	560/776 (72.2%)	1129/1545 (73.1%)
Yes	200/769 (26.0%)	216/776 (27.8%)	416/1545 (26.9%)
Current drinking			
No	570/768 (74.2%)	572/776 (73.7%)	1142/1544 (74.0%)
Yes	198/768 (25.8%)	204/776 (26.3%)	402/1544 (26.0%)
SBP on arrival			
n	766	775	1541
Mean (SD)	171.6 (28.90)	171.2 (28.82)	171.4 (28.85)
Median (Q1; Q3)	170.0 (150.0; 190.0)	171.0 (150.0; 190.0)	171.0 (150.0; 190.0)
min max	82 265	91 261	82 265
DBP on arrival			
n	766	775	1541
Mean (SD)	98.1 (18.72)	98.5 (19.68)	98.3 (19.20)
Median (Q1; Q3)	98.0 (86.0; 110.0)	98.0 (85.0; 110.0)	98.0 (85.0; 110.0)

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
min max	42 167	11 197	11 197
Heart rate on arrival			
n	768	776	1544
Mean (SD)	79.5 (15.10)	80.4 (14.96)	79.9 (15.03)
Median (Q1; Q3)	80.0 (69.0; 88.0)	80.0 (70.0; 88.5)	80.0 (70.0; 88.0)
min max	46 208	20 140	20 208
Respiratory rate on arrival			
n	755	757	1512
Mean (SD)	19.2 (3.85)	19.3 (3.65)	19.3 (3.75)
Median (Q1; Q3)	19.0 (18.0; 20.0)	19.0 (18.0; 20.0)	19.0 (18.0; 20.0)
min max	10 98	10 76	10 98
Body temperature on arrival			
n	769	776	1545
Mean (SD)	36.59 (0.355)	36.62 (0.406)	36.61 (0.381)
Median (Q1; Q3)	36.50 (36.40; 36.80)	36.60 (36.50; 36.80)	36.60 (36.40; 36.80)
min max	35.7 39.1	35.0 39.8	35.0 39.8
first GCS on arrival			
n	741	742	1483
Mean (SD)	11.6 (2.81)	11.7 (2.88)	11.6 (2.85)
Median (Q1; Q3)	12.0 (10.0; 14.0)	12.0 (10.0; 14.0)	12.0 (10.0; 14.0)
min max	3 15	3 15	3 15

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
first NIHSS on arrival			
n	765	769	1534
Mean (SD)	16.2 (7.98)	16.2 (8.05)	16.2 (8.01)
Median (Q1; Q3)	15.0 (10.0; 21.0)	15.0 (10.0; 20.0)	15.0 (10.0; 20.0)
min max	0 42	1 42	0 42
NIHSS category			
NIHSS >=15	415/765 (54.2%)	416/769 (54.1%)	831/1534 (54.2%)
NIHSS < 15	350/765 (45.8%)	353/769 (45.9%)	703/1534 (45.8%)
Time from onset to arrival (hour)			
n	769	777	1546
Mean (SD)	5.5 (6.64)	5.1 (6.08)	5.3 (6.36)
Median (Q1; Q3)	3.1 (2.0; 5.7)	3.0 (1.9; 5.2)	3.0 (1.9; 5.4)
min max	0 47	0 46	0 47
Time from onset to randomisation (hour)			
n	769	777	1546
Mean (SD)	18.0 (12.49)	17.6 (11.79)	17.8 (12.14)
Median (Q1; Q3)	15.1 (7.3; 25.9)	15.4 (7.4; 25.1)	15.2 (7.3; 25.7)
min max	2 58	1 61	1 61
Time from onset to first medicine given (hour)			
n	769	777	1546
Mean (SD)	22.7 (14.11)	22.1 (13.32)	22.4 (13.72)
Median (Q1; Q3)	20.0 (11.1; 31.0)	19.8 (11.5; 29.1)	20.0 (11.3; 30.3)

	<b>FYTF-919</b>	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
min max	2 109	2 84	2 109
First method of study medication			
Oral admission (awake, 33ml/time, tid)	378/767 (49.3%)	381/777 (49.0%)	759/1544 (49.2%
Nasogastric tube (coma, 25ml/time, q6h)	389/767 (50.7%)	396/777 (51.0%)	785/1544 (50.8%
Previous hypertension	508/767 (66.2%)	535/774 (69.1%)	1043/1541 (67.7%
Antihypertensive medication	479/508 (94.3%)	505/535 (94.4%)	984/1043 (94.3%
ACEI ARB	36/479 (7.5%)	49/505 (9.7%)	85/984 (8.6%)
Beta blocker	11/479 (2.3%)	12/505 (2.4%)	23/984 (2.3%)
Ca antagonist	77/479 (16.1%)	91/505 (18.0%)	168/984 (17.1%
Diuretics	2/479 (0.4%)	5/505 (1.0%)	7/984 (0.7%)
Other antihypertensives	366/479 (76.4%)	369/505 (73.1%)	735/984 (74.7%
Reserpine Co	5/366 (1.4%)	4/369 (1.1%)	9/735 (1.2%)
Unknown	361/366 (98.6%)	365/369 (98.9%)	726/735 (98.8%
Previous diabetes	65/769 (8.5%)	70/776 (9.0%)	135/1545 (8.7%
Antidiabetic medication	24/65 (36.9%)	34/70 (48.6%)	58/135 (43.0%)

Characteristics	FYTF-919 (N=815)	Placebo (N=826)	Overall (N=1641)
Insulin	1/24 (4.2%)	0/34 (0.0%)	1/58 (1.7%)
Biguanide	3/24 (12.5%)	2/34 (5.9%)	5/58 (8.6%)
Sulfonylurea	1/24 (4.2%)	0/34 (0.0%)	1/58 (1.7%)
Glycosidase inhibitor	2/24 (8.3%)	0/34 (0.0%)	2/58 (3.4%)
Other	20/24 (83.3%)	32/34 (94.1%)	52/58 (89.7%)
Euphridine	1/20 (5.0%)	0/32 (0.0%)	1/52 (1.9%)
Repaglinide	1/20 (5.0%)	0/32 (0.0%)	1/52 (1.9%)
Unknown	18/20 (90.0%)	32/32 (100.0%)	50/52 (96.2%)
Previous hyperlipidaemia	10/769 (1.3%)	9/777 (1.2%)	19/1546 (1.2%)
Lipid lowering agent	8/10 (80.0%)	7/9 (77.8%)	15/19 (78.9%)
Statin	5/8 (62.5%)	3/7 (42.9%)	8/15 (53.3%)
Cholesterol absorption inhibitor	0/8 (0.0%)	0/7 (0.0%)	0/15 (0.0%)
PCSK9 inhibitor	0/8 (0.0%)	0/7 (0.0%)	0/15 (0.0%)
Other (All unknown)	3/8 (37.5%)	4/7 (57.1%)	7/15 (46.7%)

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
Previous coronary heart disease	39/769 (5.1%)	27/777 (3.5%)	66/1546 (4.3%)
Previous atrial fibrillation	1/769 (0.1%)	5/777 (0.6%)	6/1546 (0.4%)
Any anticoagulation treatment	1/769 (0.1%)	3/777 (0.4%)	4/1546 (0.3%)
Any antiplatelet treatment	34/769 (4.4%)	26/777 (3.3%)	60/1546 (3.9%)
Aspirin	30/34 (88.2%)	23/26 (88.5%)	53/60 (88.3%)
Clopidogrel	8/34 (23.5%)	6/26 (23.1%)	14/60 (23.3%)
Other	1/34 (2.9%)	2/26 (7.7%)	3/60 (5.0%)
Total TCM score (TCM 1-5)			
n	738	740	1478
Mean (SD)	1.1 (1.25)	1.1 (1.26)	1.1 (1.25)
Median (Q1; Q3)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)	1.0 (0.0; 2.0)
min max	0 5	0 5	0 5
Anxiety	91/737 (12.3%)	83/740 (11.2%)	174/1477 (11.8%)
Red face/T>37.5	148/737 (20.1%)	151/739 (20.4%)	299/1476 (20.3%)
Dry mouth/Bad breath	181/732 (24.7%)	184/735 (25.0%)	365/1467 (24.9%)

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
Yellow tongue coating	161/718 (22.4%)	167/725 (23.0%)	328/1443 (22.7%)
Red tongue coating	250/718 (34.8%)	246/724 (34.0%)	496/1442 (34.4%)
No Stool in the last 48h	227/738 (30.8%)	251/737 (34.1%)	478/1475 (32.4%)

Table S22. Study medication in the per protocol population

	FYTF-919	Placebo	Overall
Characteristics	(N=769)	( <b>N=777</b> )	(N=1546)
<b>Duration of study treatment (Days)</b>			
n	768	777	1545
Mean (SD)	25.3 (9.89)	25.8 (8.77)	25.5 (9.34)
Median (Q1; Q3)	768	777	1545
min max	1 108	1 103	1 108
Duration of study treatment by category			
1 - 7 days	62/768 (8.1%)	53/777 (6.8%)	116/1545 (7.4%)
8 - 14 days	68/768 (8.9%)	51/777 (6.6%)	119/1545 (7.7%)
15 - 21 days	28/768 (3.6%)	40/777 (5.1%)	68/1545 (4.4%)
22 - 28 days	168/768 (21.9%)	161/777 (20.7%)	329/1545 (21.3%)
29 - 40 days	437/768 (56.9%)	461/777 (59.3%)	898/1545 (58.1%)
40+ days	5/768 (0.7%)	11/777 (1.4%)	16/1545 (1.0%)
Bottles completed			
n	769	777	1546
Mean (SD)	23.5 (8.37)	24.1 (7.75)	23.8 (8.07)
Median (Q1; Q3)	28.0 (25.0; 28.0)	28.0 (26.3; 28.0)	28.0 (26.0; 28.0)
min max	1 28	0 28	0 28
Complete ≥80% of medication	592/769 (77.0%)	613/777 (78.9%)	1205/1546 (77.9%)
Complete study medication following protocol <sup>1</sup>	476/769 (61.9%)	487/777 (62.7%)	963/1546 (62.3%)

Table S23. Clinical assessment of outcomes over time in the per protocol population

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
NIHSS			
Baseline			
n	765	769	1534
Mean (SD)	16.2 (7.98)	16.2 (8.05)	16.2 (8.01)
Median (Q1; Q3)	15.0 (10.0; 21.0)	15.0 (10.0; 20.0)	15.0 (10.0; 20.0)
min max	0 42	1 42	0 42
Follow up 1 - 24h(±3h)			
n	736	748	1484
Mean (SD)	16.1 (8.26)	16.3 (8.52)	16.2 (8.39)
Median (Q1; Q3)	15.0 (10.0; 21.0)	15.0 (10.0; 21.0)	15.0 (10.0; 21.0)
min max	0 42	0 41	0 42
Follow up 2 - D7±D1			
n	726	732	1458
Mean (SD)	13.3 (8.26)	13.8 (8.70)	13.5 (8.49)
Median (Q1; Q3)	12.0 (8.0; 18.0)	12.0 (7.0; 18.5)	12.0 (7.0; 18.0)
min max	0 40	0 40	0 40
Follow up 3 - D14±D2			
n	648	666	1314
Mean (SD)	10.9 (7.64)	11.6 (8.12)	11.3 (7.89)
Median (Q1; Q3)	10.0 (5.0; 15.0)	10.0 (6.0; 15.0)	10.0 (6.0; 15.0)

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
min max	0 39	0 41	0 41
Follow up 4 - D28±D3			
n	515	526	1041
Mean (SD)	8.3 (7.12)	9.0 (7.58)	8.7 (7.36)
Median (Q1; Q3)	7.0 (3.0; 12.0)	7.0 (3.0; 12.0)	7.0 (3.0; 12.0)
min max	0 37	0 42	0 42
GCS			
Baseline			
n	741	742	1483
Mean (SD)	11.6 (2.81)	11.7 (2.88)	11.6 (2.85)
Median (Q1; Q3)	12.0 (10.0; 14.0)	12.0 (10.0; 14.0)	12.0 (10.0; 14.0)
min max	3 15	3 15	3 15
Follow up 1 - 24h(±3h)			
n	718	713	1431
Mean (SD)	11.6 (2.94)	11.7 (2.97)	11.7 (2.95)
Median (Q1; Q3)	12.0 (10.0; 14.0)	13.0 (10.0; 14.0)	12.0 (10.0; 14.0)
min max	2 15	3 15	2 15
Follow up 2 - D7±D1			
n	696	686	1382
Mean (SD)	12.8 (2.73)	12.7 (2.81)	12.7 (2.77)
Median (Q1; Q3)	14.0 (11.0; 15.0)	14.0 (11.0; 15.0)	14.0 (11.0; 15.0)

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
min max	3 15	3 15	3 15
Follow up 3 - D14±D2			
n	644	649	1293
Mean (SD)	13.5 (2.27)	13.4 (2.59)	13.4 (2.44)
Median (Q1; Q3)	15.0 (12.0; 15.0)	15.0 (13.0; 15.0)	15.0 (12.0; 15.0)
min max	3 15	2 15	2 15
Follow up 4 - D28±D3			
n	568	580	1148
Mean (SD)	14.1 (1.80)	14.0 (2.07)	14.1 (1.94)
Median (Q1; Q3)	15.0 (14.0; 15.0)	15.0 (14.0; 15.0)	15.0 (14.0; 15.0)
min max	5 15	3 15	3 15
mRS			
Baseline (Before stroke onset)			
0: No symptoms	696/768 (90.6%)	705/777 (90.7%)	1401/1545 (90.7%
1: No significant disability	46/768 (6.0%)	40/777 (5.1%)	86/1545 (5.6%)
2: Slight disability	26/768 (3.4%)	32/777 (4.1%)	58/1545 (3.8%)
3: Moderate disability	0/768 (0.0%)	0/777 (0.0%)	0/1545 (0.0%)
4: Moderately severe disability	0/768 (0.0%)	0/777 (0.0%)	0/1545 (0.0%)
5: Severe disability	0/768 (0.0%)	0/777 (0.0%)	0/1545 (0.0%)
6: Death	0/768 (0.0%)	0/777 (0.0%)	0/1545 (0.0%)

### Follow up 4 - D28±D3

Characteristics	FYTF-919 (N=815) 28/744 (3.8%)	Placebo (N=826) 33/751 (4.4%)	Overall (N=1641) 61/1495 (4.1%)
1: No significant disability			
2: Slight disability	90/744 (12.1%)	87/751 (11.6%)	177/1495 (11.8%)
3: Moderate disability	99/744 (13.3%)	108/751 (14.4%)	207/1495 (13.8%)
4: Moderately severe disability	281/744 (37.8%)	267/751 (35.6%)	548/1495 (36.7%)
5: Severe disability	62/744 (8.3%)	92/751 (12.3%)	154/1495 (10.3%)
6: Death	65/744 (8.7%)	62/751 (8.3%)	127/1495 (8.5%)
Follow up 5 - D90±D7			
0: No symptoms	61/757 (8.1%)	60/770 (7.8%)	121/1527 (7.9%)
1: No significant disability	147/757 (19.4%)	149/770 (19.4%)	296/1527 (19.4%)
2: Slight disability	113/757 (14.9%)	116/770 (15.1%)	229/1527 (15.0%)
3: Moderate disability	148/757 (19.6%)	151/770 (19.6%)	299/1527 (19.6%)
4: Moderately severe disability	171/757 (22.6%)	163/770 (21.2%)	334/1527 (21.9%)
5: Severe disability	29/757 (3.8%)	48/770 (6.2%)	77/1527 (5.0%)
6: Death	88/757 (11.6%)	83/770 (10.8%)	171/1527 (11.2%)
Barthel Index			
Follow up 4 - D28±D3			
n	677	689	1366
Mean (SD)	56.0 (32.61)	53.9 (33.18)	54.9 (32.91)
Median (Q1; Q3)	55.0 (25.0; 90.0)	50.0 (25.0; 85.0)	55.0 (25.0; 90.0)
min max	0 100	0 100	0 100

Follow up 5 - D90±D7

Characteristics	FYTF-919 (N=815) 670	Placebo (N=826) 690	Overall (N=1641) 1360
Mean (SD)			
Median (Q1; Q3)	80.0 (50.0; 100.0)	80.0 (50.0; 100.0)	80.0 (50.0; 100.0)
min max	0 100	0 100	0 100
EQ5D5L VAS			
Follow up 4 - D28±D3			
n	667	681	1348
Mean (SD)	63.4 (24.23)	62.6 (25.08)	63.0 (24.66)
Median (Q1; Q3)	70.0 (50.0; 80.0)	65.0 (50.0; 80.0)	65.0 (50.0; 80.0)
min max	0 100	0 100	0 100
Follow up 5 - D90±D7			
n	670	689	1359
Mean (SD)	72.0 (22.16)	71.4 (22.35)	71.7 (22.25)
Median (Q1; Q3)	77.0 (60.0; 90.0)	80.0 (60.0; 90.0)	80.0 (60.0; 90.0)
min max	0 100	0 100	0 100
EQ5D5L Utility score in survivors			
Follow up 4 - D28±D3			
n	668	680	1348
Mean (SD)	0.419 (0.4142)	0.409 (0.4104)	0.414 (0.4122)
Median (Q1; Q3)	0.374 (0.090; 0.827)	0.363 (0.062; 0.800)	0.363 (0.062; 0.827)
min max	-0.39 1.00	-0.39 1.00	-0.39 1.00

<b>FYTF-919</b>	Placebo	Overall
(N=815)	(N=826)	(N=1641)
660	607	1356
· · · · · · · · · · · · · · · · · · ·	, , ,	0.581 (0.3902)
	*	,
-0.39 1.00	-0.39 1.00	-0.39 1.00
733	742	1475
0.382 (0.4129)	0.375 (0.4089)	0.378 (0.4108)
0.220 (0.024; 0.783)	0.218 (0.000; 0.783)	0.220 (0.013; 0.783)
-0.39 1.00	-0.39 1.00	-0.39 1.00
757	770	1527
0.513 (0.4159)	0.519 (0.4060)	0.516 (0.4108)
0.620 (0.101; 0.893)	0.596 (0.120; 0.898)	0.620 (0.112; 0.898)
	` '	` '
	669 0.580 (0.3957) 0.734 (0.212; 0.942) -0.39 1.00 733 0.382 (0.4129) 0.220 (0.024; 0.783) -0.39 1.00 757 0.513 (0.4159)	(N=815)     (N=826)       669     687       0.580 (0.3957)     0.582 (0.3851)       0.734 (0.212; 0.942)     0.720 (0.201; 0.934)       -0.39 1.00     -0.39 1.00       733     742       0.382 (0.4129)     0.375 (0.4089)       0.220 (0.024; 0.783)     0.218 (0.000; 0.783)       -0.39 1.00     -0.39 1.00       757     770       0.513 (0.4159)     0.519 (0.4060)

Table S24: Descriptives of outcomes in the per protocol population at  $28\ and\ 90\ days$ 

	<b>FYTF-919</b>	Placebo	Overall
	(N=815)	(N=826)	(N=1641)
Utility weighted mRS at Day 90			
n	738	748	1526
Mean (SD)	0.505 (0.3503)	0.496 (0.3608)	0.500 (0.3555)
Median (Q1; Q3)	0.550 (0.200; 0.880)	0.550 (0.200; 0.880)	0.550 (0.200; 0.880)
min max	-0.19 0.97	-0.19 0.97	-0.19 0.97
Death or disability (mRS 4-6) at Day 28	408/744 (54.8%)	421/751 (56.1%)	829/1495 (55.5%)
Death or disability (mRS 4-6) at Day 90	288/757 (38.0%)	294/770 (38.2%)	582/1527 (38.1%)
Death at Day 28	65/769 (8.5%)	62/777 (8.0%)	127/1546 (8.2%)
Death at Day 90	88/769 (11.4%)	83/777 (10.7%)	171/1546 (11.1%)
Disability (mRS 4-5) at Day 28	343/744 (46.1%)	359/751 (47.8%)	702/1495 (47.0%)
Disability (mRS 4-5) at Day 90	200/757 (26.4%)	211/770 (27.4%)	411/1527 (26.9%)
Stroke associated pneumonia (SAP)	31/725 (4.3%)	28/737 (3.8%)	59/1462 (4.0%)
Hospital discharge by Day 28	581/712 (81.6%)	597/733 (81.4%)	1178/1445 (81.5%)

Table S25. Modelling results of the outcomes in the per protocol population 1.  $\,$ 

		Primary model (1)			Adjusted model (2)	)
Outcome	$N^*$	OR/MD(95%CI)**	p value	<b>N</b> *	OR/MD(95%CI)**	p value
Primary Outcome						
uwMRS Day 90	1486	0.008 (-0.023, 0.040)	0.60	1485	0.015 (-0.015, 0.046)	0.32
uwMRS Day 90 - sensitivity 1	1486	0.005 (-0.029, 0.038)	0.79			
uwMRS Day 90 - sensitivity 2	1325	0.003 (-0.030, 0.036)	0.85			
uwMRS Day 90 - sensitivity 3	1486	0.005 (-0.029, 0.038)	0.79			
Secondary Outcomes						
Ordinal mRS Day 28**	1460	0.87 (0.73, 1.05)	0.15	1459	0.84 (0.70, 1.02)	0.07
Ordinal mRS Day 90**	1486	1.00 (0.84, 1.20)	0.96	1485	0.96 (0.80, 1.15)	0.68
Death or disability - mRS [4-6] Day 28**	1460	0.92 (0.72, 1.17)	0.50	1459	0.89 (0.70, 1.14)	0.36
Death or disability - mRS [4-6] Day 90**	1486	0.99 (0.78, 1.25)	0.93	1485	0.93 (0.73, 1.18)	0.54
Death Day 28**	1503	1.02 (0.69, 1.50)	0.92	1502	0.94 (0.63, 1.41)	0.77
Death Day 90**	1503	1.05 (0.75, 1.47)	0.78	1502	0.97 (0.68, 1.39)	0.87
Disability - mRS [4-5] Day 28**	1460	0.91 (0.73, 1.15)	0.44	1459	0.91 (0.72, 1.15)	0.43
Disability - mRS [4-5] Day 90**	1486	0.96 (0.75, 1.22)	0.72	1485	0.94 (0.73, 1.20)	0.61
NIHSS Day 1	1452	-0.20 (-0.78, 0.39)	0.51	1451	-0.22 (-0.81, 0.36)	0.45
NIHSS Day 7	1425	-0.55 (-1.24, 0.14)	0.12	1424	-0.60 (-1.29, 0.08)	0.09
Barthel Index Day 28	1338	1.90 (-1.08, 4.88)	0.21	1337	2.26 (-0.71, 5.23)	0.14
Barthel Index Day 90	1325	0.67 (-2.18, 3.51)	0.65	1324	1.21 (-1.58, 4.00)	0.39

		Primary model (1)		Adjusted model (2)			
Outcome	N*	OR/MD(95%CI)**	p value	<b>N</b> *	OR/MD(95%CI)**	p value	
EQ5D5L VAS in survivors Day 28	1252	0.41 (-1.90, 2.72)	0.73	1251	0.56 (-1.72, 2.87)	0.63	
EQ5D5L VAS in survivors Day 90	1294	-0.43 (-2.54, 1.67)	0.69	1293	-0.23 (-2.33, 1.87)	0.83	
EQ5D5L Utility score in survivors Day 28	1254	0.00 (-0.03, 0.04)	0.85	1253	0.01 (-0.03, 0.04)	0.75	
EQ5D5L Utility score in survivors Day 90	1294	-0.01 (-0.05, 0.02)	0.48	1293	-0.01 (-0.04, 0.03)	0.69	
EQ5D5L VAS Day 28 (impute death = 0)	1441	0.59 (-2.10, 3.27)	0.667	1440	0.97 (-1.68, 3.61)	0.47	
EQ5D5L VAS Day 90 (impute death = 0)	1485	-0.30 (-3.13, 2.53)	0.84	1484	0.21 (-2.53, 2.96)	0.88	
EQ5D5L Utility score Day 28 (impute death = 0)	1445	0.01 (-0.03, 0.05)	0.57	1444	0.01 (-0.02, 0.05)	0.44	
EQ5D5L Utility score Day 90 (impute death = 0)	1486	-0.01 (-0.04, 0.03)	0.76	1485	0.00 (-0.03, 0.04)	0.93	
Any SAP**	1420	1.11 (0.63, 1.95)	0.72	1420	1.09 (0.62, 1.93)	0.76	
Discharge alive within 28 days	1411	0.95 (0.69, 1.30)	0.74	1410	0.97 (0.71, 1.34)	0.87	

Table S11. Modelling results of the outcomes in the per protocol population  ${\bf 2.}$ 

	Primary model					Ad	justed	l model				
	Inte	ervention		Cor	ntrol		I	ntervent	tion	$\mathbf{C}$	ontrol	
Outcome	N	Mean	<b>%</b>	N	Mean	<b>%</b>	N	Mean	<b>%</b>	N	Mean	%
uwMRS Day 90 - adjusted	738	0.45		748	0.44		737	0.43		748	0.42	
uwMRS Day 90 - sensitivity 1	738	0.47		748	0.46		737	0.52		748	0.51	
uwMRS Day 90 - sensitivity 2	655	0.56		670	0.56		654	0.58		670	0.57	
uwMRS Day 90 - sensitivity 3	738	0.47		748	0.46		737	0.52		748	0.51	
Ordinal mRS Day 28												
Ordinal mRS Day 90												
Death or disability - mRS [4-6] Day 28	726	43.5		734	57.3		725	52.4		734	55.2	
Death or disability - mRS [4-6] Day 90	738	43.5		748	43.7		737	46.2		748	48.1	
Death Day 28	749	11.2		753	11.0		748	12.0		753	12.6	
Death Day 90	749	16.3		754	15.7		748	17.7		754	18.2	
Disability - mRS [4-5] Day 28	726	20.6		734	22.1		725	46.2		734	47.8	
Disability - mRS [4-5] Day 90	738	26.6		748	22.0		737	26.6		748	27.1	
NIHSS Day 1	720	15.72		732	15.92		719	15.97		732	16.19	
NIHSS Day 7	710	12.83		715	13.38		709	12.99		715	13.60	
Barthel Index Day 28	664	54.49		674	52.59		663	54.92		674	52.65	
Barthel Index Day 90	655	69.40		670	68.74		654	67.58		670	66.36	

		Prima	ary mode	el			Adjusted model					
	Inte	erventior	1	Cor	ntrol		I	ntervent	tion	$\mathbf{C}$	ontrol	
Outcome	N	Mean	%	$\mathbf{N}$	Mean	<b>%</b>	N	Mean	<b>%</b>	N	Mean	<b>%</b>
EQ5D5L VAS in survivors Day 28	623	61.48		629	61.06		622	63.41		629	62.85	
EQ5D5L VAS in survivors Day 90	642	70.35		652	70.78		641	70.71		652	70.94	
EQ5D5L Utility score in survivors Day 28	624	0.44		630	0.43		623	0.45		630	0.45	
EQ5D5L Utility score in survivors Day 90	642	0.58		652	0.60		641	0.56		652	0.57	
EQ5D5L VAS Day 28 (impute death = 0)	716	51.91		725	51.33		715	51.56		725	50.59	
EQ5D5L VAS Day 90 (impute death = 0)	738	56.15		747	56.45		737	54.07		747	53.86	
EQ5D5L Utility score Day 28 (impute death = 0)	719	0.37		726	0.36		718	0.37		726	0.35	
EQ5D5L Utility score Day 90 (impute death = 0)	738	0.46		748	0.47		737	0.44		748	0.44	
Any SAP	706		0.005	714		0.005	706		0.004	714		0.003
Discharge alive within 28 days	697		96.1	714		96.3	696	9	96.0	714		96.1

Table S27. Analysis for the outcomes at 180 days:

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
Utility weighted mRS			
n	814	826	1640
Mean (SD)	0.55 (0.36)	0.55 (0.36)	0.55 (0.36)
Median (Q1; Q3)	0.55 (0.20; 0.88)	0.55 (0.20; 0.88)	0.55 (0.20; 0.88)
min max	-0.19 0.97	-0.19 0.97	-0.19 0.97
Death or disability (mRS 4-6)	262/814 (32.2%)	262/826 (31.7%)	524/1640 (32.0%)
Death	113/815 (13.9%)	111/826 (13.4%)	224/1641 (13.7%)
Disability (mRS 4-5)	149/814 (18.3%)	151/826 (18.3%)	300/1640 (18.3%)

mRS denotes modified Rankin scale

 $Table \ S28. \ Causes \ of \ death \ until \ 90 \ days$ 

	<b>FYTF-919</b>	Placebo	Overall
Overcome	(N=815)	(N=826)	(N=1641)
Dooth her Dorr 00			
Death by Day 90	717/015 (00 0)	700/00 (00 T)	1 450/1 641 (00 4)
No	717/815 (88.0)	733/826 (88.7)	1450/1641 (88.4)
Yes	98/815 (12.0)	93/826 (11.3)	191/1641 (11.6)
Cause of death			
CNS damage from index stroke*	51/96 (53.1)	40/92 (43.5)	91/188 (48.4)
Lung infection	11/96 (11.5)	14/92 (15.2)	25/188 (13.3)
Cardiovascular disease	3/96 (3.1)	2/92 (2.2)	5/188 (2.7)
Stroke recurrence	1/96 (1.0)	4/92 (4.3)	5/188 (2.7)
Other	30/96 (31.3)	32/92 (34.8)	62/188 (33.0)
Respiratory failure	5/30 (16.7)	5/32 (15.6)	10/62 (16.1)
Respiratory and circulatory failure	1/30 (3.3)	2/32 (6.3)	3/62 (4.8)
Gastrointestinal bleeding	1/30 (3.3)	1/32 (3.1)	2/62 (3.2)
Heart failure	2/30 (6.7)	0/32 (0.0)	2/62 (3.2)
Multiple organ failure	1/30 (3.3)	1/32 (3.1)	2/62 (3.2)
Cachectic state	1/30 (3.3)	0/32 (0.0)	1/62 (1.6)
Circulatory / respiratory failure	0/30 (0.0)	1/32 (3.1)	1/62 (1.6)
Epilepsy	1/30 (3.3)	0/32 (0.0)	1/62 (1.6)
Pulmonary embolism	0/30 (0.0)	1/32 (3.1)	1/62 (1.6)
Septicaemia	1/30 (3.3)	0/32 (0.0)	1/62 (1.6)
Sudden death	1/30 (3.3)	0/32 (0.0)	1/62 (1.6)
Unknown	16/30 (53.3)	21/32 (65.6)	37/62 (59.7)

Data are n (%)

<sup>\*</sup>CNS denotes central nervous system

Table S29. Reported stroke-related complications by visit until 90 days

`			
	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
Respiratory infection			
Baseline	275/815 (33.7)	309/826 (37.4)	584/1641 (35.6)
Follow up 1 - $24h(\pm 3h)$	324/815 (39.8)	364/825 (44.1)	688/1640 (42.0)
Follow up 2 - D7±D1	361/802 (45.0)	397/812 (48.9)	758/1614 (47.0)
Follow up 3 - D14±D2	245/752 (32.6)	265/778 (34.1)	510/1530 (33.3)
Follow up 4 - D28±D3	128/718 (17.8)	145/732 (19.8)	273/1450 (18.8)
Urinary tract infection			
Baseline	6/815 (0.7)	4/826 (0.5)	10/1641 (0.6)
Follow up 1 - $24h(\pm 3h)$	10/815 (1.2)	2/825 (0.2)	12/1640 (0.7)
Follow up 2 - D7±D1	16/802 (2.0)	7/812 (0.9)	23/1614 (1.4)
Follow up 3 - D14±D2	21/752 (2.8)	10/778 (1.3)	31/1530 (2.0)
Follow up 4 - D28±D3	15/718 (2.1)	12/732 (1.6)	27/1450 (1.9)
Intestinal infection			
Baseline	1/815 (0.1)	0/826 (0.0)	1/1641 (0.1)
Follow up 1 - $24h(\pm 3h)$	0/815 (0.0)	0/825 (0.0)	0/1640 (0.0)
Follow up 2 - D7±D1	0/802 (0.0)	0/812 (0.0)	0/1614 (0.0)
Follow up 3 - D14±D2	0/752 (0.0)	0/778 (0.0)	0/1530 (0.0)
Follow up 4 - D28±D3	0/718 (0.0)	1/732 (0.1)	1/1450 (0.1)
Other infection			
Baseline	2/815 (0.2)	1/826 (0.1)	3/1641 (0.2)
Follow up 1 - $24h(\pm 3h)$	7/815 (0.9)	8/825 (1.0)	15/1640 (0.9)
Follow up 2 - D7±D1	16/802 (2.0)	18/812 (2.2)	34/1614 (2.1)
Follow up 3 - D14±D2	18/752 (2.4)	18/778 (2.3)	36/1530 (2.4)
Follow up 4 - D28±D3	11/718 (1.5)	13/732 (1.8)	24/1450 (1.7)

	<b>FYTF-919</b>	Placebo	Overall	
Characteristics	(N=815)	(N=826)	(N=1641)	
Acute renal injury				
Baseline	0/815 (0.0)	1/826 (0.1)	1/1641 (0.1)	
Follow up 1 - $24h(\pm 3h)$	1/815 (0.1)	1/825 (0.1)	2/1640 (0.1)	
Follow up 2 - D7±D1	2/802 (0.2)	2/812 (0.2)	4/1614 (0.2)	
Follow up 3 - D14±D2	2/752 (0.3)	1/778 (0.1)	3/1530 (0.2)	
Follow up 4 - D28±D3	1/718 (0.1)	0/732 (0.0)	1/1450 (0.1)	
Gastrointestinal haemorrhage				
Baseline	19/815 (2.3)	23/826 (2.8)	42/1641 (2.6)	
Follow up 1 - $24h(\pm 3h)$	25/815 (3.1)	27/825 (3.3)	52/1640 (3.2)	
Follow up 2 - D7±D1	24/802 (3.0)	26/812 (3.2)	50/1614 (3.1)	
Follow up 3 - D14±D2	22/752 (2.9)	17/778 (2.2)	39/1530 (2.5)	
Follow up 4 - D28±D3	13/718 (1.8)	18/732 (2.5)	31/1450 (2.1)	
Hyperosmolar coma				
Baseline	0/815 (0.0)	0/826 (0.0)	0/1641 (0.0)	
Follow up 1 - 24h(±3h)	0/815 (0.0)	0/825 (0.0)	0/1640 (0.0)	
Follow up 2 - D7±D1	0/802 (0.0)	0/812 (0.0)	0/1614 (0.0)	
Follow up 3 - D14±D2	0/752 (0.0)	0/778 (0.0)	0/1530 (0.0)	
Follow up 4 - D28±D3	0/718 (0.0)	0/732 (0.0)	0/1450 (0.0)	
Pulmonary embolism				
Baseline	0/815 (0.0)	0/826 (0.0)	0/1641 (0.0)	
Follow up 1 - $24h(\pm 3h)$	0/815 (0.0)	0/825 (0.0)	0/1640 (0.0)	
Follow up 2 - D7±D1	0/802 (0.0)	0/812 (0.0)	0/1614 (0.0)	
Follow up 3 - D14±D2	0/752 (0.0)	1/778 (0.1)	1/1530 (0.1)	
Follow up 4 - D28±D3	1/718 (0.1)	1/732 (0.1)	2/1450 (0.1)	

## Raised intracranial pressure or herniation

	FYTF-919	Placebo	Overall	
Characteristics	(N=815)	(N=826)	(N=1641)	
Baseline	45/815 (5.5)	53/826 (6.4)	98/1641 (6.0)	
Follow up 1 - $24h(\pm 3h)$	31/815 (3.8)	51/825 (6.2)	82/1640 (5.0)	
Follow up 2 - D7±D1	23/802 (2.9)	29/812 (3.6)	52/1614 (3.2)	
Follow up 3 - D14±D2	8/752 (1.1)	16/778 (2.1)	24/1530 (1.6)	
Follow up 4 - D28±D3	3/718 (0.4)	7/732 (1.0)	10/1450 (0.7)	
Hydrocephalus				
Baseline	11/815 (1.3)	17/826 (2.1)	28/1641 (1.7)	
Follow up 1 - $24h(\pm 3h)$	5/815 (0.6)	21/825 (2.5)	26/1640 (1.6)	
Follow up 2 - D7±D1	7/802 (0.9)	15/812 (1.8)	22/1614 (1.4)	
Follow up 3 - D14±D2	2/752 (0.3)	11/778 (1.4)	13/1530 (0.8)	
Follow up 4 - D28±D3	1/718 (0.1)	6/732 (0.8)	7/1450 (0.5)	
Intracranial re-haemorrhage				
Baseline	5/815 (0.6)	8/826 (1.0)	13/1641 (0.8)	
Follow up 1 - $24h(\pm 3h)$	10/815 (1.2)	11/825 (1.3)	21/1640 (1.3)	
Follow up 2 - D7±D1	11/802 (1.4)	13/812 (1.6)	24/1614 (1.5)	
Follow up 3 - D14±D2	3/752 (0.4)	5/778 (0.6)	8/1530 (0.5)	
Follow up 4 - D28±D3	0/718 (0.0)	6/732 (0.8)	6/1450 (0.4)	
Hyperthermia				
Baseline	7/815 (0.9)	6/826 (0.7)	13/1641 (0.8)	
Follow up 1 - $24h(\pm 3h)$	15/815 (1.8)	11/825 (1.3)	26/1640 (1.6)	
Follow up 2 - D7±D1	13/802 (1.6)	10/812 (1.2)	23/1614 (1.4)	
Follow up 3 - D14±D2	2/752 (0.3)	4/778 (0.5)	6/1530 (0.4)	
Follow up 4 - D28±D3	0/718 (0.0)	0/732 (0.0)	0/1450 (0.0)	
Other				
Baseline	93/815 (11.4)	102/826 (12.3)	195/1641 (11.9	

	FYTF-919	Placebo	Overall
Characteristics	(N=815)	(N=826)	(N=1641)
Follow up 1 - 24h(±3h)	92/815 (11.3)	111/825 (13.5)	203/1640 (12.4)
Follow up 2 - D7±D1	153/802 (19.1)	164/812 (20.2)	317/1614 (19.6)
Follow up 3 - D14±D2	120/752 (16.0)	131/778 (16.8)	251/1530 (16.4)
Follow up 4 - D28±D3	74/718 (10.3)	72/732 (9.8)	146/1450 (10.1)
Any adverse event reported			
Respiratory infection	447/815 (54.8)	483/826 (58.5)	930/1641 (56.7)
Urinary tract infection	39/815 (4.8)	24/826 (2.9)	63/1641 (3.8)
Intestinal infection	1/815 (0.1)	1/826 (0.1)	2/1641 (0.1)
Other infection	33/815 (4.0)	30/826 (3.6)	63/1641 (3.8)
Acute renal injury	3/815 (0.4)	3/826 (0.4)	6/1641 (0.4)
Gastrointestinal haemorrhage	50/815 (6.1)	51/826 (6.2)	101/1641 (6.2)
Hyperosmolar coma	0/815 (0.0)	0/826 (0.0)	0/1641 (0.0)
Pulmonary embolism	1/815 (0.1)	2/826 (0.2)	3/1641 (0.2)
Raised intracranial pressure or herniation	54/815 (6.6)	69/826 (8.4)	123/1641 (7.5)
Hydrocephalus	17/815 (2.1)	32/826 (3.9)	49/1641 (3.0)
Intracranial re-haemorrhage	21/815 (2.6)	29/826 (3.5)	50/1641 (3.0)
Hyperthermia	28/815 (3.4)	25/826 (3.0)	53/1641 (3.2)
Other	253/815 (31.0)	277/826 (33.5)	530/1641 (32.3)

Data are n (%)

Table S30. Adverse events by description until 90 days

	FYTF-919	Placebo	Overall	
Classification	(N=815)	(N=826)	(N=1641)	p value
Adverse Event	1761# 650/815 (79.8)	1751# 665/826 (80.5)	3512# 1315/1641 (80.1)	0.70
Relation to treatment				
Definitely related	10/1748 (0.6)	6/1740 (0.3)	16/3488 (0.5)	
Possibly related	106/1748 (6.1)	69/1740 (4.0)	175/3488 (5.0)	
Probably not relevant	436/1748 (24.9)	410/1740 (23.6)	846/3488 (24.3)	
Definitely irrelevant	1176/1748 (67.3)	1241/1740 (71.3)	2417/3488 (69.3)	
Unable to determine	20/1748 (1.1)	14/1740 (0.8)	34/3488 (1.0)	
Serious Adverse Event	507# 338/815 (41.5)	541# 358/826 (43.3)	1048# 696/1641 (42.4)	0.44
Relation to treatment				
Definitely related	4/507 (0.8)	0/541 (0.0)	4/1048 (0.4)	
Possibly related	5/507 (1.0)	5/541 (0.9)	10/1048 (1.0)	
Probably not relevant	69/507 (13.6)	53/541 (9.8)	122/1048 (11.6)	
Definitely irrelevant	427/507 (84.2)	481/541 (88.9)	908/1048 (86.6)	
Unable to determine	2/507 (0.4)	2/541 (0.4)	4/1048 (0.4)	
Adverse Event of Special Interest	116# 111/815 (13.6)	81# 78/826 (9.4)	197# 189/1641 (11.5)	0.01
Relation to treatment				
Definitely related	3/116 (2.6)	2/81 (2.5)	5/197 (2.5)	
Possibly related	55/116 (47.4)	26/81 (32.1)	81/197 (41.1)	
Probably not relevant	27/116 (23.3)	25/81 (30.9)	52/197 (26.4)	
Definitely irrelevant	29/116 (25.0)	25/81 (30.9)	54/197 (27.4)	
Unable to determine	2/116 (1.7)	3/81 (3.7)	5/197 (2.5)	
Haematoma enlargement (>6 mL or33%)	18# 18/815 (2.2)	14# 14/826 (1.7)	32# 32/1641 (2.0)	

	<b>FYTF-919</b>	Placebo	Overall	
Classification	(N=815)	(N=826)	(N=1641)	p value
Relation to treatment				
Definitely related	1/18 (5.6)	0/14 (0.0)	1/32 (3.1)	
Possibly related	0/18 (0.0)	0/14 (0.0)	0/32 (0.0)	
Probably not relevant	3/18 (16.7)	4/14 (28.6)	7/32 (21.9)	
Definitely irrelevant	14/18 (77.8)	10/14 (71.4)	24/32 (75.0)	
Unable to determine	0/18 (0.0)	0/14 (0.0)	0/32 (0.0)	
New intracranial hematoma	9* 9/815 (1.1)	12# 12/826 (1.5)	21# 21/1641 (1.3)	
Relation to treatment				
Definitely related	0/9 (0.0)	0/12 (0.0)	0/21 (0.0)	
Possibly related	0/9 (0.0)	0/12 (0.0)	0/21 (0.0)	
Probably not relevant	2/9 (22.2)	2/12 (16.7)	4/21 (19.0)	
Definitely irrelevant	7/9 (77.8)	10/12 (83.3)	17/21 (81.0)	
Unable to determine	0/9 (0.0)	0/12 (0.0)	0/21 (0.0)	
Diarrhoea	89# 86/815 (10.6)	55# 54/826 (6.5)	144# 140/1641 (8.5)	
Relation to treatment				
Definitely related	2/89 (2.2)	2/55 (3.6)	4/144 (2.8)	
Possibly related	55/89 (61.8)	26/55 (47.3)	81/144 (56.3)	
Probably not relevant	22/89 (24.7)	19/55 (34.5)	41/144 (28.5)	
Definitely irrelevant	8/89 (9.0)	5/55 (9.1)	13/144 (9.0)	
Unable to determine	2/89 (2.2)	3/55 (5.5)	5/144 (3.5)	

Data are n (%)

Table S31. Serious adverse events by condition until  $90\ days$ 

	FYTF-919	Placebo	Overall
Serious Adverse Event	(N=815)	(N=826)	(N=1641)
Respiratory, thoracic and mediastinal disorders	237 227 (27.9)	250 233 (28.2)	487 460 (28.0)
Pneumonia	220 218 (26.7)	228 228 (27.6)	448 446 (27.2)
Acute respiratory failure	15 15 (1.8)	18 17(2.0)	33 32 (2.0)
Haemoptysis	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Pleural effusion	1 1 (0.1)	1 1 (0.1)	2 2 (0.1)
Pulmonary embolism	0 0 (0.0)	3 3 (0.4)	3 3 (0.2)
Cardiac disorders	81 78 (9.6)	94 92 (11.1)	175 170 (10.4)
Cardiac arrest	76 75 (9.2)	85 85 (10.3)	161 160 (9.8)
Cardiac failure	3 3 (0.4)	2 2 (0.2)	5 5 (0.3)
Atrial fibrillation	2 2 (0.2)	2 2 (0.2)	4 4 (0.2)
Acute myocardial infarction	0 0 (0.0)	2 2 (0.2)	2 2 (0.2)
Acute respiratory failure	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Supraventricular tachycardia	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Ventricular fibrillation	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Vascular disorders	52 50 (6.1)	58 52 (6.3)	110 102 (6.2)
Deep venous thrombosis	42 41 (5.0)	40 38 (4.6)	82 79 (4.8)
Anaemia	9 9 (1.1)	10 9 (1.1)	19 18 (1.1)
Leg ulcer	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Coagulopathy	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Leukcopaenia	0 0 (0.0)	2 2 (0.2)	2 2 (0.1)
Thrombocytopaenia	0 0 (0.0)	5 5 (0.6)	5 5 (0.3)
Nervous system disorders	53 47 (5.8)	61 54 (6.5)	114 101 (6.2)
Intracerebral haemorrhage	14 13 (1.6)	14 14 (1.7)	28 27 (1.6)
Hydrocephalus	12 12 (1.5)	11 11 (1.3)	23 23 (1.4)
Intracerebral haemorrhage	10 10 (1.2)	14 14 (1.7)	24 24 (1.5)

	<b>FYTF-919</b>	Placebo	Overall
Serious Adverse Event	(N=815)	(N=826)	(N=1641)
Raised intracranial pressure	6 6 (0.7)	7 7 (0.8)	13 13 (0.8)
Acute ischaemic stroke	2 2 (0.2)	2 2 (0.2)	4 4 (0.2)
Epilepsy	2 2 (0.2)	4 4 (0.5)	6 6 (0.4)
Intracranial haemorrhage	2 2 (0.2)	2 2 (0.2)	4 4 (0.2)
Acute stroke undefined	1 1 (0.1)	1 1 (0.1)	2 2 (0.1)
Acute subdural haematoma	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Intraventricular haemorrhage	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Ischaemic stroke	1 1 (0.1)	4 4 (0.5)	5 5 (0.3)
Subarachnoid haemorrhage	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Cognitive impairment	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Raise intracranial pressure	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Infections and infestations	37 35 (4.3)	36 36 (4.4)	73 71 (4.3)
Meningitis	24 24 (2.9)	30 30 (3.6)	54 54 (3.3)
Septicaemia	7 7 (0.9)	0 0 (0.0)	7 7 (0.4)
Sepsis	4 4 (0.5)	5 5 (0.6)	9 9 (0.5)
Septicaemia	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Urinary tract infection	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Anaphylactic shock	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Gastrointestinal disorders	26 25 (3.1)	27 26 (3.1)	53 51 (3.1)
Abnormal liver function	11 11 (1.3)	12 12 (1.5)	23 23 (1.4)
Upper gastrointestinal bleeding	8 8 (1.0)	11 11 (1.3)	19 19 (1.2)
Upper gastrointestinal bleeding	4 4 (0.5)	2 2 (0.2)	6 6 (0.4)
Diaorrhea	2 2 (0.2)	1 1 (0.1)	3 3 (0.2)
Gastroesophageal reflux	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Acute liver failure	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Metabolism and nutrition disorders	16 12 (1.5)	8 7 (0.8)	24 19 (1.2)

	FYTF-919	Placebo	Overall
Serious Adverse Event	(N=815)	(N=826)	(N=1641)
Multiple organ failure	3 3 (0.4)	1 1 (0.1)	4 4 (0.2)
Electrolyte imbalance	2 2 (0.2)	0 0 (0.0)	2 2 (0.1)
Hypoalbuminaemia	2 2 (0.2)	1 1 (0.1)	3 3 (0.2)
Hypocalcaemia	2 2 (0.2)	0 0 (0.0)	2 2 (0.1)
Malnutrition	2 2 (0.2)	1 1 (0.1)	3 3 (0.2)
Metabolic alkalosis	2 2 (0.2)	0 0 (0.0)	2 2 (0.1)
Acute respiratory failure	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Hypokaleamia	1 1 (0.1)	3 3 (0.4)	4 4 (0.2)
Hyponatraemia	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Hyperkalaemia	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Hypernatraemia	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Renal and urinary disorders	3 3 (0.4)	6 6 (0.7)	9 9 (0.5)
Acute renal failure	3 3 (0.4)	6 6 (0.7)	9 9 (0.5)
Endocrine disorders	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Central diabetes insipidus	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Psychiatric disorders	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Anxiety	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Injury, poisoning and procedural complications	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Fracture	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)

 $\begin{tabular}{ll} \textbf{Table S32.} & \textbf{Adverse Events in the per protocol population until 90 days} \\ \end{tabular}$ 

	<b>FYTF-919</b>	Placebo	Overall	
Adverse Event	$(\mathbf{N} = 769)$	$(\mathbf{N} = 777)$	(N = 1546)	p value
Adverse Event	1679# 621/769 (80.8)	1671# 628/777 (80.8)	3350# 1249/1546 (80.8)	0.97
Relation to treatment				
Definitely related	10/1667 (0.6)	6/1661 (0.4)	16/3328 (0.5)	
Possibly related	100/1667 (6.0)	68/1661 (4.1)	168/3328 (5.0)	
probably not relevant	412/1667 (24.7)	386/1661 (23.2)	798/3328 (24.0)	
Definitely irrelevant	1127/1667 (67.6)	1187/1661 (71.5)	2314/3328 (69.5)	
Unable to determine	18/1667 (1.1)	14/1661 (0.8)	32/3328 (1.0)	
Serious Adverse Event	478# 322/769 (41.9)	513# 341/777 (43.9)	991# 663/1546 (42.9)	0.42
Relation to treatment				
Definitely related	4/478 (0.8)	0/513 (0.0)	4/991 (0.4)	
Possibly related	5/478 (1.0)	5/513 (1.0)	10/991 (1.0)	
probably not relevant	63/478 (13.2)	49/513 (9.6)	112/991 (11.3)	
Definitely irrelevant	404/478 (84.5)	457/513 (89.1)	861/991 (86.9)	
Unable to determine	2/478 (0.4)	2/513 (0.4)	4/991 (0.4)	
Adverse Event of Special Interest	108# 105/769 (13.7)	78# 75/777 (9.7)	186# 180/1546 (11.6)	0.01
<b>Relation to treatment</b>				
Definitely related	3/108 (2.8)	2/78 (2.6)	5/186 (2.7)	
Possibly related	53/108 (49.1)	26/78 (33.3)	79/186 (42.5)	
probably not relevant	23/108 (21.3)	23/78 (29.5)	46/186 (24.7)	
Definitely irrelevant	28/108 (25.9)	24/78 (30.8)	52/186 (28.0)	
Unable to determine	1/108 (0.9)	3/78 (3.8)	4/186 (2.2)	

	<b>FYTF-919</b>	Placebo	Overall	
Adverse Event	(N = 769)	$(\mathbf{N} = 777)$	(N = 1546)	p value
Hematoma enlargement (>6mL	17# 17/769 (2.2)	13# 13/777 (1.7)	30# 30/1546 (1.9)	
or33)				
Relation to treatment				
Definitely related	1/17 (5.9)	0/13 (0.0)	1/30 (3.3)	
Possibly related	0/17 (0.0)	0/13 (0.0)	0/30 (0.0)	
probably not relevant	3/17 (17.6)	3/13 (23.1)	6/30 (20.0)	
Definitely irrelevant	13/17 (76.5)	10/13 (76.9)	23/30 (76.7)	
Unable to determine	0/17 (0.0)	0/13 (0.0)	0/30 (0.0)	
New intracranial hematoma	9* 9/769 (1.2)	12# 12/777 (1.5)	21# 21/1546 (1.4)	
Relation to treatment				
Definitely related	0/9 (0.0)	0/12 (0.0)	0/21 (0.0)	
Possibly related	0/9 (0.0)	0/12 (0.0)	0/21 (0.0)	
probably not relevant	2/9 (22.2)	2/12 (16.7)	4/21 (19.0)	
Definitely irrelevant	7/9 (77.8)	10/12 (83.3)	17/21 (81.0)	
Unable to determine	0/9 (0.0)	0/12 (0.0)	0/21 (0.0)	
Diarrhoea	82* 81/769 (10.5)	53# 52/777 (6.7)	135# 133/1546 (8.6)	
Relation to treatment				
Definitely related	2/82 (2.4)	2/53 (3.8)	4/135 (3.0)	
Possibly related	53/82 (64.6)	26/53 (49.1)	79/135 (58.5)	
probably not relevant	18/82 (22.0)	18/53 (34.0)	36/135 (26.7)	
Definitely irrelevant	8/82 (9.8)	4/53 (7.5)	12/135 (8.9)	
Unable to determine	1/82 (1.2)	3/53 (5.7)	4/135 (3.0)	

 $Table \ S33.2 \ \ Adverse \ event \ terms \ in \ the \ per \ protocol \ population \ until \ 90 \ days$ 

	FYTF-919	Placebo	Overall
Serious Adverse Event	(N = 769)	(N = 777)	(N = 1546)
AE SOC/PT term			
Respiratory, thoracic and mediastinal disorders	223 215 (28.0)	241 226 (29.1)	464 441 (28.5)
Pneumonia	207 206 (26.8)	221 221 (28.4)	428 427 (27.6)
Acute respiratory failure	12 12 (1.6)	7 7 (0.9)	19 19 (1.2)
Acute respiratory failure	2 2 (0.3)	9 8 (1.0)	11 10 (0.6)
Haemoptysis	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Pleural effusion	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Acute respiratory failure	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Pulmonary embolism	0 0 (0.0)	3 3 (0.4)	3 3 (0.2)
Cardiac disorders	74 71 (9.2)	84 82 (10.6)	158 153 (9.9)
Cardiac arrest	70 69 (9.0)	75 75 (9.7)	145 144 (9.3)
Atrial fibrillation	2 2 (0.3)	2 2 (0.3)	4 4 (0.3)
Cardiac failure	2 2 (0.3)	2 2 (0.3)	4 4 (0.3)
Acute myocardial infarction	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Acute myocardial infarction	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Acute respiratory failure	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Supraventricular tachycardia	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Ventricular fibrillation	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Vascular disorders	51 49 (6.4)	57 51 (6.6)	108 100 (6.5)
Deep venous thrombosis	42 41 (5.3)	39 37 (4.8)	81 78 (5.0)
Anaemia	8 8 (1.0)	10 9 (1.2)	18 17 (1.1)
Leg ulcer	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)

	FYTF-919	Placebo	Overall
Serious Adverse Event	$(\mathbf{N} = 769)$	(N = 777)	(N = 1546)
Coagulopathy	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Leukcopaenia	0 0 (0.0)	2 2 (0.3)	2 2 (0.1)
Thrombocytopaenia	0 0 (0.0)	5 5 (0.6)	5 5 (0.3)
Nervous system disorders	49 43 (5.6)	57 50 (6.4)	106 93 (6.0)
Intracerebral haemorrhage	14 13 (1.7)	13 13 (1.7)	27 26 (1.7)
Hydrocephalus	10 10 (1.3)	10 10 (1.3)	20 20 (1.3)
Intracerebral haemorrhage	10 10 (1.3)	13 13 (1.7)	23 23 (1.5)
Raised intracranial pressure	6 6 (0.8)	7 7 (0.9)	13 13 (0.8)
Acute ischaemic stroke	2 2 (0.3)	2 2 (0.3)	4 4 (0.3)
Epilepsy	2 2 (0.3)	3 3 (0.4)	5 5 (0.3)
Acute subdural haematoma	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Intracranial haemorrhage	1 1 (0.1)	2 2 (0.3)	3 3 (0.2)
Intraventricular haemorrhage	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Ischaemic stroke	1 1 (0.1)	4 4 (0.5)	5 5 (0.3)
Subarachnoid haemorrhage	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Acute stroke undefined	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Cognitive impairment	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Raised intracranial pressure	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Infections and infestations	37 35 (4.6)	36 36 (4.6)	73 71 (4.6)
Meningitis	24 24 (3.1)	30 30 (3.9)	54 54 (3.5)
Septicaemia	7 7 (0.9)	0 0 (0.0)	7 7 (0.5)
Sepsis	4 4 (0.5)	5 5 (0.6)	9 9 (0.6)
Septicaemia	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Urinary tract infection	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)

	FYTF-919	Placebo	Overall
Serious Adverse Event	$(\mathbf{N} = 769)$	(N=777)	(N = 1546)
Anaphylactic shock	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Gastrointestinal disorders	24 23 (3.0)	26 25 (3.2)	50 48 (3.1)
Abnormal liver function	10 10 (1.3)	12 12 (1.5)	22 22 (1.4)
Upper gastrointestinal bleeding	7 7 (0.9)	10 10 (1.3)	17 17 (1.1)
Uppe rgastrointestinal bleeding	4 4 (0.5)	2 2 (0.3)	6 6 (0.4)
Diaorrhea	2 2 (0.3)	1 1 (0.1)	3 3 (0.2)
Gastroesophageal reflux	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Acute liver failure	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Metabolism and nutrition disorders	16 12 (1.6)	7 6 (0.8)	23 18 (1.2)
Multiple organ failure	3 3 (0.4)	1 1 (0.1)	4 4 (0.3)
Electrolyte imbalance	2 2 (0.3)	0 0 (0.0)	2 2 (0.1)
Hypoalbuminaemia	2 2 (0.3)	1 1 (0.1)	3 3 (0.2)
Hypocalcaemia	2 2 (0.3)	0 0 (0.0)	2 2 (0.1)
Malnutrition	2 2 (0.3)	0 0 (0.0)	2 2 (0.1)
Metabolic alkalosis	2 2 (0.3)	0 0 (0.0)	2 2 (0.1)
Acute respiratory failure	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Hypokalaemia	1 1 (0.1)	3 3 (0.4)	4 4 (0.3)
Hyponatraemia	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Hyperkalaemia	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Hypernatraemia	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Renal and urinary disorders	2 2 (0.3)	4 4 (0.5)	6 6 (0.4)
Acute renal failure	2 2 (0.3)	4 4 (0.5)	6 6 (0.4)

	<b>FYTF-919</b>	Placebo	Overall
Serious Adverse Event	(N = 769)	(N = 777)	(N = 1546)
Endocrine disorders	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Central diabetes insipidus	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Psychiatric disorders	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Anxiety	1 1 (0.1)	0 0 (0.0)	1 1 (0.1)
Injury, poisoning and procedural complications	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)
Fracture	0 0 (0.0)	1 1 (0.1)	1 1 (0.1)

Table S34. List of1 deaths by Day 180

Subject ID	Treatment group	Days from randomisation to death	Death reason
1001-0008	FYTF-919	19	Nervous system damage from this stroke
1001-0014	Placebo	163	Other - Unknown
1001-0030	FYTF-919	34	Nervous system damage from this stroke
1001-0038	Placebo	28	Cardiovascular disease
1001-0040	Placebo	21	Other - Respiratory failure
1001-0042	FYTF-919	9	Nervous system damage from this stroke
1001-0044	FYTF-919	50	Other - Unknown
1001-0049	FYTF-919	103	Cardiovascular disease
1002-0002	FYTF-919	9	Other - Unknown
1002-0019	Placebo	25	Nervous system damage from this stroke
1002-0025	Placebo	17	Nervous system damage from this stroke
1002-0027	FYTF-919	16	Nervous system damage from this stroke
1003-0007	FYTF-919	92	Nervous system damage from this stroke
1003-0011	FYTF-919	4	Other - Unknown
1003-0013	Placebo	6	Other - Respiratory failure
1003-0014	Placebo	15	Nervous system damage from this stroke
1003-0018	FYTF-919	117	Lung infection
1003-0023	FYTF-919	5	Stroke recurrence
1003-0024	FYTF-919	179	Cardiovascular disease
1003-0025	FYTF-919	73	Lung infection
1003-0030*	FYTF-919	92	Lung infection
1003-0033	FYTF-919	8	Nervous system damage from this stroke
1003-0034	Placebo	116	Other - Unknown
1003-0037*	Placebo	98	Lung infection
1003-0046	FYTF-919	58	Lung infection

003-0053         FYTF-919         57         Lung infection           003-0057         Placebo         42         Lung infection           003-0059         FYTF-919         31         Lung infection           003-0067         FYTF-919         37         Other - Unknown           003-0076         Placebo         16         Nervous system damage from this stroke           003-0081         Placebo         113         Lung infection           003-0087         FYTF-919         32         Lung infection           004-0010         Placebo         80         Nervous system damage from this stroke           005-0055         Placebo         85         Nervous system damage from this stroke           005-0067         FYTF-919         6         Nervous system damage from this stroke           005-0012         FYTF-919         6         Nervous system damage from this stroke           006-001*         FYTF-919         0ther - Unknown           006-001*         FYTF-919         Nervous system damage from this stroke           006-001*         FYTF-919         Nervous system damage from this stroke           006-001*         FYTF-919         Nervous system damage from this stroke           006-0029         Placebo         5	Subject ID	Treatment group	Days from randomisation to death	Death reason
003-0057         Placebo         42         Lung infection           003-0059         FYTF-919         31         Lung infection           003-0067         FYTF-919         37         Other - Unknown           003-0076         Placebo         16         Nervous system damage from this stroke           003-0081         Placebo         113         Lung infection           003-0087         FYTF-919         32         Lung infection           004-0010         Placebo         80         Nervous system damage from this stroke           005-0055         Placebo         85         Nervous system damage from this stroke           005-0067         FYTF-919         8         Nervous system damage from this stroke           005-0012         FYTF-919         6         Nervous system damage from this stroke           005-0012         FYTF-919         Other - Unknown           006-0018         FYTF-919         Other - Unknown           006-0018*         Placebo         13         Nervous system damage from this stroke           006-0018         Placebo         5         Nervous system damage from this stroke           006-0029         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0036	1003-0051*	FYTF-919	13	Lung infection
003-0059         FYTF-919         31         Lung infection           003-0067         FYTF-919         37         Other - Unknown           003-0076         Placebo         16         Nervous system damage from this stroke           003-0081         Placebo         113         Lung infection           003-0087         FYTF-919         32         Lung infection           004-0010         Placebo         80         Nervous system damage from this stroke           005-0055         Placebo         85         Nervous system damage from this stroke           005-012         FYTF-919         6         Nervous system damage from this stroke           005-0012         FYTF-919         6         Nervous system damage from this stroke           006-001*         FYTF-919         Other - Unknown           006-0018*         FYTF-919         Nervous system damage from this stroke           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         4         Other - Circulatory failure and Respiratory failure	1003-0053	FYTF-919	57	Lung infection
003-0067         FYTF-919         37         Other - Unknown           003-0076         Placebo         16         Nervous system damage from this stroke           003-0081         Placebo         113         Lung infection           003-0087         FYTF-919         32         Lung infection           004-0010         Placebo         80         Nervous system damage from this stroke           005-0055         Placebo         85         Nervous system damage from this stroke           005-0067         FYTF-919         8         Nervous system damage from this stroke           005-0112         FYTF-919         6         Nervous system damage from this stroke           006-001*         FYTF-919         Other - Unknown           006-0008*         FYTF-919         Nervous system damage from this stroke           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         16         Other - Unknown           006-0059	1003-0057	Placebo	42	Lung infection
003-0076         Placebo         16         Nervous system damage from this stroke           003-0081         Placebo         113         Lung infection           003-0087         FYTF-919         32         Lung infection           004-0010         Placebo         80         Nervous system damage from this stroke           005-0055         Placebo         85         Nervous system damage from this stroke           005-0067         FYTF-919         8         Nervous system damage from this stroke           005-0112         FYTF-919         6         Nervous system damage from this stroke           006-00112         FYTF-919         Other - Unknown           006-0008*         FYTF-919         Other - Unknown           006-0018*         Placebo         13         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0059         Placebo         16         Other - Unknown           006-0070         Placebo         14         Lung infection	1003-0059	FYTF-919	31	Lung infection
003-0081         Placebo         113         Lung infection           003-0087         FYTF-919         32         Lung infection           004-0010         Placebo         80         Nervous system damage from this stroke           005-0055         Placebo         85         Nervous system damage from this stroke           005-0067         FYTF-919         8         Nervous system damage from this stroke           005-0112         FYTF-919         6         Nervous system damage from this stroke           006-0001*         FYTF-919         Other - Unknown           006-0008*         FYTF-919         Nervous system damage from this stroke           006-0013*         Placebo         13         Nervous system damage from this stroke           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         16         Other - Unknown           006-0059         Placebo         16         Other - Unknown           006-0070         Placebo         14         Lung infection           006-0071	1003-0067	FYTF-919	37	Other - Unknown
003-0087         FYTF-919         32         Lung infection           004-0010         Placebo         80         Nervous system damage from this stroke           005-0055         Placebo         85         Nervous system damage from this stroke           005-0067         FYTF-919         8         Nervous system damage from this stroke           005-0112         FYTF-919         6         Nervous system damage from this stroke           006-001*         FYTF-919         Other - Unknown           006-0008*         FYTF-919         Other - Unknown           006-0013*         Placebo         Other - Unknown           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0018         Placebo         5         Nervous system damage from this stroke           006-0029         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0036         Placebo         16         Other - Unknown           006-0059         Placebo         16         Other - Unknown           006-0063         FYTF-919         7         Nervous system damage from this stroke           006-0070         Placebo<	1003-0076	Placebo	16	Nervous system damage from this stroke
004-0010         Placebo         80         Nervous system damage from this stroke           005-0055         Placebo         85         Nervous system damage from this stroke           005-0067         FYTF-919         8         Nervous system damage from this stroke           005-0112         FYTF-919         6         Nervous system damage from this stroke           006-0001*         FYTF-919         Other - Unknown           006-0008*         FYTF-919         Other - Unknown           006-0013*         Placebo         13         Nervous system damage from this stroke           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0059         Placebo         16         Other - Unknown           006-0063         FYTF-919         7         Nervous system damage from this stroke           006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         97         Other - Respiratory failure	1003-0081	Placebo	113	Lung infection
005-0055         Placebo         85         Nervous system damage from this stroke           005-0067         FYTF-919         8         Nervous system damage from this stroke           005-0112         FYTF-919         6         Nervous system damage from this stroke           006-0001*         FYTF-919         Other - Unknown           006-0008*         FYTF-919         Other - Unknown           006-0013*         Placebo         Other - Unknown           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0059         Placebo         16         Other - Unknown           006-0063         FYTF-919         7         Nervous system damage from this stroke           006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         15         Other - Unknown           006-0073         FYTF-919         97         Other - Respiratory failure           006-0070         FYTF-919         11         Nervous system damage from this stroke           006-0073 <t< td=""><td>1003-0087</td><td>FYTF-919</td><td>32</td><td>Lung infection</td></t<>	1003-0087	FYTF-919	32	Lung infection
005-0067         FYTF-919         8         Nervous system damage from this stroke           005-0112         FYTF-919         6         Nervous system damage from this stroke           006-0001*         FYTF-919         Other - Unknown           006-0013*         Placebo         Other - Unknown           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0059         Placebo         16         Other - Unknown           006-0063         FYTF-919         7         Nervous system damage from this stroke           006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         15         Other - Unknown           006-0073         FYTF-919         97         Other - Respiratory failure           006-0074         FYTF-919         11         Nervous system damage from this stroke           006-0074         FYTF-919         27         Other - Heart failure	1004-0010	Placebo	80	Nervous system damage from this stroke
005-0112         FYTF-919         6         Nervous system damage from this stroke           006-0001*         FYTF-919         Other - Unknown           006-0008*         FYTF-919         Other - Unknown           006-0013*         Placebo         Other - Unknown           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0059         Placebo         16         Other - Unknown           006-0063         FYTF-919         7         Nervous system damage from this stroke           006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         15         Other - Unknown           006-0073         FYTF-919         97         Other - Respiratory failure           006-0074         FYTF-919         11         Nervous system damage from this stroke           006-0084         FYTF-919         27         Other - Heart failure	1005-0055	Placebo	85	Nervous system damage from this stroke
006-0001*         FYTF-919         Other - Unknown           006-0008*         FYTF-919         Other - Unknown           006-0013*         Placebo         Other - Unknown           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0059         Placebo         16         Other - Unknown           006-0063         FYTF-919         7         Nervous system damage from this stroke           006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         15         Other - Unknown           006-0073         FYTF-919         97         Other - Respiratory failure           006-0074         FYTF-919         11         Nervous system damage from this stroke           006-0084         FYTF-919         27         Other - Heart failure	1005-0067	FYTF-919	8	Nervous system damage from this stroke
006-0008*         FYTF-919         Other - Unknown           006-0013*         Placebo         Other - Unknown           006-0014*         FYTF-919         Nervous system damage from this stroke           006-0018         Placebo         13         Nervous system damage from this stroke           006-0029         Placebo         5         Nervous system damage from this stroke           006-0036         Placebo         4         Other - Circulatory failure and Respiratory failure           006-0059         Placebo         16         Other - Unknown           006-0063         FYTF-919         7         Nervous system damage from this stroke           006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         15         Other - Unknown           006-0073         FYTF-919         97         Other - Respiratory failure           006-0077         FYTF-919         11         Nervous system damage from this stroke           006-0084         FYTF-919         27         Other - Heart failure	1005-0112	FYTF-919	6	Nervous system damage from this stroke
006-0013*PlaceboOther - Unknown006-0014*FYTF-919Nervous system damage from this stroke006-0018Placebo13Nervous system damage from this stroke006-0029Placebo5Nervous system damage from this stroke006-0036Placebo4Other - Circulatory failure and Respiratory failure006-0059Placebo16Other - Unknown006-0063FYTF-9197Nervous system damage from this stroke006-0070Placebo14Lung infection006-0072FYTF-91915Other - Unknown006-0073FYTF-91997Other - Respiratory failure006-0077FYTF-91911Nervous system damage from this stroke006-0084FYTF-91927Other - Heart failure	1006-0001*	FYTF-919		Other - Unknown
006-0014*FYTF-919Nervous system damage from this stroke006-0018Placebo13Nervous system damage from this stroke006-0029Placebo5Nervous system damage from this stroke006-0036Placebo4Other - Circulatory failure and Respiratory failure006-0059Placebo16Other - Unknown006-0063FYTF-9197Nervous system damage from this stroke006-0070Placebo14Lung infection006-0072FYTF-91915Other - Unknown006-0073FYTF-91997Other - Respiratory failure006-0077FYTF-91911Nervous system damage from this stroke006-0084FYTF-91927Other - Heart failure	1006-0008*	FYTF-919		Other - Unknown
006-0018Placebo13Nervous system damage from this stroke006-0029Placebo5Nervous system damage from this stroke006-0036Placebo4Other - Circulatory failure and Respiratory failure006-0059Placebo16Other - Unknown006-0063FYTF-9197Nervous system damage from this stroke006-0070Placebo14Lung infection006-0072FYTF-91915Other - Unknown006-0073FYTF-91997Other - Respiratory failure006-0077FYTF-91911Nervous system damage from this stroke006-0084FYTF-91927Other - Heart failure	1006-0013*	Placebo		Other - Unknown
006-0029Placebo5Nervous system damage from this stroke006-0036Placebo4Other - Circulatory failure and Respiratory failure006-0059Placebo16Other - Unknown006-0063FYTF-9197Nervous system damage from this stroke006-0070Placebo14Lung infection006-0072FYTF-91915Other - Unknown006-0073FYTF-91997Other - Respiratory failure006-0077FYTF-91911Nervous system damage from this stroke006-0084FYTF-91927Other - Heart failure	1006-0014*	FYTF-919		Nervous system damage from this stroke
006-0036Placebo4Other - Circulatory failure and Respiratory failure006-0059Placebo16Other - Unknown006-0063FYTF-9197Nervous system damage from this stroke006-0070Placebo14Lung infection006-0072FYTF-91915Other - Unknown006-0073FYTF-91997Other - Respiratory failure006-0077FYTF-91911Nervous system damage from this stroke006-0084FYTF-91927Other - Heart failure	1006-0018	Placebo	13	Nervous system damage from this stroke
006-0059         Placebo         16         Other - Unknown           006-0063         FYTF-919         7         Nervous system damage from this stroke           006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         15         Other - Unknown           006-0073         FYTF-919         97         Other - Respiratory failure           006-0077         FYTF-919         11         Nervous system damage from this stroke           006-0084         FYTF-919         27         Other - Heart failure	1006-0029	Placebo	5	Nervous system damage from this stroke
006-0063FYTF-9197Nervous system damage from this stroke006-0070Placebo14Lung infection006-0072FYTF-91915Other - Unknown006-0073FYTF-91997Other - Respiratory failure006-0077FYTF-91911Nervous system damage from this stroke006-0084FYTF-91927Other - Heart failure	1006-0036	Placebo	4	Other - Circulatory failure and Respiratory failure
006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         15         Other - Unknown           006-0073         FYTF-919         97         Other - Respiratory failure           006-0077         FYTF-919         11         Nervous system damage from this stroke           006-0084         FYTF-919         27         Other - Heart failure	1006-0059	Placebo	16	Other - Unknown
006-0070         Placebo         14         Lung infection           006-0072         FYTF-919         15         Other - Unknown           006-0073         FYTF-919         97         Other - Respiratory failure           006-0077         FYTF-919         11         Nervous system damage from this stroke           006-0084         FYTF-919         27         Other - Heart failure	1006-0063	FYTF-919	7	Nervous system damage from this stroke
006-0073FYTF-91997Other - Respiratory failure006-0077FYTF-91911Nervous system damage from this stroke006-0084FYTF-91927Other - Heart failure	1006-0070	Placebo	14	
006-0077 FYTF-919 11 Nervous system damage from this stroke 006-0084 FYTF-919 27 Other - Heart failure	1006-0072	FYTF-919	15	Other - Unknown
006-0084 FYTF-919 27 Other - Heart failure	1006-0073	FYTF-919	97	Other - Respiratory failure
006-0084 FYTF-919 27 Other - Heart failure	1006-0077	FYTF-919	11	Nervous system damage from this stroke
006-0109 Placebo 64 Other - Unknown	1006-0084	FYTF-919	27	
	1006-0109	Placebo	64	Other - Unknown

Subject ID	Treatment group	Days from randomisation to death	Death reason
1006-0110	Placebo	25	Other - Unknown
1006-0125	Placebo	4	Nervous system damage from this stroke
1006-0132	Placebo	29	Nervous system damage from this stroke
1006-0137	Placebo	27	Other - Unknown
1006-0138	FYTF-919	15	Nervous system damage from this stroke
1006-0139	FYTF-919	25	Other - Unknown
1006-0141	Placebo	32	Other - Unknown
1006-0144	Placebo	121	Other - Unknown
1006-0145	Placebo	31	Other - Unknown
1006-0147	FYTF-919	172	Other - Unknown
1006-0154	FYTF-919	3	Nervous system damage from this stroke
1006-0169	FYTF-919	8	Other - Unknown
1006-0178	Placebo	126	Nervous system damage from this stroke
1006-0194	FYTF-919	12	Other - Unknown
1006-0201	Placebo	44	Other - Unknown
1006-0203	Placebo	8	Nervous system damage from this stroke
1007-0012	Placebo	115	Nervous system damage from this stroke
1007-0016	FYTF-919	38	Nervous system damage from this stroke
1007-0017	FYTF-919	6	Cardiovascular disease
1007-0036	FYTF-919	83	Lung infection
1007-0063	FYTF-919	10	Nervous system damage from this stroke
1007-0070	FYTF-919	105	Nervous system damage from this stroke
1007-0075	Placebo	136	Nervous system damage from this stroke
1007-0076	FYTF-919	98	Lung infection
1009-0001	FYTF-919	11	Nervous system damage from this stroke
1009-0008	Placebo	130	Other - Unknown
1009-0041	Placebo	76	Nervous system damage from this stroke

Subject ID Treatment group Days from rando		Days from randomisation to death	Death reason
1009-0047	FYTF-919	82	Nervous system damage from this stroke
1009-0052	Placebo	3	Nervous system damage from this stroke
1010-0021	FYTF-919	152	Other - Unknown
1010-0036	Placebo	50	Lung infection
1011-0003	FYTF-919	10	Nervous system damage from this stroke
1011-0004	FYTF-919	60	Nervous system damage from this stroke
1011-0010	Placebo	36	Nervous system damage from this stroke
1011-0017	Placebo	17	Other - Unknown
1011-0021	FYTF-919	28	Nervous system damage from this stroke
1011-0032	FYTF-919	9	Other - Unknown
1011-0033	Placebo	15	Nervous system damage from this stroke
1011-0036	FYTF-919	43	Nervous system damage from this stroke
1011-0040*	Placebo	94	Other - Unknown
1011-0042	Placebo	7	Nervous system damage from this stroke
011-0043	FYTF-919	10	Nervous system damage from this stroke
1011-0046	Placebo	23	Nervous system damage from this stroke
011-0050	FYTF-919	12	Nervous system damage from this stroke
1011-0056	Placebo	37	Nervous system damage from this stroke
1011-0068*	FYTF-919	93	Other - Unknown
1011-0080*	FYTF-919	8	Nervous system damage from this stroke
1011-0081	FYTF-919	13	Nervous system damage from this stroke
1011-0094	Placebo	13	Nervous system damage from this stroke
1012-0007	Placebo	4	Other - Unknown
012-0009	FYTF-919	6	Nervous system damage from this stroke
1012-0011	Placebo	3	Nervous system damage from this stroke
1012-0015	Placebo	85	Other - Unknown
1012-0021	FYTF-919	44	Nervous system damage from this stroke

Subject ID	Treatment group	Days from randomisation to death	Death reason
1012-0023	FYTF-919	15	Other - Unknown
1012-0029	Placebo	16	Nervous system damage from this stroke
1012-0038	Placebo	92	Other - Multiple organ failure
1012-0041	Placebo	4	Other - Unknown
1012-0042	FYTF-919	2	Other - Unknown
1012-0043	Placebo	48	Other - Unknown
1013-0001*	FYTF-919	28	Other - Sudden death
1013-0008	Placebo	14	Other - Respiratory failure
1013-0024	Placebo	5	Nervous system damage from this stroke
1014-0004	FYTF-919	10	Nervous system damage from this stroke
1014-0008*	FYTF-919	30	Other - Unknown
1014-0009	FYTF-919	2	Nervous system damage from this stroke
1014-0011	Placebo	30	Lung infection
1014-0012	FYTF-919	11	Nervous system damage from this stroke
1014-0015	Placebo	93	Other - Unknown
1014-0016	Placebo	12	Nervous system damage from this stroke
1014-0017	Placebo	4	Lung infection
1014-0018	FYTF-919	10	Other - Multiple organ failure
1014-0019	FYTF-919	7	Lung infection
1014-0020	Placebo	19	Lung infection
1015-0012	Placebo	15	Nervous system damage from this stroke
1015-0013	Placebo	23	Stroke recurrence
1015-0025	FYTF-919	19	Other - Respiratory failure
1015-0027	Placebo	17	Other - Unknown
1015-0035	Placebo	21	Lung infection
1015-0036	Placebo	2	Stroke recurrence
1015-0045	Placebo	12	Nervous system damage from this stroke

015-0050         Placebo         6         Nervous system damage from this stroke           015-0052         FYTF-919         10         Nervous system damage from this stroke           015-0058         FYTF-919         136         Nervous system damage from this stroke           016-0004         FYTF-919         64         Other - Unknown           016-0008         Placebo         24         Lung infection           016-0010         Placebo         87         Lung infection           016-0015         Placebo         9         Cardiovascular disease           016-0028         Placebo         9         Nervous system damage from this stroke           017-0008         Placebo         5         Nervous system damage from this stroke           017-0012         Placebo         101         Stroke recurrence           017-0018         Placebo         3         Nervous system damage from this stroke           017-0054         Placebo         4         Lung infection           017-0078         Placebo         39         Other - Gastrointestinal bleeding           017-0105         Placebo         47         Other - Unknown           017-0108         FYTF-919         5         Nervous system damage from this stroke	Subject ID	Treatment group	Days from randomisation to death	Death reason
015-0052         FYTF-919         10         Nervous system damage from this stroke           015-0058         FYTF-919         136         Nervous system damage from this stroke           016-0004         FYTF-919         64         Other - Unknown           016-0008         Placebo         24         Lung infection           016-0010         Placebo         87         Lung infection           016-0015         Placebo         9         Cardiovascular disease           016-0028         Placebo         9         Cardiovascular disease           016-0029         Placebo         7         Nervous system damage from this stroke           017-0008         Placebo         5         Nervous system damage from this stroke           017-0012         Placebo         3         Nervous system damage from this stroke           017-0018         Placebo         4         Lung infection           017-0054         Placebo         39         Other - Gastrointestinal bleeding           017-0078         Placebo         47         Other - Gastrointestinal bleeding           017-0105         Placebo         47         Other - Unknown           017-0106         PSTF-919         5         Nervous system damage from this stroke	1015-0046	FYTF-919	22	Other - Unknown
015-0058         FYTF-919         136         Nervous system damage from this stroke           016-0004         FYTF-919         64         Other - Unknown           016-0008         Placebo         24         Lung infection           016-0010         Placebo         87         Lung infection           016-0028         Placebo         9         Cardiovascular disease           016-0029         Placebo         7         Nervous system damage from this stroke           017-0008         Placebo         5         Nervous system damage from this stroke           017-0012         Placebo         3         Nervous system damage from this stroke           017-0018         Placebo         4         Lung infection           017-0054         Placebo         3         Nervous system damage from this stroke           017-0063         FYTF-919         3         Nervous system damage from this stroke           017-0105         Placebo         47         Other - Gastrointestinal bleeding           017-0105         Placebo         47         Nervous system damage from this stroke           017-0108         FYTF-919         5         Nervous system damage from this stroke           017-0124         Placebo         68         Nervous system damage from	1015-0050	Placebo	6	Nervous system damage from this stroke
016-0004         FYTF-919         64         Other - Unknown           016-0008         Placebo         24         Lung infection           016-0010         Placebo         155         Lung infection           016-0015         Placebo         87         Lung infection           016-0028         Placebo         9         Cardiovascular disease           016-0029         Placebo         7         Nervous system damage from this stroke           017-0008         Placebo         5         Nervous system damage from this stroke           017-0012         Placebo         3         Nervous system damage from this stroke           017-0018         Placebo         4         Lung infection           017-0054         Placebo         4         Lung infection           017-0063         FYTF-919         3         Nervous system damage from this stroke           017-0105         Placebo         47         Other - Gastrointestinal bleeding           017-0105         Placebo         47         Nervous system damage from this stroke           017-0108         FYTF-919         5         Nervous system damage from this stroke           017-0124         Placebo         15         Nervous system damage from this stroke           0	1015-0052	FYTF-919	10	Nervous system damage from this stroke
016-0008         Placebo         24         Lung infection           016-0010         Placebo         155         Lung infection           016-0015         Placebo         87         Lung infection           016-0028         Placebo         9         Cardiovascular disease           016-0029         Placebo         7         Nervous system damage from this stroke           017-0008         Placebo         5         Nervous system damage from this stroke           017-0012         Placebo         3         Nervous system damage from this stroke           017-0018         Placebo         3         Nervous system damage from this stroke           017-0018         Placebo         4         Lung infection           017-0054         Placebo         4         Lung infection           017-0063         FYTF-919         3         Nervous system damage from this stroke           017-0078         Placebo         47         Other - Gastrointestinal bleeding           017-0105         Placebo         47         Nervous system damage from this stroke           017-0124         Placebo         68         Nervous system damage from this stroke           017-0134         Placebo         15         Nervous system damage from this stroke	1015-0058	FYTF-919	136	Nervous system damage from this stroke
016-0010         Placebo         155         Lung infection           016-0015         Placebo         87         Lung infection           016-0028         Placebo         9         Cardiovascular disease           016-0029         Placebo         7         Nervous system damage from this stroke           017-0008         Placebo         5         Nervous system damage from this stroke           017-0012         Placebo         3         Nervous system damage from this stroke           017-0018         Placebo         4         Lung infection           017-0054         Placebo         4         Nervous system damage from this stroke           017-0063         FYTF-919         3         Nervous system damage from this stroke           017-0078         Placebo         47         Other - Gastrointestinal bleeding           017-0105         Placebo         47         Other - Unknown           017-0108         FYTF-919         5         Nervous system damage from this stroke           017-0124         Placebo         68         Nervous system damage from this stroke           017-0134         Placebo         15         Nervous system damage from this stroke           017-0163         Placebo         15         Nervous system damage from th	1016-0004	FYTF-919	64	Other - Unknown
016-0015Placebo87Lung infection016-0028Placebo9Cardiovascular disease016-0029Placebo7Nervous system damage from this stroke017-0008Placebo5Nervous system damage from this stroke017-0012Placebo101Stroke recurrence017-0018Placebo3Nervous system damage from this stroke017-0054Placebo4Lung infection017-0063FYTF-9193Nervous system damage from this stroke017-0078Placebo39Other - Gastrointestinal bleeding017-0105Placebo47Other - Unknown017-0108FYTF-9195Nervous system damage from this stroke017-0124Placebo68Nervous system damage from this stroke017-0134Placebo15Nervous system damage from this stroke017-0163Placebo15Nervous system damage from this stroke017-0170Placebo23Lung infection017-0171Placebo23Lung infection017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0124Placebo7Nervous system damage from this stroke	1016-0008	Placebo	24	Lung infection
016-0028         Placebo         9         Cardiovascular disease           016-0029         Placebo         7         Nervous system damage from this stroke           017-0008         Placebo         5         Nervous system damage from this stroke           017-0012         Placebo         101         Stroke recurrence           017-0018         Placebo         4         Lung infection           017-0054         Placebo         4         Lung infection           017-0063         FYTF-919         3         Nervous system damage from this stroke           017-0078         Placebo         39         Other - Gastrointestinal bleeding           017-0105         Placebo         47         Other - Unknown           017-0108         FYTF-919         5         Nervous system damage from this stroke           017-0124         Placebo         68         Nervous system damage from this stroke           017-0134         Placebo         15         Nervous system damage from this stroke           017-0163         Placebo         23         Lung infection           017-0171         Placebo         23         Lung infection           017-0175         FYTF-919         56         Other - Respiratory and circulatory failure	1016-0010	Placebo	155	Lung infection
016-0029Placebo7Nervous system damage from this stroke017-0008Placebo5Nervous system damage from this stroke017-0012Placebo101Stroke recurrence017-0018Placebo3Nervous system damage from this stroke017-0054Placebo4Lung infection017-0063FYTF-9193Nervous system damage from this stroke017-0078Placebo39Other - Gastrointestinal bleeding017-0105Placebo47Other - Unknown017-0108FYTF-9195Nervous system damage from this stroke017-0124Placebo68Nervous system damage from this stroke017-0134Placebo15Nervous system damage from this stroke017-0163Placebo10Lung infection017-0171Placebo23Lung infection017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1016-0015	Placebo	87	Lung infection
017-0008Placebo5Nervous system damage from this stroke017-0012Placebo101Stroke recurrence017-0018Placebo3Nervous system damage from this stroke017-0054Placebo4Lung infection017-0063FYTF-9193Nervous system damage from this stroke017-0078Placebo39Other - Gastrointestinal bleeding017-0105Placebo47Other - Unknown017-0108FYTF-9195Nervous system damage from this stroke017-0124Placebo68Nervous system damage from this stroke017-0134Placebo15Nervous system damage from this stroke017-0163Placebo10Lung infection017-0171Placebo23Lung infection017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1016-0028	Placebo	9	Cardiovascular disease
017-0012Placebo101Stroke recurrence017-0018Placebo3Nervous system damage from this stroke017-0054Placebo4Lung infection017-0063FYTF-9193Nervous system damage from this stroke017-0078Placebo39Other - Gastrointestinal bleeding017-0105Placebo47Other - Unknown017-0108FYTF-9195Nervous system damage from this stroke017-0124Placebo68Nervous system damage from this stroke017-0134Placebo15Nervous system damage from this stroke017-0163Placebo10Lung infection017-0171Placebo23Lung infection017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1016-0029	Placebo	7	Nervous system damage from this stroke
017-0018Placebo3Nervous system damage from this stroke017-0054Placebo4Lung infection017-0063FYTF-9193Nervous system damage from this stroke017-0078Placebo39Other - Gastrointestinal bleeding017-0105Placebo47Other - Unknown017-0108FYTF-9195Nervous system damage from this stroke017-0124Placebo68Nervous system damage from this stroke017-0134Placebo15Nervous system damage from this stroke017-0163Placebo10Lung infection017-0171Placebo23Lung infection017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1017-0008	Placebo	5	Nervous system damage from this stroke
017-0054 Placebo 4 Lung infection 017-0063 FYTF-919 3 Nervous system damage from this stroke 017-0078 Placebo 39 Other - Gastrointestinal bleeding 017-0105 Placebo 47 Other - Unknown 017-0108 FYTF-919 5 Nervous system damage from this stroke 017-0124 Placebo 68 Nervous system damage from this stroke 017-0134 Placebo 15 Nervous system damage from this stroke 017-0163 Placebo 10 Lung infection 017-0171 Placebo 23 Lung infection 017-0175 FYTF-919 56 Other - Septicemia 017-0190 Placebo 93 Other - Respiratory and circulatory failure 017-0192 FYTF-919 56 Other - Respiratory and circulatory failure 017-0264 Placebo 7 Nervous system damage from this stroke	1017-0012	Placebo	101	Stroke recurrence
Nervous system damage from this stroke O17-0078 O17-0078 O17-0078 O17-0105 O17-0105 O17-0108 O17-0108 FYTF-919 O17-0124 Placebo O17-0134 Placebo O17-0163 O17-0163 O17-0171 Placebo O17-0171 Placebo O17-0175 O17-0175 FYTF-919 D17-0170 O17-0170 O17-	1017-0018	Placebo	3	Nervous system damage from this stroke
017-0078Placebo39Other - Gastrointestinal bleeding017-0105Placebo47Other - Unknown017-0108FYTF-9195Nervous system damage from this stroke017-0124Placebo68Nervous system damage from this stroke017-0134Placebo15Nervous system damage from this stroke017-0163Placebo10Lung infection017-0171Placebo23Lung infection017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1017-0054	Placebo	4	Lung infection
O17-0105 Placebo 47 Other - Unknown O17-0108 FYTF-919 5 Nervous system damage from this stroke O17-0124 Placebo 68 Nervous system damage from this stroke O17-0134 Placebo 15 Nervous system damage from this stroke O17-0163 Placebo 10 Lung infection O17-0171 Placebo 23 Lung infection O17-0175 FYTF-919 56 Other - Septicemia O17-0190 Placebo 93 Other - Respiratory and circulatory failure O17-0192 FYTF-919 56 Other - Respiratory and circulatory failure O17-0264 Placebo 7 Nervous system damage from this stroke	1017-0063	FYTF-919	3	Nervous system damage from this stroke
017-0108FYTF-9195Nervous system damage from this stroke017-0124Placebo68Nervous system damage from this stroke017-0134Placebo15Nervous system damage from this stroke017-0163Placebo10Lung infection017-0171Placebo23Lung infection017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1017-0078	Placebo	39	Other - Gastrointestinal bleeding
017-0124Placebo68Nervous system damage from this stroke017-0134Placebo15Nervous system damage from this stroke017-0163Placebo10Lung infection017-0171Placebo23Lung infection017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1017-0105	Placebo	47	Other - Unknown
017-0134 Placebo 15 Nervous system damage from this stroke 017-0163 Placebo 10 Lung infection 017-0171 Placebo 23 Lung infection 017-0175 FYTF-919 56 Other - Septicemia 017-0190 Placebo 93 Other - Respiratory and circulatory failure 017-0192 FYTF-919 56 Other - Respiratory and circulatory failure 017-0264 Placebo 7 Nervous system damage from this stroke	1017-0108	FYTF-919	5	Nervous system damage from this stroke
017-0163 Placebo 10 Lung infection 017-0171 Placebo 23 Lung infection 017-0175 FYTF-919 56 Other - Septicemia 017-0190 Placebo 93 Other - Respiratory and circulatory failure 017-0192 FYTF-919 56 Other - Respiratory and circulatory failure 017-0264 Placebo 7 Nervous system damage from this stroke	1017-0124	Placebo	68	Nervous system damage from this stroke
017-0171 Placebo 23 Lung infection 017-0175 FYTF-919 56 Other - Septicemia 017-0190 Placebo 93 Other - Respiratory and circulatory failure 017-0192 FYTF-919 56 Other - Respiratory and circulatory failure 017-0264 Placebo 7 Nervous system damage from this stroke	1017-0134	Placebo	15	Nervous system damage from this stroke
017-0175FYTF-91956Other - Septicemia017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1017-0163	Placebo	10	Lung infection
017-0190Placebo93Other - Respiratory and circulatory failure017-0192FYTF-91956Other - Respiratory and circulatory failure017-0264Placebo7Nervous system damage from this stroke	1017-0171	Placebo	23	Lung infection
017-0192 FYTF-919 56 Other - Respiratory and circulatory failure 017-0264 Placebo 7 Nervous system damage from this stroke	1017-0175	FYTF-919	56	Other - Septicemia
017-0264 Placebo 7 Nervous system damage from this stroke	1017-0190	Placebo	93	Other - Respiratory and circulatory failure
	1017-0192	FYTF-919	56	Other - Respiratory and circulatory failure
017-0267 FYTF-919 90 Other - Cachectic state	1017-0264	Placebo	7	Nervous system damage from this stroke
	1017-0267	FYTF-919	90	Other - Cachectic state

1017-0316	Subject ID	Treatment group	Days from randomisation to death	Death reason
1017-0327	1017-0291	FYTF-919	13	Nervous system damage from this stroke
1017-0333	1017-0316	FYTF-919	10	Nervous system damage from this stroke
1017-0338	1017-0327	Placebo	2	Other - Respiratory and circulatory failure
1017-0355	1017-0333	FYTF-919	120	Stroke recurrence
1017-0357         FYTF-919         16         Other - Unknown           1017-0358         Placebo         13         Nervous system damage from this stroke           1017-0365         Placebo         134         Nervous system damage from this stroke           1017-0394         Placebo         3         Nervous system damage from this stroke           1019-0002         FYTF-919         6         Cardiovascular disease           1019-0013         Placebo         2         Nervous system damage from this stroke           1019-0014         Placebo         7         Nervous system damage from this stroke           1019-0014         Placebo         31         Other - Unknown           1019-0020*         Placebo         27         Lung infection           1019-0023         Placebo         27         Lung infection           1019-0029         FYTF-919         3         Nervous system damage from this stroke           1019-0031         Placebo         5         Other - Respiratory failure           1019-0042         Placebo         5         Other - Unknown           1019-0043         FYTF-919         17         Other - Unknown           1019-0045         FYTF-919         60         Other - Unknown           1019-005	1017-0338	Placebo	52	Other - Unknown
1017-0358	1017-0355	Placebo	167	Other - Unknown
1017-0365	1017-0357	FYTF-919	16	Other - Unknown
1017-0394	1017-0358	Placebo	13	Nervous system damage from this stroke
1019-0002         FYTF-919         6         Cardiovascular disease           1019-0013         Placebo         2         Nervous system damage from this stroke           1019-0014         Placebo         7         Nervous system damage from this stroke           1019-0020*         Placebo         31         Other - Unknown           1019-0023         Placebo         27         Lung infection           1019-0029         FYTF-919         3         Nervous system damage from this stroke           1019-0031         Placebo         174         Other - Respiratory failure           1019-0042         Placebo         5         Other - Unknown           1019-0043         FYTF-919         17         Other - Unknown           1019-0045         FYTF-919         60         Other - Unknown           1019-0046         Placebo         72         Other - Unknown           1019-0052         Placebo         80         Other - Unknown           1020-0008         Placebo         5         Nervous system damage from this stroke           1020-0010         FYTF-919         4         Nervous system damage from this stroke           1020-0034         FYTF-919         6         Nervous system damage from this stroke	1017-0365	Placebo	134	Nervous system damage from this stroke
1019-0013	1017-0394	Placebo	3	Nervous system damage from this stroke
1019-0014	1019-0002	FYTF-919	6	Cardiovascular disease
1019-0020*         Placebo         31         Other - Unknown           1019-0023         Placebo         27         Lung infection           1019-0029         FYTF-919         3         Nervous system damage from this stroke           1019-0031         Placebo         174         Other - Respiratory failure           1019-0042         Placebo         5         Other - Unknown           1019-0043         FYTF-919         17         Other - Unknown           1019-0045         FYTF-919         60         Other - Unknown           1019-0046         Placebo         72         Other - Unknown           1019-0052         Placebo         80         Other - Unknown           1020-0008         Placebo         5         Nervous system damage from this stroke           1020-0010         FYTF-919         4         Nervous system damage from this stroke           1020-0034         FYTF-919         6         Nervous system damage from this stroke	1019-0013	Placebo	2	Nervous system damage from this stroke
1019-0023	1019-0014	Placebo	7	Nervous system damage from this stroke
1019-0029	1019-0020*	Placebo	31	Other - Unknown
1019-0031         Placebo         174         Other - Respiratory failure           1019-0042         Placebo         5         Other - Unknown           1019-0043         FYTF-919         17         Other - Unknown           1019-0045         FYTF-919         60         Other - Unknown           1019-0046         Placebo         72         Other - Unknown           1019-0052         Placebo         80         Other - Unknown           1020-0008         Placebo         5         Nervous system damage from this stroke           1020-0010         FYTF-919         4         Nervous system damage from this stroke           1020-0014         FYTF-919         6         Nervous system damage from this stroke           1020-0034         FYTF-919         28         Nervous system damage from this stroke	1019-0023	Placebo	27	Lung infection
1019-0042	1019-0029	FYTF-919	3	Nervous system damage from this stroke
1019-0043         FYTF-919         17         Other - Unknown           1019-0045         FYTF-919         60         Other - Unknown           1019-0046         Placebo         72         Other - Unknown           1019-0052         Placebo         80         Other - Unknown           1020-0008         Placebo         5         Nervous system damage from this stroke           1020-0010         FYTF-919         4         Nervous system damage from this stroke           1020-0014         FYTF-919         6         Nervous system damage from this stroke           1020-0034         FYTF-919         28         Nervous system damage from this stroke	1019-0031	Placebo	174	Other - Respiratory failure
1019-0045 FYTF-919 60 Other - Unknown 1019-0046 Placebo 72 Other - Unknown 1019-0052 Placebo 80 Other - Unknown 1020-0008 Placebo 5 Nervous system damage from this stroke 1020-0010 FYTF-919 4 Nervous system damage from this stroke 1020-0014 FYTF-919 6 Nervous system damage from this stroke 1020-0034 FYTF-919 28 Nervous system damage from this stroke	1019-0042	Placebo	5	Other - Unknown
1019-0046 Placebo 72 Other - Unknown 1019-0052 Placebo 80 Other - Unknown 1020-0008 Placebo 5 Nervous system damage from this stroke 1020-0010 FYTF-919 4 Nervous system damage from this stroke 1020-0014 FYTF-919 6 Nervous system damage from this stroke 1020-0034 FYTF-919 28 Nervous system damage from this stroke	1019-0043	FYTF-919	17	Other - Unknown
Placebo 80 Other - Unknown 1020-0008 Placebo 5 Nervous system damage from this stroke 1020-0010 FYTF-919 4 Nervous system damage from this stroke 1020-0014 FYTF-919 6 Nervous system damage from this stroke 1020-0034 FYTF-919 28 Nervous system damage from this stroke	1019-0045	FYTF-919	60	Other - Unknown
1020-0008 Placebo 5 Nervous system damage from this stroke	1019-0046	Placebo	72	Other - Unknown
Nervous system damage from this stroke	1019-0052	Placebo	80	Other - Unknown
1020-0014 FYTF-919 6 Nervous system damage from this stroke Nervous system damage from this stroke Nervous system damage from this stroke	1020-0008	Placebo	5	Nervous system damage from this stroke
1020-0034 FYTF-919 28 Nervous system damage from this stroke	1020-0010	FYTF-919	4	Nervous system damage from this stroke
, c	1020-0014	FYTF-919	6	Nervous system damage from this stroke
1020-0039 FYTF-919 25 Other - Heart failure	1020-0034	FYTF-919	28	Nervous system damage from this stroke
	1020-0039	FYTF-919	25	Other - Heart failure

Subject ID	Subject ID Treatment group Days from randomisation to death Death r		Death reason
1020-0044	FYTF-919	20	Nervous system damage from this stroke
1020-0054	Placebo	22	Other - Pulmonary embolism
1020-0059	FYTF-919	27	Other - Epilepsy
1020-0060	FYTF-919	9	Nervous system damage from this stroke
1020-0065	Placebo	27	Nervous system damage from this stroke
1020-0066	FYTF-919	3	Nervous system damage from this stroke
1020-0070	Placebo	2	Nervous system damage from this stroke
1023-0004	FYTF-919	52	Nervous system damage from this stroke
1023-0006	FYTF-919	2	Nervous system damage from this stroke
1023-0007	Placebo	164	Other - Unknown
1025-0001*	Placebo		Other - Unknown
1025-0004	FYTF-919	9	Nervous system damage from this stroke
1026-0009	Placebo	104	Other - Unknown
1026-0010	FYTF-919	6	Nervous system damage from this stroke
1026-0018*	FYTF-919	97	Other - Unknown
1026-0024	Placebo	14	Nervous system damage from this stroke
1026-0031	FYTF-919	2	Nervous system damage from this stroke
1026-0032	Placebo	29	Lung infection
1026-0036	FYTF-919	109	Stroke recurrence
1026-0042	FYTF-919	23	Lung infection
1026-0043	Placebo	13	Other - Unknown
1026-0050	FYTF-919	4	Nervous system damage from this stroke
1028-0001	Placebo	23	Other - Unknown
1028-0005	FYTF-919	12	Lung infection
1028-0006	Placebo	11	Other - Respiratory failure
1028-0009	FYTF-919	10	Other - Respiratory failure
1028-0011	FYTF-919	19	Other - Respiratory failure

Subject ID	Treatment group	Days from randomisation to death	Death reason
1028-0019	FYTF-919	11	Other - Respiratory failure
1029-0009	FYTF-919	63	Other - Gastrointestinal bleeding
1030-0003	FYTF-919	12	Nervous system damage from this stroke
1031-0006	FYTF-919	150	Nervous system damage from this stroke
1031-0040	Placebo	13	Other - Respiratory failure
1031-0051	FYTF-919	29	Nervous system damage from this stroke
1031-0052	Placebo	7	Stroke recurrence
1031-0060	FYTF-919	9	Nervous system damage from this stroke
1031-0082	FYTF-919	74	Other - Unknown
1031-0083	FYTF-919	15	Nervous system damage from this stroke

Table S35.2 List of all serious adverse events by Day 180

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1001-0001	Placebo	25NOV2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1001-0002	Placebo	01DEC2021	Pneumonia	probably not relevant	Recovered/Resolved
1001-0007	Placebo	13DEC2021	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1001-0008	FYTF-919	28DEC2021	Respiratory failure	probably not relevant	death
		15DEC2021	Stroke-associated pneumonia	Definitely irrelevant	death
1001-0010	Placebo	21DEC2021	Pneumonia	probably not relevant	Recovered/Resolved
1001-0012	FYTF-919	08JAN2022	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
1001-0014	Placebo	21JUN2022	Death	Definitely irrelevant	death
1001-0015	FYTF-919	13JAN2022	Sepsis	Definitely irrelevant	Recovered/Resolved
1001-0022	FYTF-919	02FEB2022	Pneumonia	probably not relevant	Recovered/Resolved
1001-0027	FYTF-919	14MAR2022	Pneumonia	probably not relevant	Recovered/Resolved
		06MAR2022	Epilepsy	probably not relevant	Recovered/Resolved
1001-0030	FYTF-919	28APR2022	Death	Definitely irrelevant	death
1001-0031	FYTF-919	29MAR2022	Pneumonia	probably not relevant	Recovered/Resolved
1001-0034	FYTF-919	06MAY2022	Pneumonia	probably not relevant	Recovered/Resolved
1001-0036	Placebo	22NOV2022	Anemia	Definitely irrelevant	Recovered/Resolved
1001-0037	Placebo	08DEC2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		08DEC2022	Acute myocardial infarction	probably not relevant	Recovered/Resolved
1001-0038	Placebo	26JAN2023	Hyperkalaemia	Definitely irrelevant	death
		29JAN2023	Sepsis	Definitely irrelevant	death
		29JAN2023	Pneumonia	Definitely irrelevant	death
1001-0039	FYTF-919	09FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1001-0040	Placebo	15APR2023	Respiratory failure	Definitely irrelevant	death
1001-0041	Placebo	06APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		16APR2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		05APR2023	Anaemia	Definitely irrelevant	Recovered/Resolved
1001-0042	FYTF-919	15APR2023	Respiratory failure	Definitely irrelevant	death
1001-0044	FYTF-919	15MAY2023	Pneumonia	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		29JUN2023	Death	Definitely irrelevant	death
1001-0045	FYTF-919	06JUN2023	Pneumonia	probably not relevant	Recovered/Resolved
		07JUN2023	Intracranial infection	probably not relevant	Recovered/Resolved
1001-0047	FYTF-919	17JUN2023	Pneumonia	probably not relevant	Recovered/Resolved
1001-0048	Placebo	24JUL2023	Anaemia	Definitely irrelevant	Recovered/Resolved
1001-0049	FYTF-919	16NOV2023	Death	Definitely irrelevant	death
1001-0050	FYTF-919	22AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0001	FYTF-919	15JAN2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0002	FYTF-919	18JAN2022	Pneumonia	Definitely irrelevant	death
		25JAN2022	Heart failure	Definitely irrelevant	death
1002-0004	FYTF-919	02FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0007	FYTF-919	11APR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		11APR2022	Intracerebral haemorrhage	Definitely irrelevant	Recovered/Resolved
1002-0008	Placebo	25MAY2022	Intracerebral haemorrhage	Definitely irrelevant	Recovered/Resolved
1002-0009	Placebo	10MAY2022	Haematoma expansion	probably not relevant	Recovered/resolved with sequelae
1002-0019	Placebo	13JAN2022	Death	Definitely irrelevant	death
1002-0024	FYTF-919	18MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0025	Placebo	09APR2022	Ischaemic stroke	Definitely irrelevant	death
		11APR2022	Death	Definitely irrelevant	death
1002-0026	Placebo	01APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0027	FYTF-919	24APR2023	Brain herniation	Definitely irrelevant	death
		24APR2023	Intracerebral haemorrhage	Definitely irrelevant	death
1002-0028	Placebo	13MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0030	FYTF-919	21MAY2023	Haematoma expansion	Definitely irrelevant	Recovered/Resolved
1002-0032	FYTF-919	14SEP2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0033	Placebo	28SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0035	FYTF-919	18OCT2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1002-0036	Placebo	22OCT2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1003-0007	FYTF-919	17MAY2022	Death	probably not relevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1003-0011	FYTF-919	25MAR2022	Death	Definitely irrelevant	death
		22FEB2022	Heart failure	Definitely irrelevant	death
		23FEB2022	Hydrocephalus	Definitely irrelevant	death
1003-0012	Placebo	22FEB2022	Stroke-associated pneumonia	Definitely irrelevant	Recovered/Resolved
1003-0013	Placebo	01MAR2022	Death	probably not relevant	death
1003-0014	Placebo	10MAR2022	Death	probably not relevant	death
1003-0018	FYTF-919	18MAR2022	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		03JUL2022	Death	Definitely irrelevant	death
1003-0020	Placebo	20MAR2022	Stroke-associated pneumonia	probably not relevant	Recovered/Resolved
1003-0023	FYTF-919	28MAR2022	Haematoma expansion	probably not relevant	death
		31MAR2022	Death	probably not relevant	death
		28MAR2022	Stroke-associated pneumonia	probably not relevant	death
1003-0024	FYTF-919	23SEP2022	Cardiogenic shock	Definitely irrelevant	death
		24SEP2022	Death	probably not relevant	death
1003-0025	FYTF-919	10JUN2022	Death	Definitely irrelevant	death
1003-0030	FYTF-919	11OCT2022	Death	Definitely irrelevant	death
1003-0033	FYTF-919	25JUL2022	Death	probably not relevant	death
1003-0034	Placebo	25NOV2022	Death	Definitely irrelevant	death
		09AUG2022	Pneumonia	probably not relevant	Recovered/resolved with sequelae
1003-0037	Placebo	17APR2023	Death	Definitely irrelevant	death
1003-0046	FYTF-919	07FEB2023	Death	Definitely irrelevant	death
		14DEC2022	Hydrocephalus	probably not relevant	Recovered/resolved with sequelae
1003-0051	FYTF-919	17APR2023	Death	Definitely irrelevant	death
1003-0053	FYTF-919	12FEB2023	Diarrhea	probably not relevant	Recovered/Resolved
		06APR2023	Death	probably not relevant	death
1003-0057	Placebo	17MAR2023	Acute respiratory failure	probably not relevant	Recovered/resolved with sequelae
		29MAR2023	Death	probably not relevant	death
1003-0059	FYTF-919	22MAR2023	Death	probably not relevant	death
1003-0061	FYTF-919	04MAR2023	Venous thrombosis limb	probably not relevant	Recovered/resolved with sequelae

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		03MAR2023	Haematoma expansion	probably not relevant	Recovered/Resolved
1003-0066	FYTF-919	07MAR2023	Haematoma expansion	probably not relevant	Recovered/Resolved
1003-0067	FYTF-919	23APR2023	Death	probably not relevant	death
		15MAR2023	Stroke-associated pneumonia	probably not relevant	Recovered/Resolved
1003-0070	FYTF-919	24MAR2023	Stroke-associated pneumonia	probably not relevant	Recovered/Resolved
1003-0072	FYTF-919	24MAR2023	Stroke-associated pneumonia	probably not relevant	Recovered/Resolved
1003-0074	Placebo	14APR2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1003-0076	Placebo	24MAR2023	Hydrocephalus	Definitely irrelevant	Recovered/resolved with sequelae
		09MAY2023	Death	Definitely irrelevant	death
1003-0077	FYTF-919	14MAY2023	Intracranial infection	probably not relevant	Recovered/Resolved
1003-0081	Placebo	08SEP2023	Death	Definitely irrelevant	death
1003-0087	FYTF-919	14OCT2023	Multiple organ failure	Definitely irrelevant	death
		08NOV2023	Death	Definitely irrelevant	death
1004-0010	Placebo	07APR2023	Death	Definitely irrelevant	death
1005-0003	Placebo	04JUN2022	Intracerebral haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
1005-0012	Placebo	06MAY2022	Venous thrombosis limb	Definitely irrelevant	Recovered/Resolved
1005-0013	FYTF-919	06MAY2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		06MAY2022	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1005-0019	FYTF-919	23NOV2022	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1005-0020	Placebo	31JAN2023	Venous thrombosis limb	Definitely irrelevant	Recovered/Resolved
		19FEB2023	Myocardial infarction	Definitely irrelevant	Recovered/Resolved
		29JAN2023	Thrombocytopenia	Definitely irrelevant	Recovered/Resolved
		29JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1005-0022	Placebo	06FEB2023	Venous thrombosis deep	Definitely irrelevant	Recovered/Resolved
1005-0026	Placebo	12FEB2023	Lymphocyte count decreased	Definitely irrelevant	Recovered/Resolved
1005-0027	FYTF-919	12FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1005-0028	FYTF-919	20FEB2023	Intermuscular venous thrombosis	Definitely irrelevant	Recovered/Resolved
1005-0029	Placebo	12FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		14FEB2023	Lymphocyte count decreased	Definitely irrelevant	Recovered/Resolved

	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1005-0031	Placebo	17FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		22FEB2023	Venous thrombosis deep	Definitely irrelevant	Recovered/Resolved
1005-0033	Placebo	23FEB2023	Brain herniation	Definitely irrelevant	Recovered/Resolved
		23FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1005-0037	Placebo	02MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1005-0038	Placebo	03MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1005-0040	FYTF-919	13MAR2023	Intermuscular venous thrombosis	Definitely irrelevant	Recovered/Resolved
1005-0043	Placebo	20MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		07APR2023	Venous thrombosis deep	Definitely irrelevant	Recovered/Resolved
		12JUL2023	Intracerebral haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
1005-0046	Placebo	25MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1005-0047	Placebo	07APR2023	Pulmonary embolism	Definitely irrelevant	Recovered/Resolved
		13APR2023	Hepatic function abnormal	Definitely irrelevant	Recovered/Resolved
		05APR2023	Venous thrombosis deep	Definitely irrelevant	Recovered/Resolved
		24MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		06APR2023	Atrial fibrillation	Definitely irrelevant	Recovered/Resolved
		06APR2023	Cardiac insufficiency	Definitely irrelevant	Recovered/Resolved
1005-0048	Placebo	31MAR2023	Renal insufficiency	Definitely irrelevant	Recovered/Resolved
		31MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1005-0051	Placebo	01MAY2023	Bacterial pneumonia	Definitely irrelevant	Recovered/Resolved
1005-0055	Placebo	15MAY2023	Pneumonia	Definitely irrelevant	death
1005-0056	FYTF-919	11MAY2023	Venous thrombosis limb	Definitely irrelevant	Recovered/Resolved
1005-0061	Placebo	05JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		28JUN2023	Thrombocytopenia	Definitely irrelevant	Recovered/Resolved
1005-0067	FYTF-919	13AUG2023	Death	Definitely irrelevant	death
		08AUG2023	Intracranial infection	Definitely irrelevant	death
		13AUG2023	Venous thrombosis deep	Definitely irrelevant	death
1005-0094	FYTF-919	02NOV2023	Hydrocephalus	Definitely irrelevant	Recovered/Resolved
1005-0098	Placebo	06FEB2024	Intracerebral haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1005-0102	Placebo	15NOV2023	Hypokalaemia	Definitely irrelevant	Recovered/Resolved
1005-0111	FYTF-919	14DEC2023	Hepatic function abnormal	Definitely irrelevant	Recovered/Resolved
1005-0112	FYTF-919	18DEC2023	Venous thrombosis deep	Definitely irrelevant	death
		18DEC2023	Cardiogenic shock	Definitely irrelevant	death
		18DEC2023	Septic shock	Definitely irrelevant	death
1005-0113	FYTF-919	22DEC2023	Venous thrombosis limb	Definitely irrelevant	Recovered/resolved with sequelae
1005-0116	FYTF-919	03JAN2024	Venous thrombosis limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0001	FYTF-919		Death	Unable to determine	death
1006-0006	Placebo	12DEC2021	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		12DEC2021	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
		19DEC2021	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0008	FYTF-919		Death	Definitely irrelevant	death
		25DEC2021	Intracranial infection	Definitely irrelevant	death
		14DEC2021	Hydrocephalus	Definitely irrelevant	death
		12DEC2021	Pneumonia	Definitely irrelevant	death
1006-0009	Placebo	18DEC2021	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
		18DEC2021	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0010	FYTF-919	29DEC2021	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0012	FYTF-919	01JAN2022	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
1006-0013	Placebo	03JAN2022	Sepsis	Definitely irrelevant	death
		01JAN2022	Pneumonia	probably not relevant	death
			Death	Definitely irrelevant	death
1006-0014	FYTF-919		Death	Definitely irrelevant	death
		30DEC2021	Respiratory failure	Definitely irrelevant	death
1006-0015	FYTF-919	09JAN2022	Venous thrombosis deep limb	probably not relevant	Recovered/resolved with sequelae
		02JAN2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1006-0018	Placebo	09JAN2022	Intracranial infection	Definitely irrelevant	death
			Death	Definitely irrelevant	death
1006-0020	Placebo	11JAN2022	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae

Placebo 11FEB2022 Brain herniation Definitely irrelevant 09FEB2022 Pneumonia Definitely irrelevant 1006-0031 Placebo 20FEB2022 Intracranial infection Definitely irrelevant 1006-0035 FYTF-919 09MAR2022 Venous thrombosis deep limb Definitely irrelevant Placebo 09MAR2022 Death Definitely irrelevant R 1006-0040 Placebo 20MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0044 FYTF-919 24MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0045 Placebo 22MAR2022 Pneumonia Definitely irrelevant 1006-0050 FYTF-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0051 Placebo 28APR2022 Intracranial infection Definitely irrelevant 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant P 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant P 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant P 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelevant P 1006-0055 PYTF-919 Venous thrombosis deep limb Definitely irrelev	Recovered/resolved with sequelae death death Recovered/Resolved Recovered/resolved with sequelae death Recovered/resolved with sequelae Recovered/resolved with sequelae Recovered/Resolved Recovered/Resolved Recovered/resolved with sequelae
1006-0031 Placebo 20FEB2022 Intracranial infection Definitely irrelevant 1006-0035 FYTF-919 09MAR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0036 Placebo 09MAR2022 Death Definitely irrelevant 1006-0040 Placebo 20MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0044 FYTF-919 24MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0045 Placebo 22MAR2022 Pneumonia Definitely irrelevant 1006-0050 FYTF-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0051 Placebo 28APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	death Recovered/Resolved Recovered/resolved with sequelae death Recovered/resolved with sequelae Recovered/resolved with sequelae Recovered/Resolved
1006-0031 Placebo 20FEB2022 Intracranial infection Definitely irrelevant 1006-0035 FYTF-919 09MAR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0036 Placebo 09MAR2022 Death Definitely irrelevant 1006-0040 Placebo 20MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0044 FYTF-919 24MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0045 Placebo 22MAR2022 Pneumonia Definitely irrelevant 1006-0050 FYTF-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant 1006-0051 Placebo 28APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/Resolved Recovered/resolved with sequelae death Recovered/resolved with sequelae Recovered/resolved with sequelae Recovered/Resolved
1006-0035 FYTF-919 09MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0036 Placebo 09MAR2022 Death Definitely irrelevant Definitely irrelevant Placebo 20MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0044 FYTF-919 24MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0045 Placebo 22MAR2022 Pneumonia Definitely irrelevant Definitely irrelevant Prytr-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant R 08APR2022 Intracranial infection Definitely irrelevant Definitely irrelevant Definitely irrelevant Placebo 28APR2022 Venous thrombosis deep limb Definitely irrelevant Definitely irrelevant Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/resolved with sequelae death Recovered/resolved with sequelae Recovered/resolved with sequelae Recovered/Resolved
1006-0036 Placebo 09MAR2022 Death Definitely irrelevant 1006-0040 Placebo 20MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0044 FYTF-919 24MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0045 Placebo 22MAR2022 Pneumonia Definitely irrelevant 1006-0050 FYTF-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant 1006-0051 Placebo 28APR2022 Intracranial infection Definitely irrelevant 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	death Recovered/resolved with sequelae Recovered/resolved with sequelae Recovered/Resolved
1006-0040 Placebo 20MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0044 FYTF-919 24MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0045 Placebo 22MAR2022 Pneumonia Definitely irrelevant Definitely irrelevant R 1006-0050 FYTF-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0051 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/resolved with sequelae Recovered/resolved with sequelae Recovered/Resolved
1006-0044 FYTF-919 24MAR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0045 Placebo 22MAR2022 Pneumonia Definitely irrelevant Definitely irrelevant R 1006-0050 FYTF-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0051 Placebo 28APR2022 Venous thrombosis deep limb Definitely irrelevant Definitely irrelevant R 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/resolved with sequelae Recovered/Resolved
1006-0045 Placebo 22MAR2022 Pneumonia Definitely irrelevant 1006-0050 FYTF-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant 1006-0051 Placebo 28APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/Resolved
1006-0050 FYTF-919 10MAY2022 Venous thrombosis deep limb Definitely irrelevant R 08APR2022 Intracranial infection Definitely irrelevant 1006-0051 Placebo 28APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	
1006-0051 Placebo 28APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/resolved with sequelae
1006-0051 Placebo 28APR2022 Venous thrombosis deep limb Definitely irrelevant 1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/resolved with sequerae
1006-0052 Placebo 17APR2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/Resolved
1006-0055 FYTF-919 09MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/Resolved
1006-0057 Placebo 19MAY2022 Venous thrombosis deep limb Definitely irrelevant R 1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/resolved with sequelae
1006-0059 Placebo 30JUN2022 Renal insufficiency probably not relevant	Recovered/resolved with sequelae
	Recovered/resolved with sequelae
09JUL2022 Venous thrombosis deep limb Definitely irrelevant	death
	death
02JUL2022 Pneumonia Definitely irrelevant	death
1006-0060 Placebo 09SEP2022 Hepatic function abnormal probably not relevant	Recovered/Resolved
1006-0061 FYTF-919 04AUG2022 Venous thrombosis deep limb Definitely irrelevant R	Recovered/resolved with sequelae
1006-0062 Placebo 11AUG2022 Venous thrombosis deep limb Definitely irrelevant R	Recovered/resolved with sequelae
09AUG2022 Intracranial infection Definitely irrelevant R	Recovered/resolved with sequelae
1006-0064 Placebo 03SEP2022 Venous thrombosis deep limb Definitely irrelevant R	Recovered/resolved with sequelae
16AUG2022 Pneumonia Definitely irrelevant R	Recovered/resolved with sequelae
1006-0065 FYTF-919 25SEP2022 Venous thrombosis deep limb Definitely irrelevant	Recovered/Resolved
29AUG2022 Pneumonia Definitely irrelevant R	Recovered/resolved with sequelae
1006-0067 Placebo 19NOV2022 Pneumonia Definitely irrelevant	Recovered/Resolved
1006-0068 Placebo 08DEC2022 Pneumonia probably not relevant	Recovered/Resolved
1006-0069 FYTF-919 10DEC2022 Venous thrombosis deep limb Definitely irrelevant R	Recovered/resolved with sequelae

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1006-0070	Placebo	23DEC2022	Death	Definitely irrelevant	death
1006-0071	Placebo	11DEC2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1006-0072	FYTF-919	11FEB2023	Death	Definitely irrelevant	death
1006-0073	FYTF-919	07MAY2023	Death	Definitely irrelevant	death
1006-0075	FYTF-919	20FEB2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
		14FEB2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0077	FYTF-919	12FEB2023	Pneumonia	Definitely irrelevant	death
1006-0079	Placebo	06MAR2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0083	Placebo	12MAR2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1006-0084	FYTF-919	08MAR2023	Pneumonia	probably not relevant	death
		03APR2023	Death	Definitely irrelevant	death
1006-0085	Placebo	01APR2023	Venous thrombosis limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0087	FYTF-919	13MAR2023	Fever	probably not relevant	Recovered/Resolved
1006-0088	Placebo	20MAR2023	Venous thrombosis limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0089	FYTF-919	25MAR2023	Hepatic function abnormal	probably not relevant	Recovered/resolved with sequelae
1006-0090	FYTF-919	23MAR2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0091	FYTF-919	23MAR2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0093	Placebo	10APR2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0094	FYTF-919	12APR2023	Pneumonia	probably not relevant	Recovered/resolved with sequelae
		19APR2023	Intracranial infection	probably not relevant	Recovered/resolved with sequelae
1006-0097	Placebo	23APR2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		25APR2023	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
		23APR2023	Hepatic function abnormal	probably not relevant	Recovered/Resolved
1006-0098	Placebo	25APR2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
		20APR2023	Hypoxemia	Definitely irrelevant	Recovered/Resolved
1006-0099	Placebo	28APR2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
		21APR2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0100	FYTF-919	01MAY2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0101	FYTF-919	30APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		04MAY2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1006-0102	FYTF-919	04MAY2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		09MAY2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0105	FYTF-919	06MAY2023	Brain herniation	Definitely irrelevant	Recovered/resolved with sequelae
		06MAY2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0109	Placebo	15MAY2023	Pneumonia	Definitely irrelevant	death
		17JUL2023	Death	Definitely irrelevant	death
1006-0110	Placebo	15JUN2023	Death	probably not relevant	death
		23MAY2023	Brain herniation	Definitely irrelevant	death
1006-0113	FYTF-919	04JUN2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0118	FYTF-919	07JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1006-0119	FYTF-919	09JUN2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0121	FYTF-919	17JUN2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0122	Placebo	20JUN2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0124	FYTF-919	26JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		29JUN2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1006-0125	Placebo	04JUL2023	Death	Definitely irrelevant	death
1006-0126	FYTF-919	05JUL2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0127	Placebo	09JUL2023	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
1006-0128	FYTF-919	13JUL2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0130	Placebo	25JUL2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		22JUL2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0132	Placebo	24AUG2023	Death	Definitely irrelevant	death
		30JUL2023	Intracranial infection	Definitely irrelevant	death
1006-0134	FYTF-919	15AUG2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0136	Placebo	18AUG2023	Sepsis	Definitely irrelevant	Recovered/resolved with sequelae
		08SEP2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0137	Placebo	12AUG2023	Venous thrombosis deep limb	probably not relevant	death
		12AUG2023	Pneumonia	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		12AUG2023	Venous thrombosis deep limb	Definitely irrelevant	death
1006-0138	FYTF-919	19AUG2023	Intracranial infection	Definitely irrelevant	death
		28AUG2023	Death	Definitely irrelevant	death
1006-0139	FYTF-919	17AUG2023	Pneumonia	Definitely irrelevant	death
		20AUG2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		10SEP2023	Death	Definitely irrelevant	death
1006-0141	Placebo	20SEP2023	Death	Definitely irrelevant	death
1006-0142	FYTF-919	24AUG2023	Venous thrombosis deep limb	probably not relevant	Recovered/resolved with sequelae
		10SEP2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1006-0143	FYTF-919	29AUG2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0144	Placebo	02SEP2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		19FEB2024	Death	Definitely irrelevant	death
1006-0145	Placebo	28AUG2023	Pneumonia	Definitely irrelevant	death
		27SEP2023	Death	Definitely irrelevant	death
1006-0146	FYTF-919	01SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1006-0147	FYTF-919	04SEP2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		21FEB2024	Death	Definitely irrelevant	death
1006-0148	Placebo	08SEP2023	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
1006-0149	Placebo	04SEP2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0150	FYTF-919	09SEP2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0151	Placebo	12SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		19SEP2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0152	Placebo	20SEP2023	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
1006-0153	Placebo	21SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1006-0154	FYTF-919	22SEP2023	Death	Definitely irrelevant	death
1006-0155	FYTF-919	22SEP2023	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
1006-0157	Placebo	23SEP2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1006-0159	Placebo	28SEP2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0160	FYTF-919	27SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1006-0161	FYTF-919	16NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
		08OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0162	Placebo	11OCT2023	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
1006-0163	Placebo	09OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0164	FYTF-919	10OCT2023	Anemia	probably not relevant	Recovered/Resolved
1006-0166	FYTF-919	18OCT2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0167	Placebo	19OCT2023	Intracranial infection	Definitely irrelevant	Recovered/resolved with sequelae
1006-0169	FYTF-919	25OCT2023	Death	Definitely irrelevant	death
1006-0171	FYTF-919	23OCT2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1006-0172	Placebo	25OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0173	Placebo	25OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0174	FYTF-919	26OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0175	FYTF-919	01NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1006-0176	FYTF-919	30OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		05NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0178	Placebo	14NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
		28OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		01MAR2024	Death	Definitely irrelevant	death
1006-0179	Placebo	04NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0180	FYTF-919	02NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		06NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
		06NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0181	FYTF-919	02NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0183	FYTF-919	08NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1006-0185	Placebo	14NOV2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
		06NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0186	Placebo	07NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0190	Placebo	22NOV2023	Liver failure	probably not relevant	Recovered/Resolved
		30NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1006-0191	FYTF-919	14NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0192	Placebo	17NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0193	FYTF-919	14NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0194	FYTF-919	14NOV2023	Pneumonia	Definitely irrelevant	death
		25NOV2023	Death	Definitely irrelevant	death
1006-0199	Placebo	22NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0201	Placebo	04DEC2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		16JAN2024	Death	Definitely irrelevant	death
1006-0202	FYTF-919	05DEC2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1006-0203	Placebo	06DEC2023	Pneumonia	Definitely irrelevant	death
		14DEC2023	Brain herniation	Definitely irrelevant	death
		14DEC2023	Death	probably not relevant	death
1007-0003	Placebo	08DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1007-0009	Placebo	30JAN2022	Hydrocephalus	Definitely irrelevant	Recovered/resolved with sequelae
		22FEB2022	Cerebellar infarction	Unable to determine	Recovered/resolved with sequelae
1007-0012	Placebo	03JUN2022	Death	Definitely irrelevant	death
1007-0013	Placebo	20FEB2022	Uremia	Definitely irrelevant	Recovered/resolved with sequelae
1007-0016	FYTF-919	14MAR2022	Intracerebral hemorrhage	Definitely irrelevant	death
		02MAR2022	Pneumonia	Definitely irrelevant	death
		07APR2022	Death	Definitely irrelevant	death
		03APR2022	Brain herniation	Definitely irrelevant	death
		03APR2022	Intracranial infection	Definitely irrelevant	death
1007-0017	FYTF-919	07MAR2022	Death	Definitely irrelevant	death
		04MAR2022	Atrial fibrillation	Definitely irrelevant	death
		04MAR2022	Septicemia	Definitely irrelevant	death
1007-0027	Placebo	04JUL2022	Cardiac arrest	Definitely irrelevant	Recovered/resolved with sequelae
1007-0032	Placebo	02SEP2022	Acute upper gastrointestinal bleeding	Definitely irrelevant	Recovered/Resolved
1007-0036	FYTF-919	01JAN2023	Death	Definitely irrelevant	death
		09NOV2022	Pneumonia	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1007-0051	FYTF-919	26APR2023	Acute upper gastrointestinal bleeding	probably not relevant	Recovered/resolved with sequelae
1007-0060	Placebo	18AUG2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1007-0063	FYTF-919	05SEP2023	Death	Definitely irrelevant	death
		25AUG2023	Brain herniation	Definitely irrelevant	death
		31AUG2023	Hydrocephalus	Definitely irrelevant	death
1007-0070	FYTF-919	06FEB2024	Intracerebral hemorrhage	Definitely irrelevant	death
1007-0075	Placebo	08DEC2023	Pneumonia	Definitely irrelevant	death
		05DEC2023	Intracranial infection	Definitely irrelevant	death
1009-0001	FYTF-919	30JAN2022	Respiratory acidosis	Definitely irrelevant	death
		30JAN2022	Hypoalbuminemia	Definitely irrelevant	death
		29JAN2022	Pneumonia	Definitely irrelevant	death
		01FEB2022	Venous thrombosis limb	Definitely irrelevant	death
1009-0003	Placebo	15APR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		14APR2022	Upper gastrointestinal bleeding	probably not relevant	Recovered/Resolved
		27APR2022	Sepsis	Definitely irrelevant	Recovered/Resolved
1009-0008	Placebo	11AUG2022	Stress ulcer bleeding	Definitely irrelevant	Recovered/Resolved
		15AUG2022	Hepatic function abnormal	Definitely irrelevant	death
		16DEC2022	Death	Definitely irrelevant	death
1009-0013	Placebo	14NOV2022	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		15NOV2022	Thrombocytopenia	Definitely irrelevant	Recovered/Resolved
1009-0014	FYTF-919	14NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1009-0023	Placebo	24DEC2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1009-0024	Placebo	10JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		11JAN2023	Chronic renal failure acute exacerbation?	Possibly related	Recovered/resolved with sequelae
		11JAN2023	Hypoxemia	Definitely irrelevant	Recovered/Resolved
1009-0025	FYTF-919	27JAN2023	Acute renal insufficiency	Definitely irrelevant	Recovered/Resolved
1009-0035	FYTF-919	26MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1009-0038	FYTF-919	03JUL2023	Electrolyte imbalance	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1009-0039	Placebo	30JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		16JUL2023	Supraventricular tachycardia	Definitely irrelevant	Recovered/Resolved
1009-0040	FYTF-919	15AUG2023	Urinary tract infection	Definitely irrelevant	Recovered/Resolved
1009-0041	Placebo	04SEP2023	Gastrointestinal bleeding	probably not relevant	Recovered/Resolved
		15NOV2023	Death	Definitely irrelevant	death
1009-0042	FYTF-919	01OCT2023	Bacteremia	Definitely irrelevant	Recovered/resolved with sequelae
1009-0044	Placebo	15NOV2023	Intracerebral hemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
		16NOV2023	Upper gastrointestinal bleeding	Definitely irrelevant	Recovered/Resolved
1009-0046	Placebo	01DEC2023	Hepatic function abnormal	Definitely irrelevant	Recovered/Resolved
1009-0047	FYTF-919	20DEC2023	Hepatic function abnormal	Definitely irrelevant	death
1009-0049	FYTF-919	03DEC2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1009-0051	Placebo	05DEC2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		05DEC2023	Venous thrombosis limb	Definitely irrelevant	Recovered/resolved with sequelae
1009-0052	Placebo	11DEC2023	Death	Definitely irrelevant	death
1010-0001	Placebo	05APR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1010-0003	Placebo	19MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		26MAR2023	Sepsis	Definitely irrelevant	Recovered/Resolved
1010-0005	FYTF-919	14APR2023	Stroke-associated pneumonia	Definitely irrelevant	Recovered/Resolved
		12APR2023	Upper gastrointestinal bleeding	probably not relevant	Recovered/Resolved
1010-0014	FYTF-919	17AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		17AUG2023	Upper gastrointestinal bleeding	probably not relevant	Recovered/Resolved
1010-0021	FYTF-919	05SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1010-0025	Placebo	24SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1010-0036	Placebo	01NOV2023	Stroke-associated pneumonia	Definitely irrelevant	death
		19DEC2023	Death	Definitely irrelevant	death
1010-0037	Placebo	01NOV2023	Stroke-associated pneumonia	Definitely irrelevant	Recovered/Resolved
1010-0039	FYTF-919	28NOV2023	Electrolyte imbalance	Definitely irrelevant	Recovered/Resolved
		10DEC2023	Anemia	Possibly related	Recovered/resolved with sequelae
		01DEC2023	Hepatic function abnormal	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1011-0003	FYTF-919	01DEC2021	Pneumonia	Definitely irrelevant	death
		10DEC2021	Death	Definitely irrelevant	death
		02DEC2021	Anemia	Definitely irrelevant	death
1011-0004	FYTF-919	27DEC2021	Acute upper gastrointestinal bleeding	Definitely irrelevant	death
		04FEB2022	Death	Definitely irrelevant	death
1011-0005	FYTF-919	16DEC2021	Gastrointestinal bleeding	probably not relevant	Recovered/Resolved
1011-0006	Placebo	19DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0007	Placebo	27DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0010	Placebo	08FEB2022	Death	Unable to determine	death
1011-0014	FYTF-919	14FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		18FEB2022	Gastrointestinal bleeding	Possibly related	Recovered/Resolved
		18FEB2022	Diarrhea	Possibly related	Recovered/Resolved
1011-0017	Placebo	27MAR2022	Death	Definitely irrelevant	death
1011-0021	FYTF-919	24APR2022	Hemoptysis	Definitely irrelevant	death
		19APR2022	Pneumonia	Definitely irrelevant	death
		28APR2022	Anemia	Definitely irrelevant	death
1011-0030	FYTF-919	25SEP2022	Hypoalbuminemia	Definitely irrelevant	Recovered/Resolved
		25SEP2022	Malnutrition	Definitely irrelevant	Recovered/Resolved
1011-0032	FYTF-919	15OCT2022	Pneumonia	Definitely irrelevant	death
		16OCT2022	Gastrointestinal bleeding	Definitely irrelevant	death
		17OCT2022	Death	Definitely irrelevant	death
1011-0033	Placebo	17OCT2022	Intracranial infection	Definitely irrelevant	death
		19OCT2022	Gastrointestinal bleeding	Definitely irrelevant	death
		11OCT2022	Pneumonia	Definitely irrelevant	death
		25OCT2022	Death	Definitely irrelevant	death
1011-0035	FYTF-919	17OCT2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0036	FYTF-919	21NOV2022	Upper gastrointestinal bleeding	probably not relevant	Recovered/Resolved
		05DEC2022	Septic shock	Definitely irrelevant	death
		05DEC2022	Anemia	probably not relevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		17NOV2022	Pneumonia	Definitely irrelevant	death
1011-0037	FYTF-919	20NOV2022	Upper gastrointestinal bleeding	Possibly related	Recovered/Resolved
		22NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0040	Placebo	10APR2023	Death	Definitely irrelevant	death
1011-0042	Placebo	17DEC2022	Death	Definitely irrelevant	death
1011-0043	FYTF-919	21DEC2022	Respiratory failure	Definitely irrelevant	death
		15DEC2022	Pneumonia	Definitely irrelevant	death
		18DEC2022	Obstructive hydrocephalus	Definitely irrelevant	death
		24DEC2022	Death	Definitely irrelevant	death
1011-0046	Placebo	13FEB2023	Pneumonia	Definitely irrelevant	death
		10FEB2023	Symptomatic epilepsy	Definitely irrelevant	death
		12FEB2023	Respiratory failure type 2	Definitely irrelevant	death
1011-0050	FYTF-919	06MAR2023	Brain herniation	Definitely irrelevant	death
		06MAR2023	Intracerebral haemorrhage	Definitely irrelevant	death
1011-0054	Placebo	30MAR2023	Intracerebral haemorrhage	Definitely irrelevant	Recovered/Resolved
1011-0056	Placebo	14APR2023	Intracerebral haemorrhage	Definitely irrelevant	death
		18MAY2023	Death	Definitely irrelevant	death
1011-0060	FYTF-919	01MAY2023	Intracerebral haemorrhage	Definitely irrelevant	Recovered/Resolved
1011-0063	FYTF-919	11MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
011-0068	FYTF-919	22JUN2023	Aspiration pneumonia	Definitely irrelevant	death
		07OCT2023	Sepsis	Definitely irrelevant	Recovered/Resolved
1011-0070	FYTF-919	26JUL2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0072	Placebo	21AUG2023	Symptomatic epilepsy	Definitely irrelevant	Recovered/Resolved
1011-0073	Placebo	23AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0077	Placebo	14SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0079	Placebo	08OCT2023	Acute upper gastrointestinal bleeding	Definitely irrelevant	Recovered/Resolved
		28SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0080	FYTF-919		Death	Definitely irrelevant	death
1011-0081	FYTF-919	21OCT2023	Intracerebral haemorrhage	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		13OCT2023	Pneumonia	Definitely irrelevant	death
		23OCT2023	Death	Definitely irrelevant	death
1011-0084	FYTF-919	26OCT2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		02NOV2023	Gastrointestinal bleeding	probably not relevant	Recovered/Resolved
		02NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		03NOV2023	Intracranial haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
1011-0087	Placebo	06NOV2023	Anaemia	Possibly related	Recovered/Resolved
1011-0088	FYTF-919	06NOV2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1011-0094	Placebo	26DEC2023	Pneumonia	Definitely irrelevant	death
		24DEC2023	Anemia	Definitely irrelevant	death
		29DEC2023	Death	Definitely irrelevant	death
1012-0001	FYTF-919	27JAN2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0002	Placebo	28JAN2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0003	FYTF-919	09FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0004	FYTF-919	26FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0005	Placebo	01MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0007	Placebo	12MAR2022	Death	Definitely irrelevant	death
		08MAR2022	Pneumonia	Definitely irrelevant	death
1012-0008	Placebo	30MAR2022	Haematoma expansion	probably not relevant	Recovered/resolved with sequelae
1012-0009	FYTF-919	19AUG2022	Haematoma expansion	Definitely irrelevant	death
		19AUG2022	Haematoma expansion	probably not relevant	death
		19AUG2022	Pneumonia	Definitely irrelevant	death
1012-0010	Placebo	23AUG2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		08NOV2022	Respiratory failure	Definitely irrelevant	Recovered/Resolved
		08NOV2022	Thrombocytopenia	Definitely irrelevant	Recovered/Resolved
1012-0011	Placebo	07SEP2022	Death	Definitely irrelevant	death
1012-0013	FYTF-919	09SEP2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0014	Placebo	09SEP2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		30SEP2022	Acute respiratory distress syndrome	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		12OCT2022	Respiratory failure	Definitely irrelevant	Recovered/Resolved
1012-0015	Placebo	23OCT2022	Acute respiratory distress	probably not relevant	Recovered/Resolved
			syndrome		
		13OCT2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		02JAN2023	Death	Definitely irrelevant	death
1012-0019	Placebo	11FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0021	FYTF-919	23MAR2023	Pneumonia	Definitely irrelevant	death
		10APR2023	Anemia	Definitely irrelevant	death
		04APR2023	Respiratory failure	Definitely irrelevant	death
		06APR2023	Pleural effusion	Definitely irrelevant	death
		12APR2023	Malnutrition	Definitely irrelevant	death
		04MAY2023	Multiple organ failure	Definitely irrelevant	death
1012-0023	FYTF-919	28MAR2023	Pneumonia	Definitely irrelevant	death
		03APR2023	Acute subdural haematoma	Definitely irrelevant	death
		08APR2023	Death	Definitely irrelevant	death
1012-0024	Placebo	11APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0025	Placebo	11APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		21APR2023	Central respiratory depression	Definitely irrelevant	Recovered/Resolved
		23APR2023	Central respiratory depression	Definitely irrelevant	Recovered/Resolved
1012-0026	Placebo	28APR2023	Haematoma expansion	Definitely irrelevant	Recovered/Resolved
		28APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		01MAY2023	Thrombocytopenia	Definitely irrelevant	Recovered/Resolved
		01MAY2023	Anaemia	Definitely irrelevant	Recovered/Resolved
		03MAY2023	Anaemia	Definitely irrelevant	Recovered/Resolved
		02MAY2023	Respiratory failure	probably not relevant	Recovered/Resolved
1012-0028	Placebo	07MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0029	Placebo	05JUN2023	Death	Definitely irrelevant	death
		18MAY2023	Pneumonia	Definitely irrelevant	death
1012-0030	FYTF-919	24MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		26MAY2023	Metabolic alkalosis	Definitely irrelevant	Recovered/Resolved
				<del>-</del>	

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1012-0031	FYTF-919	06JUN2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		08JUN2023	Multiple organ failure	Definitely irrelevant	Recovered/Resolved
		08JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		07JUN2023	Respiratory failure	Definitely irrelevant	Recovered/Resolved
		06JUN2023	Bacteraemia	Definitely irrelevant	Recovered/Resolved
1012-0038	Placebo	04JUL2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		28SEP2023	Death	Definitely irrelevant	death
		03JUL2023	Difficulty breathing	Definitely irrelevant	Recovered/Resolved
		09JUL2023	Pleural effusion	Definitely irrelevant	death
		20JUL2023	Gastrointestinal bleeding	probably not relevant	death
		20JUL2023	Malnutrition	Definitely irrelevant	death
1012-0039	FYTF-919	11JUL2023	Pneumonia	probably not relevant	Recovered/Resolved
1012-0041	Placebo	04AUG2023	Death	probably not relevant	death
		02AUG2023	Pneumonia	Definitely irrelevant	death
1012-0042	FYTF-919	11AUG2023	Death	Unable to determine	death
		11AUG2023	Respiratory failure	Definitely irrelevant	Recovered/Resolved
		11AUG2023	Hyponatraemia	probably not relevant	death
1012-0043	Placebo	03SEP2023	Respiratory failure	probably not relevant	death
		30AUG2023	Pneumonia	Definitely irrelevant	death
1012-0044	Placebo	03SEP2023	Respiratory failure	probably not relevant	Recovered/Resolved
		31AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1012-0045	Placebo	14OCT2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1013-0001	FYTF-919		Death	Definitely irrelevant	death
1013-0004	Placebo	07MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1013-0006	FYTF-919	13JUL2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1013-0007	Placebo	20NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		22NOV2022	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1013-0008	Placebo	28DEC2022	Brain herniation	Definitely irrelevant	death
		28DEC2022	Respiratory failure	Definitely irrelevant	death

	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		25DEC2022	Pneumonia	Definitely irrelevant	death
1013-0009	FYTF-919	20JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1013-0010	Placebo	20JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1013-0020	Placebo	23AUG2023	Intracerebral haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
1013-0024	Placebo	11NOV2023	Death	Definitely irrelevant	death
		07NOV2023	Obstructive hydrocephalus	Definitely irrelevant	death
1014-0004	FYTF-919	16MAR2023	Septic shock	Definitely irrelevant	death
		09MAR2023	Fever	Definitely irrelevant	death
		09MAR2023	Acute renal insufficiency	Definitely irrelevant	death
		09MAR2023	Stroke-associated pneumonia	Definitely irrelevant	death
1014-0008	FYTF-919		Death	Definitely irrelevant	death
1014-0009	FYTF-919	04APR2023	Death	Definitely irrelevant	death
		03APR2023	Stroke-associated pneumonia	Definitely irrelevant	death
1014-0011	Placebo	28APR2023	Multiple organ failure	Definitely irrelevant	death
		30APR2023	Pneumonia	Definitely irrelevant	death
		09MAY2023	Venous thrombosis deep limb	Definitely irrelevant	death
1014-0012	FYTF-919	29APR2023	Haematoma expansion	probably not relevant	death
1014-0015	Placebo		Death	Definitely irrelevant	death
1014-0016	Placebo	19MAY2023	Death	Definitely irrelevant	death
1014-0017	Placebo	08MAY2023	Stroke-associated pneumonia	Definitely irrelevant	death
1014-0018	FYTF-919	14MAY2023	Pneumonia	Definitely irrelevant	death
1014-0019	FYTF-919	15JUN2023	Respiratory failure	Definitely irrelevant	death
1014-0020	Placebo	08NOV2023	Pneumonia	Definitely irrelevant	death
1015-0006	FYTF-919	18MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		18MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1015-0008	Placebo	20MAR2023	Haematoma expansion	probably not relevant	Recovered/Resolved
		21MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1015-0010	FYTF-919	29MAR2023	Liver damage	Definitely irrelevant	Recovered/Resolved
1015-0011	Placebo	02APR2023	Anaphylactic shock	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1015-0012	Placebo	01APR2023	Pneumonia	Definitely irrelevant	death
		13APR2023	Death	Definitely irrelevant	death
		03APR2023	Hepatic function abnormal	probably not relevant	Recovered/resolved with sequelae
1015-0013	Placebo	01APR2023	Pneumonia	Definitely irrelevant	death
		19APR2023	Ischaemic stroke	Definitely irrelevant	death
		21APR2023	Death	Definitely irrelevant	death
1015-0025	FYTF-919	26MAY2023	Death	Definitely irrelevant	death
1015-0027	Placebo	07JUN2023	Death	Definitely irrelevant	death
1015-0035	Placebo	12JUN2023	Bacterial pneumonia	Definitely irrelevant	death
		18JUN2023	Acute renal failure	Definitely irrelevant	death
		03JUL2023	Death	Definitely irrelevant	death
1015-0036	Placebo	17JUN2023	Death	Definitely irrelevant	death
1015-0037	Placebo	06JUL2023	Obstructive hydrocephalus	Definitely irrelevant	Recovered/Resolved
1015-0038	FYTF-919	08JUL2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1015-0045	Placebo	01OCT2023	Death	Definitely irrelevant	death
1015-0046	FYTF-919	11OCT2023	Death	Definitely irrelevant	death
1015-0050	Placebo	16OCT2023	Death	Definitely irrelevant	death
1015-0052	FYTF-919	11NOV2023	Death	Definitely irrelevant	death
1016-0003	FYTF-919	11MAY2022	Gastroesophageal reflux	Definitely irrelevant	Recovered/Resolved
1016-0004	FYTF-919	19FEB2022	Pneumonia	Definitely irrelevant	death
		18APR2022	Death	Definitely irrelevant	death
1016-0005	Placebo	16MAR2022	Cognitive impairment	Definitely irrelevant	Recovered/resolved with sequelae
		25MAR2022	Gastrointestinal bleeding	probably not relevant	Recovered/Resolved
1016-0006	Placebo	25MAR2022	Fracture	Definitely irrelevant	Recovered/Resolved
1016-0008	Placebo	27APR2022	Pneumonia	Definitely irrelevant	death
		20MAY2022	Death	Definitely irrelevant	death
1016-0009	Placebo	28APR2022	Stroke-associated pneumonia	Definitely irrelevant	Recovered/Resolved
		06JUN2022	Diarrhea	Definitely irrelevant	Recovered/Resolved
1016-0010	Placebo	12JUL2022	Stroke-associated pneumonia	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		05DEC2022	Death	Definitely irrelevant	death
1016-0011	FYTF-919	31JUL2022	Stroke-associated pneumonia	Definitely irrelevant	Recovered/Resolved
		17JAN2023	Pressure ulcer	Definitely irrelevant	Recovered/resolved with sequelae
1016-0013	FYTF-919	12SEP2022	Anxiety	Definitely irrelevant	Recovered/Resolved
1016-0014	FYTF-919	29SEP2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		29SEP2022	Brain herniation	Definitely irrelevant	Recovered/resolved with sequelae
1016-0015	Placebo	29SEP2022	Stroke-associated pneumonia	Definitely irrelevant	Recovered/Resolved
		02OCT2022	Gastrointestinal bleeding	Possibly related	Recovered/resolved with sequelae
		18DEC2022	Death	Definitely irrelevant	death
1016-0018	Placebo	22FEB2023	Hernia	Definitely irrelevant	Recovered/Resolved
1016-0019	FYTF-919	03NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		03NOV2022	Consciousness impairment	Definitely irrelevant	Recovered/Resolved
		17NOV2022	Venous thrombosis deep	Definitely irrelevant	Recovered/resolved with sequelae
1016-0025	Placebo	20JAN2023	Hematoma expansion	Definitely irrelevant	Recovered/Resolved
		27JAN2023	Stroke-associated pneumonia	Definitely irrelevant	Recovered/Resolved
1016-0026	Placebo	10MAR2023	Venous thrombosis limb	Definitely irrelevant	Recovered/Resolved
1016-0028	Placebo	02JUN2023	Heart failure	Definitely irrelevant	death
1016-0029	Placebo	05JUN2023	Hydrocephalus	Definitely irrelevant	death
		05JUN2023	Stroke-associated pneumonia	Definitely irrelevant	death
1016-0033	FYTF-919	02OCT2023	Haematoma expansion	Definitely irrelevant	Recovered/Resolved
1016-0038	Placebo	04DEC2023	Venous thrombosis deep	Definitely irrelevant	Recovered/Resolved
1017-0003	FYTF-919	20DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
		16DEC2021	Hydrocephalus	Definitely irrelevant	Recovered/Resolved
1017-0004	Placebo	17DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0005	FYTF-919	19DEC2021	Hypokalaemia	Definitely irrelevant	Recovered/Resolved
		17DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0006	FYTF-919	19DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0008	Placebo	18DEC2021	Haematoma expansion	Definitely irrelevant	death
		21DEC2021	Death	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1017-0010	FYTF-919	18DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
		21DEC2021	Hydrocephalus	Definitely irrelevant	Recovered/Resolved
1017-0012	Placebo	23DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
		30MAR2022	Death	Definitely irrelevant	death
1017-0015	FYTF-919	22DEC2021	Obstructive hydrocephalus	Definitely irrelevant	Recovered/Resolved
		27DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0017	Placebo	27DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0018	Placebo	24DEC2021	Intracerebral haemorrhage	Definitely irrelevant	death
		26DEC2021	Death	Definitely irrelevant	death
1017-0019	Placebo	26DEC2021	Obstructive hydrocephalus	Definitely irrelevant	Recovered/Resolved
1017-0023	FYTF-919	30DEC2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0025	FYTF-919	02JAN2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0026	FYTF-919	10JAN2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0027	Placebo	04JAN2021	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0030	Placebo	10JAN2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0037	Placebo	24JAN2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0039	FYTF-919	02FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0040	Placebo	13FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0042	FYTF-919	16FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0043	Placebo	16FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0045	FYTF-919	18FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0051	Placebo	21FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0054	Placebo	22FEB2022	Pneumonia	Definitely irrelevant	death
		24FEB2022	Death	Definitely irrelevant	death
1017-0057	FYTF-919	25FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0062	Placebo	01MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0063	FYTF-919	01MAR2022	Death	Definitely irrelevant	death
		28FEB2022	Obstructive hydrocephalus	Definitely irrelevant	death
1017-0064	Placebo	27FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1017-0065	Placebo	28FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0067	FYTF-919	01MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0068	FYTF-919	05MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0072	Placebo	04MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0078	Placebo	15APR2022	Gastrointestinal bleeding	Definitely irrelevant	death
		10MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0081	FYTF-919	12MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0083	Placebo	10MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0087	FYTF-919	12MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0090	FYTF-919	16MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0092	Placebo	15MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0093	FYTF-919	16MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0102	FYTF-919	24MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0105	Placebo	09MAY2022	Death	Definitely irrelevant	death
1017-0106	FYTF-919	28MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0107	Placebo	26MAR2022	Haematoma expansion	Definitely irrelevant	Recovered/Resolved
		27MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0108	FYTF-919	03APR2022	Intraventricular haemorrhage	Definitely irrelevant	death
1017-0110	FYTF-919	06APR2022	Haematoma expansion	Definitely related	Recovered/Resolved
		08APR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0111	Placebo	02JUL2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0112	FYTF-919	02JUL2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0120	FYTF-919	20JUL2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0122	Placebo	22JUL2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0123	FYTF-919	23JUL2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0124	Placebo	01OCT2022	Death	Definitely irrelevant	death
		26JUL2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		29JUL2022	Venous thrombosis limb	Definitely irrelevant	death
1017-0125	Placebo	26JUL2022	Pneumonia	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1017-0131	Placebo	05AUG2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0133	FYTF-919	12AUG2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0134	Placebo	17AUG2022	Pulmonary embolism	Definitely irrelevant	death
		26AUG2022	Death	Definitely irrelevant	death
1017-0141	Placebo	23AUG2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0142	Placebo	23AUG2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0144	FYTF-919	02SEP2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		02SEP2022	Haematoma expansion	Definitely irrelevant	Recovered/Resolved
1017-0146	FYTF-919	06SEP2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0148	FYTF-919	08SEP2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		07SEP2022	Haematoma expansion	Definitely irrelevant	Recovered/Resolved
1017-0153	Placebo	28SEP2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0157	Placebo	17OCT2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0160	Placebo	24OCT2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0161	Placebo	27OCT2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0163	Placebo	09NOV2022	Pneumonia	Definitely irrelevant	death
1017-0165	FYTF-919	16NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		19NOV2022	Acute ischaemic stroke	Definitely irrelevant	Recovered/resolved with sequelae
1017-0166	FYTF-919	18NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0171	Placebo	16DEC2022	Death	Definitely irrelevant	death
		25NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0173	Placebo	25NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0174	FYTF-919	26NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0175	FYTF-919	21JAN2023	Death	Definitely irrelevant	death
		27NOV2022	Pneumonia	Definitely irrelevant	death
1017-0176	FYTF-919	01FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		30JAN2023	Haematoma expansion	Definitely irrelevant	Recovered/resolved with sequelae
1017-0178	FYTF-919	31JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0190	Placebo	09MAY2023	Death	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
	_	09FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0191	Placebo	07FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0192	FYTF-919	02APR2023	Death	Definitely irrelevant	death
1017-0197	Placebo	08FEB2023	Obstructive hydrocephalus	Definitely irrelevant	Recovered/Resolved
		14FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0201	FYTF-919	11FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0203	FYTF-919	12FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0206	Placebo	13FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0207	Placebo	13FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0208	Placebo	26FEB2023	Anemia	Definitely irrelevant	Recovered/resolved with sequelae
1017-0210	Placebo	15FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0217	Placebo	16FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0237	Placebo	01MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		26FEB2023	Obstructive hydrocephalus	Definitely irrelevant	Recovered/Resolved
1017-0239	Placebo	24FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		23FEB2023	Obstructive hydrocephalus	Definitely irrelevant	Recovered/Resolved
1017-0240	FYTF-919	25FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0248	Placebo	27FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0249	Placebo	27FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0256	Placebo	05MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0259	FYTF-919	15MAR2023	Stress ulcer bleeding	probably not relevant	Recovered/Resolved
		04MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0262	FYTF-919	03MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0264	Placebo	09MAR2023	Death	Definitely irrelevant	death
1017-0265	FYTF-919	08MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0266	FYTF-919	03MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0267	FYTF-919	04MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		31MAY2023	Death	Definitely irrelevant	death
1017-0271	Placebo	12APR2023	Cerebellar infarction	Definitely irrelevant	Recovered/resolved with sequelae

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		25MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		06APR2023	Obstructive hydrocephalus	Definitely irrelevant	Recovered/Resolved
1017-0279	Placebo	29MAR2023	Stress ulcer bleeding	probably not relevant	Recovered/resolved with sequelae
1017-0285	Placebo	11APR2023	Ischaemic stroke	Definitely irrelevant	Recovered/resolved with sequelae
1017-0287	FYTF-919	29MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0288	Placebo	29MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0289	FYTF-919	03APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0290	FYTF-919	10APR2023	Gastrointestinal bleeding	probably not relevant	Recovered/Resolved
		04APR2023	Pneumonia	probably not relevant	Recovered/Resolved
1017-0291	FYTF-919	14APR2023	Death	Definitely irrelevant	death
		03APR2023	Obstructive hydrocephalus	Definitely related	Recovered/Resolved
1017-0292	Placebo	03APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0293	Placebo	06APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0302	FYTF-919	11APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0303	Placebo	14APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0304	Placebo	15APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0305	Placebo	01MAY2023	Epilepsy	Definitely irrelevant	Recovered/Resolved
		15APR2023	Haematoma expansion	Definitely irrelevant	Recovered/Resolved
		01MAY2023	Cerebral edema	probably not relevant	Recovered/Resolved
1017-0307	FYTF-919	17APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0311	FYTF-919	27APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		30APR2023	Subarachnoid haemorrhage	Definitely irrelevant	Recovered/Resolved
1017-0314	Placebo	06MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0315	FYTF-919	09MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0316	FYTF-919	20MAY2023	Death	Definitely irrelevant	death
1017-0318	Placebo	18MAY2023	Haematoma expansion	Definitely irrelevant	Recovered/Resolved
1017-0319	Placebo	21MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0321	FYTF-919	27MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0322	Placebo	27MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1017-0326	Placebo	04JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0327	Placebo	06JUN2023	Death	Definitely irrelevant	death
1017-0332	Placebo	18JUN2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1017-0333	FYTF-919	15JUN2023	Venous thrombosis limb	Definitely irrelevant	death
		08OCT2023	Ischaemic stroke	Definitely irrelevant	death
1017-0334	FYTF-919	12JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		15JUN2023	Venous thrombosis limb	Definitely irrelevant	Recovered/resolved with sequelae
1017-0340	Placebo	02JUL2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1017-0341	Placebo	04JUL2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0345	FYTF-919	16JUL2023	Intracranial haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
1017-0355	Placebo	20JAN2024	Death	Definitely irrelevant	death
		14AUG2023	Venous thrombosis limb	Definitely irrelevant	death
1017-0357	FYTF-919	12AUG2023	Pneumonia	Definitely irrelevant	death
		12AUG2023	Venous thrombosis limb	Definitely irrelevant	death
1017-0358	Placebo	11AUG2023	Pneumonia	Definitely irrelevant	death
		18AUG2023	Intracranial haemorrhage	Definitely irrelevant	death
1017-0361	FYTF-919	23AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0364	Placebo	05SEP2023	Pulmonary embolism	Definitely irrelevant	Recovered/Resolved
		05SEP2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/Resolved
1017-0365	Placebo	03JAN2024	Death	Definitely irrelevant	death
1017-0366	Placebo	26AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0367	Placebo	25AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0369	FYTF-919	27AUG2023	Venous thrombosis deep limb	Definitely irrelevant	Recovered/resolved with sequelae
1017-0370	FYTF-919	05SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0371	FYTF-919	04SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0372	Placebo	07SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0373	FYTF-919	09SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0374	Placebo	13SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0375	Placebo	13SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1017-0376	FYTF-919	19SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0377	FYTF-919	22SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0378	FYTF-919	21SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0379	Placebo	23SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0380	Placebo	23SEP2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0391	FYTF-919	23DEC2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0392	FYTF-919	23DEC2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1017-0394	Placebo	26DEC2023	Intracranial haemorrhage	Definitely irrelevant	death
		26DEC2023	Brain herniation	Definitely irrelevant	death
1019-0001	Placebo	29MAR2022	Intracranial infection	probably not relevant	Recovered/Resolved
1019-0002	FYTF-919	31MAR2022	Death	Definitely irrelevant	death
1019-0003	Placebo	09APR2022	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1019-0012	FYTF-919	05APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1019-0013	Placebo	11APR2023	Death	Definitely irrelevant	death
1019-0014	Placebo	15APR2023	Hypernatremia	Definitely irrelevant	death
		12APR2023	Hypokalaemia	Definitely irrelevant	Recovered/Resolved
		19APR2023	Death	Definitely irrelevant	death
1019-0017	Placebo	21APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1019-0019	FYTF-919	03MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1019-0020	Placebo		Death	Definitely irrelevant	death
1019-0023	Placebo	03JUN2023	Ventricular fibrillation	probably not relevant	death
		03JUN2023	Death	probably not relevant	death
		25MAY2023	Pneumonia	Definitely irrelevant	death
1019-0025	Placebo	23MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1019-0026	FYTF-919	31MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1019-0029	FYTF-919	30MAY2023	Haematoma expansion	Definitely irrelevant	death
		01JUN2023	Respiratory failure	probably not relevant	death
		01JUN2023	Death	probably not relevant	death
1019-0031	Placebo	13DEC2023	Death	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1019-0040	FYTF-919	03NOV2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1019-0041	Placebo	07NOV2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1019-0042	Placebo	08NOV2023	Death	Definitely irrelevant	death
1019-0043	FYTF-919	24NOV2023	Death	Definitely irrelevant	death
1019-0045	FYTF-919	08JAN2024	Death	Definitely irrelevant	death
1019-0046	Placebo	24JAN2024	Death	Definitely irrelevant	death
1019-0052	Placebo	11FEB2024	Death	Definitely irrelevant	death
		15DEC2023	Intracerebral haemorrhage	Definitely irrelevant	death
1019-0054	FYTF-919	13JAN2024	Acute ischaemic stroke	Definitely irrelevant	Recovered/resolved with sequelae
1019-0058	Placebo	15DEC2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1019-0060	FYTF-919	17DEC2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0002	FYTF-919	04JAN2022	Intracerebral haemorrhage	probably not relevant	Recovered/Resolved
1020-0003	Placebo	14JAN2022	Pneumonia	probably not relevant	Recovered/Resolved
1020-0006	Placebo	17FEB2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0007	FYTF-919	01MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0008	Placebo	09MAR2022	Pneumonia	Definitely irrelevant	death
1020-0009	Placebo	11MAR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0010	FYTF-919	15MAR2022	Death	Definitely irrelevant	death
1020-0014	FYTF-919	27MAR2022	Death	Definitely related	death
1020-0015	Placebo	27APR2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
		03MAY2022	Grand mal epilepsy	Definitely irrelevant	Recovered/Resolved
1020-0017	FYTF-919	04MAY2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0022	FYTF-919	09AUG2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0023	FYTF-919	06AUG2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0024	Placebo	05AUG2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0027	Placebo	27OCT2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0028	Placebo	04NOV2022	Respiratory failure type 1	Definitely irrelevant	Recovered/Resolved
		01NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1020-0030	FYTF-919	11NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved

020-0037Placebo02JAN2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0038FYTF-91915JAN2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0039FYTF-91912FEB2023Heart failureDefinitely irrelevantdeath020-0042FYTF-91916FEB2023PneumoniaDefinitely irrelevantdeath020-0044FYTF-91924FEB2023Kidney failureDefinitely irrelevantdeath020-0045Placebo09MAR2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0045Placebo09MAR2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0052Placebo09MAR2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0053FYTF-91925JUL2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0054Placebo20AUG2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0055Placebo28OCT2023PneumoniaDefinitely irrelevantdeath020-0056Placebo28OCT2023PneumoniaDefinitely irrelevantdeath020-0059FYTF-91903DEC2023DeathDefinitely irrelevantRecovered/Resolved020-0060FYTF-91909NOV2023DeathDefinitely irrelevantdeath020-0066PYTF-91910NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0066PYTF-91910NOV2023PneumoniaDefi	Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
020-0038 FYTF-919 15JAN2023 Pneumonia Definitely irrelevant death 12FEB2023 Heart failure Definitely irrelevant death 12FEB2023 Pneumonia Definitely irrelevant death 020-0042 FYTF-919 16FEB2023 Pneumonia Definitely irrelevant death 020-0044 FYTF-919 24FEB2023 Kidney failure Definitely irrelevant death 13MAR2023 Death Definitely irrelevant death 020-0045 Placebo 09MAR2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0047 Placebo 04APR2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0052 Placebo 28JUN2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0053 FYTF-919 25JUL2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0054 Placebo 20AUG2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0055 Placebo 28OCT2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0056 Placebo 28OCT2023 Pneumonia Definitely irrelevant death 05SEP2023 Death Definitely irrelevant death 020-0056 Placebo 28OCT2023 Pneumonia Definitely irrelevant death 020-0059 FYTF-919 03DEC2023 Death Definitely irrelevant Recovered/Resolved 08NOV2023 Hydrocephalus Definitely irrelevant death 020-0060 FYTF-919 09NOV2023 Hydrocephalus Definitely irrelevant death 020-0066 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant death 020-0066 FYTF-919 10NOV2023 Death Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 10NOV2023 Death Definitely irrelevant death 020-0066 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 17NOV2023 Death Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0067 Placebo 05DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0068 Placebo 05DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0067 Placebo 05DEC2023 Death Defin	1020-0034	FYTF-919	29DEC2022	Death	Definitely irrelevant	death
Prytr-919   12FEB2023   Heart failure   Definitely irrelevant   death	1020-0037	Placebo	02JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
12FEB2023   Pneumonia   Definitely irrelevant   death	1020-0038	FYTF-919	15JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
020-0042 FYTF-919 16FEB2023 Pneumonia Definitely irrelevant death 13MAR2023 Death Definitely irrelevant death 020-0044 FYTF-919 24FEB2023 Kidney failure Definitely irrelevant death 020-0045 Placebo 09MAR2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0047 Placebo 04APR2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0052 Placebo 28JUN2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0053 FYTF-919 25JUL2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0054 Placebo 20AUG2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0054 Placebo 28OCT2023 Pneumonia Definitely irrelevant death 05SEP2023 Death Definitely irrelevant death 020-0056 Placebo 28OCT2023 Pneumonia Definitely irrelevant death 020-0059 FYTF-919 03DEC2023 Death Definitely irrelevant death 020-0069 FYTF-919 09NOV2023 Intracranial infection Definitely irrelevant death 13NOV2023 Hydrocephalus Definitely irrelevant death 020-0060 FYTF-919 09NOV2023 Pneumonia Definitely irrelevant death 020-0061 Placebo 09NOV2023 Pneumonia Definitely irrelevant death 020-0062 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0065 Placebo 08DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant death 020-0066 Placebo 08DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0066 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0067 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0060 FYTF-919 31OCT2022 Pneumonia Definitely irrelevant Recovered/	1020-0039	FYTF-919	12FEB2023	Heart failure	Definitely irrelevant	death
O20-0044   FYTF-919   24FEB2023   Kidney failure   Definitely irrelevant   death			12FEB2023	Pneumonia	Definitely irrelevant	death
13MAR2023 Death Definitely irrelevant death 020-0045 Placebo 09MAR2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0047 Placebo 04APR2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0052 Placebo 28JUN2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0053 FYTF-919 25JUL2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0054 Placebo 20AUG2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0054 Placebo 20AUG2023 Pneumonia Definitely irrelevant death 05SEP2023 Death Definitely irrelevant death 020-0056 Placebo 28OCT2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0059 FYTF-919 03DEC2023 Death Definitely irrelevant death 020-0060 FYTF-919 09NOV2023 Intracranial infection Definitely irrelevant death 020-0060 FYTF-919 09NOV2023 Hydrocephalus Definitely irrelevant death 020-0061 Placebo 09NOV2023 Pneumonia Definitely irrelevant death 020-0062 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0065 Placebo 08DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0067 Placebo 20NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 05DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0070 Placebo 05DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0070 Placebo 05DEC2023 Pneumonia Definitely irrelevant Recovered/Resolved 023-0004 FYTF-919 31OCT2022 Pneumonia Definitely irrelevant Recovered/Resolved	1020-0042	FYTF-919	16FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
020-0045 Placebo 09MAR2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0047 Placebo 04APR2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0052 Placebo 28JUN2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0053 FYTF-919 25JUL2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0054 Placebo 20AUG2023 Pneumonia Definitely irrelevant death 05SEP2023 Death Definitely irrelevant death 020-0056 Placebo 28OCT2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0059 FYTF-919 03DEC2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0060 FYTF-919 09NOV2023 Intracranial infection Definitely irrelevant Recovered/Resolved 08NOV2023 Hydrocephalus Definitely irrelevant death 13NOV2023 Haematoma expansion Definitely irrelevant death 020-0061 Placebo 09NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0062 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0065 Placebo 08DEC2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant death 020-0066 Placebo 08DEC2023 Death Definitely irrelevant death 020-0068 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 05DEC2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 05DEC2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 05DEC2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0070 Placebo 05DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0070 Placebo 05DEC2023 Death Definitely irrelevant Recovered/Resolved 023-0004 FYTF-919 02JAN2023 Death Definitely irrelevant death	1020-0044	FYTF-919	24FEB2023	Kidney failure	Definitely irrelevant	death
020-0047Placebo04APR2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0052Placebo28JUN2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0053FYTF-91925JUL2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0054Placebo20AUG2023PneumoniaDefinitely irrelevantdeath020-0056Placebo28OCT2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0059FYTF-91903DEC2023DeathDefinitely irrelevantRecovered/Resolved020-0060FYTF-91909NOV2023Intracranial infectionDefinitely irrelevantRecovered/Resolved08NOV2023HydrocephalusDefinitely irrelevantdeath020-0061Placebo09NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0062FYTF-91910NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0065Placebo08DEC2023DeathDefinitely irrelevantdeath020-0066FYTF-91917NOV2023DeathDefinitely irrelevantdeath020-0066PYTF-91917NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0067Placebo05DEC2023DeathDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevant			13MAR2023	Death	Definitely irrelevant	death
020-0052Placebo28JUN2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0053FYTF-91925JUL2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0054Placebo20AUG2023PneumoniaDefinitely irrelevantdeath020-0056Placebo28OCT2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0059FYTF-91903DEC2023DeathDefinitely irrelevantdeath020-0060FYTF-91909NOV2023Intracranial infectionDefinitely irrelevantRecovered/Resolved08NOV2023HydrocephalusDefinitely irrelevantdeath020-0061Placebo09NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0062FYTF-91910NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0065Placebo08DEC2023DeathDefinitely irrelevantdeath020-0066FYTF-91917NOV2023DeathDefinitely irrelevantdeath020-0066FYTF-91917NOV2023DeathDefinitely irrelevantRecovered/Resolved020-0067Placebo20NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantRecovered/Resolved023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevant	1020-0045	Placebo	09MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
020-0053 FYTF-919 25JUL2023 Pneumonia Definitely irrelevant death 020-0054 Placebo 20AUG2023 Pneumonia Definitely irrelevant death 020-0056 Placebo 28OCT2023 Pneumonia Definitely irrelevant death 020-0059 FYTF-919 03DEC2023 Death Definitely irrelevant death 020-0060 FYTF-919 09NOV2023 Intracranial infection Definitely irrelevant death 13NOV2023 Hydrocephalus Definitely irrelevant death 020-0061 Placebo 09NOV2023 Pneumonia Definitely irrelevant death 020-0062 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0065 Placebo 08DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant death 020-0066 Placebo 20NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0066 Placebo 20NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0066 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 05DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0070 Placebo 05DEC2023 Death Definitely irrelevant death 023-0003 FYTF-919 31OCT2022 Pneumonia Definitely irrelevant Recovered/Resolved 023-0004 FYTF-919 02JAN2023 Death Definitely irrelevant death	1020-0047	Placebo	04APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
020-0054Placebo20AUG2023PneumoniaDefinitely irrelevantdeath020-0056Placebo28OCT2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0059FYTF-91903DEC2023DeathDefinitely irrelevantdeath020-0060FYTF-91909NOV2023Intracranial infectionDefinitely irrelevantRecovered/Resolved08NOV2023HydrocephalusDefinitely irrelevantdeath020-0061Placebo09NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0062FYTF-91910NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0065Placebo08DEC2023DeathDefinitely irrelevantdeath020-0066FYTF-91917NOV2023DeathDefinitely irrelevantdeath020-0067Placebo20NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantRecovered/Resolved023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantRecovered/Resolved	1020-0052	Placebo	28JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
Definitely irrelevant death  Definitely irrelevant death  Definitely irrelevant Recovered/Resolved  Definitely irrelevant Recovered/Resolved  Definitely irrelevant death  Definitely irrelevant death  Definitely irrelevant death  Definitely irrelevant Recovered/Resolved  Definitely irrelevant Recovered/Resolved  Definitely irrelevant death  Definitely irrelevant Recovered/Resolved  Definitely irrelevant Recovered/Resolved  Definitely irrelevant Recovered/Resolved  Definitely irrelevant Recovered/Resolved  Definitely irrelevant death  Definitely irrelevant Recovered/Resolved  Definitely irrelevant death  Definitely irrelevant Recovered/Resolved	1020-0053	FYTF-919	25JUL2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
020-0056Placebo28OCT2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0059FYTF-91903DEC2023DeathDefinitely irrelevantdeath020-0060FYTF-91909NOV2023Intracranial infectionDefinitely irrelevantRecovered/Resolved08NOV2023HydrocephalusDefinitely irrelevantdeath020-0061Placebo09NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0062FYTF-91910NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0065Placebo08DEC2023DeathDefinitely irrelevantdeath020-0066FYTF-91917NOV2023DeathDefinitely irrelevantdeath020-0067Placebo20NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantRecovered/Resolved	1020-0054	Placebo	20AUG2023	Pneumonia	Definitely irrelevant	death
020-0059FYTF-91903DEC2023DeathDefinitely irrelevantdeath020-0060FYTF-91909NOV2023Intracranial infectionDefinitely irrelevantRecovered/Resolved08NOV2023HydrocephalusDefinitely irrelevantdeath13NOV2023Haematoma expansionDefinitely irrelevantdeath020-0061Placebo09NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0062FYTF-91910NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0065Placebo08DEC2023DeathDefinitely irrelevantdeath020-0066FYTF-91917NOV2023DeathDefinitely irrelevantdeath020-0067Placebo20NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantRecovered/Resolved			05SEP2023	Death	Definitely irrelevant	death
020-0060 FYTF-919 09NOV2023 Intracranial infection Definitely irrelevant death 13NOV2023 Haematoma expansion Definitely irrelevant death 020-0061 Placebo 09NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0062 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0065 Placebo 08DEC2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Pneumonia Definitely irrelevant death 020-0067 Placebo 20NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 05DEC2023 Death Definitely irrelevant Recovered/Resolved 020-0070 Placebo 05DEC2023 Death Definitely irrelevant death 023-0003 FYTF-919 31OCT2022 Pneumonia Definitely irrelevant Recovered/Resolved 023-0004 FYTF-919 02JAN2023 Death Definitely irrelevant death	1020-0056	Placebo	28OCT2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
13NOV2023 Hydrocephalus Definitely irrelevant death 13NOV2023 Haematoma expansion Definitely irrelevant death 13NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0061 Placebo 09NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0062 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0065 Placebo 08DEC2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Death Definitely irrelevant death 020-0067 Placebo 20NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 05DEC2023 Death Definitely irrelevant death 020-0070 Placebo 05DEC2023 Death Definitely irrelevant death 023-0003 FYTF-919 31OCT2022 Pneumonia Definitely irrelevant Recovered/Resolved 023-0004 FYTF-919 02JAN2023 Death Definitely irrelevant death	1020-0059	FYTF-919	03DEC2023	Death	Definitely irrelevant	death
13NOV2023 Haematoma expansion Definitely irrelevant death 020-0061 Placebo 09NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0062 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0065 Placebo 08DEC2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Death Definitely irrelevant death 020-0067 Placebo 20NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0070 Placebo 05DEC2023 Death Definitely irrelevant death 023-0003 FYTF-919 31OCT2022 Pneumonia Definitely irrelevant Recovered/Resolved 023-0004 FYTF-919 02JAN2023 Death Definitely irrelevant death	1020-0060	FYTF-919	09NOV2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
020-0061 Placebo 09NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0062 FYTF-919 10NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0065 Placebo 08DEC2023 Death Definitely irrelevant death 020-0066 FYTF-919 17NOV2023 Death Definitely irrelevant death 020-0067 Placebo 20NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0068 Placebo 25NOV2023 Pneumonia Definitely irrelevant Recovered/Resolved 020-0070 Placebo 05DEC2023 Death Definitely irrelevant death 023-0003 FYTF-919 31OCT2022 Pneumonia Definitely irrelevant Recovered/Resolved 023-0004 FYTF-919 02JAN2023 Death Definitely irrelevant death			08NOV2023	Hydrocephalus	Definitely irrelevant	death
020-0062FYTF-91910NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0065Placebo08DEC2023DeathDefinitely irrelevantdeath020-0066FYTF-91917NOV2023DeathDefinitely irrelevantdeath020-0067Placebo20NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantdeath			13NOV2023	Haematoma expansion	Definitely irrelevant	death
020-0065Placebo08DEC2023DeathDefinitely irrelevantdeath020-0066FYTF-91917NOV2023DeathDefinitely irrelevantdeath020-0067Placebo20NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantdeath	1020-0061	Placebo	09NOV2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
020-0066FYTF-91917NOV2023DeathDefinitely irrelevantdeath020-0067Placebo20NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantdeath	1020-0062	FYTF-919	10NOV2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
020-0067Placebo20NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantdeath	1020-0065	Placebo	08DEC2023	Death	Definitely irrelevant	death
020-0068Placebo25NOV2023PneumoniaDefinitely irrelevantRecovered/Resolved020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantdeath	1020-0066	FYTF-919	17NOV2023	Death	Definitely irrelevant	death
020-0070Placebo05DEC2023DeathDefinitely irrelevantdeath023-0003FYTF-91931OCT2022PneumoniaDefinitely irrelevantRecovered/Resolved023-0004FYTF-91902JAN2023DeathDefinitely irrelevantdeath	1020-0067	Placebo	20NOV2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
023-0003 FYTF-919 31OCT2022 Pneumonia Definitely irrelevant Recovered/Resolved 023-0004 FYTF-919 02JAN2023 Death Definitely irrelevant death	1020-0068	Placebo	25NOV2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
023-0004 FYTF-919 02JAN2023 Death Definitely irrelevant death	1020-0070	Placebo	05DEC2023	Death	Definitely irrelevant	death
	1023-0003	FYTF-919	31OCT2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
023-0006 FYTF-919 26JAN2023 Respiratory failure Definitely irrelevant death	1023-0004	FYTF-919	02JAN2023	Death	Definitely irrelevant	death
	1023-0006	FYTF-919	26JAN2023	Respiratory failure	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1023-0007	Placebo	23JUL2023	Death	Definitely irrelevant	death
		04MAY2023	Intracerebral haemorrhage	Definitely irrelevant	Unknown
1023-0010	FYTF-919	21AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1025-0001	Placebo	25MAR2023	Haematoma expansion	Definitely irrelevant	death
			Death	Definitely irrelevant	death
1025-0004	FYTF-919	08APR2023	Respiratory failure	Definitely irrelevant	death
		06APR2023	Central diabetes insipidus	probably not relevant	death
1026-0001	Placebo	08FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0002	FYTF-919	13FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0004	FYTF-919	26FEB2023	Anemia	Definitely irrelevant	Recovered/Resolved
		16FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0005	FYTF-919	20FEB2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0007	Placebo	01MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0008	Placebo	14MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0009	Placebo	03JUL2023	Death	Definitely irrelevant	death
1026-0010	FYTF-919	23MAR2023	Impaired liver function	probably not relevant	death
		22MAR2023	Anaemia	Definitely irrelevant	death
		23MAR2023	Pneumonia	Definitely irrelevant	death
		24MAR2023	stroke-related neurologic deficit	Definitely irrelevant	death
1026-0013	Placebo	02APR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		14APR2023	Impaired liver function	probably not relevant	Recovering/Resolving
1026-0014	FYTF-919	03APR2023	Pneumonia	probably not relevant	Recovered/Resolved
1026-0015	FYTF-919	03APR2023	Pneumonia	Definitely irrelevant	Unknown
1026-0016	Placebo	16APR2023	Pneumonia	probably not relevant	Recovered/Resolved
1026-0018	FYTF-919	19APR2023	Pneumonia	Definitely irrelevant	death
1026-0019	Placebo	13MAY2023	Impaired liver function	probably not relevant	Recovered/Resolved
		05MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0020	FYTF-919	07MAY2023	Hypocalcaemia	Definitely related	Recovered/Resolved
		08MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1026-0022	FYTF-919	20MAY2023	Pneumonia	probably not relevant	Recovered/Resolved
1026-0023	Placebo	03JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0024	Placebo	04JUN2023	Haematoma expansion	Definitely irrelevant	death
		02JUN2023	Pneumonia	probably not relevant	death
		15JUN2023	Stroke-related neurologic deficit	Definitely irrelevant	death
1026-0025	FYTF-919	05JUN2023	Hepatic function abnormal	Possibly related	Recovered/Resolved
1026-0026	FYTF-919	10JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0027	Placebo	15JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0029	Placebo	30JUN2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1026-0030	Placebo	30JUN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0032	Placebo	16JUL2023	Pneumonia	Definitely irrelevant	death
		17JUL2023	Hypoalbuminaemia	Definitely irrelevant	death
		17JUL2023	Anemia	Definitely irrelevant	death
1026-0033	Placebo	17JUL2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		22JUL2023	Liver damage	probably not relevant	Recovered/resolved with sequelae
1026-0034	Placebo	17JUL2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0035	FYTF-919	18JUL2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0036	FYTF-919	20JUL2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		23JUL2023	Impaired liver function	probably not relevant	Recovered/Resolved
		03NOV2023	Death	Definitely irrelevant	death
		20JUL2023	Intracerebral haemorrhage	Definitely irrelevant	Recovered/Resolved
1026-0037	Placebo	02AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0038	FYTF-919	28JUL2023	Pneumonia	probably not relevant	Recovered/Resolved
1026-0040	Placebo	03AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0041	Placebo	12AUG2023	Pneumonia	Possibly related	Recovered/Resolved
		14AUG2023	Hypokalemia	Definitely irrelevant	Recovered/Resolved
1026-0042	FYTF-919	13AUG2023	Aspiration pneumonia	Definitely irrelevant	death
1026-0043	Placebo	14AUG2023	Intracerebral haemorrhage	Definitely irrelevant	death
		13AUG2023	Pneumonia	Definitely irrelevant	Unknown

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		17AUG2023	Impaired liver function	probably not relevant	death
1026-0044	FYTF-919	18AUG2023	Pneumonia	probably not relevant	Recovered/Resolved
		18AUG2023	Respiratory failure type 2	probably not relevant	Recovered/Resolved
1026-0045	FYTF-919	18AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0048	FYTF-919	31AUG2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1026-0050	FYTF-919	29AUG2023	Pneumonia	Definitely irrelevant	death
		29AUG2023	Acidosis	Definitely irrelevant	Recovered/Resolved
		29AUG2023	Hypocalcaemia	Definitely irrelevant	death
1028-0001	Placebo	02MAR2022	Intracranial infection	probably not relevant	death
		23MAR2022	Death	probably not relevant	death
		03MAR2022	Haematoma expansion	probably not relevant	death
		04MAR2022	Pneumonia	Definitely irrelevant	death
1028-0005	FYTF-919	30APR2022	Septic shock	probably not relevant	death
		21APR2022	Pneumonia	Definitely irrelevant	death
		01MAY2022	Death	Definitely irrelevant	death
1028-0006	Placebo	20JUL2022	Circulatory failure	probably not relevant	death
		16JUL2022	Intracranial infection	Definitely irrelevant	death
1028-0007	FYTF-919	18JUL2022	Intracranial infection	probably not relevant	Recovered/Resolved
		20JUL2022	Pneumonia	probably not relevant	Recovered/Resolved
1028-0008	Placebo	24JUL2022	Pneumonia	probably not relevant	Recovered/Resolved
		22JUL2022	Intracranial infection	probably not relevant	Recovered/Resolved
1028-0009	FYTF-919	09AUG2022	Respiratory failure	Definitely irrelevant	death
1028-0010	Placebo	25AUG2022	Pneumonia	probably not relevant	Recovered/Resolved
1028-0011	FYTF-919	18OCT2022	Venous thrombosis limb	Definitely irrelevant	Recovered/Resolved
		31OCT2022	Anemia	Definitely irrelevant	death
		19OCT2022	Pneumonia	Definitely irrelevant	death
1028-0012	Placebo	19NOV2022	Intracranial infection	Definitely irrelevant	Recovered/Resolved
		16NOV2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1028-0014	FYTF-919	16DEC2022	Venous thrombosis limb	probably not relevant	Recovered/Resolved

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		06DEC2022	Pneumonia	Definitely irrelevant	Recovered/Resolved
1028-0016	Placebo	05JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1028-0017	FYTF-919	16JAN2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1028-0019	FYTF-919	21MAR2023	Pneumonia	Definitely irrelevant	death
		21MAR2023	Intracranial infection	Definitely irrelevant	death
1028-0020	FYTF-919	06APR2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1028-0021	FYTF-919	06MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		28APR2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1028-0022	Placebo	15MAY2023	Intracranial infection	Definitely irrelevant	Recovered/Resolved
1028-0024	Placebo	06DEC2023	Pneumonia	probably not relevant	Recovered/Resolved
		11DEC2023	Intracranial infection	probably not relevant	Recovered/Resolved
1029-0005	FYTF-919	27DEC2022	Pneumonia	probably not relevant	Recovered/Resolved
1029-0008	Placebo	07MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
1029-0009	FYTF-919	16MAR2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		16MAY2023	Death	Definitely irrelevant	death
1030-0002	Placebo	14DEC2022	Venous thrombosis limb	Definitely irrelevant	Recovered/Resolved
1030-0003	FYTF-919	05MAR2023	Septic shock	probably not relevant	death
		03MAR2023	Respiratory failure	probably not relevant	death
		04MAR2023	Atrial fibrillation	probably not relevant	Recovered/Resolved
1031-0004	FYTF-919	24JAN2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0006	FYTF-919	26JAN2023	Bacterial pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		23JUN2023	Death	Definitely irrelevant	death
1031-0013	FYTF-919	09FEB2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0019	Placebo	07MAR2023	Gastrointestinal bleeding	probably not relevant	Recovered/resolved with sequelae
1031-0029	FYTF-919	04APR2023	Intracerebral haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
1031-0037	FYTF-919	22APR2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0038	FYTF-919	23APR2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		23APR2023	Impaired liver function	Definitely irrelevant	Recovered/Resolved
1031-0040	Placebo	30APR2023	Pneumonia	Definitely irrelevant	death

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
		02MAY2023	Acute respiratory failure	Definitely irrelevant	Recovered/Resolved
		10MAY2023	Atrial fibrillation	Definitely irrelevant	Recovered/Resolved
		07MAY2023	Impaired liver function	Definitely irrelevant	death
		30APR2023	Renal insufficiency	Definitely irrelevant	death
		12MAY2023	Ischemic stroke	Definitely irrelevant	death
1031-0041	FYTF-919	03MAY2023	Pneumonia	Definitely irrelevant	Recovered/Resolved
		17MAY2023	Impaired liver function	probably not relevant	Recovered/Resolved
1031-0043	Placebo	08MAY2023	Intracerebral haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
		10MAY2023	Anemia	Definitely irrelevant	Recovered/Resolved
		10MAY2023	Coagulation disorder	Definitely irrelevant	Recovered/Resolved
1031-0048	FYTF-919	20MAY2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0050	Placebo	22MAY2023	Haematoma expansion	Definitely irrelevant	Recovered/resolved with sequelae
		24MAY2023	Hepatic function abnormal	Possibly related	Recovered/Resolved
1031-0051	FYTF-919	25MAY2023	Pneumonia	Definitely irrelevant	death
		22JUN2023	Death	Definitely irrelevant	death
1031-0052	Placebo	30MAY2023	Hematoma expansion	Definitely irrelevant	death
		03JUN2023	Death	Definitely irrelevant	death
		02JUN2023	Intracerebral haemorrhage	Definitely irrelevant	death
1031-0055	FYTF-919	03JUL2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0058	FYTF-919	02SEP2023	Acute respiratory failure	Definitely irrelevant	Recovered/Resolved
		27AUG2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0059	Placebo	26SEP2023	Communicating hydrocephalus	Definitely irrelevant	Recovered/resolved with sequelae
1031-0060	FYTF-919	17SEP2023	Pneumonia	Definitely irrelevant	death
		18SEP2023	Intracerebral haemorrhage	Definitely irrelevant	death
1031-0062	Placebo	06OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0063	Placebo	18OCT2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0067	Placebo	14NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
		10APR2024	New Intracerebral haemorrhage	Definitely irrelevant	Recovered/resolved with sequelae
1031-0068	FYTF-919	14NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae

Subject ID	Treatment group	Onset date	AE term	Relationship with treatment	Outcome
1031-0071	Placebo	18NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0075	FYTF-919	30NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0076	FYTF-919	30NOV2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0077	FYTF-919	07DEC2023	Pneumonia	Definitely irrelevant	Recovered/resolved with sequelae
1031-0079	FYTF-919	16DEC2023	Cardiac arrest?	Definitely irrelevant	Recovered/Resolved
		01MAY2024	Ischaemic stroke	Definitely irrelevant	Recovered/resolved with sequelae
1031-0082	FYTF-919	26DEC2023	Pneumonia	Definitely irrelevant	death
		08MAR2024	Death	Definitely irrelevant	death
1031-0083	FYTF-919	03JAN2024	Hepatic function abnormal	Definitely irrelevant	death
		11JAN2024	Death	Definitely irrelevant	death

## 18. Figures

Figure S1. Trial profile to Day 180





Figure S2. National Institutes of Health Stroke Scale score distribution over time



\*

Figure S3. Analysis of the treatment effect across re-classification of subgroups at 90 davs

aays	FYTF-91	Placebo				p value for
	N Mean (SD)	N Mean (SD)	MD	MD	(95% CI)	interaction
Haematoma volu	me, ml				<del>.</del>	0.23
≤10	261 0.64 (0.32)	273 0.67 (0.30)			(-0.07 to 0.0	
10-26	235 0.51 (0.34)	273 0.49 (0.35)	_		(-0.04 to 0.0	,
>26	266 0.36 (0.33)	238 0.32 (0.33)	-	0.05	(-0.01  to  0.1)	10)
NIHSS					(0.05 ( 0	0.82
2-12	282 0.70 (0.29)	286 0.70 (0.30)	+	0.00	(-0.05 to 0.	*
13-19	270 0.49 (0.32)	287 0.46 (0.31)	+	0.02	(-0.03  to  0.	*
20-42	245 0.29 (0.31)	238 0.29 (0.33)	+	0.01	(-0.05  to  0.	06)
GCS						0.18
3-10	268 0.29 (0.31)	271 0.31 (0.34)	+		(-0.06  to  0.0	
11-14	390 0.60 (0.32)	, ,	-		(-0.05 to 0.0	
15	112 0.74 (0.25)		<del>  •</del>	- 0.07	(-0.01 to 0.1	14)
Time from onset	to randomisation, h	` ,				0.098
<12	335 0.49 (0.35	3B31 0.53 (0.36)	-		(-0.06  to  0.0	*
12-24	220 0.48 (0.36)				(-0.07  to  0.07)	
≥24	246 0.54 (0.34)	, ,	-	0.06	(0.00  to  0.1)	1)
Surgery	, ,	. ,		0.02	(-0.02 to 0.0	0.39
Yes	388 0.39 (0.34)	378 0.36 (0.34)	+=-			
No	413 0.62 (0.33)	440 0.61 (0.34)	+	-0.00	(-0.04 to 0.0	<i>)</i> 4)
1,0		-0.2	0.0	0.2		
•		Favours pla	cebo Fav	ours FY	TF-91	

Figure S4. Analysis of the treatment effect across subgroups at 180 days

	FYTF-91	Placebo				1 6
	N Mean (SD)	N Mean (SD)	MD	MD	(95% CI)	p value for interaction
Sex	520 0 56 (0 25)				(004) 00	0.71
Male	528 0.56 (0.35)	551 0.56 (0.36)	+	0.00	(-0.04  to  0.0	,
Female	286 0.52 (0.37)	275 0.52 (0.36)	+	-0.01	(-0.06  to  0.0	04)
Age, y	171 0 50 (0 00)					0.24
18-64	451 0.62 (0.33)	494 0.63 (0.32)	4		(-0.05  to  0.0)	03)
≥65	363 0.46 (0.38)	332 0.43 (0.39)	· <b>†=</b> −	0.03	(-0.02 to 0.0	07)
Time to randomisa	ation, h					0.10
0-12	339 0.54 (0.36)	334 0.59 (0.35)	-■+		(-0.08  to  0.0	*
≥12	475 0.55 (0.36)	492 0.52 (0.36)	<del> </del> ■−	0.02	(-0.02  to  0.02)	06)
NIHSS		25 ( 20 ( 20 )				0.48
0-14	370 0.71 (0.30)	376 0.69 (0.32)	+	0.01	(-0.04 to 0.0	)6)
15-42	440 0.42 (0.35)	442 0.42 (0.35)	-	-0.01	(-0.06  to  0.0	03)
Haematoma volun	ne, ml					0.17
<15	336 0.65 (0.33)	362 0.68 (0.33)	-■+		(-0.07  to  0.0	•
≥15	439 0.46 (0.35)	430 0.45 (0.35)	<b>───</b> ──	0.02	(-0.02  to  0.02)	06)
Haematoma locati					(0.04 0.0	0.03
Cortical	79 0.63 (0.36)	74 0.50 (0.43)	<del></del>	<del></del> 0.11	(0.01  to  0.2)	*
Deep	663 0.54 (0.36)	682 0.56 (0.35)	-■		(-0.06 to 0.0	,
Infratentorial	56 0.53 (0.38)	54 0.50 (0.39)	-	0.07	(-0.05  to  0.1]	19)
		$-0.2_{-0.2}$	0.0	0.2		
		<b>←</b>		<b></b>		
		Favours plac	ebo Fav	ours FY	TF-91	

Figure S5. Analysis of the treatment effect across re-classification of subgroups at  $180 \,$  days

	FYTF-91	Placebo		p va	p value for	
	N Mean (SD)	N Mean (SD)	MD MD		raction	
Haematoma vo	olume, ml			(0.07 . 0.02)	0.56	
≤10	266 0.68 (0.31)		-0.02	·		
10-26	238 0.55 (0.36)	275 0.54 (0.36)	0.00	· ·		
>26	271 0.41 (0.35)	243 0.39 (0.35)	0.02	(-0.03  to  0.08)		
NIHSS			0.00	(0.05 . 0.06)	0.80	
2-12	286 0.73 (0.30)	289 0.73 (0.31)	0.00	` /		
13-19	273 0.53 (0.34)	289 0.52 (0.33)	0.01	(-0.04  to  0.06)		
20-42	251 0.35 (0.33)	240 0.37 (0.35)	-0.02	(-0.07 to 0.04)		
GCS					0.073	
3-10	274 0.34 (0.33)	274 0.39 (0.36)	-0.05	` /		
11-14	397 0.65 (0.32)	385 0.64 (0.33)	<b>+</b> 0.00	(-0.04  to  0.05)		
15	112 0.77 (0.25)	132 0.70 (0.31)	0.06	(-0.02 to 0.14)		
Time to rando	omisation, h				0.18	
<12	339 0.54 (0.36)	334 0.59 (0.35)	-0.03			
12-24	224 0.53 (0.36)	257 0.52 (0.37)	-0.00			
≥24	251 0.57 (0.37)	235 0.53 (0.36)	0.04	(-0.02 to 0.10)		
Surgery		,			0.37	
Yes	397 0.44 (0.36)	381 0.42 (0.37)	0.02			
No	417 0.65 (0.33)	445 0.66 (0.331)	<u>-</u> -0.01	(-0.06  to  0.03)		
		-0.2	0.0 -0.2			
		←	<b>— →</b>			

Favours placebo Favours FYTF-91

Chinese herbal medicine (Zhongfeng Xingnao preparations) for spontaneous intracerebral hemorrhage: a systematic review and meta-analysis of randomized controlled trials

Qihua Guo,<sup>1, 2#</sup> Taijun Jiang,<sup>3#</sup> Yang Zhao,<sup>4,5#</sup> Yunke Li,<sup>4</sup> Tingting Xie,<sup>6</sup>, Wanzhen Cui,<sup>1</sup> Siming Zhong,<sup>7</sup> Yun Lu,<sup>8</sup> Linda Zhong,<sup>9</sup> Lili Song,<sup>4,5</sup> Xiaojia Ni,<sup>1, 10\*</sup> Jianwen Guo.<sup>1, 10, 11\*</sup> and Xi Wu<sup>12\*</sup>

- **1.** Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
- **2.** Department of Traditional Chinese Medicine, Zhongshan City People's Hospital, Zhongshan, China.
- 3. Rehabilitation Medicine Department, Chengdu First people's Hospital, Chengdu, China.
- **4.** Institute of Science and Technology for Brain-inspired Intelligence, Fudan University, Shanghai, China.
- 5. The George Institute for Global Health, University of New South Wales, Sydney, Australia.
- **6.** General Medicine, The Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China.
- **7.** Department of Neurology, The Fourth Affiliated Hospital of Guangzhou Medical University (Zengcheng District People's Hospital of Guangzhou), Guangzhou, China.
- **8.** Emergency Department, The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- 9. Hong Kong Baptist University, Hongkong, China.
- **10.** Guangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Guangzhou, China.
- 11. State Key Laboratory of Traditional Chinese Medicine Syndrome/Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong, China.
- **12.** Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

<sup>&</sup>lt;sup>#</sup> The authors contributed equally to the work.

# \*The corresponding authors:

Xi Wu, E-mail: wuxi@cdutcm.edu.cn, Address: 37 Shi Er Qiao Rd, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.

Jianwen Guo, E-mail: jianwen\_guo@qq.com, Address: 111 Dade Road, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Xiaojia Ni, E-mail: grace1984325@126.com, Address: 111 Dade Road, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Abstract

**Background:** Intracerebral hemorrhage (ICH) is a sub-type of fatal and poorly treatable stroke.

Zhongfeng Xingnao (ZFXN) preparation, is a multi-herb prescription of Chinese herbal

medicine, which was patented as a novel medicine, and manufactured as an oral solution for

the clinical treatment of ICH. This systematic review was to assess the efficacy and safety of

ZFXN for ICH.

Methods: To identify eligible RCTs on ZFXN for acute ICH, electronic databases, clinical trial

registries and unpublished reports were searched up to March 2024. Literature screening, data

extraction and risk of bias assessment were performed by two independent reviewers and

validated by the third one. A pairwise meta-analysis was conducted followed by subgroup

analyses and sensitivity analyses. The evidence quality was assessed by the GRADE approach.

**Results:** A total of nine RCTs were included to the review. Evidence of moderate quality

suggested that in the participants with ICH, the adjunct use of ZFXN preparation to

conventional medicine reduced mortality (RR: 0.54, 95%CI: 0.40 to 0.74, I<sup>2</sup>=31%, n=6 RCTs,

1060 participants), improved 90-day activities of daily living per Barthel index (MD: 13.76,

95%CI: 11.22 to 16.30, I<sup>2</sup>=33%, n=5 RCTs, 431 participants), and decreased the volume of

cerebral hematoma (MD: -3.88 ml, 95%CI: -4.87 to -2.88, I<sup>2</sup>=45%, n=4 RCTs, 694 participants).

Though ZFXN presented add-one effect on improved neurological impairments per National

Institute of Health stroke scale (MD: -2.37, 95%CI: -3.34 to -1.39, I<sup>2</sup>=66%, n=6 RCTs, 994

participants), the evidence was low quality due to heterogeneity and risk of bias. Generally,

ZFXN did not increase the risk of adverse events (RR: 1.08, 95%CI: 0.69, 1.69, I<sup>2</sup>=53%, n=7

RCTs, 1079 participants), but the occurrence of diarrhea was markedly increased. The

subgroup-analyses suggested that ICH participants with 20-35 ml hematoma volume at baseline

and those with the therapeutic duration  $\geq 28$  days were likely to benefit most from ZFXN.

Conclusion: Clinical evidence of low-to-moderate quality suggested that adjunct ZFXN

preparation was potentially effective and safe for acute ICH. However, a multi-site, larger

sample, confirmatory RCT with improved methodological design and quality control was

needed, before its comparative research with other proprietary Chinese medicine.

Registration: PROSPERO No. CRD42021247243.

**Keywords:** spontaneous intracerebral hemorrhage; Chinese herbal medicine; meta-analysis

185

### Introduction

Intracerebral hemorrhage (ICH), caused by rupture of blood vessels in the brain, is one of the most fatal and poorly treatable subtypes of stroke, and it affects more than 3 million people annually worldwide.<sup>[1]</sup> It is a life-threatening and disabling event in which 13%-61% patients die within the first month of ictus, leaving less than 30% survivors achieving functional independence at 6-months.<sup>[2-3]</sup> For individuals with mild to moderate ICH, the strategy of lowering acute blood pressure aiming at limiting blood pressure variability and achieving a smooth, sustained blood pressure, is considered beneficial to functional outcomes and with strong recommendations in clinical practice guidelines.<sup>[4]</sup> Regarding the large or severe ICH, the evacuation of hematoma and surgical decompression are likely to reduce the mortality, but it was not associated with improved functional outcomes.<sup>[5]</sup> A recent international multi-site clinical trial suggests that the goal-directed care bundle of early physiological control including the intensive BP lowering, glycaemic control, and treatment of pyrexia, and the reversal of anticoagulation in the participants of ICH is associated with a reduced death at 6 months, but it has no apparent impacts on major disability in those survivors. [6] Though the rehabilitation and recovery are critical to better functional outcomes and quality of life after ICH of moderate severity, [4,7] the timing of implementing rehabilitation activities is conflicting as some study suggests that very early aggressive mobilization might cause a higher mortality. [8,9] In summary, there is no certain evidence on any single medication that has been shown to significantly improve mortality and neurological outcome after ICH, and an increase in the number of ICH clinical trials may provide continued hope for reducing its burden.<sup>[10]</sup>

Chinese herbal medicine (CHM) has long been applied in the treatment of stroke, and it continues to be widely used in modern China, [11,12] and accumulated clinical evidence suggests that CHM as an adjunct to conventional medications and rehabilitation provides additional benefits to the patients with stroke. [13] However, most high-quality clinical trials are for ischemic stroke. [14-16] and the CHM recommendations specific to ICH in clinical practice guidelines are mostly based on expert consensus and evidence of low quality. [17] Given the unmet demand for the research and discovery of new drugs for ICH, medical scientists attempt to assess the effect and safety of CHM for ICH, and a meta-analysis pooling 45 clinical trials showed that the add-one use of CHM to conventional treatments safely improved the dependency, neurological impairments, and volume of hematoma and perihematomal edema; however, it did not offer additional benefits to mortality. [18]

Zhongfeng Xingnao (ZFXN) preparation, a multi-herbal formula of CHM, developed from Dr. Shaohong Chen, the Master of Chinese Medicine entitled by Chinese national government, has been used in the treatments of ICH for more than 25 years. From the perspective of Traditional Chinese medicine (TCM) theory, Dr Chen believes that Qi deficiency is essential to the pathophysiological process of acute ICH, which is quiet different from the theory and clinical experience of other TCM practitioners [19,20] ZFXN preparations are currently composed of four herbs, namely, Ginseng (Radix Ginseng), Chuanxiong (Rhizoma Ligustici Chuanxiong), Sanqi (Radix Notoginseng), and Dahuang (Radix et Rhizoma Rhei), which is patented as a novel treatment for cerebrovascular disease in 2005.<sup>[21]</sup> A review of laboratory experiments suggests that ZFXN preparations can be well penetrated to the blood brain barrier (BBB), and the whole formula presents the effect of anti-inflammations, anti-oxidants, the inhibition of excitatory toxicity, antiapoptosis, neuro-protection and maintaining the integrity of BBB. [22] To be specific, in a rat model of collagenase-VII-induced ICH, five-days treatment of ZFXN is able to improve the neurological deficits, the hematoma and perihematoma edema, which may be via the mechanism that ZFXN down-regulates expressions of CaMKII/NF-κB p65/NLRP3/GSDMD signaling axis-related protein around the hematoma area, and attenuates the inflammatory response by regulating the activation of NLRP3 inflammasome after ICH. [23] A study using the network pharmacology and molecular docking techniques suggests that ZFXN inhibits neuronal apoptosis and inflammatory response through PI3K/AKT/p53 pathway to protect the BBC, thereby slowing down microcirculatory impairment in cerebral hemorrhage, which is validated by the experiment conducted in ICH rat models.<sup>[24]</sup>

ZFXN preparation has been manufactured as an oral solution, and put into use in the Hospital of Chendu University of TCM for almost 17 years, which is approved and regulated by Sichuan Medical Products Administration (Batch number: Z20070623). Over the decades, small-to-middle scale clinical trials on ZFXN preparations for ICH had been performed to assess its effect and safety, and to further explore the optimal timing of administration and best-fit subgroup population; however, a systematic review and meta-analysis pooling these studies was lacking. Therefore, we conducted this systematic review and meta-analysis on ZFXN for ICH to address these clinical questions, including

- Did ZFXN benefit the patients with acute ICH per critical outcomes?
- Did the add-one use of ZFXN to conventional treatment bring additional risks to the patients with acute ICH?
- Which was the best administration timing and therapeutic duration of ZFXN?

■ What type of ICH patients would benefit best from the treatment of ZFXN?

### Methods

The protocol of this systematic review was prospectively registered in PROSPERO (CRD42021247243),<sup>[26]</sup> and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020.<sup>[27]</sup>

1. Eligibility Criteria

Studies met the following inclusion criteria were included to the systematic review.

Types of studies

Randomized controlled trials (RCTs) were eligible.

**Participants** 

The participants were diagnosed as spontaneous ICH confirmed by imaging.

Interventions and controls

The experimental intervention was ZFXN preparations consisting of Ginseng (*Radix Ginseng*), Chuanxiong (*Rhizoma Ligustici Chuanxiong*), Sanqi (*Radix Notoginseng*), and Dahuang (*Radix et Rhizoma Rhei*), in the forms of traditional CHM decoction, and proprietary CHM, such as oral solution and granule. The control included no treatment, placebo, standard care, disease management (e.g. controlling blood pressure, glucose, and temperature, and the prevention from medical complications), and medical treatments (e.g. pharmacotherapy to decrease the intracranial pressure, or surgery). Studies examining either the independent or the add-one effect of ZFXN were included.

Outcome measurements

The primary outcomes were the mortality and neurological impairments such as National Institutes of Health Stroke Scale (NIHSS). The secondary outcomes included dependency assessed with modified Rankin Scale (mRS), and Barthel Index (BI), volume of hematoma, and perihematomal edema. The safety outcomes including general adverse events, and specific to ICH.

If the studies met one of the following criteria were excluded:

■ ICH was certainly due to brain trauma, aneurysm, cerebrovascular malformation, tumor and inappropriate use of anti-coagulant or anti-platelet treatment;

- Other CHM regimens were used in the intervention groups;
- The basic care and treatment differed between the intervention and control group; and
- Duplicates.

## 2. Data sources and search strategies

We searched eight databases, including the Cochrane Library, PubMed, EMbase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), WanFang database, VIP Chinese SciTech Periodical Database (VIP) and China Biological Medicine Database (CBM) from their inceptions until March 2024. We also searched studies completed yet unpublished in clinical trial registries including Chinese Clinical Trial Registry (ChiCTR) and ClinicalTrials.gov. In addition, we contacted the research and development team of ZFXN for detailed research reports and datasets of unpublished RCTs. The full search strategies are presented in Supplementary Table S1.

## 3. Study selection and data extraction

After removing duplicates, two reviewers independently screened the literature by reviewing the titles and abstracts, followed by reading the full texts to identify the relevant studies. The data were extracted in the manner of double entry. The data item included the author, publication year, study design, sample size, age, sex, diagnosis, time of onset (hour), hematoma volume (ml), and the details of interventions such as type of preparations, dosage, therapeutic duration, and outcome. Disagreements in the process of study selection and data extraction were settled through discussion or consultation with a third reviewer.

## 4. Risk of bias assessment and evidence quality

Two independent reviewers assessed the risk of bias (RoB) of included studies using the Cochrane RoB 2 tool. [28] Five domains including bias arising from the randomization process, bias due to deviations from intended interventions, due to missing outcome, bias in measurement of the outcome, and bias in selection of the reported result were evaluated using signaling questions. The RoB judgement for each domain was categorised as low risk of bias, some concerns, or high risk of bias. These levels of Rob were applicable to an overall RoB judgement. Any disagreement was resolved by discussion or consultation with a third reviewer. As different impacts of blinding on the objective outcomes from clinician/participants reporting outcomes existed, we assessed the domains related to blinding per type of outcome measures.

The evidence quality of critical outcomes based on the consensus of the review panel, was assessed by the approach of Grading of Recommendations Assessment, Development, and Evaluation (GRADE),<sup>[29]</sup> and the certainty of evidence body was graded as high, moderate, low, or very low by considering the risk of bias, inconsistency, indirectness, imprecision, and publication bias.

### 5. Data presentation and meta-analysis

Dichotomous outcomes were presented as the risk ratio (RR) with a 95% confidence interval (CI), while continuous outcomes were primarily presented with mean differences (MD). Heterogeneity was assessed by the Cochrane Q-statistic test with the I² value. A fixed effect model was applied in the meta-analysis when the I² was less than 50%; otherwise, a random effect model was used. Sensitivity analysis was performed by omitting each study in turn. To explore the heterogeneity and identify the effect in certain types of participants, subgroup-analyses were conducted in terms of age, sex, time of onset, disease severity such as NIHSS scores and hematoma volume during the baseline, the types, dose, therapeutic duration of intervention and the type of control. Publication bias was assessed by the funnel plots with Egger's test when the meta-analysis included more than 10 studies. The data were analyze using the Review Manager software 5.3 and STATA 14.0.

### **Results**

## 1. Study identification

The literature search identified 4,874 relevant records, three records identified thorough Chinese clinical trial registry. After removing duplicates and literature screening, a total of 9 RCTs published were finally included in the systematic review. [30,31,32,33,34,35,36,37,38] The full process of literature screening is specified in Figure 1.

### **2.** Characteristics of the included studies

Table 1 detailed the basic characteristics of included studies. The included studies were published in Chinese medical journals between 2003 and 2023. The sample size ranged from 38 to 547, with an average of 160. All the included studies were ransomised, paralelled, controlled trials, and six of them were implemented in multiple sites. [33,34,35,36,37,38] Both the research personnel and participants were blinded in two trials, [37,38] while one study blinded the outcome assessor. [38] The participants were aged 66.12 years, and the male accounted for 44.4% of the total sample. In terms of the ICH definition, though different versions of national diagnostic standards were endorsed, including version 1995 (n=3), version 2005 (n=4), and version 2 (n=2), all of them were confirmed by clinical signs and imaging. Almost all the studies recruited the participants with an onset of ICH with 72 hours except one study also included participants with a disease course between 72 hours and seven days. All the studies had basal ganglia area as the local lesions, of which, five studies also included participants with other lesions, including lobe, cerebellum, and brainstem. [30,34,35,36,38] Regarding the ICH severity, among those reporting the NIHSS scores during the baseline, four scored more than 15 points<sup>[33,34,35,38]</sup> and two scored 5-15 points<sup>[30,37]</sup>; while in terms of hematoma volume, the range was between 15 ml and 35ml, five studies with more than 20ml<sup>[30,32,35,36,38]</sup> and two with less than 20ml. [34,37] Nursing, management of blood pressure, glucose, temperature, treatment on the complications such as pepticulcer, cerebral hernia and lung infection were implemented in compliance with clinical guidelines for all the participants. The participants in one trial underwent surgery treatment. [38] Although all the ZFXN preparation included Ginseng (Radix Ginseng), Chuanxiong (Rhizoma Ligustici Chuanxiong), Sanqi (Radix Notoginseng), and Dahuang (Radix et Rhizoma Rhei), they differed in preparations, including oral solution (n=6 studies), traditional decoction (n=2 studies), and granule (n=1 study). Dehydrants were forbidden in two studies. [30,32] The placebo to mimic ZFXN preparations was applied in three studies.[35,37,38] As for the outcome measurements, mortality was endorsed in six studies, neurological functions was measured in eight studies, including NIHSS (n=6 studies), ESS (n=1), and MESSS (n=2), dependency was assessed in six studies, including Barthel index for activities of daily living (n=6), modified Ranking scale for disability (n=2), and post-treatment hematoma volume was calculated in six studies. Almost all the studies monitor the safety except one study.<sup>[36]</sup>

#### 3. Risk of bias

Bias arising from the randomization process

Three studies<sup>[35,37,38]</sup> was judged as low risk of bias arising from the randomization process because they full reported the methods to generate the random sequence (eg. computer software and central randomization system) and the concealment of sequence allocation (eg. opaque sealed envelopes and central allocation system) while bias in other studies<sup>[30,31,32,33,36]</sup> were considered as some concerns mainly because they did not concealed the allocation.

Bias due to deviations from intended interventions and bias in measurement of the outcome

For the bias due to deviations from intended interventions and bias in measurement of the outcome, we made the judgments per outcomes including clinician-reporting outcome (CRO) such as NIHSS and objective outcome such as mortality. A total of eight studies measure the objective outcomes, two of which were allocated with low risk in bias due to deviations from intended interventions as they were double-blinded RCTs and they treated the outcome data with appropriate statistical methods<sup>[35,37]</sup>; another two<sup>[35,37]</sup> were judged as some concern because they were open-labeled, but they used intention-to-treat (ITT) analysis for the data of objective outcomes. Other studies<sup>[30,31,32,38]</sup> were at high risk of bias due to deviations from intended interventions because all of them did not treat the outcome data properly. A total of eight studies measured CROs, two of which were judged as low risk in this domain, because they were double-blinded and used ITT analysis, while bias in other studies were considered as high risk because they did not analyse the outcome data appropriately<sup>[38]</sup> or lacking the blinding<sup>[30,31,34,33,36]</sup>. For eight studies procedure of assessing objective  $outcomes^{[30,31,32,33,34,35,37,38]}$ , low risk of bias in measurement of the outcome were applicable to all of them as these results were usually unaffected by the assessors. For those with CROs, two studied<sup>[37,38]</sup> blinded the outcome assessors, and they were judged as low risk in this domain, while other studies without the independent assessors were all considered as high risk in bias.

Bias due to missing outcome data and bias in selection of the reported result

The bias due to missing outcome data in four studies were judged as low risk because they were either with very low rate of drop-out, or treated in the proper statistical methods. [33,34,35,37] The

bias in other five studies were considered as high risk as they did not clearly report the dropout with reasons.<sup>[30,32,31,36,38]</sup> Regarding the bias in selection of the reported result, only one study registered the protocol and fully reported all the predefined outcomes while other studies did not had registration records nor publish protocols.<sup>[30,31,32,33,34,35,36,38]</sup>

In summary, the overall judgement as low risk of bias was only applicable to one randomized, double-blinded, placebo-controlled clinical trial as all domains for it were at low risk of bias.<sup>[34]</sup> Some concerns in the objective outcomes were allocated to two double-blinded RCTs<sup>[33,35]</sup> and high risk of bias were for the remaining studies. Risk of bias in individual studies were shown Figure 2.

# **4.** Meta-analysis of estimated effect

## **4.1** Mortality at the end of treatment and follow-ups

A total of six RCTs measured mortality after the treatment of ZFXN preparations. [30,31,32,33,34,38] The homogeneous meta-analysis of mortality suggested that compared with conventional medicine alone, ZFXN as an adjunct treatment reduced the mortality by 41% (RR: 0.54, 95% CI 0.40 to 0.74, I<sup>2</sup>=31%, n= 6 RCTs,1060 participants; Figure 3). One study [34] also assessed the mortality in 90-days follow-ups, which suggested that the add-on effect of adjunct ZFXN preparation on reducing the death maintained well (RR: 0.62, 95% CI 0.40 to 0.96, 547 participants). Specific to the placebo-controlled trials, the ZFXN preparation outperformed placebo in the reduction of mortality (RR: 0.16, 95% CI 0.04 to 0.70); however the effect was estimated from a RCT with 103 participants. [38]

Three studies also examined the cause of death, [30,32,34] and the mortality probably resulted from ICH complications including brain hernia, and post hemorrhage pneumonia and recurrent hemorrhage was reduced by 43% in the group with ZFXN preparation compared with the conventional medicine alone (RR: 0.57, 95% CI 0.40 to 0.81, I<sup>2</sup>=50%, n=3 RCTs, 810 participants; Supplementary Figure 1).

## **4.2** Neurological impairments at the end of treatment and follow-ups

A total of six RCTs assessed the neurological impairments of ICH participants after the ZFXN treatment, by using NIHSS (n=6 RCTs)<sup>[30,33,34,35,37,38]</sup>. Overall, the meta-analysis of NIHSS suggested that the additional use of ZFXN preparations to the conventional medicine reduced the total scores of NIHSS both at the end of treatment (MD:-2.37, 95% CI -3.34 to -1.39, I<sup>2</sup>=66%, n=6 RCTs, 994 participants; <u>Figure 4A</u>) and in 90-day follow-ups (MD:-2.85, 95% CI -3.83 to -1.86, I<sup>2</sup>=52%, n=3 RCTs, 734 participants; Figure 4B). Specific to the placebo-

controlled trials, ZFXN preparation outperformed placebo in improving neurological impairments measured with NIHSS, at the end of treatment (MD:-2.13, 95% CI -3.34 to -0.92,  $I^2=75\%$ , n=3 RCTs, 302 participants; <u>Figure 4A</u>) and at 90-day follow-ups (MD:-2.28, 95% CI -3.03 to -1.53, n=1 RCTs, 137 participants; <u>Figure 4B</u>).

Other scales including MESSS (n=2 RCTs) [30,31], and ESS (n=1 RCTs) [36] were also applied in the evaluation of neurological impairments. A small-scale RCT with MESSS suggested that ZFXN preparation was effective in improving neurological impairments (MD: -4.13, 95% CI-8.25 to -0.01; Supplementary Figure 2). The meta-analysis of these scales in the follow-ups suggested that the effectiveness of ZFXN maintained well in 90 days, as showed in either MESSS (MD:-5.46, 95% CI -7.68 to -3.24, I<sup>2</sup>=0%, n=2 RCTs, 83 participants) or ESS (MD: 16.69, 95% CI 13.98 to 19.40, n=1 RCT, 122 participants; Supplementary Figure 3-4).

## **4.3** Dependency

The dependency in terms of BI was measured at the end of the ZFXN treatment (n=3 RCTs) [30,35,37] and in the 90-day follow-up visits (n=5 RCTs) [30,31,35,36,38] Overall, the meta-analysis of BI at the end of treatment suggested that the add-one application of ZFXN preparation in the conventional medicine improved the scores of BI (MD: 13.40, 95% CI 7.50 to 19.29, I²=55%, n= 3 RCTs, 239 participants; Figure 5A), while the meta-analysis was of moderate heterogeneity. The additional benefits brought by ZFXN preparations to activities of daily living (ADL) maintained well in 90-day follow-ups as shown in a homogeneous meta-analysis (MD: 13.76, 95% CI 11.22 to 16.30, I²=33%, n=5 RCTs, 431 participants; Figure 5B). Specific to the placebo-controlled trials, the ZFXN preparation outperformed placebo in improving ADL measured with BI, at the end of treatment (MD:14.82, 95% CI 8.79 to 20.82, I²=61%, n=2 RCTs, 201 participants; Figure 5A) and at 90-day follow-ups (MD:13.31, 95% CI 10.31 to 16.31, I²=79%, n=2 RCTs, 238participants; Figure 5B). Another two RCTs assessed the dependency with mRS, and their meta-analysis of homogeneity also showed the add-one effectiveness of ZFXN preparations on improving disability at the end of 90-day follow-ups (MD -1.12, 95% CI -1.33 to -0.90, I²=0%, n=2 RCTs, 238 participants; Figure 5C).

## **4.4** The volume of hematoma and perihematomal edema

A total of four RCTs measured the volume of hematoma. [30,31,34,37] The meta-analysis about the volume of hematoma at the end of treatment showed that the additional use of ZFXN preparations provided additional benefits to the conventional medication in reducing the volume of hematoma (MD -3.88 ml, 95% CI -4.87 ml to -2.88 ml, I<sup>2</sup>=45%, n=4 RCTs, 694

participants; <u>Figure 6</u>). As there was no minimal clinically important difference (MCID) for the volume of hematoma, its standardised mean difference (SMD) was also computed (SMD -0.74, 95%CI -1.30 to -0.18, I<sup>2</sup>=82%, n=4 RCTs, 694 participants). Only one included RCT measured perihematomal edema, which suggested that the perihematomal edema after the 14-day adjunct treatment of ZFXN preparations was not significantly reduced compared with the control group treated with diuretic and dehydration.

## **4.5** Other analyses

## **4.5.1** Subgroup-analysis

The subgroup-analyses in terms of sex, age, the baseline characteristics including the volume of hematoma, NIHSS scores and days after the onset of ICH, and the dosage form and therapeutic duration of ZFXN preparation, and inclusion/exclusion of diuretic dehydration suggested that the hematoma volume during the baseline and therapeutic duration affected the post-treatment effectiveness most, across the mortality, neurological impairments measured with NIHSS and ADL assessed with BI. It appeared that the ICH participants with hematoma volume > 20 ml (up to 35ml) and those with the therapeutic duration equal or longer than 28 days benefited most from the ZFXN preparation, and the results were of homogeneity. Table 2 detailed the statistical results of subgroup analyses.

### **4.5.2** Sensitivity analysis and publication bias

Sensitivity analysis by omitting one study in turn did not alter the results of primary metaanalysis (<u>Supplementary Figure 5 to 10</u>), which suggested the results were robust. Due to the limited number of RCTs included in the meta-analysis, the detection of publication bias was inapplicable to the current data.

### **5.** Safety assessment

A total of seven studies reported the adverse events other than death and current haemorrhage<sup>[30,31,33,34,35,37,38]</sup>. In general, the meta-analysis of adverse events suggested that the add-one use of ZFXN preparation to the conventional medicine, did not bring additional probability in adverse events (RR: 1.08, 95%CI 0.69 to 1.69, I<sup>2</sup>=53%, n=7 RCTs, 1079 participants). Regarding specific types of adverse events, the occurrence of diarrhea was obviously increased (RR 10.02, 95%CI 3.61 to 27.81, I<sup>2</sup>=0%, n= 6 RCTs, 1046 participants), and this was likely caused by *Radix et Rhizoma Rhei*, one of the ingredients of ZFXN, while other types of adverse events were reduced when ZFXN was used, such as electrolyte disorder, hepatic and renal dysfunction, and hypotension (Supplementary Figure 11).

# **6.** GRADE evidence quality

The evidence quality per critical outcomes were graded by GRADE approach (<u>Table 3</u>). The evidence of moderate quality suggested that the adjunct ZFXN preparation provide additional benefits in reducing mortality among the participants with ICH, while the evidence of low quality revealed that the ZFXN in combination with conventional medicine improved neurological impairments of ICH patients.

### **Discussion**

The summary of main findings and strength

This systematic review and meta-analysis of nine RCTs with 1448 participants showed that the adjunct use of ZFXN preparations to conventional medicine in the participants with ICH brought additional benefits to the primary outcomes including mortality and neurological impairments, as well as secondary outcomes including dependency and the volume of cerebral hematoma. Regarding safety, the meta-analysis suggested that though ZFXN did not increase the risk of adverse events in general, though the occurrence of diarrhea was markedly increased. Overall, the present study provided promising evidence for ZFXN preparation in the patients with ICH, either in effectiveness or safety. In almost 20 years from the first publication of ZFXN preparation, though the research and clinical practice of ICH have achieved many progress, RCTs on haemostatic therapies failed to provide supportive evidence on the reduced mortality and improved dependency,<sup>[39]</sup> and the promising preclinical results of numerous neuroprotective agents have not yet translated into positive clinical trials in patients with ICH.<sup>[40]</sup> As the focus for treatment of patients after ICH is the prevention of secondary brain damage, and anti-inflammatory and neuro-protective agents are the future research agenda,<sup>[41]</sup> the promising evidence from ZFXN preparations is encouraging.

Comparison with previous studies and potential pharmacological mechanism

The result in our meta-analysis was generally consistent with a previous systematic review<sup>[42]</sup> on "*Promoting blood circulation for removing blood stasis therapy*" (PBCRBS) for acute ICH, which showed that PBCRBS interventions used in combination with conventional medicine improved neurological impairments and dependency, as well as reduced the mortality, the volume of hematoma and perihematomal edema. However, conflicting evidences and distinct expert opinions on the safety issue were noted that herbs with the function of PBCRBS might lead to the enlargement of hematoma volume and recurrent haemorrhage. The herbs most frequently reported in the previous meta-analysis<sup>[42]</sup> was *Sanqi (NOTOGINSENG RADIX ET RHIZOMA)*, has long been used for stroke in Chinese medicine. A laboratory experiment published very early<sup>[43]</sup> had suggested that the treatment of *Panax notoginseng saponins*, an active ingredient from *Sanqi (NOTOGINSENG RADIX ET RHIZOMA)*, worsened the brain edema and neurological functioning when it was applied at the early stage of ICH. Though ZFXN preparations also included *Sanqi (NOTOGINSENG RADIX ET RHIZOMA)*, the duration from the onset was 12.43 hours on average among the included studies, which was safe in general because hematoma expansion mainly occurs within 6 hours of onset which commonly

lead to a quick disease progress in acute ICH.[44] A meta-analysis of Panax notoginseng saponins (PNS), [45] the extract from Sangi (NOTOGINSENG RADIX ET RHIZOMA), administrated as intravenous drip for ICH, suggested that all the clinical outcomes were remarkably improved without additional risks in safety, when the PNS treatment lasted for at least 28 days and the treatment started within 48 hours after ICH onset, which was similar as the results of subgroup-analysis in the systematic review of ZFXN preparations (Table 2). ZFXN preparations also included Chuanxiong (CHUANXIONG RHIZOMA), another Chinese herb relevant to the PBCRBS principle and the treatment option of priority for headache in Chinese medicine literature, [46] which was reported as a Chinese herb of high frequency in another systematic review<sup>[47]</sup> on CHM for ICH. This updated meta-analysis<sup>[47]</sup> including 15 RCTs also demonstrated that CHM with the function of PBCRBS as an adjunct improved neurological impairments in terms of NIHSS and dependency assessed with BI, as well as decreased the cerebral hematoma and edema. Though the pharmacological mechanism on Chuanxiong (CHUANXIONG RHIZOMA) for ICH was not fully elucidated, considerable laboratory evidence<sup>[48,49]</sup> suggested tetramethylpyrazine, an active ingredient from *Chuanxiong* (CHUANXIONG RHIZOMA), was able to reduce the permeability of blood-brain barrier (BBB) in animal model of traumatic brain injury and in vitro model of ischemia. This might explain its protective role in ICH as the disruption of BBC was considered essential to the secondary pathophysiology of ICH.<sup>[50]</sup> However, the safety of *Chuanxiong (CHUANXIONG RHIZOMA)* had not been comprehensively evaluated for ICH patients, which required further research.

Dahuang (Radix et Rhizoma Rhei), another herb in ZFXN preparations, with the function of freeing bowels and expelling stools, represented another therapeutic principle of Chinese medicine for ICH. Laboratory experiments showed that Dahuang (Radix et Rhizoma Rhei) and its active ingredients presented protective feature for ICH by multiple pharmacological actions, including protecting the integrity of BBB, reducing the massive cascade of inflammations, inhibiting apoptosis and oxidative stress of the brain tissues, and decreasing lactic acid accumulation at the bleeding location, ultimately to improve the hematoma absorption and edema removal in clinical, which suggested that Dahuang (Radix et Rhizoma Rhei) was able to ameliorate the prognosis of ICH by acting both the primary and secondary phases of pathophysiology as complex inflammatory responses were accompanied by the hematoma formation and expansion, and the secondary peri-hematomal edema. Despite the promising evidence of Dahuang (Radix et Rhizoma Rhei) for ICH, the event of diarrhea, side effect due to its its original function of freeing bowels and expelling stools was noted.

According to traditional theory of CHM, *Dahuang (Radix et Rhizoma Rhei)* processed by wine was not functioning as a strong laxative. Furthermore, though either raw *Dahuang (Radix et Rhizoma Rhei)* or the processed one was capable of promoting the hematoma absorption and improved neurological impairments, modern experiments showed that the wine-processed one had stronger effect of anti-inflammation in the animal model of ICH than the raw. These evidences should be taken into the consideration in future research to secure the safety utility of ZFXN. *Ginseng (Radix Ginseng)*, was a representative herb to tonify *Qi* in CHM theory, corresponding to the clinical experience proposed by Dr Shaohong Chen, that *Qi* deficiency is essential to acute ICH from the perspective of Chinese medicine. Though the use and potential mechanism of Ginseng for acute ICH was not widely reported and extensively studied, a few in-vivo research suggested [53,54] that active ingredients extracted from *Ginseng (Radix Ginseng)*, including Ginsenoside Rg1, and Ginsenoside Rg2, were capable to ameliorate ICH-induced neurological disorders, probably via modulating the BBB permeability and reducing neuroinflammations in the hemorrhagic hemispheres of animal model.

In summary, the effectiveness of ZFXN preparations for ICH was likely via its protective role in the maintenance of BBC integrity and the reduction of inflammations around the hematomal brain, instead of resolving the haematoma. Differing from *Naoxueshu oral liquid*, other oral Chinese Proprietary Medicine containing leech with the function of anti-coagulation, and inhibiting platelet-aggregation, aiming at resolve the hematoma, [55,56] ZFXN preparations probably protected the individuals with ICH from the secondary injury from hematoma expansion, when brain tissue reacts to hematoma development, and local extra-vascular blood products and peripheral expansion trigger an inflammatory response to disintegrate the hematoma, and vasogenic edema is formed as increased extravasated fluid accumulation due to BBB disruption of endothelial tight junctions. [57]

### Evidence completeness and quality

Though this systematic review and meta-analysis provided supportive evidence for the use of ZFXN for acute ICH, we should treat the results cautiously for clinical practice and future research as the evidence certainty was of variety across outcome measures, and evidence incompleteness might exist for some predefined clinical questions. Regarding the primary outcomes, the ZFXN evidence on mortality right after the treatment was of moderate evidence, which suggested that the true effect was likely to be close to the estimate one. As for the neurological impairment, another primary outcome, the ZFXN evidence on NIHSS scores was of low quality, which suggested that our confidence in the effect estimate was limited. One of

the significant factors reducing the evidence quality per NIHSS was the heterogeneity, which was resolved by subgroup-analyses in term of therapeutic duration of ZFXN preparations and the hematoma volume at baseline. And the statistical results implied that the ICH participants with 20-35 ml hematoma volume at baseline and those with the therapeutic duration equal or longer than 28 days benefited most from the ZFXN preparation without any heterogeneity, and the difference between groups was larger than the minimal clinically important difference (MCID) of NIHSS scores in acute stroke patients.<sup>[58]</sup>

Regarding the secondary clinical outcomes relevant to the dependency of ICH participants, the ZFXN evidence on ADL assessed with BI at the 90-day follow-up visit was of moderate quality, and the mean differences between groups was larger than the MCID of BI in stroke patients, which suggested that this result was of clinical significant alongside with statistical significance. With regard to the secondary biological outcomes, the ZFXN evidence on hematoma volume was of moderate quality, and the estimated SMD was considered representing an effect in moderate magnitude. The evidence on other clinical outcomes such as mRs supported the benefits of ZFXN to ICH patients, but the evidence quality was of low-to-very low due to limited number of studies. The other secondary biological outcome such as perihematomal edema was only reported in one RCT treated with diuretic and dehydration, which failed to examine the primary effectiveness of ZFXN preparation on the reduction of edema.

## Limitations and implications for future research

The time-window of CHM treatment including PBCRBSH herbs is a long unresolved question, as hematoma expansion usually occurs in the first 24 hours after ICH, which causes additional death and worse prognosis<sup>[61]</sup>. Though this meta-analysis of ZFXN preparation identified the optimal administration timing potentially beneficial to all clinical outcomes, its precise time window was uncertain. The subgroup-analysis suggested that the participants with an clinical presentation within 72 hours after an onset of ICH was able to benefit from the ZFXN treatment generally; however, the risk of recurrent ICH within 24 hours after onset was uncertain clinically due to the limited information of safety assessment and the lack of measuring nonfatal recurrent ICH. In addition, the increase of perihematomal edema during 72 hours was associated with worse functional outcomes after ICH<sup>[62]</sup>; however, the included RCTs seldom reported the condition of perihematomal edema before-and-after treatments of ZFXN. Previous evidence showed that the lobar ICH location was associated with a higher risk of recurrent ICH<sup>[63]</sup>; but most of the ZFXN RCTs included the cases with other bleeding locations alongside with basal ganglia ICH, which might cause heterogeneity in effectiveness and harm. These

clinical questions should be considered in the methodological design and statistical analysis plan of future RCTs. Regarding safety, the increased occurrence of diarrhoea probably due to ZFXN was noted. Previous studies identified the high prevalence of constipation after ICH and proposed the necessity of laxative therapy<sup>[64-65]</sup>. *Dahuang (Radix et Rhizoma Rhei)* in ZFXN preparation seems appropriate for the ICH participants with concurrent constipation as it is a common herb with laxative effect without known toxicity. However, whether an increased occurrence of diarrhoea was beneficial or harmful to the acute ICH patients without constipation remained unknown. An prior statistical analysis plan considering this subgroup participants should be considered in future RCTs.

As the current evidence was from small and exploratory RCTs, a multi-site, larger sample, confirmatory RCT with improved methodological design, better quality control, and reporting adherence to CONSORT Extension for Chinese Herbal Medicine Formulas <sup>[66]</sup> was needed. An ongoing multicenter, prospective, randomized, double-blind clinical trial--the CHAIN trial (Clinicaltrials.gov: NCT05066620) slated for completion recently will hopefully fill in the gap <sup>[67]</sup>

#### Conclusion

Clinical evidence of low-to-moderate quality suggested that adjunct ZFXN preparation was potentially effective and safe for acute ICH. However, a multi-site, larger sample, confirmatory RCT with improved methodological design and quality control was needed, before its comparative research with other proprietary Chinese medicine.

# Acknowledgement

None.

## **Funding**

This research was funded by the Key-Area Research and Development Program of Guangdong Province (No. 2020B1111100009), the National Natural Science Foundation of China (No. 81974559), the Natural Science Foundation of Guangdong Province (No. 2020A1515010992), and the Xinglin Scholar Research Premotion Project of Chengdu University of TCM (No. XKTD2021004).

## **Conflicts of interest**

None.

### References

- 1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0
- Cordonnier C, Demchuk A, Ziai W, Anderson CS. Intracerebral haemorrhage: current approaches to acute management [published correction appears in Lancet. 2019 Feb 2;393(10170):406]. Lancet. 2018;392(10154):1257-1268. doi:10.1016/S0140-6736(18)31878-6
- 3. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167-176. doi:10.1016/S1474-4422(09)70340-0
- Kuramatsu JB, Biffi A, Gerner ST, et al. Association of Surgical Hematoma Evacuation vs Conservative Treatment With Functional Outcome in Patients With Cerebellar Intracerebral Hemorrhage. JAMA. 2019;322(14):1392-1403. doi:10.1001/jama.2019.13014
- Ma L, Hu X, Song L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial [published correction appears in Lancet. 2023 Jul 15;402(10397):184]. Lancet. 2023;402(10395):27-40. doi:10.1016/S0140-6736(23)00806-1
- 7. Liu N, Cadilhac DA, Andrew NE, et al. Randomized controlled trial of early rehabilitation after intracerebral hemorrhage stroke: difference in outcomes within 6 months of stroke. Stroke. 2014;45(12):3502-3507. doi:10.1161/STROKEAHA.114.005661
- 8. Bernhardt J, Borschmann K, Collier JM, et al. Fatal and Nonfatal Events Within 14 days After Early, Intensive Mobilization Poststroke. Neurology. 2021;96(8):e1156-e1166. Published 2021 Feb 22. doi:10.1212/WNL.000000000011106

- 9. AVERT Trial Collaboration group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial [published correction appears in Lancet. 2015 Jul 4;386(9988):30] [published correction appears in Lancet. 2017 May 13;389(10082):1884]. Lancet. 2015;386(9988):46-55. doi:10.1016/S0140-6736(15)60690-0
- 10. Magid-Bernstein J, Girard R, Polster S, et al. Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. Circ Res. 2022;130(8):1204-1229. doi:10.1161/CIRCRESAHA.121.319949
- 11. Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019;18(4):394-405. doi:10.1016/S1474-4422(18)30500-3
- 12. Zhu T, Wang L, Feng Y, Sun G, Sun X. Classical Active Ingredients and Extracts of Chinese Herbal Medicines: Pharmacokinetics, Pharmacodynamics, and Molecular Mechanisms for Ischemic Stroke. Oxid Med Cell Longev. 2021;2021:8868941. Published 2021 Mar 13. doi:10.1155/2021/8868941
- 13. Zhong LL, Zheng Y, Lau AY, et al. Would integrated Western and traditional Chinese medicine have more benefits for stroke rehabilitation? A systematic review and meta-analysis. Stroke Vasc Neurol. 2022;7(1):77-85. doi:10.1136/svn-2020-000781
- Venketasubramanian N, Young SH, Tay SS, et al. CHInese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy. Cerebrovasc Dis. 2015;39(5-6):309-318. doi:10.1159/000382082
- 15. Wu L, Song H, Zhang C, et al. Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(6):e2317574. Published 2023 Jun 1. doi:10.1001/jamanetworkopen.2023.17574
- 16. Cai Y, Zhang X, Huang Y, et al. The add-on effect of dengzhan shengmai capsules on secondary prevention of ischemic stroke: A multicentre, randomised, placebo-controlled clinical trial. Complement Ther Med. 2019;46:189-194. doi:10.1016/j.ctim.2019.08.015
- 17. Ni X, Lin H, Li H, et al. Evidence-based practice guideline on integrative medicine for stroke 2019. J Evid Based Med. 2020;13(2):137-152. doi:10.1111/jebm.12386
- 18. Wang HL, Zeng H, Xu MB, et al. Efficacy and Safety of Chinese Herbal Medicine for

- Primary Intracerebral Hemorrhage: A Systematic Review of Randomized Controlled Trials. Front Pharmacol. 2019;10:1139. Published 2019 Oct 10. doi:10.3389/fphar.2019.01139
- Guo, J. W., Zhang, X. Y., Lan, W. C., Zhang, J, Chen, S. H. "The Core pathogenesis of stroke" of Professor Chen Shaohong. Tianjin Traditional Chinese Medicine, 2006;(01):7-9. (Article in Chinese)
- 20. Guo QH, Cui WZ., Li MZ, Yang JC, Lu Y, Tang GH, et al, To Explore the Core Pathogenesis of Hemorrhagic Stroke from "Deficiency-Blood Stasis-Toxic". Journal of Emergency in Traditional Chinese Medicine, 2022;31(02):242-246.(Article in Chinese)
- 21. Chen SH, Compositions for the treatment of cerebrovascular diseases and methods for their preparation and applications[P]. Chinese patent: : CN01823262.0. 2002.11.21.
- 22. Liu L, Zhang H, Chen SH, Zhang XY. Research Progress on Pharmacological Effects of Zhongfeng Xingnao Liquid on Stroke. Pharmacology and Clinics of Chinese Materia Medica. 2021;37(02),227-233. (Article in Chinese)
- 23. Yu J, Zhou H, Guo JW, Chen T, Shao C, Pan Z, Yang J, Wan H. Zhongfeng Xingnao prescription alleviates injury of intracerebral hemorrhage via regulating the CaMKII/NF-κB p65/ NLRP3/GSDMD signaling axis, Journal of Traditional and Complementary Medicine, doi: https://doi.org/10.1016/j.jtcme.2024.03.005.
- 24. Zhong XQ, Hu DF, Wang Y, Ning ZQ, Deng MZ. Mechanism of Zhongfeng Xingnao Decoction in improving microcirculatory disorders in cerebral hemorrhage based on network pharmacology and molecular docking techniques. China Journal of Chinese Materia Medica. 2023;48(22):6115-6127. (Article in Chinese).
- 25. Sichuan Food and Drug Administration to change the medical institution preparation approval number announcement, SiChuan Medical Products Administration, 2007. Available from:https://yjj.sc.gov.cn/scyjj/c103155/2007/9/19/73aeb72b1cbb427baeaabb653ec5e409 .shtml.[Accessed 19 September 2007].
- 26. Taijun Jiang, Yi Tang, Xi Wu, Yun Lu. Effectiveness and Safety of Zhongfeng Xingnao Oral Liquid in patient with Acute Spontaneous (non-traumatic) intracerebral haemorrhage: A Systematic Review and Meta-Analysis. PROSPERO 2021 CRD42021247243 Available from: https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42021247243

- 27. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Published 2021 Mar 29. doi:10.1136/bmj.n71
- 28. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. In: Cochrane handbook for systematic reviews of interventions version 6.3. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane; [(updated February 2022)]. 2022. Chapter 8: assessing risk of bias in a randomized trial.
- 29. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-406. doi:10.1016/j.jclinepi.2010.07.015
- 30. Liu ZB. Research overview of Chinese and Western medicine and clinical study of Apoplexy Xingnao oral liquid in the treatment of acute cerebral hemorrhage. 2003. Chengdu University of Traditional Chinese Medicine. (Article in Chinese).
- 31. Chen XR. The pathogenesis and treatment of cerebral edema in hemorrhagic stroke. 2005. Chengdu University of Traditional Chinese Medicine. (Article in Chinese).
- 32. Chen SH, Zhang XY. Efficacy of "Zhongfeng Xingnao oral liquid" in the treatment of 108 cases with acute intracerebral hemorrhage. Proceedings of the 2nd academic conference of Encephalopathy Branch of China Association of Traditional Chinese Medicine, 2010:33-41. (Article in Chinese).
- 33. Guo XH. A Multicenter randomized clinical trial of integration of traditional Chinese and Western medicine treatment for intracranial hypertension in acute intracerebral hemorrhage. 2012. Chengdu University of Traditional Chinese Medicine. (Article in Chinese).
- 34. Li, YQ. Clinical trials of Zhongfeng xingnao oral liquid for acute hemorrhagic strok. 2012. Chengdu University of Traditional Chinese Medicine. (Article in Chinese).
- 35. Zhang H. Clinical study of integrated TCM and Western medicine in the treatment of acute intracerebral hemorrhage. 2013. Chengdu University of Traditional Chinese Medicine. (Article in Chinese).
- 36. Li K, Xiang ZD, Zhang XY. Effect of Zhongfeng Xingnao Oral liquid on nerve function defect in patients with acute cerebral hemorrhage. J Mil Surg Southwest Chin, 2015;17(06): 640-64. (Article in Chinese).
- 37. Liu L. Clinical Efficacy and Anti-inflammatory Mechanism of Zhongfeng Xingnao

- Granule in Intracerebral Hemorrhage. 2021. Chengdu University of Traditional Chinese Medicine. (Article in Chinese).
- 38. Guo XH. A multicenter, double-blind, randomized placebo-controlled trial on the safety and efficacy of Zhongfeng Xingnao formula in the treatment of moderate and severe intracerebral hemorrhage. 2023. Chengdu University of Traditional Chinese Medicine. (Article in Chinese).
- 39. Eilertsen H, Menon CS, Law ZK, et al. Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev. 2023;10(10):CD005951. Published 2023 Oct 23. doi:10.1002/14651858.CD005951.pub5
- 40. Kearns KN, Ironside N, Park MS, et al. Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2021;35(3):862-886. doi:10.1007/s12028-021-01311-3
- 41. Sheth KN. Spontaneous Intracerebral Hemorrhage [published correction appears in N Engl J Med. 2023 Apr 13;388(15):1440]. N Engl J Med. 2022;387(17):1589-1596. doi:10.1056/NEJMra2201449
- 42. Li HQ, Wei JJ, Xia W, et al. Promoting blood circulation for removing blood stasis therapy for acute intracerebral hemorrhage: a systematic review and meta-analysis. Acta Pharmacol Sin. 2015;36(6):659-675. doi:10.1038/aps.2014.139
- 43. Nie YX, Wang D, Zhang X. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006;26(10):922-925.
- 44. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996;27(10):1783-1787. doi:10.1161/01.str.27.10.1783
- 45. Xu D, Huang P, Yu Z, Xing DH, Ouyang S, Xing G. Efficacy and Safety of Panax notoginseng Saponin Therapy for Acute Intracerebral Hemorrhage, Meta-Analysis, and Mini Review of Potential Mechanisms of Action. Front Neurol. 2015;5:274. Published 2015 Jan 7. doi:10.3389/fneur.2014.00274
- 46. Liu GH, Yang HT, Bai L, et al. Data mining-based analysis on medication rules of Chinese herbal medicine treating headache with blood stasis syndrome. Heliyon. 2023;9(4):e14996. Published 2023 Mar 30. doi:10.1016/j.heliyon.2023.e14996
- 47. Lin W, Hou J, Han T, Zheng L, Liang H, Zhou X. Efficacy and safety of traditional Chinese medicine for intracranial hemorrhage by promoting blood circulation and removing blood

- stasis: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:942657. Published 2022 Sep 28. doi:10.3389/fphar.2022.942657
- 48. Wu S, Wang N, Li J, et al. Ligustilide Ameliorates the Permeability of the Blood-Brain Barrier Model In Vitro During Oxygen-Glucose Deprivation Injury Through HIF/VEGF Pathway. J Cardiovasc Pharmacol. 2019;73(5):316-325. doi:10.1097/FJC.00000000000000664
- 49. Wang A, Zhu G, Qian P, Zhu T. Tetramethylpyrazine reduces blood-brain barrier permeability associated with enhancement of peripheral cholinergic anti-inflammatory effects for treating traumatic brain injury. Exp Ther Med. 2017;14(3):2392-2400. doi:10.3892/etm.2017.4754
- 50. Bautista W, Adelson PD, Bicher N, Themistocleous M, Tsivgoulis G, Chang JJ. Secondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage. Ther Adv Neurol Disord. 2021;14:17562864211049208. Published 2021 Oct 13. doi:10.1177/17562864211049208
- 51. Qi DH, Ma H, Chen YY. Rhubarb and its research progress formula compatibility treatment of intracerebral hemorrhage. Chinese journal of experimental formulas of Chinese medicine, 2023;29 (16): 237-249.(Chinese) doi: 10.13422 / j.carol carroll nki syfjx. 20230738.
- 52. Wang K, Guan D, Zhao X, Qiao D, Yang Y, Cui Y. Proteomics and metabolomics of raw rhubarb and wine-processed rhubarb in the treatment of rats with intracerebral hemorrhage. Ann Transl Med. 2020;8(24):1670. doi:10.21037/atm-20-7831
- 53. Cai L, Hu F, Fu W, et al. Ginsenoside Rg2 Ameliorates Brain Injury After Intracerebral Hemorrhage in a Rat Model of Preeclampsia. Reprod Sci. 2021;28(12):3431-3439. doi:10.1007/s43032-021-00692-2
- 54. Bai YL, Fang ZH, Ding CZ. Effects of ginsenoside Rg1 regulating miR-144-3p/FPR2/p38 signaling pathway on blood-brain barrier injury and neuroinflammation in experimental cerebral hemorrhage rats. Chinese Journal of Immunology, 2019;39(12):2534-2539. (Chinese)
- 55. Song J, Nie Y, Qin X, Wang P, Lu H, Gao L. Efficacy of Naoxueshu in acute spontaneous intracerebral hemorrhage: a multicenter observational study. Neurol Sci. 2022;43(3):1885-1891. doi:10.1007/s10072-021-05582-8

56. Song J, Lyu Y, Wang P, et al. Treatment of Naoxueshu Promotes Improvement of Hematoma Absorption and Neurological Function in Acute Intracerebral Hemorrhage Patients. Front Physiol. 2018;9:933. Published 2018 Jul 20.

doi:10.3389/fphys.2018.00933

- 57. Bautista W, Adelson PD, Bicher N, Themistocleous M, Tsivgoulis G, Chang JJ. Secondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage. Ther Adv Neurol Disord. 2021;14:17562864211049208. Published 2021 Oct 13. doi:10.1177/17562864211049208
- 58. Adams HP Jr, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999;53(1):126-131. doi:10.1212/wnl.53.1.126
- 59. Hsieh YW, Wang CH, Wu SC, Chen PC, Sheu CF, Hsieh CL. Establishing the minimal clinically important difference of the Barthel Index in stroke patients. Neurorehabil Neural Repair. 2007;21(3):233-238. doi:10.1177/1545968306294729
- 60. Andrade C. How to Use Percentiles to Better Understand Standardized Mean Difference (SMD) as a Measure of Effect Size. J Clin Psychiatry. 2023;84(4):23f15028. Published 2023 Aug 7. doi:10.4088/JCP.23f15028
- 61. Magid-Bernstein J, Girard R, Polster S, Srinath A, Romanos S, Awad IA, Sansing LH. Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. Circ Res. 2022 Apr 15;130(8):1204-1229. doi: 10.1161/CIRCRESAHA.121.319949.
- 62. Murthy SB, Moradiya Y, Dawson J, Lees KR, Hanley DF, Ziai WC; VISTA-ICH Collaborators. Perihematomal Edema and Functional Outcomes in Intracerebral Hemorrhage: Influence of Hematoma Volume and Location. Stroke. 2015 Nov;46(11):3088-92. doi: 10.1161/STROKEAHA.115.010054. Epub 2015 Sep 22. PMID: 26396030.
- 63. Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):660-7. doi: 10.1136/jnnp-2013-306476. Epub 2013 Nov 21. PMID: 24262916.
- 64. Chen W, Zhao J, Li X, Wang X, Chen J, Zhang T, Ma L, Li D. Using Electronic Medical Records of Nursing Care to Characterize Constipation in Patients with Intracerebral Hemorrhage. Cerebrovasc Dis. 2021;50(5):535-542. doi: 10.1159/000515706.

- 65. Wang M, Lu J, Lu Z, Wang Z, Wang Z, Wu C. Influencing Factors of Constipation in Elderly Patients With Intracerebral Hemorrhage: Implication for Clinical Care. Biol Res Nurs. 2024 Jul;26(3):390-398. doi: 10.1177/10998004241229181.
- 66. Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, Bian ZX; CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. Ann Intern Med. 2017 Jun 27;167(2):112-121. doi: 10.7326/M16-2977. PMID: 28654980.
- 67. Zhao Y, Cui W, Xie T, Zhao K, Li Y, Wang Y, et al; CHAIN investigators; Efficacy and Safety of Chinese Herbal Medicine in Patients with Acute Intracerebral Hemorrhage: Protocol for a Randomized Placebo-Controlled Double-Blinded Multicenter Trial. Cerebrovasc Dis 2023; https://doi.org/10.1159/000534761




Figure 1. Flowchart of literature screening.

CHM: Chinese Herbal Medicine; RCT: Randomized Clinical Trial; TCM: Traditional Chinese Medicine; ZFXN: Zhongfeng Xingnao preparations.

Study ID	Outcome	<u>D1</u>	<u>D2</u>	<u>D3</u>	<u>D4</u>	D5	Overall		
Liu 2003	Objective outcome	1	•	•	•	1	<u> </u>	•	Lowrisk
Liu 2003	CRO	1	Ŏ	ĕ	•	1	ĕ	<u> </u>	Some concerns
Chen 2010	Objective outcome	1	•	Ŏ	ĕ	1	Ō	•	High risk
Zhang 2013	Objective outcome	•	•	•	•	1	(Ī)		
Zhang 2013	CRO	•	•	•	•	1	Ö	D1	Randomisation process
Chen 2005	Objective outcome	1	•	•	•	1	•	D2	Deviations from the intended interventions
Chen 2005	CRO	1	•	•	•	1	<u> </u>	D3	Missing outcome data
Li 2012	Objective outcome	1	1	ě	ĕ	1	<u> </u>	D4	Measurement of the outcome
Li 2012	CRO	1	•	•	•	1	ĕ	D5	Selection of the reported result
Guo 2012	Objective outcome	1	1	•	ĕ	1	Ō		-
Guo 2012	CRO	1	•	•	•	1	ĕ		
Li 2015	CRO	1	ĕ	ĕ	ĕ	1	ĕ		
Liu 2021	Objective outcome	•	ĕ	ě	ĕ	•	<b>⊕</b>		
Liu 2021	CRO	ě	ĕ	· ·	ĕ	· ě	Ĭ.		
Guo 2023	Objective outcome	•	•	•	•	1	ĕ		
Guo 2023	CRO	ĕ	ĕ	ĕ	ă	1	ă		

Figure 2. Risk of bias of included studies.

D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: due to missing outcome; D4: bias in measurement of the outcome; D5: bias in selection of the reported result. CRO: clinician-reporting outcome.





Figure 3. The forest plot of mortality at the end of treatment.








Figure 4. The forest plot of NIHSS

A. at the end of treatment, B. at the end of follow-ups








Figure 5. The forest plot of dependency

A. Barthel Index (BI) at the end of treatment, B. BI at the end of 90-day follow-ups, C. modified Rankin Scale (mRS) at the end of 90-day follow-ups.




Figure 6. The forest plot of hematoma volume at the end of treatment.

Table 1. Basic characteristics of included studies

Study	Sample	Age, y	Sex,	Time of	Disease	Intervention			Control	Outcome
	size	mean (sd)	M/F	onset , hours, mean (sd)	severity, mean (sd)	Treatment	Form, Dosage, administration	Course		
Liu Z, 2003	50	T: 60.5 (9.11) C: 62.9 (5.45)	T: 15/10 C: 14/11	< 48h	NIHSS: T:12.50 (4.10) C:12.76 (4.07)	ZFXN+CM	Oral solution, 30ml q6h,by nasogastric tube	30d	Diuretic dehydration+ CM	Death, NIHSS, Hematoma volume, BI, Adverse events
Chen S, 2010	225	T: 68.12 C: 68.12	NS	< 72h	NHISS: NS	ZFXN+CM	Oral solution, 25ml q6h, by nasogastric tube	28d	Diuretic dehydration+ CM	Death, Hematoma volume, Adverse events
Zhang H, 2013	164	T: 63.7 (7.95) C: 63.68 (7.55)	T: 49/34 C: 48/33	T: 12.21 (16.22) C: 9.77 (10.15)	NHISS: T:21.9 (7.37) C:22.19 (8.24)	ZFXN+Diureti c dehydration+C M	Decoction, 50ml q6h, by nasogastric tube	28d	Placebo, Diuretic dehydration+ CM	Death, NIHSS, Hematoma volume, BI, mRS
Chen X, 2005	38	T: 63.18 (7.90) C: 64.69 (8.16)	NS	T 8.03 (1.09) C: 7.84 (1.09)	NHISS: NS	ZFXN+Diureti c dehydration+C M	Oral solution, 30ml q6h, by nasogastric tube	14d	Diuretic dehydration+ CM	Death, MESSS, Hematoma volume, BI, Adverse events
Li Y, 2012	547	T: 66.13 (9.25) C: 66.06 (8.88)	T: 150/27 0 C: 46/81	T: 12.51 (18.64) C: 12.45 (17.64)	NIHSS: T: 20.77(7.68) C: 21.87(8.17)	ZFXN+Diureti c dehydration+C M	Decoction, 50ml q6h, by nasogastric tube	21d	Diuretic dehydration+ CM	Death, NIHSS, Hematoma volume, Adverse events
Guo X, 2012	114	T: 66.37 (10.19) C: 66.75 (9.36)	T:34/23 C:31/26	T: 16.16 (18.99) C: 14.72 (16.62)	NIHSS: T: 30.82(6.55) C: 31.28(6.95)	ZFXN+Diureti c dehydration+C M	Oral solution, 25ml q6h oral administration/ng	7d	Diuretic dehydration+ CM	Death, NIHSS
Li K, 2015	122	T: 69.63 (11.35) C: 71.34 (12.21)	T:33/29 C:32/28	< 72h	NS	ZFXN+Diureti c dehydration+C M	Oral solution, 25ml q6h,by nasogastric tube	28d	Diuretic dehydration+ CM	ESS, BI,Adverse events

Liu L, 2021	70	T:68 C:62	T:17/18 C:19/16		NIHSS: T: 11.49(3.67) C: 12.17(2.19)	ZFXN+Diureti c dehydration+C	Granule, 8g q8h, by nasogastric tube	21d	Placebo,Diur etic dehydration+	NIHSS,Hemato ma volume, BI, Adverse events
						M			CM	
Guo S, 2023	118	T: 68.93 (5.18) C: 65.57 (11.73)	NS	< 48h	NIHSS: T:16.40(4.81) C:16.20(4.54)	ZFXN+Surgery +Diuretic dehydration+C M	Oral solution, 25ml q6h, administration by nasogastric tube	28d	Placebo,Surg ery+Diuretic dehydration+ CM	Death, NIHSS, Hematoma volume, BI, mRS, Adverse
										events

Notes: For studies without the data in the forms of mean (standard deviation), information in their original forms were presented. Abbreviations: BI: Barthel index ,d: day, h: hour, NIHSS:National Institute of Health stroke scale; mRs: modified Rankin scale, NS: not stated, sd:standard deviation, y: year.

Table 2. Subgroup-analyses in terms of Mortality, National Institute of Health stroke, Barthel index and Hematoma volume

Mortality				
Subgroup	RCTs, No	Total patients, No	RR (95% CI)	I <sup>2</sup> , %
Sex				
the proportion of male ≤50%	3	683	0.65 [0.39, 1.09]	58
the proportion of male > 50%	3	377	0.48 [0.33, 0.72]	0
Age				
≤65	2	83	0.55 [0.21, 1.47]	0
>65	4	977	0.54 [0.39, 0.75]	58
Hematoma volume				
≤ 20ml	2	580	0.91 [0.51, 1.63]	0
>20ml	3	366	0.38 [0.25, 0.58]	0
Baseline NIHSS				
≤15	1	50	0.50 [0.17, 1.45]	/
>15	3	764	0.66 [0.43, 1.04]	57
Timing of enrollment				
<48h	2	153	0.24 [0.09, 0.64]	18
<72h	2	327	0.39 [0.22, 0.66]	51
<1w	1	547	0.90 [0.46, 1.74]	13
Dosage form			2 , 1	
oral liquid	5	513	0.44 [0.30, 0.64]	0
decoction	1	547	0.91 [0.50, 1.65]	/
Therapeutic duration				
<28 days	3	694	0.85 [0.53, 1.36]	0
≥28 days	3	366	0.38 [0.25, 0.58]	0
Diuretic dehydration				
Exclude	2	263	0.43 [0.27, 0.67]	0
Include	4	797	0.67 [0.43, 1.04]	36
NIHSS				

Subgroup	RCTs, No	Total patients, No	MD [95% CI]	I <sup>2</sup> , %
Overall	6	994	-2.37 [- 3.34, -1.39]	
Sex				
the proportion of male≤50%	2	648	-3.71 [- 5.05, -2.38]	0
the proportion of male > 50%	4	346	-1.82 [- 2.74, -0.90]	55
Age				
≤65	2	187	-2.45 [- 3.27, -1.64]	0
>65	4	807	-2.31 [- 3.92, -0.69]	74

Hematoma volume				
≤20ml	2	611	-2.32 [- 4.82, 0.19]	85
>20ml	3	288	-2.64 [- 3.39, -1.89]	0
Baseline NIHSS				
≤15	2	114	-1.91 [- 3.69, -0.12]	71
>15	4	880	-2.70 [- 3.80, -1.60]	41
Timing of enrollment				
<24h	1	63	-1.18 [- 1.84, -0.52]	/
<48h	2	151	-3.35 [- 4.68, -2.01]	0
<72h	2	232	-2.14 [- 3.00, -1.28]	23
<1w	1	547	-3.75 [- 5.59, -1.92]	/
Dosage form				
Oral liquid	3	246	-2.69 [- 4.25, -1.13]	40
Granula	1	64	-1.18 [- 1.84, -0.52]	/
Decoction	2	684	-2.80 [- 4.14, -1.46]	47
Therapeutic duration				
<28 days	3	706	-1.88 [- 3.65, -0.11]	71
≥28 days	3	288	-2.64 [- 3.39, -1.89]	0
Diuretic dehydration				
Exclude	1	50	-3.05 [- 4.90, -1.20]	/
Include	5	944	-3.05 [- 4.90, -1.20]	70
BI				

Subgroup	RCTs, No	Total patients, No	MD [95% CI]	I <sup>2</sup> , %
Sex				
the proportion of male≤50%	2	134	7.56 [1.70, 13.42]	0
the proportion of male > 50%	3	297	15.19 [12.38, 18.00]	0
Age				
≤65	3	208	15.40 [12.45, 18.35]	0
>65	2	223	9.13 [4.17, 14.09]	0
Hematoma volume				
≤20ml	1	33	9.92 [-8.77, 28.61]	/

> 20 1	1 4	200	12.02.511.27.16.201	40
>20ml	4	398	13.83 [11.27, 16.39]	49
Baseline NIHSS	1	20	16 60 510 61 22 771	,
<u>≤15</u>	1	38	16.69 [10.61, 22.77]	/
>15	2	238	11.67 [4.01, 19.34]	79
Timing of enrollment				
<48h	2	139	12.06 [7.73, 16.40]	78
<72h	2	259	14.78 [11.61, 17.95]	0
Dosage form				
Oral liquid	4	294	12.06 [8.29, 15.83]	34
Decoction	1	137	15.17 [11.74, 18.60]	/
Therapeutic duration				
<28 days	1	33	9.92 [-8.77, 28.61]	/
≥28 days	4	398	13.28 [9.32, 17.25]	49
Diuretic dehydration				
Exclude	1	38	16.69 [10.61, 22.77]	/
Include	4	393	13.14 [10.35, 15.93]	39
Hematoma volume (ml)				
Subgroup	RCTs, No	Total patients, No	MD [95% CI]	$I^2$ , %
Overall	4	694	-3.88 [-4.87, -2.88]	45
Sex				
the proportion of male≤50%	2	580	-3.51 [-5.35, -1.68]	11
the proportion of male > 50%	2	114	-4.03 [-5.22, -2.84]	76
Age				
≤65	2	83	-4.56 [-5.96, -3.15]	60
>65	2	611	-3.19 [-4.60, -1.78]	17
Hematoma volume				
≤20ml	3	644	-3.01 [-4.34, -1.68]	0
>20ml	1	50	-5.00 [-6.51, -3.49]	/
Baseline NIHSS				
≤15	2	114	-4.03 [-5.22, -2.84]	76
>15	1	547	-4.05 [-6.14, -1.96]	/
Timing of enrollment				
<24h	1	64	-2.46 [-4.38, -0.54]	/
<48h	1	50	-5.00 [-6.51, -3.49]	/
<1w	1	547	-4.05 [-6.14, -1.96]	/
Dosage form			, , , , , ,	
Oral liquid	2	83	-4.56 [-5.96, -3.15]	60
Granula	1	64	-2.46 [-4.38, -0.54]	/
Decoction	1	547	-4.05 [-6.14, -1.96]	/
Therapeutic duration			. / -3	
<28 days	3	655	-3.01 [-4.34, -1.68]	0
≥28 days	1	50	-5.00 [-6.51, -3.49]	/
Diuretic dehydration	-			
Exclude	1	50	-5.00 [-6.51, -3.49]	/
Include	3	644	-3.01 [-4.34, -1.68]	0
Notes: DI: Douthal index NILIC				_

Notes: BI: Barthel index, NIHSS:National Institute of Health stroke scale, mRs: modified Rankin scale.

Table 3. GRADE evidence quality of critical outcomes

<u>l'able</u>	<u> 3. GRA</u>	DE evidenc	e quality of	f critical ou	itcomes	5			
Morta	ality (po	st-treatment)							
ZFXN	$\sqrt{1 + con}$	ventional me	dicine vs. c	ontrol					
Quali	ty asses	sment			No. of patients		Relati ve effect	- Certain	Importa
No. of Trai ls	Risk of bias	Inconsiste ncy	Indirectn ess	Imprecis ion	ZFX N	contr ol	RR (95% CI)	ty	nce
6 RCT s	seriou s	not serious	not serious	not serious	684	376	0.54 (0.40 to 0.74)	⊕⊕⊕ ○ Moder ate	CRITIC AL
NIHS	S score	s (post-treatr	nent)						
		ventional me	dicine vs. c	ontrol	ı		1	1	
	ty asses				No. of patien		Relati ve effect	Certain	Importa
No. of Trai ls	Risk of bias	Inconsiste ncy	Indirectn ess	Imprecis ion	ZFX N	contr ol	MD (95% CI)	ty	nce
6 RC Ts	seriou s	serious	not serious	not serious	656	338	-2.37 (-3.34 to - 1.39)	⊕⊕○ ○ Low	CRITIC AL
NIHS	S score	s (follow-ups	s)						
ZFXN	V + con	ventional me	dicine vs. c	ontrol					
Quali	ty asses	sment			No. of patients		Relati ve effect	Contain	Turan cut c
No. of Trai ls	Risk of bias	Inconsiste ncy	Indirectn ess	Imprecis ion	ZFX N	contr ol	MD (95% CI)	Certain ty	Importa nce
3 RC Ts	serio us	serious	not serious	not serious	519	215	-2.85 (-3.83 to - 1.86)	⊕⊕○ ○ Low	CRITIC AL
		(follow-ups	,						
		ventional me	dicine vs. c	ontrol	ı		l	1	
Quali	ty asses				No. of patien		Relati ve effect	Certain	Importa
No. of Trai ls	Risk of bias	Inconsiste ncy	Indirectn ess	Imprecis ion	ZFX N	contr	MD (95% CI)	ty	nce

5 RC Ts	serio us	not serious	not serious	not serious	229	202	13.76 (11.2 2, 16.30	⊕⊕⊕ ○ Moder ate	CRITIC AL
		olume (post t							
ZFXN	V + con	ventional me	dicine vs. c	ontrol					
Quali	ty asses	sment			No. of patien		Relati ve effect	Contain	Importo
No. of Trai ls	Risk of bias	Inconsiste ncy	Indirectn ess	Imprecis ion	ZFX N	contr	MD (95% CI)	Certain ty	Importa nce
4 RC Ts	serio us	not serious	not serious	not serious	495	199	-3.88 (- 4.87, -2.88)	⊕⊕⊕ ○ Moder ate	CRITIC AL

# The supplementary tables

- Supplementary Table 1. Search strategies.
- Supplementary Figure 1. The forest plot of case fatality at the end of treatment.
- Supplementary Figure 2. The forest plot of MESSS at the end of ZFXN treatment
- Supplementary Figure 3. The forest plot of MESSS in 90 days follow-ups.
- Supplementary Figure 4. The forest plot of ESS in 90 days follow-ups.
- Supplementary Figure 5. The sensitivity analysis of mortality at the end of ZFXN treatment.
- Supplementary Figure 6. The sensitivity analysis of NIHSS at the end of ZFXN treatment.
- Supplementary Figure 7. The sensitivity analysis of NIHSS in 90-day follow-ups.
- Supplementary Figure 8. The sensitivity analysis of BI at the end of ZFXN treatment.
- Supplementary Figure 9. The sensitivity analysis of BI in 90-day follow-ups.
- Supplementary Figure 10. The sensitivity analysis of hmatoma volume at the end of ZFXN treatment.
- Supplementary Figure 11. The forest plot of adverse events

# **Supplementary materials**

Supplementary Table 1. Search strategies.

PubMed search strategy

#1 "Cerebral Hemorrhage" [MeSH Terms] OR "intracranial hemorrhage, hypertensive" [MeSH Terms] OR "Hemorrhagic Stroke" [MeSH Terms] #2 (((Fossa\* OR Intracranial\* OR Brain\* OR Cerebr\*) AND (Hemorrhage\* OR Hematoma\*)) OR ICH OR ICHs)

#3 #1 OR #2

#4 "Medicine, Chinese Traditional" [Mesh] OR "Drugs, Chinese Herbal" [Mesh] OR "Plants, Medicinal" [Mesh] OR "Herbal Medicine" [Mesh]

#6 #4 OR #5

# 7 randomized controlled trial[Publication Type] OR randomized[Title/Abstract] OR placebo[Title/Abstract]

## # 8 #7 AND #3 AND #6

- Cochrane search strategy
- #1 cerebral hemorrhage
- #2 intracranial hemorrhage, hypertensive
- #3 hemorrhagic stroke
- #4 (((Fossa\* or Intracranial\* or Brain\* or Cerebr\*) and (Hemorrhage\* or Hematoma\*)) or ICH or ICHs) .tw
- #5 #1 OR #2 OR #3 OR #4
- #6 Medicine, Chinese Traditional
- #7 Drugs, Chinese Herbal
- #8 Plants, Medicinal
- #9 Herbal Medicine

#10 (Traditional Chinese Medicine):ab,ti,kw OR (Traditional Medicine, Chinese):ab,ti,kw OR (Chinese Traditional Medicine):ab,ti,kw OR (Chinese Medicine, Traditional):ab,ti,kw OR (Chinese Herbal Drugs):ab,ti,kw OR (Herbal Drugs, Chinese):ab,ti,kw OR (Herbal formulation):ab,ti,kw OR (Fuyuan Xingnao Decoction):ab,ti,kw OR (Fuyuan Xingnao oral liquid):ab,ti,kw OR (Zhongfeng Xingnao oral liquid):ab,ti,kw OR (Zhongfeng Xingnao Decoction):ab,ti,kw OR (Zhuyu Huatan Decoction):ab,ti,kw OR (Zhuyu Huatan oral liquid):ab,ti,kw #11 #6 OR #7 OR #8 OR #9 OR #10

#12 (randomized controlled trial):ab,ti,kw OR (randomized):ab,ti,kw OR (placebo):ab,ti,kw OR (RCT):ab,ti,kw

#### #13 #5 AND #11 AND #12

- Embase search strategy
- #1 cerebral hemorrhage
- #2 intracranial hemorrhage, hypertensive
- #3 hemorrhagic stroke
- #4 ('fossa\*':ab,ti OR 'intracranial\*':ab,ti OR 'brain\*':ab,ti OR 'cerebr\*':ab,ti) AND ('hemorrhage\*':ab,ti OR 'hematoma\*':ab,ti) OR ('ich':ab,ti OR 'ichs':ab,ti)
- #5 Medicine, Chinese Traditional
- #6 Drugs, Chinese Herbal

- #7 Plants, Medicinal
- #8 Herbal Medicine
- #9 'Traditional Chinese Medicine':ab,ti OR 'Traditional Medicine, Chinese':ab,ti OR 'Chinese Traditional Medicine':ab,ti OR 'Chinese Medicine, Traditional':ab,ti OR 'Chinese Herbal Drugs':ab,ti OR 'Herbal Drugs, Chinese':ab,ti OR 'Herbal formulation':ab,ti OR 'Fuyuan Xingnao Decoction':ab,ti OR 'Fuyuan Xingnao oral liquid':ab,ti OR 'Zhongfeng Xingnao Decoction':ab,ti OR 'Zhuyu Huatan Decoction':ab,ti OR 'Zhuyu Huatan oral liquid':ab,ti
- #10 'randomized controlled trial':ab,ti OR 'randomized':ab,ti OR 'placebo':ab,ti OR 'RCT':ab,ti
- #11 #1 OR #2 OR #3 OR #4
- #12 #5 OR #6 OR #7 OR #8 OR #9
- #13 #10 AND #11 AND #12
- Web of Science search strategy
- #1 TS=(Cerebral hemorrhage OR Hemorrhagic Stroke OR Intracranial Hemorrhage, Hypertensive OR ICH OR ices) OR TS=((Fossa\* OR Intracranial\* OR Brain\* OR Cerebr\*) AND (Hemorrhage\* OR Hematoma\*))
- #2 TS=(Medicine, Chinese Traditional OR Drugs, Chinese Herbal OR Plants, Medicinal OR Herbal Medicine OR Traditional Chinese Medicine OR Traditional Medicine, Chinese OR Chinese Traditional Medicine OR Chinese Medicine, Traditional OR Chinese Herbal Drugs OR Herbal Drugs, Chinese OR Herbal formulation OR Fuyuan Xingnao Decoction OR Fuyuan Xingnao oral liquid OR Zhongfeng Xingnao oral liquid OR Zhongfeng Xingnao Decoction OR Zhuyu Huatan Decoction OR Zhuyu Huatan oral liquid)
- #3 TS=(randomized controlled trial OR randomized OR placebo OR RCT) #4 #1 AND #2 AND #3

Chinese search strategy

- 1. intracranial hemorrhage
- 1.1 Mesh term

脑出血;颅内出血;壳核出血;脑出血,创伤性;颅内出血,高血压性;中风;卒中;脑血管基底神经节出血;脑血管障碍

1.2 Entry term

高血压性脑出血;脑血管疾病;高血压病脑出血;脑血管意外;急性脑血管病;脑实质内出血;脑中风;急性脑血管意外;急性脑血管病;脑溢血;脑血管病;脑血管病变;卒中;脑卒中;出血性脑卒中;出血性中风;出血性卒中;出血性脑中风;高血压脑出血;基底节区脑出血;基底节出血;基底节脑出血;基底节核区脑出血;

2. Zhongfeng xingnao

2.1 Mesh term

中成药;中药;中草药;中医学

2.2 Entry term

院内制剂;成方制剂;中风醒脑;中风醒脑液;中风醒脑口服液;中风醒脑 方;中风醒脑合剂;中风醒脑复方;中风醒脑汤;中风醒脑胶囊;复元醒脑; 复元醒脑汤;复元醒脑方;复元醒脑口服液;复元醒脑颗粒;复元醒脑法;逐 瘀化痰;逐瘀化痰口服液;逐瘀化痰汤;逐瘀化痰方;逐瘀化痰法;逐瘀化痰丸;中医;中西医**结**合;

**3.** RCT

**3.1** Mesh term

随机对照试验


3.2 Entry term

随机对照;RCT;随机对照实验;随机对照研究;随机







Supplementary Figures




Supplementary figure 1. The forest plot of case fatality at the end of treatment.




# Supplementary figure 2. The forest plot of MESSS at the end of ZFXN treatment



Supplementary figure 3. The forest plot of MESSS in 90 days follow-ups.




Supplementary figure 4. The forest plot of ESS in 90 days follow-ups.




Supplementary figure 5. The sensitivity analysis of mortality at the end of ZFXN treatment.








Supplementary figure 6. The sensitivity analysis of NIHSS at the the end of ZFXN treatment.




Supplementary figure 7. The sensitivity analysis of NIHSS in 90-day follow-ups.








Supplementary figure 8. The sensitivity analysis of BI at the end of ZFXN treatment.



Supplementary figure 9. The sensitivity analysis of BI in 90-day follow-ups.








Supplementary figure 10. The sensitivity analysis of hmatoma volume at the end of ZFXN treatment.







Supplementary figure 11. The forest plot of adverse events





CHAIN Protocol Version 4.0 Date: 18 September 2021







# Chinese Herbal medicine in Acute INtracerebral haemorrhage (CHAIN) trial



An investigator-initiated and conducted multicentre, prospective, randomised, double-blinded placebo-controlled clinical trial to evaluate the efficacy and safety of Chinese herbal medicine in patients with acute intracerebral haemorrhage

STUDY PROTOCOL (Version 4.0, 18 September 2021) GI register no.

ClinicalTrial.gov: NCTXX

**CONTACT DETAILS** 

This protocol has been developed by the CHAIN Steering Committee and its contents are the intellectual property of this group. It is an offence to reproduce or use the information and data in this protocol for any purpose other than the CHAIN study without prior approval from the project office of the CHAIN study.



**CHAIN Protocol** Version 4.0 Date: 18 September 2021

# INVESTIGATOR AGREEMENT

I have read the following protocol:

Protocol Title: Chinese Herbal medicine in Acute INtracerebral haemorrhage (CHAIN)

trial

**Version and Date:** Version 4.0 – 18 September 2021

I have read this protocol and associated procedure manuals and agree that it contains all the necessary details for carrying out the study. I will conduct the study as outlined herein and will complete the study within the time designated. I will provide copies of the protocol and all pertinent information to all individuals responsible to me who assist in the conduct of the study. I will discuss this material with them to ensure that they are fully informed regarding the study intervention and the conduct of the study.

Investigator's Signature Date (Day / N	nonth / Year)	
Name of Investigator (Printed)		
Name of Institution (Printed)		
`		
Principal Investigator		
Co-Principal Investigator Professor Jianwen Guo Guangdong Provincial Hospital of Chinese		
Medicine, Guangzhou, China	Date	Signature
Co-Principal Investigator Professor Craig Anderson The George Institute for Global	24 September 2021	Ch
Health, Australia	Date	Signature 





CHAIN Protocol Version 4.0 Date: 18 September 2021

**Trial Statistician**Mr Qiang Li
The George Institute for Global
Health, Australia

Date	Signature	





# **CONTENTS**

1. ADMINISTRATIVE INFORMATION	238
2. LIST OF ARREVIATIONS AND TERMS	240
3. PROTOCOL SYNOPSIS	241
4. BACKGROUND AND RATIONALE	242
4.1 Heavy Burden of ICH	242
4.2 Chinese Herbal Medicine for ICH Treatment	243
4.3 Chinese Herbal Medicine FYTF-919 and Underlying Mechanisms	244
4.4 Previous Clinical Trials on Chinese Herbal Medicine FYTF-919	
5. AIMS AND OBJECTIVES	245
6. METHODS	246
6.1 Overall Design	246
6.2 Inclusion Criteria	248
6.3 Exclusion Criteria	248
6.4 Ethical Issues	248
6.4.1 Institutional Ethics Committee Approval	248
6.4.2 Consent	
6.4.3 Confidentiality and Privacy	250
6.5 Study Site Selection, Participation and Responsibilities of Staff	
6.6 Randomisation	
6.7 Intervention	252
6.8 Outcome Measures	253
6.8.1 Primary Outcome	253
6.8.2 Secondary Outcomes	253
6.8.3 Safety Outcomes	254
6.9 Data Collection and Follow-up	254
6.9.1 Screening and Enrolment log	255
6.9.2 Patient Contact Details log	255
6.9.3 Information Collected at Each Stage	256
7. SAFETY	259
7.1 Data and Safety Monitoring Board (DSMB)	259
7.2 Serious Adverse Events (SAEs)	259
8. QUALITY ASSURANCE	
8.1 Monitoring of Sites	261
8.2 Collection and Storage of Essential Documents	261
9. HEALTH ECONOMIC EVALUATION	262
10. DATA MANAGEMENT	262
11. STATISTICAL CONSIDERATIONS	263
12. PUBLICATIONS, REPORTS AND DATA SHARING	264
13. FUNDING	
14. TIMELINES	266
15. REFERENCES	267





# 1. ADMINISTRATIVE INFORMATION

# **Protocol History**

Version Number	Version Date	Summary of Revisions Made:
3.0	28 June 2021	The initial version of the study implementation.
4.0	18 September 2021	The inclusion criteria for item 3) was changed from "Presentation within 24 hours of symptom onset (or last seen well)" to "Presentation within 48 hours of symptom onset (or last seen well)";
		Updating the inclusion criteria for item 4) Meet any of the following criteria: a) NIHSS ≥8, or b) GCS 7-14;
		Adding 'secondary to antiplatelet treatment' into the exclusion criteria;
		Adding the UW-mRS scores at 180 days as secondary outcome;
		Adding the Barthel Index at 28 days, 90 days, and 180 days as secondary outcome;
		Adding the mRS/ EQ-5D/5L at 28 days and 180 days as secondary outcome;
		Keeping three stratification factors, including site, neurological severity (NIHSS <15 vs≥15), and haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle);
		Updating the randomization to 'double-blinded randomization will commence within 48 hours';

# **Trial/Study Registration**

The study has been registered with ClinicalTrials.gov (NCTXXXX).

# **Funding**

This study receives its principle funding from the following grants: Key-Area Research and Development Program of Guangdong Province (No.2020B1111100009)

# **Study Management & Oversight**

CHAIN is an investigator initiated and conducted study managed by The George Institute for Global Health in Beijing, China (GI China). The study will be overseen by a committee of international experts in the fields of neurology, neurosurgery, hypertension, cardiovascular disease, epidemiology, and clinical trials.







Steering Committee (SC): The Steering Committee will comprise of the principal investigators, and expert academic researchers, with the chairman held by an independent SC member. The SC is responsible for the execution of the study design, protocol, data collection and analysis plan, as well as publications. The SC has the right to appoint new members and co-opt others to add to the integrity of the conduct of the study and analyses. The steering committee charter will govern the steering committee. The SC will be co-chaired by Professor Craig Anderson and Professor Jianwen Guo.

Central Coordinating Centre (CCC): The CCC is based at GI China and is supported by project staff. Responsibilities: Day-to-day management of the study, data and project management, committee coordination, assistance with ethics committee (EC) and regulatory applications, protocol and procedures for training of participating sites, overseeing of initiation visits and activation of participating centres, monitoring of data quality and adherence to protocol, applicable guidelines and regulations, and preparation of study data for analysis and publication.





# 2. LIST OF ARREVIATIONS AND TERMS

BP	Blood pressure
BI	Barthel index
ССВ	Calcium channel blocker
CCC	Central coordinating centre
CHAIN	Chinese Herbal medicine in Acute INtracerebral haemorrhage
CI	Confidence interval
CPIS	Clinical pulmonary infection score
CRF	Case reports form
СТ	Computerised tomography
CV	Curriculum vitae
DALY	Disability-adjusted-life-years
DSMB	Data and safety monitoring board
EC	Ethics committee
EDC	Electronic data collection
EQ-5D	EuroQoL Group 5-dimension self-report questionnaire
GCP	Good Clinical Practice
GCS	Glasgow coma scale
HOQ	Hospital organisation questionnaire
HR	Heart rate
HRQoL	Health-related quality of life
IC	Informed consent
ICER	Incremental cost-effectiveness ratio
ICF	Inform consent form
ICH	Intracerebral haemorrhage
ICH-GCP	ICH Guidelines for Good Clinical Practice
ICMJE	International Committee of Medical Journal Editors
IRB	Institutional review board
mRS	Modified Rankin scale
NIHSS	National Institute of Health Stroke Scale
NB	Note
OC	Operations committee
PBC	Promote blood circulation
PI	Principal investigator
PIS	Patient information sheet
ICF	Patient information sheet and inform consent form
RBS	Remove blood stasis
RCC	Regional coordinating centre
RCTs	Randomised clinical trials
ROS	Reactive oxygen species





SA	Sensitivity analyses
SAE	Serious adverse event
SAP	Stroke-associated pneumonia
SC	Steering committee
SD	Standard deviation
SOP	Standard operation process
TCM	Traditional Chinese medicine
TGI CHINA	The George Institute for Global Health, China; Or the George Institute for Global Health (Australia), Beijing representative office
UW-mRS	Utility-weighted modified Rankin scale
WHO	World Health Organisation

# 3. PROTOCOL SYNOPSIS

Co-Sponsors: Guang Dong Provincial Hospital of Chinese Medicine and The George Institute for Global Health	Trial Registration: Clinicaltrials.gov XXXX		
Title: Chinese Herbal medicine in Acute INtracerebral haemorrhage (CHAIN) trial			
Study Duration 4 years	Clinical Phase III		

**Objective:** To determine the effectiveness and safety of a Chinese herbal medicine as compared to placebo on functional recovery in patients with spontaneous intracerebral haemorrhage (ICH).

Number of Participants: 1504 patients to be enrolled from 20-30 hospital sites in China

**Study Design:** Multicenter, prospective, randomised, double-blind trial to determine the effectiveness and safety of a Chinese herbal medicine in patients with acute ICH. The double-blinded randomisation will commence within 48 hours after the definite onset of symptoms for a treatment period of 28 days. Outcome assessments are to be made at 90 and 180 days post-randomisation.

Inclusion Criteria: Patients must meet all following criteria:

- 1) Age ≥18 years;
- 2) Diagnosis of spontaneous ICH, confirmed by brain imaging;
- 3) Presentation within 48 hours of symptom onset (or last seen well);
- 4) Meet any of the following criteria: a) NIHSS ≥8, or b) GCS 7-14;
- 5) Provide written informed consent by patient (or approved surrogate);

Exclusion Criteria: Patients will NOT be eligible if there is one or more of the following:

- 1) ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischaemic stroke), or secondary to cerebral amyloid angiopathy, or secondary to reperfusion treatment for ischaemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment.
- 2) Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment;
- 3) Other medical illness that will interfere with outcome assessments and follow-up (e.g. known significant pre-stroke disability [modified Rankin scale {mRS} scores 3-5], advanced cancer and severe renal failure);
- 4) Known definite contraindication to the Chinese herbal medicine;
- 5) Women who are known to be pregnant or lactating:
- 6) Currently participating in another trial which would interfere with outcome assessments.







Randomisation and study intervention: Randomisation via a central internet-based system, stratified by site, neurological severity (NIHSS <15 vs ≥15), and haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle) to ensure balance in key prognostic factors. Randomisation is to Intervention group (Chinese herbal medicine oral liquid 33 mL t.i.d. [or 25 mL q.i.d via nasogastric tube if unconscious or dysphagia]) or Control group (matching placebo liquid). The intervention after the randomization should be performed as soon as possible.

#### **Outcome Measures**

<u>Primary outcome</u>: Utility-weighted modified Rankin scale (UW-mRS)) scores at 90 days.

#### Secondary outcomes:

- 1) Utility-weighted mRS scores at 180 days
- 2) Ordinal analysis of 7 levels of mRS at 28 days, 90 days and 180 days;
- 3) Poor prognosis, defined as mRS 4-6 points at 28 days, 90 days and 180 days;
- 4) NIHSS score at 7 days and 28 days;
- 5) Mortality rate at 28 days, 90 days and 180 days;
- 6) Discharge rate at 28 days;
- 7) EQ-5D-5L at 28 days, 90 days and 180 days;
- 8) Barthel index (BI) at 28 days, 90 days and 180 days;
- 9) The cerebral edema volume at baseline, 24 hours, 7 days, 14 days or at discharge;
- 10) The hematoma volume at baseline, 24 hours, 7 days, 14 days or discharge;
- 11) The incidence of stroke-associated pneumonia (SAP) patients;
- 12) Clinical pulmonary infection score (CPIS) at the onset of SAP, 3 days and 7 days after the occurrence of SAP:
- 13) Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture at the onset of SAP, 3 days and 7 days after the occurrence of SAP;
- 14) Antibiotic usage among patients with SAP.

# 4. BACKGROUND AND RATIONALE

#### 4.1 Heavy Burden of ICH

Stroke is a major cause of global disease burden for which there are limited therapies. It is currently the second largest contributor of disability-adjusted-life-years (DALYs) lost, after ischaemic heart disease, in developing countries, and the third largest contributor of DALYs in developed countries (after ischaemic heart disease, and low back and neck pain). In 2015, there were 9 million new cases of acute stroke, 42 million stroke survivors, and over 100 million DALYs lost from stroke, worldwide [1].

Stroke prevalence was greater in China than in other countries. Current stroke incidence (247/100 000 person-years, 95% confidence interval [CI] 211–283) and mortality rates (115/100 000 person-years) in China are among the highest in the world [2]. Stroke has been the leading cause of death in China for decades [2, 3].

Among all the subtypes of stroke, ICH is associated with the greatest morbidity and mortality [4]. More than 5 million haemorrhage strokes occur each year, globally [5]. The proportion of ICH in China (approximately 25%) is significantly greater than in high-income countries (9-







13%) and similar to many low- to middle-income countries (14-27%). In contrast to declines in rates of acute ischaemic stroke, rates of ICH have remained stable in recent decades, and its outcome remains poor, with about two thirds of patients either dying or remaining disabled.

Efforts to find treatments for ICH have not produced similarly positive results that have arisen from trials in acute ischaemic stroke. Several trials such as INTERACT2 [6] and ATACH II [7] evaluated early intensive blood pressure (BP) lowering treatment, while MISTIE III [8] and STICH II [9] evaluated minimally-invasive surgery, with inconsistent results. As progress has been slow in reliably defining the efficacy of approaches to the treatment of ICH, physicians can feel powerless in their management of ICH patients. More high quality trials in ICH are therefore a high priority.

#### 4.2 Chinese Herbal Medicine for ICH Treatment

In traditional Chinese medicine (TCM), stroke has been investigated for thousands of years. Although TCM herbal medicine is a widely established contemporary treatment in ICH patients, it remains important component of the treatment plan for patients with ICH in China. In general, such treatment appears safe [10], and several studies suggest a potential benefit of combination therapy [11-13]. Herbal medicine is reported to promote blood circulation (PBC) and remove blood stasis (RBS), which are common methods in patients who receive TCM. Thus, such treatment is recommended for the management of ICH in China [14].

There are multiple potential pathways for the action of PBC and RBS in ICH, to enhance the reabsorption of the haematoma and cerebral oedema, and to reduce mass effect and hydrocephalus [15]. Polygonaceae and Araliaceae herbals are frequently used; these include Dahuang (Radix et Rhizoma Rhei), Sanqi (Radix Notoginseng), Chuanxiuong (Rhizoma Ligustici Chuanxiong), and Chishao (Radix Paeoniae Rubra) [10]. Moreover, the role of herbal medicine may have other pathways for benefit, including a reduction in the risk of stroke-associated pneumonia (SAP) through effects on commensal microbiota and the respiratory system [16. 17]. However, there is controversy over the effects early after the onset of ICH, as one trial of ultra-early administration of two formulas had no significant beneficial effects on clinical outcomes but did increase haematoma growth [14].

Currently, most of studies of TCM are retrospective or single-centre, which have not widely influenced clinical practice. In a meta-analysis [10], all 45 included studies had a low rating for quality, none provided information on the botanical material, and voucher specimens for testing were absent. Thus, TCM treatment is probably safe for patients with ICH, but the





effects and mechanisms are unclear. A high-quality clinical trial is therefore required to resolve uncertainties and guide clinical practice.

#### 4.3 Chinese Herbal Medicine FYTF-919 and Underlying Mechanisms

The Chinese herbal medicine FYTF-919 comprises mainly the four Chinese herbs of red ginseng, notoginseng, rhizoma ligustici wallichii, and rhubarb. FYTF-919 is reported to suppress neurosclerosis and antioxidant free radicals, which provides a potential mechanistic effect to reabsorb the haematoma and reduce oedema **(Table 1)**.

Table 1. The elements contained in FYTF-919 and potential effect mechanism

Elements	Effect mechanism
Red ginseng	Ginsenoside is the main component. May promote haematoma reabsorption.
Notoginseng	May reduce bleeding, haematoma formation, swelling and pain, and protect neuronal tissue by increasing blood flow and improving energy metabolism.
Rhizoma ligustici wallichii	May alleviate haematoma and inhibit platelet aggregation.
Rhubarb	May promote adhesion and aggregation of platelets, reduce clotting time, and promote vascular contraction.

Previous animal model studies of Chinese herbal medicine FYTF-919 undertaken by researchers from the Guangdong Provincial Hospital indicate a decrease in intracranial pressure, anti-inflammatory and anti-oedema effects, neuroprotection, and reduction in bleeding and promotion haematoma absorption in ICH. A rat ICH model study showed that ginseng and notoginseng not only reduced haematoma volume and early brain oedema, but they also improved neurological function on a deficit score [18]. Brain tissue immunohistochemical analysis indicated the FYTF-919 treated group had significantly decreased MMP-2 protein content compared to the control group, whereas claudin-5 protein content had significantly increased [18]. Another study showed that the cerebrospinal fluid in Beagle dogs fed FYTF-919 contained some concentration of Chinese herbal medicine, and that the neurons of rats cultured with this cerebrospinal fluid were more likely to be normal (less swelling and rupture) in terms of form and cell activity, compared with a control group [19]. These findings suggest that FYTF-919 may protect neurons by penetrating the bloodbrain barrier [19-21]. A study in rabbits suggests FYTF-919 decreases intracranial pressure over a longer effect period compared with mannitol, reducing damage to neurons and glial cells, and improving survival [22]. It is well recognised that ICH results in a variety of secondary inflammatory effects involving cytokines such as IL-1β, IL-6, and TNF-α [23]. Ligustilide and ligustilide are two main active components of TCM; both inhibit the TRL4 /







NF-kB signaling pathways by reducing TLR4 levels on microglia surrounding haematoma, thereby limiting the inflammatory cascade [24]. In addition, ligusticolactone appears to also regulate the expression of anti-apoptotic and pro-apoptotic proteins by inhibiting the PI3K/Akt/NF-kB signaling pathway such that it has a neuroprotective role [25]. As an effective component of rhubarb, chrophanthol can regulate the overexpression of GFAP and prevent the formation of glial scar caused by the abnormal proliferation of astrocytes, providing protection of the blood-brain barrier, and expansion of inflammation and create a microenvironment for nerve regeneration in the latter phase [26]. In addition, chrysophanol can also inhibit the excessive production of reactive oxygen species (ROS) and free radicals in neurons, and reduce oxidative stress response [27].

#### 4.4 Previous Clinical Trials on Chinese Herbal Medicine FYTF-919

Since 1988, findings from a few clinical trials about Chinese herbal medicine FYTF-919 have been reported in China: 3 of them included more than 200 patients with moderate to severe ICH who were older than 60 years, and have 20mL haematoma volume, NIHSS scores of 20-30, a basal ganglia location, and less than 1 week from the ictus [28-30]. Except for regular treatment, the treatment group initiated FYTF-919 within 24 hours for a duration of 28 days. The results suggest that regular treatment with FYTF-919 improves haematoma absorption, functional outcome, and reduces mortality, compared with regular treatment only.

# 4.5 Summary

TCM is an essential context of the ICH management in Chinese culture. Given the potential benefits of Chinese herbal medicine FYTF-919 in reducing haematoma and bleeding after acute ICH from fundamental research and small clinical studies, more reliable evidence is required to guide ICH treatment using TCM. This study aims to determine the effectiveness and safety of TCM in a larger sample of patients with moderate-severe ICH and provide evidence for TCM clinical guidelines on ICH management. The presumed mechanism of action is in promoting the reabsorption of the haematoma and perihematomal oedema in ICH.

# 5. AIMS AND OBJECTIVES

# **Primary aim**

To determine the effectiveness and safety of a Chinese herbal medicine FYTF-919 as compared to placebo on functional recovery according Utility-weighted modified Rankin scale (UW-mRS) at 90 days after treatment started.







# Secondary aims

Compared with placebo, the Chinese herbal medicine FYTF-919 leads to positive treatment effect on (all time are counted from treatment started): 1) Utility-weighted mRS scores at 180 days; 2)Ordinal analysis of 7 levels of mRS at 28 days, 90 days and 180 days; 3) Poor prognosis, defined as mRS 4-6 points at 28 days, 90 days and 180 days; 4) NIHSS score at 7 days and 28 days; 5) Mortality rate at 28 days, 90 days and 180 days; 6) Discharge rate at 28 days; 7) EQ-5D-5L at 28days, 90 days and 180 days; 8) BI at 28days, 90 days and 180 days; 9) The cerebral edema volume at baseline, 24 hours, 7 days, 14 days or at discharge; 10) The hematoma volume at baseline, 24 hours, 7 days, 14 days or discharge; 11) The incidence of stroke-associated pneumonia (SAP) patients; 12) Clinical pulmonary infection score (CIPS) at the onset of SAP, 3 days, and 7 days, after the occurrence of SAP; 13) Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture at the onset of SAP, 3 days, and 7 days after the occurrence of SAP; 14) Antibiotic usage among patients with SAP.

# 6. METHODS


# 6.1 Overall Design

A multicentre, prospective, randomised, double-blind, placebo-controlled trial to be conducted through hospital network of investigators in China. A total of 1504 patients with ICH will be recruited from approximately 20-30 hospitals. Randomised is via a central internet-based system according to block random grouping method stratified by site, neurological severity NIHSS <15 vs ≥15), and haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle) to ensure balance in key prognostic factors. Endpoint assessment will be blinded to treatment allocation. The study design is summarised in the following schema (**Figure 1**). After patient eligibility is confirmed,





Figure 1. Study Schema







#### 6.2 Inclusion Criteria

Patients must meet all following criteria:

- 1) Age ≥18 years;
- 2) Diagnosis of spontaneous ICH, confirmed by brain imaging;
- 3) Presentation within 48 hours of symptom onset (or last seen well);
- 4) Meet severity criteria of either (a) NIHSS ≥8, or (b) GCS 7-14;
- 5) Provide written informed consent by patient (or approved surrogate).

#### 6.3 Exclusion Criteria

Patients will NOT be eligible if there is one or more of the following:

- 1) ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischaemic stroke), or secondary to cerebral amyloid angiopathy, or secondary to reperfusion treatment for ischaemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment.
- 2) Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment;
- 3) Other medical illness that will interfere with outcome assessments and followup (e.g. known significant pre-stroke disability [mRS scores 3-5], advanced cancer and renal failure);
- 4) Known definite contraindication to the Chinese herbal medicine:
- 5) Women who are known to be pregnant or lactating;
- 6) Currently participating in another trial which would interfere with outcome assessments.

#### 6.4 Ethical Issues

#### **6.4.1 Institutional Ethics Committee Approval**

Each participating center must obtain written approval(s) from their Institutional Research Ethics Committee (e.g. Institutional Review Board [IRB]), and other regional or national regulatory bodies before patient recruitment can commence. Any protocol amendments, Serious Adverse Event (SAE) reports and routine reporting to





the IRB/IEC will be the responsibility of the Principal Investigator (PI) at each participating center.

# 6.4.2 Consent

**A consent process** is the proposed method to be used in the study, according to local/national rules and regulations.

Patient consent process after presenting at hospital: All patients will be given a inform consent form (ICF) as soon as possible following their admission to hospital, and within the first 24 hours. The patient will have the opportunity to discuss and seek explanation from a clinician familiar with the study protocol and notify of the local approved consent process for the collection of their data (in-hospital and/or follow-up assessments).

Surrogate consent: Most patients with acute ICH will require emergency care, and the nature of the condition means that many patients are unwell and unable to comprehend the information that must be given to them. If the patient is not fully competent, for example because of a reduced level of consciousness, cognition or confusion, the patient's "surrogate" will be approached and will be provided with the ICF to read and act on the patient's behalf. Under the Guardianship Act of 1987 in Australia, a "person responsible" is the legally appointed guardian, their spouse or de-facto spouse or same sex partner; or if there is none, their unpaid career; or if there is none, their relative or friend who has a close relationship with the person. In situations where the patient is unable to provide consent, the person responsible consent can be obtained, and the patient will be made aware of this as soon as they are well enough before 7 days or at discharge from hospital, so that they have an opportunity to discuss and seek explanation from a clinician familiar on the study protocol. They will be given the opportunity to re-consent of the collection of their data (in-hospital and/or follow-up assessments) during their stay in hospital or as soon as they are able to decide, according to the local approved consent process.

If the patient is dying or is still unable to record their personal consent by the completion of the follow-up assessments, the consent given by their person responsible will stand and study data will be retained or removed. The reason for not being able to obtain the patient's consent will be documented, dated, and signed in the patient's file.







**Withdrawal of consent**: The ICF provided to the patient and/or the next of kin or surrogate will clearly state that the patient can be withdrawn from the study at any time without prejudice and explanation. Such withdrawal should be documented in the patient's file. Withdraw consent will be clarified as a component of the patient information sheet (PIS), as outlined below:

- All patients and/or their person responsible will be made aware that they retain the right to withdraw the database collection,
- Details will be given about where they can obtain further information, including contact details of the site.
- If the patient and/or their person responsible decide at any time during the inpatient admission (or any time until the end of follow-up) that they wish for any personal details about themselves or their in-hospital care record, or during follow-up, not be included in the study, they may request removal of their data from the database. The requested can be assigned by completing and returning the consent withdrawal form provided. Acknowledgment of receipt and removal of their data from the database will be sent to the patient and/or their person responsible, by mail or email.
- The PI will ensure that all staff at the site is made aware of the consent withdrawal in protocol.

#### 6.4.3 Confidentiality and Privacy

Every precaution will be taken to respect the privacy of patients in the conduct of the study. Only de-identified data will be used for statistical analyses and in the publication of results to maintain the confidentiality of participants. However, as a part of the follow-up of patients, sites may need to use contact sources recorded by the sites to undertake outcome assessments of patients. Only name, phone numbers, next of kin and GP contact will be available for the follow-up assessment. The information will be encrypted and password protected using the Excel lock form before sending by email in batches. This information will be included in the ICF. While monitoring data quality and adherence to the study protocol, the monitor will refer to medical records at the participating hospital. This information will be included in the ICF. All individual and site information will be de-identified in reporting data and results to protect the confidentiality of participants.







# 6.5 Study Site Selection, Participation and Responsibilities of Staff

**Site eligibility criteria:** To participate, sites are required to fulfil certain eligibility criteria:

- Have an established acute ICH service for the management of ICH patients (i.e. in an acute stroke unit, neurosurgical unit, neurology unit), defined by (i) having staff organised as part of a coordinated multidisciplinary team; (ii) having staff with some knowledge and skills in the ICH patients management; (iii) have staff interested and capable of participating in research.
- Obtain necessary EC and other relevant approvals from hospital management.
- Nominate key research staff assigned to the project to obtain consent from participants.
- Comply with the requirements of good clinical practice (GCP/ICH-GCP).
- Agree to the following conditions:
  - > adhere to the protocol,
  - collect data on patients' stay in hospital,
  - record any SAEs noted during the 3 months of follow-up of patients,
  - ➤ Sign a contract agreement before the commencement of recruitment.

# **Responsibilities of the site PI** are:

- ensure all sub-investigators and staff, undertake the necessary pre-study training programs regarding the protocol and positioning of the patients,
- agree to comply with GCP/ICH-GCP requirements,
- submit and obtain EC approval and ensure compliance to EC requirements,
- provide refresher training for existing and new staff on the intervention on a regular basis,
- conduct spot checks adherence to the randomised intervention,
- assist in problem-solving and propose solutions to resolve any local issue that may
  pose a barrier to the adherence to the intervention,
- oversee the data collection,





- conduct spot checks of the patient screening and enrolment log,
- liaise with the CCC on issues of adherence and quality.
- Record and report all SAEs during 3 months' follow-up period.

In the selection of suitable sites, there is a hospital organisation questionnaire (HOQ), provided by CCC to collect preliminary information about the site, so the CCC can ascertain the suitability of the site to participate in the study.

Hospital organisational questionnaire (HOQ): To assist the implementation of the intervention in each site, it is important to know the organisational structure of the site and the various areas within the site that will be involved in the intervention. Therefore, each site will have to complete a HOQ to assist the CCC prepare the training and site initiation visit.

#### 6.6 Randomisation

After patient eligibility is confirmed, randomisation is via a central internet-based system according to block random grouping method stratified by site, neurological severity NIHSS <15 vs ≥15), and haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle) to ensure balance in key prognostic factors. This is to allow a broad range of patients to be included with a balance of mild, moderate and severe, clinical severity. It will also allow certain strata (ie mild or severe) groups to be blocked from being randomised to ensure balance across the groups, as the presumed mechanism for the treatment effect is on reducing the mass effect of the haematoma through enhanced reabsorption and reduced perihematomal oedema. All eligible ICH patients presenting to the hospital from the start date are to be prospectively and consecutively enrolled.

#### 6.7 Intervention

Time to initiation of Chinese herbal medicine FYTF-919 or placebo: The intervention after the randomization should be performed as soon as possible.

**Treatment duration:** 28 days







Intervention Group (Chinese herbal medicine treatment): Oral liquid 33ml TID (NB: for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding);

**Control Group (Placebo treatment):** Oral liquid 33ml TID (NB: for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding);

#### Discontinuation of the intervention

Allocated management in either group should be discontinued or modified if any of the following occur:

- a. The patient/surrogate chooses to withdraw the consent of participation in this study.
- b. SAEs, which are in the opinion of the investigator, related to the trial protocol.
- c. The investigator feels it is in the subject's best interest.

Follow-up data will be collected for all treated subjects except those who specifically withdraw

consent for release of such information.

#### 6.8 Outcome Measures

#### 6.8.1 Primary Outcome

Utility-weighted modified Rankin scale (UW-mRS) scores at 90 days [31, 32].

#### 6.8.2 Secondary Outcomes

- 1) Utility-weighted mRS scores at 180 days
- 2) Ordinal analysis of 7 levels of mRS at 28 days, 90 days and 180 days;
- 3) Poor prognosis, defined as mRS 4-6 points at 28 days, 90 days and 180 days;
- 4) NIHSS score at 7 days and 28 days;
- 5) Mortality rate at 28 days, 90 days and 180 days;
- 6) Discharge rate at 28 days;
- 7) EQ-5D-5L at 28 days, 90 days and 180 days;
- 8) Bl at 28 days, 90 days and 180 days;
- 9) The cerebral edema volume at baseline, 24 hours, 7 days, 14 days or at discharge;
- 10) The hematoma volume at baseline, 24 hours, 7 days, 14 days or discharge;
- 11) The incidence of stroke-associated pneumonia (SAP) patients;







- 12) Clinical pulmonary infection score (CPIS) at the onset of SAP, 3 days and 7 days after the occurrence of SAP;
- 13) Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture at the onset of SAP, 3 days and 7 days after the occurrence of SAP;
- 14) Antibiotic usage among patients with SAP.

#### 6.8.3 Safety Outcomes

Safety: all SAE/AESI during follow-up in all randomised patients.

#### **AESI**

- 1) Haematoma expansion
- 2) New ICH (intracerebral haemorrhage)
- 3) Diarrhea
- 4) Laboratory test index (including blood routine examination, renal function, liver function, fecal occult blood, coagulation function, routine urine test and D-Di)

#### **Any other SAEs**

#### 6.9 Data Collection and Follow-up

patients in the context of routine practice.

The sites will collect the patient's treatment status, laboratory test, imaging and other at randomization, the 1 day, 7 days, 14 days, 28 days (or at the time of discharge) after treatment started. The sample of blood, urine, stool and respiratory secretions will be collected after the authorization of patients at time points above. Hematoma, sample of respiratory secretions and brain tissue around the hematoma of patients who received craniotomy will also be collected after authorization. SAP patients also need to collect data at the occurrence of SAP, 3 days and 7 days after the occurrence, include laboratory test, imaging, and other. The overall cost of hospitalization will be collected when discharged. All of follow-up above will be performed by a blinded staff. The sites will also collect 90 days and 180 days outcome assessment and medical-related cost via a blinded staff.

All patients will be analysed according to the "intention to treat" principle. Data collection will be kept to a minimum to ensure rapid enrolment and follow-up of







Study management will be facilitated by an established internet-based system. The paper version of the case reports forms (CRFs) will be supplied together with a procedure manual, as a reference and a database completion guideline of each data element with definitions for the hospitals to ensure accuracy and consistency of data collection.

All data entry will be completed using an internet-based data management system. It will be password protected with individual log-in, with sites and role assignment at site levels to ensure security, privacy and confidentiality between sites and country. The internet-based data management system will allow for real time data entry, query generation for values entered outside the valid ranges and consistency checking.

#### 6.9.1 Screening and Enrolment log

Each participating site will register all patients who present to ED, during the intervention period, with a clinical diagnosis of ICH into the *Screening and Enrolment* log. The log will record patient's gender, initials, date and time of hospital arrival, date and time of stroke onset, date and time of CT scan, patient information form given, and consent obtained and patient's ineligibility. This form is also used as the screening log to record the patients who are ineligible for the study together with the main reason as to why a patient was excluded. Such case mix and vital status data is vital to assess potential selection bias through non-participants. All patients meet criteria will be collected initial of name, time of onset, time of admission, NIHSS, max hematoma location for randomization.

There will be a removable section at the bottom of the log for hospital use only to match the eligible patient for data collection and follow-up. The paper-based log will be a source document to be locked in the filling cabinet with the patient files, for monitoring of the data entered into the database. The log can be used by the Research Coordinator (or designated site staff), PI and the CCC to monitor and identify specific barriers to recruitment of eligible and ineligible patients.

#### 6.9.2 Patient Contact Details log

Each centre will keep a record of the contact details and information of next-of-kin for all patients recruited into the study before hospital discharge. This will be kept with the patient file in the participating centre in a locked filing cabinet in accordance with local privacy and confidential policies. This will be kept at the site and used by the







local research coordinator and PI to contact the patient or person responsible in any event or issues arising from the study. All times are counted from treatment started.

## 6.9.3 Information Collected at Each Stage

All time are counted from the treatment started.

#### **Baseline**

For eligible patients, their baseline information will be collected such as:

- Patient demographic data;
- · Smoking and drinking;
- Respiration rate, blood pressure, heart rate and body temperature at admission
- Past medical history and past medication and treatment history;
- Laboratory test results (blood cell, biochemistry, urine, stool, coagulation, etc.), electrocardiogram;
- GCS and NIHSS scores, TCM syndrome scale, mRS assessment before onset;
- · Medication and key treatment conditions;
- Brain CT imaging information (hematoma volume, location, etc.);
- The sample of blood, urine, stool, and respiratory secretions of authorized patients.

#### Day 1

On day 1 or at death/ discharge, the following information is to be entered into the database, using the patient medical records and other source documents

- Time of discharge or death;
- Respiration rate, blood pressure, heart rate and body temperature;
- If surgery is performed within 24 hours, laboratory tests ((blood cell, biochemistry, urine, stool, coagulation, etc.) are required;
- GCS and NIHSS scores, TCM stroke syndrome scale;
- Medication and key treatment conditions;
- Brain CT imaging (hematoma volume, location, etc.);
- The sample of blood, urine, and stool of authorized patients;
- The sample of hematoma and brain tissue around the hematoma of authorized craniotomy patients.

#### Day 7

On day 7 or at death/ discharge, the following information is to be entered into the database, using the patient medical records and other source documents

Time of discharge or death;







- Respiration rate, blood pressure, heart rate and body temperature;
- Laboratory tests ((blood cell, biochemistry, urine, stool, coagulation, etc.);
- GCS and NIHSS scores, TCM stroke syndrome scale;
- Medication and key treatment conditions;
- Brain CT imaging (hematoma volume, location, etc.);
- The sample of blood, urine, and stool of authorized patients.

#### Day 14

On day 14 or at death/ discharge, the following information is to be entered into the database, using the patient medical records and other source documents

- Time of discharge or death;
- Respiration rate, blood pressure, heart rate and body temperature;
- Laboratory tests ((blood cell, biochemistry, urine, stool, coagulation, etc.);
- GCS and NIHSS scores, TCM stroke syndrome scale;
- Medication and key treatment conditions;
- Brain CT imaging (hematoma volume, location, etc.);
- The sample of blood, urine, and stool of authorized patients.

#### **Day 28**

On day 28 or at death/ discharge, the following information is to be entered into the database, using the patient medical records and other source documents

- Time of discharge or death;
- Laboratory tests ((blood cell, biochemistry, urine, stool, coagulation, etc.);
- Medication and key treatment conditions;
- mRS scale and BI;
- EQ-5D-5L;
- Hospitalization cost;
- The sample of blood, urine, and stool of authorized patients.

The sample of hematoma and brain tissue around the hematoma of authorized craniotomy patients.

#### 90-day Follow-up Blinded Assessment

Standardisation of outcome assessment: These follow-up assessments will be conducted by the site staff, or blinded assessor at each site, who will be trained to collect the outcome data systematically. The trained staff will be independent and blinded to the stroke care which the patient received and other clinical information.







All surviving patients will be contacted by an appropriately trained outcome assessor using an assigned telephone script, who will be kept blinded to where patients were treated. The assessor will be managed by the site.

The information to be collected at follow-up assessments are:

- Dependency assessed with the mRS and BI
- HRQoL measured by the EQ-5D-5L
- Patient living status
- Any complications or hospitalisation since going home
- Any medication currently used
- Medical related of cost

#### 180-day Follow-up Blinded Assessment

All surviving patients will be contacted by an appropriately trained outcome assessor using an assigned telephone script, who will be kept blinded to where patients were treated. The assessor will be managed by the site.

The information to be collected at follow-up assessments are:

- Dependency assessed with the mRS and BI
- HRQoL measured by the EQ-5D-5L
- Patient living status
- Any complications or hospitalisation since going home
- Any medication currently used
- Medical related of cost

#### Stroke related pneumonia (SAP)

The hospitalization SAP will be recorded when it is happened, following assessment will be performed on first day, 3 day, and 7 day:

- Clinical syndromes
- CIPS
- Chest imaging
- Body temperature
- Laboratory tests (white blood cell count, CRP, PCT, Blood gas analysis, Culture of tracheal aspirate)







- Antibiotic usage
- The sample of respiratory secretions of authorized patients

#### Death

Patients who die prior to any of the above scheduled assessments, cause of death documentation copies of post-mortem reports, hospital record entry or death certificate if possible, should be kept with the Patient file at the site to assist in study monitoring by the CCC. An SAE form is to be completed for all deaths during the study period, stating the primary and underlying cause of death.

# 7. SAFETY

#### 7.1 Data and Safety Monitoring Board (DSMB)

The DSMB will review the safety, ethics, and outcomes of the study.

Responsibilities: Monitor the accumulating data for early benefits or potential harmful effects and provide reports to the SC on recommendations to continue or temporarily halt recruitment to the study. The DSMB will be governed by a charter that will outline their responsibilities, procedures and confidentiality. The first meeting will be held prior to the start of the study recruitment. One formal interim analysis is planned to review data relating to treatment efficacy, participant safety and quality of trial conduct. Prior to the interim analysis a detailed plan will be developed to:

- Describe the methodology to be used in the statistical analyses.
- Specify rules if the study is to be halted.
- Specify rules on data handling conventions used to perform the analyses.
- Describe the procedure to be used to account for missing data.
- Outline interim analysis.

#### 7.2 Serious Adverse Events (SAEs)

The mechanisms for reporting and notifying SAE are based on the guidelines adopted by the ICH-GCP. As defined by the WHO International Drug Monitoring Centre (1994), an SAE is any untoward medical occurrence that:

results in death,







- is life threatening in the opinion of the PI (i.e. the patient was at risk of death at the time of the event; it does not refer to an event that might hypothetically have caused death had it been more severe),
- requires inpatient hospitalisation or prolongation of existing hospitalisation,
- results in persistent or significant disability or incapacity,
- results in congenital anomaly or birth defect (NB, females in the study population are likely to be post-menopausal),
- is an important medical event in the opinion of the PI that is not immediately lifethreatening and does not result in death or hospitalisation, but which may jeopardise the patient or may require intervention to prevent one of the other outcomes listed above.

#### **Recording and reporting**

An SAE form must be used to record the details of the event and this will include a full description of the event, classification of the event using the above definitions, the Pl's opinion on the causal relationship to the randomised management group and the timing of the event. The Pl will be required to submit at least 1 follow up report to provide further information so that the outcome of the SAE can also be recorded.

An SAE form will be provided for the recording of the event to the CCC. The details of the SAE will include the event diagnosis, classification of the event using standard definitions, the PI's opinion on the causal relationship to Chinese herbal medicine treatment, and the timing of the event. All SAEs should be reported to the CCC within 24 hours or as soon as the event is recognized. The PI will be responsible for ensuring that details of investigations and outcomes of an SAE are finalized. The SAE should be documented in the medical records or patient file, and signed and dated by the investigator, for audit and monitoring. The PI is responsible for reporting the SAE to the IRB/IEC according to local guidelines. All SAE will be reviewed by a medical monitor assigned to the trial.





# 8. QUALITY ASSURANCE

The study will be conducted at sites which successfully pass the site selection process, in accordance with the principles of the GCP/ICH Guidelines for Good Clinical Practice and all relevant local, national and international guidelines and regulations. Sites will facilitate the compliance of the protocol to local requirements. The sites will receive training and assistance to set-up documentation required for the study from the CCC. There will be regular meetings/teleconference between the site and CCC staff. The CCC will provide Standard Operating Procedures (SOP) to the sites to assist the compliance to GCP/ICH-GCP principles and the protocol. Manuals and Guidelines will be developed by the CCC in liaison with the Operations committee.

#### 8.1 Monitoring of Sites

Regional-based clinical research monitors will perform remote and on-site data verification and monitor the conduct of the study according to monitoring plan or project plan for this study. The remote and on-site monitoring activities serve to verify adherence to the study protocol, GCP/ICH-GCP principles, other local and regional requirements.

In addition, the study may also be audited by external government or regulatory authorities. Access to CRFs, source documents and other files, must be made available at all participating sites for monitoring and audit purposes at mutually arranged times during the course of the study and after its completion.

#### 8.2 Collection and Storage of Essential Documents

At completion of the study, the sites will have to ensure that there are plans in place for the long-term storage of all the relevant data and source documentation (for 15 years).

Prior to the initiation of the study at any participating site, the PI, Co-Investigator(s) and Research Nurse(s) and other designated research staff will be trained on the study procedures by the CCC. In addition, all investigators will be provided with materials detailing all the study procedures. Before activating the study at each site, the following documents must be provided to the CCC:

• the PI's up-to-date curriculum vitae (CV), signed and dated

CHAIN Protocol Version 4.0 Date: 18 September 2021





- signed confidentiality agreement
- signed investigator agreement
- the formal ethics approval letter
- · the signed clinical trials agreement
- · approved version of the ICF
- approved version of the protocol (translation if applicable)

## 9. HEALTH ECONOMIC EVALUATION

Health economic evaluation provides value judgment for health policymakers when they make reimbursement decision on the proposed treatment. In the CHAIN trial, the intervention of FYTF-919 will be used in moderate to severe ICH patients, who are more likely to have a heavy financial burden and work productivity loss after the acute stage. Thus, it is important to know whether the CHAIN trial is cost-effective compared to conventional care. A within-trial economic evaluation will be conducted to compare the incremental costs including costs of intervention and difference in health service cost versus the incremental effectiveness which is expressed using quality-adjusted life years (QALYs). QALYs were estimated based on the utility values derived from the EQ-5D-5L. QALYs will use the time trade-off values for EQ-5D-5L health states established for a Chinese population. The (trial-based) incremental cost-effectiveness ratio (ICER) will be calculated and then compared to the willingness-to-pay threshold in China and other countries to determine the costeffectiveness of the CHAIN trial. The economic evaluation will be conducted from the healthcare payer's perspective. A range of sensitivity analyses (SA) including oneway SA and probabilistic SA will be conducted to test the robustness of the ICER in the base case analysis.

#### 10. DATA MANAGEMENT

All data entry will be completed via a secure web-based electronic data collection (EDC) system developed by EDC System Company. This will allow for real time data query generation for values entered outside of pre-set valid ranges and consistency checking. This system will speed up data reporting and assist overall trial







management for all participating centers. Data entry will be performed at the participating sites. Only authorised staff will have access. All entered data forms will be electronically signed (by use of the unique password) by authorised study staff. All changes made following the initial entry will have an electronically dated audit trail. Centralised coding of outcomes will be performed by a trained medical coder and reviewed by the Medical Monitor, to confirm accuracy of coding and correct reporting of outcomes by sites.

This system, developed at the CCC for data capturing and the data variables, will have logic checks within the acceptable ranges and mandatory fields to ensure accuracy and reduce missing data. Reports and data query management will also be included in the system to assist with centralised online monitoring by the CCC. Paper CRFs will be provided for sites preferring to use these for the initial collection of data. These forms will be used as source document and will need to be signed and dated by the investigator completing the form.

All computerised forms will be electronically signed (by use of the unique password) by the authorised study staff and all changes made following the initial entry will have an electronic dated audit trail. It is the requirement that the collection of data and transfer of information for the 180 days follow-up assessment has to be approved by the local IRB for each site.

Research data will be exported after study completed and stored in the data servers of Provincial Hospital of Chinese Medicine Hospital and The George Institute China, respectively.

## 11. STATISTICAL CONSIDERATIONS

The sample of 1504 patients would give 90% power ( $\alpha$  0.05) to detect a difference between average scores in the treatment and control groups greater than 20% of the Standard Deviation (SD) of control group average (0.59 vs.0.65, SD = 0.32), assuming equal group participation, 6% non-adherence rate and 10% lost to follow-up. The calculation was based on INTERACT data, 0.59 is the mean UW-mRS of the INTERACT control group [32, 33].

The primary end point was the mean score for disability on the UW-mRS at 90 days. To determine the utility-weighted score, the score on the mRS is weighted according to average values calculated from patient-centered and clinician-centered





studies.[34-36] The following weights are assigned to scores 0 through 6 on the mRS: 10.0, 9.1, 7.6, 6.5, 3.3, 0, and 0, respectively. The UW-mRS ranges from 0 (death) to 10 (no symptoms or disability). The primary analysis will be conducted to evaluate the effectiveness of a Chinese herbal medicine as compared to placebo on the mean score for disability on the UW-mRS score at 90 days in patients with spontaneous ICH, A generalized linear model (GLM) with adjustment for covariates at baseline will be used to perform the multivariable regression analysis.

# 12. PUBLICATIONS, REPORTS AND DATA SHARING

Publication of the main reports from the study will be in the name of the CHAIN Collaborative Investigators. Full editorial control will reside with a Writing Committee approved by the Steering Committee.

Investigators have the right to publish or present the results of the study. However as this is a multicenter study, investigators must agree not to publish or publicly present any interim results of the study without the prior written permission of the SC. Investigators further must agree to provide the SC at least 30 days prior notice of any submission for publication or presentation for review, copies of abstract or manuscripts (including without limitation, text and PowerPoint presentation slides and any other texts of translations or medial presentations) that reports any study results. The SC shall have the right to review and comment about the accuracy of the information, the protection of the rights of any individual, ensure a fair and balance representation and in compliance with appropriate regulations. If there is any disagreement, the investigator will agree to meet with a SC member to discuss and resolve any disagreements.

Writing Committees will be formed from members of the various committees, statisticians, research fellows and investigators. They will prepare the main reports of the study to be published in the name of "CHAIN Investigators" with credit assigned to the collaborating investigators and other research staff. Presentations of the study findings will be made at national and international meetings concerned with the management of stroke cardiovascular disease, and hypertension.

Authors of publications must meet the International Committee of Medical Journal Editors (ICMJE) guidelines for authorship that follow:







- authors must make substantial contributions to the conception and design of the study, acquisition of data, or analysis of data and interpretation of results,
- authors must draft the publication or, during draft review, provide contributions (data analysis, interpretation, or other important intellectual content) leading to significant revision of the manuscript with agreement by the other authors,
- authors must provide approval of the final draft version of the manuscript before it is submitted to the journal for publication.

All contributors who do not meet the 3 criteria for authorship should be listed in an acknowledgments section within the publication, if allowed by the journal, per ICMJE guidelines for acknowledgement.

At the completion of the study, a copy of the CHAIN dataset will be given to the Guang Dong Provincial Hospital of Chinese Medicine, for secondary analysis according to an agreed analysis plan with The George Institute China. In addition, data will be shared with other investigators on the study, and investigators from other institutions around the world, according to a strict data sharing agreement. Data sharing will be available from 12 months after publication of the main results. Investigators are to make a formal request for data sharing through the Research Office of The George Institute.


# 13. FUNDING

This study receives its principle funding from the following grants: Key-Area Research and Development Program of Guangdong Province (No.2020B1111100009).





# 14. TIMELINES









# 15. REFERENCES

- 1. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388:1545-1602.
- 2. Wang W, Jiang B, Sun H, et al. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017; 135:759-771.
- 3. Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011; 42:3651-3654.
- 4. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18(5):439-458. doi: 10.1016/S1474-4422(19)30034-1.
- Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1: e259–81
- 6. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013; 368(25):2355-65. doi: 10.1056/NEJMoa1214609.
- Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016 Sep 15;375(11):1033-43. doi: 10.1056/NEJMoa1603460.
- 8. Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019; 393(10175):1021-1032. doi: 10.1016/S0140-6736(19)30195-3.
- 9. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH; STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005; 4; 365(9457):387-97. doi: 10.1016/S0140-6736(05)17826-X.
- Wang HL, Zeng H, Xu MB, Zhou XL, Rong PQ, Jin TY, Wang Q, Zheng GQ. Efficacy and Safety of Chinese Herbal Medicine for Primary Intracerebral Hemorrhage: A Systematic Review of Randomized Controlled Trials. Front Pharmacol. 2019;10:1139.
- 11. Jiang C, Yang X, Dong J, Li G. Systematic Review and Meta-Analysis of Randomized Controlled Trials of Liangxue Tongyu Formula on Patients With Acute Intracerebral Hemorrhage. Front Pharmacol. 2020;11:437.
- 12. Ma X, Wang T, Wen J, Wang J, Zeng N, Zou W, Yang Y. Role of Xingnaojing Injection in treating acute cerebral hemorrhage: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(15):e19648.







- 13. Liu H, Yan Y, Pang P, Mao J, Hu X, Li D, Zhou B, Shan H. Angong Niuhuang Pill as adjuvant therapy for treating acute cerebral infarction and intracerebral hemorrhage: A meta-analysis of randomized controlled trials. J Ethnopharmacol. 2019;237:307-313.
- 14. Zou YH, Bin M. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the China Association of Chinese Medicine. Chinese traditional Chinese medicine modern remote education 2011;9:110–2. In Chinese.
- 15. Zeng L, Tang G, Wang J, Zhong J, Xia Z, Li J, Chen G, Zhang Y, Luo S, Huang G, Zhao Q, Wan Y, Chen C, Zhu K, Qiao H, Wang J, Huang T, Liu X, Zhang Q, Lin R, Li H, Gong B, Chen X, Zhou Y, Wen Z, Guo J. Safety and efficacy of herbal medicine for acute intracerebral hemorrhage (CRRICH): a multicentre randomised controlled trial. BMJ Open. 2019;9(5):e024932.
- **16.** 卢明,黄燕,杜宝新,梁**伟**雄,黄培新,刘茂才.中大量**脑**出血患者中西医**结**合教治后并**发**症及 其死亡原因分析.中国中西医**结**合急救**杂**志, 2003(04):226-228.
- 17. 陈婷婷,任晋婷,任丽娜,贺忠延,孙畅,王冬慧,孙明广,王芳,谢颖桢.中风急性期中经络与中脏腑痰热腑实证临床特点对比研究.北京中医药大学学报, 2018,41(01):83-88.
- 18. Xing Chen. Study on prevention of hematoma enlargement in rats with intracerebral hemorrhage and its mechanism by FYTF-919[D]. Chengdu University of Traditional Chinese Medicine,2020.
- 19. Jianwen Guo, Yinchun He, Shaohong Chen. Optimal dose of drug-containing cerebrospinal fluid to protect Beagle dogs from nerve cell injury. Chinese Medicine Bulletin,2005(04):54-58.
- Jianwen Guo, Yinchun He, Shaohong Chen, Xiaoying Zhang. Experimental study on the time window of treating acute intracerebral hemorrhage with drug-containing cerebrospinal fluid in Beagle dogs. Traditional Chinese medicine materials, 2005(10):68-71.
- 21. Jianwen Guo, Yinchun He, Shaohong Chen, Xiaoying Zhang, Yan Huang, Peixin Huang. Experimental study on the time window of intervention of cerebral spinal fluid containing drugs on apoptosis of cortical neurons injured by hemorrhage in Beagle dogs. Journal of cardiovascular and cerebrovascular diseases of integrated traditional Chinese and western medicine,2005(10):884-886.
- 22. Zhouke Guo, Mingfu Li, Farong Zhang, Shaohong Chen. Effect of FYTF-919 on experimental cerebral edema in rabbits. Journal of Chengdu College of Traditional Chinese Medicine, 1993 (01):37-41.
- 23. Shi K, Tian D C, Li Z G, et al. Global brain inflammation in stroke. Lancet Neurol, 2019, 18(11):1058-1066.
- 24. Han L, Liu DL, Zeng QK, et al. The neuroprotective effects and probable mechanisms of Ligustilide and its degradative products on intracerebral hemorrhage in mice. Int Immunopharmacol, 2018,63:43-57.
- 25. Zhang J, Jiang Y, Liu N, et al. A Network-Based Method for Mechanistic Investigation and Neuroprotective Effect on Post-treatment of Senkyunolid-H Against Cerebral Ischemic Stroke in Mouse.Front Neurol. 2019.10:1299.
- 26. Zhao YM, Fang YL, Zhao HP, et al. Chrysophanol inhibits endoplasmic reticulum stress in cerebral ischemia and reperfusion mice. Eur J Pharmacol, 2018,818:1-9.







- 27. Zhao YM, Huang YY, Fang YL, et al. Chrysophanol attenuates nitrosative/oxidative stress injury in a mouse model of focal cerebral ischemia/reperfusion. J Pharmacol Sci, 2018,138:16-22.
- 28. 张晓云, 金伟, 陈绍宏. 复元醒脑法对 351 例急性脑出血临床验证观察. 辽宁中医杂志, 2012(6):968-971. XY Zhang, W Jin, SH Chen. Clinical Observation on 351 Cases of Acute Cerebral Hemorrhage Treated by Chinese Herb Medicine FYTF-919. Liaoning Journal of Traditional Chinese Medicine, 2012; (6):968-971.
- 29. 陈绍宏,张晓云.中风醒脑口服液治疗急性脑出血临床研究.中国中医急症,2004(12):793-794+878. SH Chen, XY Zhang. Clinical study on the treatment of acute cerebral hemorrhage with Chinese herbal medicine FYTF-919. China Emergency in Traditional Chinese Medicine. 2004; (12):793-794+878.
- 30. 李艳青. 益气活血、泄热熄风法治疗出血性中风急性期的临床验证研究[D].成都中医药大学,2012. YQ li. Clinical validation study on the treatment of Chinese herb medicine for acute hemorrhagic stroke [PhD dissertation]. Chengdu University of Traditional Chinese Medicine, 2012.
- 31. X Wang, T J Moullaali TJ, Q Li, et al. Utility-Weighted Modified Rankin Scale Scores for the Assessment of Stroke Outcome: Pooled Analysis of 20 000+ Patients. Stroke. 2020; 51(8).
- 32. R.G. Nogueira, A.P. Jadhav, D.C. Haussen, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018; 378(1):11-21.
- 33. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, et al; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368: 2355–2365.
- 34. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, LuengoFernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making 2010; 30: 341-54.
- 35. Hong KS, Saver JL. Quantifying the value of stroke disability outcomes: WHO Global Burden of Disease Project disability weights for each level of the modified Rankin Scale. Stroke 2009; 40: 3828-33.
- 36. Chaisinanunkul N, Adeoye O, Lewis RJ, et al. Adopting a patient-centered approach to primary outcome analysis of acute stroke trials using a utility-weighted modified Rankin scale. Stroke 2015; 46: 2238-43.





CHAIN Protocol Version 4.0 Date: 18 September 2021





# Chinese Herbal medicine in Acute INtracerebral haemorrhage (CHAIN) trial



# **Statistical Analysis Plan (SAP)**

Version: 1.0 (Final)

Date: 11 January 2024

#### **Authors:**

Qiang Li , Lili Song , Laurent Billot, Yang Zhao, Rustam Al-Shahi Salman, Graeme Hankey, Craig S. Anderson, Jianwen Guo, on behalf of the CHAIN Investigators

#### **Corresponding author:**

Qiang Li

The George Institute for Global Health

Faculty of Medicine and Health, UNSW, Sydney, Australia

qli@georgeinstitute.org

# **Table of Contents**

_				
1	Ad	dminist	trative information	4
	1.1	Stu	dy identifiers	4
	1.1	Rev	ision history	4
	1.2	Con	tributors to the statistical analysis plan	4
	1.	2.1	Roles and responsibilities	4
	1.	2.2	Approvals	5
2	Αŀ	obrevia	itions	6
3	In	troduc	tion	7
	3.1	Stu	dy synopsis	7
	3.2	Stu	dy population	7
	3.	2.1	Inclusion criteria	7
	3.	2.2	Exclusion criteria	7
	3.3	Stu	dy interventions	7
	3.	3.1	Randomisation	7
	3.	3.2	Study treatment	7
	3.4	Out	comes	8
	3.	4.1	Primary outcome	8
	3.	4.2	Secondary outcomes	8
	3.	4.3	Safety	8
4	Ar	nalysis	principles	9
	4.1	San	nple size	9
	4.2	Soft	tware	9
	4.3	Inte	erim analyses	9
	4.4	Mu	ltiplicity adjustment	9
	4.5	Dat	a sets analysed	9
	4.	5.1	Analysis populations	9
	4.	5.2	Analysis strategy	10
5	Pl	anned	analyses	10
	4.1	Subjec	t disposition	10
	5.1	Pati	ent characteristics and baseline comparisons	10

	5.2	Con	comitant therapies and treatment of stroke	. 10
	5.3	Adh	erence to study intervention	. 10
	5.4	Ana	lysis of the primary outcome	. 10
	5.4.	1	Main analysis	.11
	5.4.	2	Adjusted analyses	. 11
	5.4.	3	Subgroup analyses	.11
	5.4.	4	Treatment of missing data	.11
	5.4.	5	Per-protocol analyses	.12
	5.4.	6	Other sensitivity analyses	.12
	5.5	Ana	lysis of secondary outcomes	.12
	5.5.	1	UW-mRS at 180 days	. 13
	5.5.	2	Ordinal analyses of mRS	.13
	5.5.	3	Binary analyses of mRS	. 13
	5.5.	4	Health related quality of life – EQ-5D-5L	. 13
	5.5.	5	Basic activity of daily living according to the Barthel Index (BI)	. 13
	5.5.	6	NIHSS score at 24 hours and 7 days	.13
	5.5.	7	Haematoma volume and cerebral oedema volume	. 14
	5.5.	8	Clinical pulmonary infection score (CPIS) and Stroke-associated Pneumonia (SAP)	. 14
	5.6	Ana	lysis of other outcomes	. 14
	5.6.	1	Serious adverse events (SAEs) and deaths	. 14
5	Refe	erenc	es	. 15
Α	ppendix	x 1: P	roposed Tables and figures	.16
	1.1	Tabl	es	.16
	a.	Figu	res	.40
	b.	Listi	ngs	.42

# 1 Administrative information

## 1.1 Study identifiers

• Protocol Number: Version: 4.0, Date: 14 September 2022

• ClinicalTrials.gov register Identifier: NCT05066620

#### 1.1 Revision history

Version	Date	Details
0.1 (draft)	05 October 2023	First draft by Q Li
0.2 (revision)	02 November 2023	Reviewed by C Anderson and L Song
0.3 (revision)	16 November 2023	Reviewed by R Salman and G Hankey
0.4 (revision)	04 December 2023	Reviewed by L Song
1.0 (Final)	18 December 2023	Reviewed by R Salman, G Hankey and L Billot
1.0 (Final)	11 January 2024	Correction of minor comments by Q Li

# 1.2 Contributors to the statistical analysis plan

#### 1.2.1 Roles and responsibilities

Name and ORCID	Affiliation	Role on study	SAP contribution
Qiang Li <sup>©</sup>	The George Institute for Global	Study statistician	Prepared initial draft
	Health, UNSW Sydney		and revisions
Lili Song <sup>©</sup>	The George Institute for Global	Program	Reviewed and
	Health, UNSW, Sydney,	investigator	approved final version
	Australia.		
	The George Institute for Global		
	Health, Beijing, China.		
Laurent Billot 🕩	The George Institute for Global	Senior adviser of	Contributed to
	Health, UNSW Sydney	statistical analysis	methodology, revision
			of the first draft, and
			review and approval
			of the final version
Yang Zhao	The George Institute for Global	Researcher	Reviewed and
	Health, UNSW, Sydney,		approved final version
	Australia.		
	The George Institute for Global		
	Health, Beijing, China.		
Rustam Al-Shahi 🔟	Centre for Clinical Brain	International expert	Contributed to
Salman	Sciences, The University of		methodology, revision
	Edinburgh, Edinburgh. UK		of the first draft, and
			review and approval
			of the final version

4 274

Version: 1.0 - Date: 11 January 2024

Name and ORCID	Affiliation	Role on study	SAP contribution
Graeme J. Hankey	Medical School, The University	International expert	Contributed to
	of Western Australia, Perth,		methodology, revision
	Australia;		of the first draft, and
	The Perron Institute for		review and approval
	Neurological and Translational		of the final version
	Science, Perth, Australia.		
Craig Anderson 💿	The George Institute for Global	Co-principal	Reviewed and
	Health, UNSW Sydney	investigator	approved all versions
Jianwen Guo	The Second Affiliated Hospital of	Co-principal	Reviewed and
	Chinese Medicine, Guangdong,	investigator	approved all versions
	China		

#### 1.2.2 Approvals

The undersigned have reviewed this plan and approve it as final. They find it to be consistent with the requirements of the protocol as it applies to their respective areas. They also find it to be compliant with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) topic E9 Statistical Principles for Clinical Trials. In particular, we confirm that this analysis plan was developed in a completely blinded manner, that is without knowledge of the effect of the intervention(s) being assessed.

Name	Signature	Date
Qiang Li	fine	17 January 2024
Lili Song		
Laurent Billot		17 January 2024
Yang Zhao		
Rustam Al-Shahi Salman	Rustam Al-Shahi Salman	15 January 2024
Graeme J. Hankey	GHarkey	JANUARY 15, 2024
Craig S. Anderson		
Jianwen Guo		

# 2 Abbreviations

ВР	Blood pressure
ВІ	Barthel index
CACE	Complier Average Cause Effect
ССВ	Calcium channel blocker
CCC	Central coordinating centre
CHAIN	Chinese Herbal medicine in Acute INtracerebral haemorrhage
CI	Confidence interval
CPIS	Clinical pulmonary infection score
CRF	Case reports form
СТ	Computerised tomography
DSMB	Data and safety monitoring board
EDC	Electronic data collection
EQ-5D	EuroQoL Group 5-dimension self-report questionnaire
GCS	Glasgow coma scale
HR	Heart rate
HRQoL	Health-related quality of life
IC	Informed consent
ICF	Inform consent form
ICH	Intracerebral haemorrhage
mRS	Modified Rankin scale
NIHSS	National Institute of Health Stroke Scale
PI	Principal investigator
PIS	Patient information sheet
ICF	Patient information sheet and inform consent form
RCC	Regional coordinating centre
RCTs	Randomised Controlled Trials
SAE	Serious adverse event
SAP	Stroke-associated pneumonia
SC	Steering committee
SD	Standard deviation
SOP	Standard operation process
TCM	Traditional Chinese medicine
TGI CHINA	The George Institute for Global Health, China; Or the George Institute for
TOTCHINA	Global Health (Australia), Beijing representative office
UW-mRS	Utility-weighted modified Rankin scale

#### 3 Introduction

#### 3.1 Study synopsis

CHAIN is an investigator initiated and conducted, multicenter, prospective, randomised, double-blind placebo-controlled trial that aims to determine the efficacy and safety of FYTF-919 in patients with acute intracerebral haemorrhage (ICH) at hospitals in China. The full protocol was published in the journal Cerebrovascular Diseases in October 2023 [1].

Version: 1.0 - Date: 11 January 2024

#### 3.2 Study population

A total of 1504 patients with diagnosis of ICH are to be recruited from approximately 20-30 hospitals in China.

#### 3.2.1 Inclusion criteria

- Age ≥18 years;
- Diagnosis of spontaneous ICH, confirmed by brain imaging;
- Presentation within 48 hours of symptom onset (or last seen well);
- Meet severity criteria of either (a) NIHSS ≥8, or (b) GCS ≤14;
- Provide written informed consent by patient (or approved surrogate).

#### 3.2.2 Exclusion criteria

- ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischemic stroke), or secondary to cerebral amyloid angiopathy, or secondary to reperfusion treatment for ischemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment;
- Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment;
- Other medical illness that will interfere with outcome assessments and follow-up (e.g. known significant pre-stroke disability [mRS scores 3-5], advanced cancer and renal failure);
- Known definite contraindication to the Chinese herbal medicine;
- Women who are known to be pregnant or lactating;
- Currently participating in another trial which would interfere with outcome assessments.

#### 3.3 Study interventions

#### 3.3.1 Randomisation

After patient eligibility is confirmed, randomisation is via a central internet-based system according to a block grouping method stratified by site, neurological severity (NIHSS scores <15 vs. ≥15), and haematoma location (basal ganglia or lobe vs. thalamus or cerebellum or brain stem or ventricle) to ensure these key prognostic factors are balanced between groups. Location of ventricle here is referring to pure intraventricular haemorrhage.

#### 3.3.2 Study treatment

The first dose of either active drug or matching placebo is given as soon as possible after randomisation. This is as an oral liquid 33 ml t.i.d.  $\times$  28 days (NB: for patients who are unconscious or have dysphagia, a dose of 25 ml \* Q.6.H is given via nasogastric tube).

7 277

Version: 1.0 - Date: 11 January 2024

**FYTF-919** (active treatment) group: The FYTF-919 (ZFXN prescription) is in accordance with Chinese good manufacture practice of medical products standards (GMP). As a type of plant compound, FYTF-919 is composed mainly of Renshen (Panax ginseng), Dahuang (Radix et Rhizoma Rhei), Sanqi (Radix Notoginseng), and Chuanxiong (Rhizoma Ligustici Chuanxiong), with sorbic acid and polysorbate 80 as auxiliary materials.

**Control** (*placebo treatment*) group: The placebo is a plant-flavored solution, composed mainly of soybean peptide and black sugar syrup combined with an edible essence and maltodextrin, salt and monosodium glutamate as auxiliary materials, and it has no biologic activity.

#### 3.4 Outcomes

#### 3.4.1 Primary outcome

Utility-weighted modified Rankin scale (UW-mRS) at 90 days [6].

The algorithm of UW-mRS is illustrated below using ICH population from previous publication [6]:

#### 3.4.2 Secondary outcomes

- UW-mRS at 180 days;
- o An ordinal analysis of the mRS at 28, 90 and 180 days;
- Death or disability, defined as mRS scores 4-6 at 28, 90 and 180 days;
- Death at 28, 90 and 180 days;
- Major disability (mRS 4-5) at 28, 90 and 180 days;
- Health-related quality of life on the EuroQoL EQ-5D-5L [10] measure at 28, 90 and 180 days;
- Basic activities of daily living according to the Barthel index (BI) at 28, 90 and 180 days;
- NIHSS at 24 hours and 7 days;
- Haematoma volume and cerebral oedema volume at 24 hours, 7 days, 14 days (or hospital discharge, if sooner);
- o The stroke-associated pneumonia (SAP) by day 7 during follow-up;
- o Clinical pulmonary infection score (CPIS) on days 0, 3 and 7 after stroke-associated pneumonia (SAP)

#### *3.4.3 Safety*

- Serious adverse events (SAEs) during follow-up
- Adverse events of special interest (AESI) during follow-up, including haematoma enlargement (>6 ml or 33%), new intracranial haematoma and diarrhoea.

8 278

# 4 Analysis principles

#### 4.1 Sample size

The sample of 1504 patients provides 90% power ( $\alpha$  0.05) to detect a difference in average scores for UW-mRS between the active and placebo groups of 0.06 (i.e., 0.59 vs. 0.65; SD = 0.32), assuming equal group participations, 6% non-adherence rate, and 10% lost to follow-up. The calculation was based on data from the second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2) where the mean UW-mRS was estimated as 0.59 in control 'less intensive BP control' group [2].

#### 4.2 Software

Analyses will be conducted primarily using SAS 9.4 on SAS Enterprise Guide (version 8.3 or above).

#### 4.3 Interim analyses

Two formal interim analyses were undertaken after 500 and 1000 patients who had completed 90-day follow-up to review the data related to treatment efficacy, participant safety and quality of trial conduct using a Haybittle-Peto stopping rule for efficacy [3]. Given the conservative rule used and the negligible amount of type-I error rate spent at the interim analysis, the significance threshold will remain at 5% for the final analysis.

#### 4.4 Multiplicity adjustment

Statistical tests are to be two-sided with a nominal level of  $\alpha$  set at 5%. Analysis of the primary outcome (UWmRS at 90 days) will not be adjusted for multiplicity. For other secondary outcomes measured in all stroke patients (i.e. ordered mRS, death or major disability, NIHSS and HRQoL at different timepoints), we will control the family-wise error rate by applying a sequential Holm-Sidak correction [4]. Briefly, the approach consists of ordering all p-values from smallest to largest, and then comparing them to an adjusted level of significance calculated as 1-(1-0.05)  $^{1/C}$ , where C indicates the number of comparisons that remain. The sequential testing procedure stops as soon as a p value fails to reach the corrected significance level. This will apply only to the primary analysis of an outcome (i.e. not to sensitivity analyses). For HRQoL, it will only apply to the analysis of the overall utility score. For clinical pulmonary infection score, it will only apply to the analysis of any stroke-associated pneumonia (SAP). For each secondary outcome only the primary time point is chosen to be adjusted for multiplicity, for example outcomes at day 90 will be used except that NIHSS and SAP are at day 7 (see Table 10). No multiplicity adjustment will be applied to safety outcomes.

#### 4.5 Data sets analysed

#### 4.5.1 Analysis populations

We will use 2 analysis populations:

- The *intention-to-treat (ITT) population* is defined as all patients who were randomised, regardless of their diagnosis or adherence to the study treatment protocol. This population includes individuals who did not withdraw their consent for the use of their data. *The ITT population will serve as the primary analysis set for all analyses*.
- The *per-protocol (PP) population* is defined as all patients from the ITT population excluding patients who had a relevant protocol violation defined as any of the following:
  - Age <18 years</li>

- o NIHSS <8 and GCS 15
- o Final diagnosis was not spontaneous ICH

Randomised >48 hours after stroke onset

• Patients who were found later in the trial to have received incorrect treatment or incorrect dose of the allocated study drug after confirmation by local investigators.

Version: 1.0 - Date: 11 January 2024

 Other major protocol violations which have been adjudicated, for example concomitant TCM contains same components of FYTF-919.

#### 4.5.2 Analysis strategy

For all outcomes, complete case analyses will be performed on the ITT population. Adjusted analyses and sensitivity analyses will be conducted on the PP population for the primary outcome only. A CACE analysis will be considered in a secondary analysis if necessary, for example more than 20% of subjects have dropped-in and dropped-out of treatment groups.

As the data collection for outcomes at 180 days will not be completed by the time of database lock, the treatment effects on secondary outcomes at 180 days will be analysed separately in a secondary analysis.

# 5 Planned analyses

#### 4.1 Subject disposition

The flow of patients through the trial will be displayed in a Consolidated Standards of Reporting Trials (CONSORT) [5] diagram (see Figure 1). The report will include: the number of screened patients who met study the inclusion criteria and the number of patients included, and reasons for exclusion of non-included patients.

#### 5.1 Patient characteristics and baseline comparisons

Baseline characteristics will be 10summarized by treatment groups (see Table 1). Discrete variables will be summarised by frequencies and percentages. Percentages will be calculated according to the number of patients for whom data are available. Continuous variables will be summarised using mean and SD, and median and interquartile range (Q1-Q3). No statistical test will be performed on baseline characteristics.

#### 5.2 Concomitant therapies and treatment of stroke

All assessments performed and interventions received between Day 1, 7, 14 and 28 will be described by treatment group. No formal statistical tests are planned for these variables.

#### 5.3 Adherence to study intervention

Duration of study treatment will be summarised in days between treatment groups. Categorical variable of treatment duration, 1-7 days, 8-14 days, 15-21 days and 22 days or more will be also analysed in case of any outlies in treatment duration. The number of completed bottles will be also summarised between treatment groups. Adequate adherence will be described and is defined as more than or equal 80% of study drug have been taken.

## 5.4 Analysis of the primary outcome

The primary outcome of UW-mRS at 90 days will be calculated from mRS and EQ-5D scores using an algorithm illustrated in our previous publication [6]. For the primary outcome, a general linear regression will be

Version: 1.0 - Date: 11 January 2024

#### 5.4.1 Main analysis

The main analysis will be performed in the ITT population using general linear regression with UW-mRS collected at Day 90 as the dependent variable. Treatment allocation will be included as a fixed categorical effect. To account for the stratification variables and to maximise precision [7], site [8], baseline NIHSS score (<15 vs ≥15) and haematoma location (basal ganglia or cerebral lobe vs thalamus or cerebellum or brainstem or ventricle) will also be included as fixed effects. The effect of the intervention will be presented as mean difference and its 95% confidence interval (CI), using the placebo arm as the reference.

performed to analyse whether FYTF-919 is superior to placebo. Raw mean and SD of UW-mRS and mean

difference and 95%CI between the treatment groups will be provided.

#### 5.4.2 Adjusted analyses

Adjusted analyses will be performed by adding the following covariates to the main linear regression model: age (continuous), mRS before stroke (categorical), sex (male vs female), time to randomisation (<12 vs ≥12 hours). The adjusted treatment effect will be reported as the adjusted mean difference and 95% CI. Adjusted analyses will also be performed in the PP analysis dataset.

#### 5.4.3 Subgroup analyses

Six pre-specified subgroup analyses will be carried out, irrespective of whether there is a significant treatment effect on the primary outcome. These subgroup analyses will only be performed in the ITT population.

Pre-randomisation subgroups are defined as follows:

- Age (<65 vs ≥65 years)</li>
- Sex (male vs female)
- Time to randomisation (<12 vs ≥12 hours)</li>
- Baseline NIHSS score (<15 vs ≥15)
- Baseline haematoma volume (<15 vs ≥15 ml))
- Haematoma location (basal ganglia or cerebral lobe vs thalamus or cerebellum or brainstem or ventricle)

The analysis for each subgroup will be performed by adding the subgroup variable as well as its interaction with the intervention as fixed effects to the main linear regression model. Within each subgroup, summary measures will include raw mean and SD within each treatment arm, as well as the mean difference for treatment effect with a 95% CI. The results will also be displayed on a forest plot, including estimated mean, SE and the p-value for heterogeneity corresponding to the interaction term between the intervention and subgroup variable.

#### 5.4.4 Treatment of missing data

The proportion of data missing for the primary outcome (UW-mRS at 90 days) will be described while blinded to the intervention. In case of non-negligible amounts of missing data (>5%), we will use multiple imputations by chained equation to assess the impact of missing data to the results. We will run an imputation model under the missing at random (MAR) assumption. This MAR imputation model will use fully conditional specification (FCS) [9] and will include the following variables: mRS at 28 days and 90 days, HRQoL EQ-5D-5L utility score at 28 days and 90 days, the NIHSS at 24 hours and 7 days (or hospital discharge, if sooner), a

Version: 1.0 – Date: 11 January 2024

variable indicating the intervention, and all key socio-demographic, clinical, and medical baseline variables. The mRS will be imputed using an ordinal logistic model. Other variables will be imputed using either linear regression (for continuous/ordinal variables) or a discriminant function method (for nominal variables). One hundred sets of imputed data will be created. Once mRS is imputed, UW-mRS will be calculated using same algorithm and analysed using the model described in section 5.4.1. 100 imputed datasets will be produced and estimates of the treatment effect and its standard errors will be combined to obtain a pooled common mean difference and 95%CI.

Multiple imputations will only be applied to the ITT analysis.

#### 5.4.5 Per-protocol analyses

The main model (section 5.4.1) as well as the adjusted analyses (section 5.4.2) will be repeated in the PP population as defined in Section 4.5.1.

Protocol deviations will be categorised and reported as the number and proportion of subjects experiencing a deviation. A listing of all protocol deviations will be provided.

#### 5.4.6 Other sensitivity analyses

In principal, we will utilize the HRQoL EQ-5D-5L utility score at day 90 to calculate the UW-mRS score. To achieve this, we will use an ordinary least squares regression model, with mRS scores serving as a categorical explanatory variable, and EQ-5D-5L utility scores as the continuous dependent variable. The model will generate beta-coefficients, which will be utilized as the weights for the UW-mRS score.

There are several reasons for not using in-study HRQoL utility scores in the primary analysis. First and foremost, approximately 15%-20% of HRQoL data at day 90 is missing, as indicated by a blinded review from the DSMB report. Secondly, the utility weights derived from previous large ICH population studies [6] are deemed more suitable and applicable.

The following section outlines three sensitivity analyses to be conducted:

In the first sensitivity analysis, we will utilize the available HRQoL EQ-5D-5L utility scores at day 90 to derive utility weights. These weights will be used to impute utility values for individuals with missing utility scores at day 90, and we will then repeat the primary analysis within the ITT population.

The second sensitivity analysis involves using available HRQoL EQ-5D-5L utility scores at day 90 to derive utility weights, which is the same as the first sensitivity analysis for this step This analysis will be then repeated specifically within the subset of subjects with non-missing HRQoL data.

In the third sensitivity analysis, in case of subjects who had missing HRQoL EQ-5D-5L utility score at day 90 but had been followed up more than 180 days with available HRQoL EQ-5D-5L utility scores, we will impute utility values at day 90 using data at day 180. Then, these imputed values will be used to derive utility weights for the UW-mRS score, which will then be applied to the entire ITT population. Subsequently, we will repeat the primary analysis.

#### 5.5 Analysis of secondary outcomes

All secondary outcome analyses described in this section will be performed in the ITT (primary) and PP (sensitivity) analyses sets as defined in Section 4.5.1

#### 5.5.1 UW-mRS at 180 days

The data collection of the UW-mRS at 180 days will not be completed by the time of database lock and will be analysed separately in secondary analysis. Exploratory analysis using repeated measurement of UW-mRS by day 28, 90 and 180 will be conducted and reported in a secondary publication and is not described in this SAP.

Version: 1.0 - Date: 11 January 2024

#### 5.5.2 Ordinal analyses of mRS

The outcome of the mRS at 28 and 90 days will be analysed separately as an ordinal variable with 7 levels. The intervention effect will be estimated as the OR of a higher mRS between the active arm and the placebo arm obtained from an ordinal logistic model. The effect of the intervention will be presented as the OR of a worse outcome and its 95% confidence interval (CI) using the placebo arm as the reference (i.e., where an OR greater than unity corresponds to an increase in mRS in the active arm compared to the placebo arm). We will also apply the covariate adjustments described in Section 5.4.2 but no subgroup or imputed analysis will be performed on this outcome.

We will assess the proportional-odds assumption using a score test. If a violation is detected, we will proceed with the analysis and interpret the intervention OR as an average effect across all mRS levels, recognizing that it may not remain constant across all levels. This assessment will be complemented by a graphical analysis of shifts across categories using bar plots.

#### 5.5.3 Binary analyses of mRS

A binary analysis of the mRS at 28 and 90 days will be performed by dichotomising the mRS as either 'poor' (scores 4-6) or 'favourable' (scores 0-3) outcomes. This analysis will be conducted using logistic regression. The effect of FYTF-919 will be presented as the OR of a poor outcome with associated 95% CI. We will also apply the covariate adjustments described in Section 5.4.2 but no subgroup or imputed analysis will be performed on this outcome. A similar analysis will be performed on mortality alone (mRS of 6 vs 0-5) and on disability alone (mRS 4-5 vs 0-3). For disability alone, the analysis will be restricted to subjects who are alive at corresponding timepoints (mRS 0-5).

#### 5.5.4 Health related quality of life - EQ-5D-5L

At day 28 and day 90, each of the 5 EQ-5D dimensions will be summarised in percentages between treatment groups and no statistical test will be performed. The visual analogous scale (score of 0 to 100) will be analysed using linear regression and the overall health utility EQ-5D-5L score will be calculated using Chinese norm [10] and compared between groups in a similar manner to that used for the visual analogous scale.

For patients who died before the planed timepoints, the EQ-5D-5L utility score will be imputed as zero. Both survivors and all subjects including deaths will be analysed separately within ITT population. We do not plan to undertake adjusted or subgroup analyses.

#### 5.5.5 Basic activity of daily living according to the Barthel Index (BI)

The Barthel Index (BI) at 28 and 90 days will be analysed as a continuous outcome using linear regression same as the primary outcome, but no subgroup or imputed analysis will be performed on this outcome.

#### 5.5.6 NIHSS score at 24 hours and 7 days

The NIHSS scores at 24 hours and at 7 days will be analysed as a continuous variable using an unadjusted linear regression model. The effect of FYTF-919 will be presented as the mean difference and associated 95%CI. The covariate adjustments described in Section 5.4.2 will also be applied but no subgroup or imputed analysis will be performed on this outcome.

13 283

#### 5.5.7 Haematoma volume and cerebral oedema volume

Haematoma volumes and cerebral edema volumes at the time of presentation from initial image data reported from the investigator will be summarised using mean and SD, median and inter-quarter range (Q1, Q3). The mean difference and 95%CI will be estimated between treatment groups using t-test and the median difference and 95%CI will be estimated using log-linear regression assuming log-normal distribution of haemotoma volumes.

Haemotoma growth and edema analysis based on imaging data will be analysed and reported in a secondary publication and is not described in this SAP.

#### 5.5.8 Clinical pulmonary infection score (CPIS) and Stroke-associated Pneumonia (SAP)

Clinical pulmonary infection score (CPIS) at baseline, day 3 and day 7 will be summarised as mean and SD between active arm and placebo arm. Any stroke-associated pneumonia (SAP) during follow-up will be summarised as the proportions and analysis will be conducted using logistic regression, same analysis method as binary mRS in section 5.5.3. Analysis will be conducted within the ITT population, and we do not have plans to perform adjusted or subgroup analyses.

#### 5.6 Analysis of other outcomes

#### 5.6.1 Serious adverse events (SAEs) and deaths

SAEs will be summarised as the number of events as well as the number and proportion of patients experiencing at least one SAE event. The overall proportion of patients with SAEs in the intervention and control arms will be compared using logistic regression, as in the binary analysis of mRS (see Section 5.5.1). Additionally, Adverse Events of Special Interest (AESI) reported by the local investigators, including hematoma enlargement (>6mL or 33%), new intracranial hematoma and diarrhea will be summarised by treatment groups. Primary and underlying causes of deaths will be summarised by treatment arm with no formal test.

A listing of all SAEs will be compiled (in an appendix).

Version: 1.0 - Date: 11 January 2024

# **5** References

1. Zhao Y, Cui W, Xie T, Zhao K, Li Y, Wan Y, Wang X, et al. Efficacy and safety of Chinese Herbal medicine in patients with Acute Intracerebral hemorrhage (CHAIN): protocol for a randomised placebo-controlled double-blinded multicenter trial. Cerebrovascular Diseases 2023 (accepted October 14, 2023; in press).

Version: 1.0 - Date: 11 January 2024

- 2. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood pressure lowering in patients with acute intracerebral hemorrhage. New Engl J Med 2013;368:2355-2365.
- 3. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Brit J Radiol 1971; 44:793-97.
- 4. Abdi H. Holm's sequential Bonferroni procedure. In Neil Salkind (Ed.), Encyclopedia of Research Design. Thousand Oaks, CA: Sage. 2010.
- 5. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
- 6. Wang X, Moullaali TJ, Li Q, Berge E, Robinson TG, Lindley R, et al. Utility-weighted modified rankin scale scores for the assessment of stroke outcome: pooled analysis of 20,000+ patients. Stroke 2020;51:2411-2417
- 7. Reeve R. Confidence interval of difference of proportions in logistic regression in presence of covariates. Stat Meth Med Res 2018;27:451-65.
- 8. Kahan BC. Accounting for centre-effects in multicentre trials with a binary outcome when, why, and how? BMC Med Res Methodol 2014;14:20.
- 9. Van Buuren, S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Meth Med Res 2007;16:219-42.
- 10. Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L Value Set for China. Value Health. 2017 Apr;20(4):662-669. doi: 10.1016/j.jval.2016.11.016.

# **Appendix 1: Proposed Tables and figures**

## 1.1 Tables

**Table 1. Baseline characteristics** 

	Active drug (N = )	Placebo drug (N = )	Total (N = )
Age (years)	XXX	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Cov		, , , , , , , , , , , , , , , , , , ,	2007
Sex	XXX	xxx	XXX
Male	xxx xx.x%	xxx xx.x%	xxx xx.x%
Female	xxx xx.x%	xxx xx.x%	xxx xx.x%
Ethnicity	XXX	xxx	xxx
Han	xxx xx.x%	xxx xx.x%	xxx xx.x%
Non-Han Minorities	xxx xx.x%	xxx xx.x%	xxx xx.x%
Height (cm)	xxx	XXX	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Tilli Tilux	AAA LO AAA	AAA LO AAA	AAA LO AAA
Weight (kg)	XXX	xxx	XXX
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
BMI (kg/m²)	xxx	XXX	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	· · · · · ·		
* * *	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Current smoking	XXX	xxx	XXX
No	xxx xx.x%	xxx xx.x%	xxx xx.x%
Yes	xxx xx.x%	xxx xx.x%	xxx xx.x%

	Active drug (N = )	Placebo drug (N = )	Total (N = )
Current drinking	XXX	xxx	xxx
No	xxx xx.x%	xxx xx.x%	xxx xx.x%
Yes	xxx xx.x%	xxx xx.x%	xxx xx.x%
Systolic Blood Pressure on arrival (mmHg)	xxx	XXX	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
IIIII IIIdx	XXX LO XXX	XXX to XXX	XXX to XXX
Diastolic Blood Pressure on arrival (mmHg)	XXX	XXX	XXX
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
IIIII IIIdx	XXX LO XXX	XXX to XXX	XXX to XXX
Heart Rate on arrival (bpm)	XXX	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
THE THAT	AAA CO AAA	AAA CO AAA	AAA CO AAA
Respiratory rate on arrival	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
First GCS on arrival	XXX	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
First NIHSS on arrival	XXX	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
NIHSS category	xxx	XXX	XXX
NIHSS <15	xxx xx.x%	xxx xx.x%	xxx xx.x%
NIHSS >=15	xxx xx.x%	xxx xx.x%	
101 >= T2	XXX XX.X%	XXX XX.X%	xxx xx.x%

	Active drug (N = )	Placebo drug (N = )	Total (N = )
Largest hematoma location	xxx	xxx	XXX
	xxx xx.x%	xxx xx.x%	xxx xx.x%
Basal ganglia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Lobe	xxx xx.x%	xxx xx.x%	xxx xx.x%
Thalamus	xxx xx.x%	xxx xx.x%	xxx xx.x%
Cerebellar			
Brain stem	xxx xx.x%	xxx xx.x%	xxx xx.x%
Brain ventricle	xxx xx.x%	xxx xx.x%	xxx xx.x%
Time from onset to arrival (hours)	xxx	XXX	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Time from onset to randomisation (hours)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Medical history	xxx	xxx	xxx
Previous Hypertension	xxx xx.x%	xxx xx.x%	xxx xx.x%
Previous Diabetes Mellitus	xxx xx.x%	xxx xx.x%	xxx xx.x%
Previous Hyperlipidemia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Previous Coronary Heart Disease	xxx xx.x%	xxx xx.x%	xxx xx.x%
Previous Atrial fibrillation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Any anticoagulant treatment	xxx xx.x%	xxx xx.x%	xxx xx.x%
Any antiplatelet treatment	xxx xx.x%	xxx xx.x%	xxx xx.x%

Table 2. Stroke treatment and therapy other than investigation medication

Medication/ Therapy Visits	Active drug (N = )	Placebo drug (N = )	Total (N = )
Adjunctive therapy	()	( /	( ,
Baseline	xxx	xxx	xxx
ICU	xxx xx.x%	xxx xx.x%	xxx xx.x%
Surgery	xxx xx.x%	xxx xx.x%	xxx xx.x%
Tracheal Intubation Tracheotomy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Mechanical Ventilation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Physical or drug hypothermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Nasal Feeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Urinary Catheter	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other Invasive treatment	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other treatments:			
Lower body temperature	xxx xx.x%	xxx xx.x%	xxx xx.x%
Analgesia and sedation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Proton pump inhibitors	xxx xx.x%	xxx xx.x%	xxx xx.x%
Diuretics	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anti-epilepsy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Dehydration	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP control	xxx xx.x%	xxx xx.x%	xxx xx.x%
Glucose control	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP elevating	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anticoagulation invert	xxx xx.x%	xxx xx.x%	xxx xx.x%
Rehabilitation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Acupuncture	xxx xx.x%	xxx xx.x%	xxx xx.x%
24h (± 3h)	XXX	xxx	xxx
ICU	xxx xx.x%	xxx xx.x%	xxx xx.x%
Surgery	xxx xx.x%	xxx xx.x%	xxx xx.x%
Tracheal Intubation Tracheotomy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Mechanical Ventilation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Physical or drug hypothermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Nasal Feeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Urinary Catheter	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other Invasive treatment	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other treatments:			
Lower body temperature	xxx xx.x%	xxx xx.x%	xxx xx.x%
Analgesia and sedation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Proton pump inhibitors	xxx xx.x%	xxx xx.x%	xxx xx.x%

Diuretics	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anti-epilepsy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Dehydration	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP control	xxx xx.x%	xxx xx.x%	xxx xx.x%
Glucose control	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP elevating	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anticoagulation invert	xxx xx.x%	xxx xx.x%	xxx xx.x%
Rehabilitation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Acupuncture	xxx xx.x%	xxx xx.x%	xxx xx.x%
Day7 (± 1day)	XXX	XXX	XXX
ICU	xxx xx.x%	xxx xx.x%	xxx xx.x%
Surgery	xxx xx.x%	xxx xx.x%	xxx xx.x%
Tracheal Intubation Tracheotomy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Mechanical Ventilation	xxx xx.x%	xxx xx.x%	xxx xx.x%
	xxx xx.x%	xxx xx.x%	xxx xx.x%
Physical or drug hypothermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Nasal Feeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Urinary Catheter Other Investigation treatment	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other Invasive treatment			
Other treatments:			
Lower body temperature	xxx xx.x%	xxx xx.x%	xxx xx.x%
Analgesia and sedation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Proton pump inhibitors	xxx xx.x%	xxx xx.x%	xxx xx.x%
Diuretics	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anti-epilepsy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Dehydration	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP control	xxx xx.x%	xxx xx.x%	xxx xx.x%
Glucose control	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP elevating	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anticoagulation invert	xxx xx.x%	xxx xx.x%	xxx xx.x%
Rehabilitation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Acupuncture	xxx xx.x%	xxx xx.x%	xxx xx.x%
Day 14 (± 2days)	XXX	XXX	XXX
ICU	xxx xx.x%	xxx xx.x%	xxx xx.x%
Surgery	xxx xx.x%	xxx xx.x%	xxx xx.x%
Tracheal Intubation Tracheotomy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Mechanical Ventilation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Physical or drug hypothermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Nasal Feeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Urinary Catheter	xxx xx.x%	xxx xx.x%	xxx xx.x%

Other treatments:         Lower body temperature         xxx xx.x%         xxx	Other Invasive treatment	xxx xx.x%	xxx xx.x%	xxx xx.x%
Analgesia and sedation	Other treatments:			
Proton pump inhibitors         xxx xx.x%         xxx xx.x% <td>Lower body temperature</td> <td>xxx xx.x%</td> <td>xxx xx.x%</td> <td>xxx xx.x%</td>	Lower body temperature	xxx xx.x%	xxx xx.x%	xxx xx.x%
Diuretics	Analgesia and sedation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anti-epilepsy         xxx xx.x%         xxx xx.x%         xxx xx.x%           Dehydration         xxx xx.x%         xxx xx.x%         xxx xx.x%           BP control         xxx xx.x%         xxx xx.x%         xxx xx.x%           Glucose control         xxx xx.x%         xxx xx.x%         xxx xx.x%           BP elevating         xxx xx.x%         xxx xx.x%         xxx xx.x%           Anticoagulation invert         xxx xx.x%         xxx xx.x%         xxx xx.x%           Rehabilitation         xxx xx.x%         xxx xx.x%         xxx xx.x%           Acupuncture         xxx xx.x%         xxx xx.x%         xxx xx.x%           Day28 (£ 3days)         xxx         xxx         xxx           ICU         xxx xx.x%         xxx xx.x%         xxx xx.x%           Surgery         xxx xx.x%         xxx xx.x%         xxx xx.x%           Mechanical Ventilation         xxx xx.x%         xxx xx.x%         xxx xx.x%           Mechanical Ventilation         xxx xx.x%         xxx xx.x%         xxx xx.x%           Physical or drug hypothermia         xxx xx.x%         xxx xx.x%         xxx xx.x%           Nasal Feeding         xxx xx.x%         xxx xx.x%         xxx xx.x%           Other Irreatments         xxx xx.x%	Proton pump inhibitors	xxx xx.x%	xxx xx.x%	xxx xx.x%
Dehydration         XXX XX.X%         XXX XX.X%         XXX XX.X%           BP control         XXX XX.X%         XXX XX.X%         XXX XX.X%           Glucose control         XXX XX.X%         XXX XX.X%         XXX XX.X%           BP elevating         XXX XX.X%         XXX XX.X%         XXX XX.X%           Anticoagulation invert         XXX XX.X%         XXX XX.X%         XXX XX.X%           Rehabilitation         XXX XX.X%         XXX XX.X%         XXX XX.X%           Acupuncture         XXX XX.X%         XXX XX.X%         XXX XX.X%           Day28 (± 3days)         XXX         XXX         XXX         XXX           ICU         XXX XX.X%         XXX XX.X%         XXX XX.X%         XXX XX.X%           Surgery         XXX XX.X%         XXX XX.X%         XXX XX.X%         XXX XX.X%           Tracheal Intubation Tracheotomy         XXX XX.X%         XXX XX.X%         XXX XX.X%           Mechanical Ventilation         XXX XX.X%         XXX XX.X%         XXX XX.X%           Physical or drug hypothermia         XXX XX.X%         XXX XX.X%         XXX XX.X%           Nasal Feeding         XXX XX.X%         XXX XX.X%         XXX XX.X%           Other Invasive treatment         XXX XX.X%         XXX XX.X%         XXX	Diuretics	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP control         xxx xx.x%         xxx xx.x%         xxx xx.x%           Glucose control         xxx xx.x%         xxx xx.x%         xxx xx.x%           BP elevating         xxx xx.x%         xxx xx.x%         xxx xx.x%           Anticoagulation invert         xxx xx.x%         xxx xx.x%         xxx xx.x%           Rehabilitation         xxx xx.x%         xxx xx.x%         xxx xx.x%           Acupuncture         xxx xx.x%         xxx xx.x%         xxx xx.x%           Day28 (± 3days)         xxx         xxx xx.x%         xxx xx.x%           BUCU         xxx xx.x%         xxx xx.x%         xxx xx.x%           Surgery         xxx xx.x%         xxx xx.x%         xxx xx.x%           Tracheal Intubation Tracheotomy         xxx xx.x%         xxx xx.x%         xxx xx.x%           Mechanical Ventilation         xxx xx.x%         xxx xx.x%         xxx xx.x%           Physical or drug hypothermia         xxx xx.x%         xxx xx.x%         xxx xx.x%           Nasal Feeding         xxx xx.x%         xxx xx.x%         xxx xx.x%           Urinary Catheter         xxx xx.x%         xxx xx.x%         xxx xx.x%           Other Invasive treatment         xxx xx.x%         xxx xx.x%         xxx xx.x%           Analgesia and s	Anti-epilepsy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Glucose control         xxx xx.x%         xxx xx.x%         xxx xx.x%           BP elevating         xxx xx.x%         xxx xx.x%         xxx xx.x%           Anticoagulation invert         xxx xx.x%         xxx xx.x%         xxx xx.x%           Rehabilitation         xxx xx.x%         xxx xx.x%         xxx xx.x%           Acupuncture         xxx xx.xx%         xxx xx.x%         xxx xx.x%           Day28 (± 3days)         xxx xx.xx%         xxx xx.x%         xxx xx.x%           ICU         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Surgery         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Tracheal Intubation Tracheotomy         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Mechanical Ventilation         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Physical or drug hypothermia         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Nasal Feeding         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Urinary Catheter         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Other Invasive treatment         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Other treatments:         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%	Dehydration	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP elevating         xxx xx.x%         xxx xx.x%         xxx xx.x%           Anticoagulation invert         xxx xx.x%         xxx xx.x%         xxx xx.x%           Rehabilitation         xxx xx.x%         xxx xx.x%         xxx xx.x%           Acupuncture         xxx xx.x%         xxx xx.x%         xxx xx.x%           Day28 (± 3days)         xxx         xxx         xxx           ICU         xxx xx.x%         xxx xx.x%         xxx xx.x%           Surgery         xxx xx.x%         xxx xx.x%         xxx xx.x%           Tracheal Intubation Tracheotomy         xxx xx.x%         xxx xx.x%         xxx xx.x%           Mechanical Ventilation         xxx xx.x%         xxx xx.x%         xxx xx.x%           Physical or drug hypothermia         xxx xx.x%         xxx xx.x%         xxx xx.x%           Nasal Feeding         xxx xx.x%         xxx xx.x%         xxx xx.x%           Urinary Catheter         xxx xx.x%         xxx xx.x%         xxx xx.x%           Other Invasive treatment         xxx xx.x%         xxx xx.x%         xxx xx.x%           Other treatments:         xxx xx.x%         xxx xx.x%         xxx xx.x%           Lower body temperature         xxx xx.x%         xxx xx.x%         xxx xx.x%           Proton pump in	BP control	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anticoagulation invert  Rehabilitation  XXX XX.X%  XXX XX.X%  XXX XX.X%  Acupuncture  XXX XX.X%  XXX XX.X%  Day28 (± 3days)  XXX XX.X%  XXX XX.X%  ICU  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  ICU  XXX XX.X%  XXX XX.XX  XXX XX.XX  XXX XX.XX  XXX XX.XX  XXX XX.XX  XXX XX.X	Glucose control	xxx xx.x%	xxx xx.x%	xxx xx.x%
Rehabilitation         xxx xx.x%	BP elevating	xxx xx.x%	xxx xx.x%	xxx xx.x%
Acupuncture         xxx xx.x%         xxx xx.x%         xxx xx.x%           Day28 (± 3days)         xxx         xxx         xxx           ICU         xxx xx.x%         xxx xx.x%         xxx xx.x%           Surgery         xxx xx.xx%         xxx xx.x%         xxx xx.xx%           Tracheal Intubation Tracheotomy         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Mechanical Ventilation         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Physical or drug hypothermia         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Nasal Feeding         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Urinary Catheter         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Other Invasive treatment         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Other treatments:         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Lower body temperature         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Proton pump inhibitors         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Diuretics         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%           Anti-epilepsy         xxx xx.xx%         xxx xx.xx%         xxx xx.xx%	Anticoagulation invert	xxx xx.x%	xxx xx.x%	xxx xx.x%
Day28 (± 3days)         xxx         xxx         xxx         xxx           ICU         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Surgery         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Tracheal Intubation Tracheotomy         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Mechanical Ventilation         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Physical or drug hypothermia         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Nasal Feeding         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Urinary Catheter         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Other Invasive treatment         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Other treatments:         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Lower body temperature         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Analgesia and sedation         xxx xx.x%         xxx xx.x%         xxx xx.x%         xxx xx.x%           Proton pump inhibitors         xxx xx.x%         xxx xx.x%	Rehabilitation	xxx xx.x%	xxx xx.x%	xxx xx.x%
ICU         XXX XX.X%         XXX XX.X%         XXX XX.X%           Surgery         XXX XX.X%         XXX XX.X%         XXX XX.X%           Tracheal Intubation Tracheotomy         XXX XX.X%         XXX XX.X%         XXX XX.X%           Mechanical Ventilation         XXX XX.X%         XXX XX.X%         XXX XX.X%           Physical or drug hypothermia         XXX XX.X%         XXX XX.X%         XXX XX.X%           Nasal Feeding         XXX XX.X%         XXX XX.X%         XXX XX.X%           Urinary Catheter         XXX XX.X%         XXX XX.X%         XXX XX.X%           Other Invasive treatment         XXX XX.X%         XXX XX.X%         XXX XX.X%           Other treatments:         XXX XX.X%         XXX XX.X%         XXX XX.X%           Analgesia and sedation         XXX XX.X%         XXX XX.X%         XXX XX.X%           Proton pump inhibitors         XXX XX.X%         XXX XX.X%         XXX XX.X%           Diuretics         XXX XX.X%         XXX XX.X%         XXX XX.X%           Anti-epilepsy         XXX XX.X%         XXX XX.X%         XXX XX.X%           BP control         XXX XX.X%         XXX XX.X%         XXX XX.X%           BP elevating         XXX XX.X%         XXX XX.X%         XXX XX.X%           Anti	Acupuncture	xxx xx.x%	xxx xx.x%	xxx xx.x%
Surgery XXX XX.X% XXX.X% XXX XXX.X% XXX XXX.X% XXX XXX	Day28 (± 3days)	xxx	xxx	xxx
Tracheal Intubation Tracheotomy  XXX XX.X%  Mechanical Ventilation  XXX XX.X%  Physical or drug hypothermia  XXX XX.X%  Other Invasive treatment  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Analgesia and sedation  XXX XX.X%  Diuretics  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Anti-epilepsy  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Anti-epilepsy  XXX XX.X%  XXX XX.XX  XXX XX XX XX.X%  XXX	ICU	xxx xx.x%	xxx xx.x%	xxx xx.x%
Mechanical Ventilation  Mechanical Ventilation  XXX XX.X%  Other Invasive treatment  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Analgesia and sedation  XXX XX.X%  XXX XX.XX  XXX XX.XX  XXX XX.XX  XXX XX XX XX.XX  XXX XX XX XX  XXX XX XX XX XX XX XX	Surgery	xxx xx.x%	xxx xx.x%	xxx xx.x%
Physical or drug hypothermia  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Urinary Catheter  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Other Invasive treatment  XXX XX.X%  XXX XX.X%  XXX XX.X%  Other treatments:  Lower body temperature  XXX XX.X%  XXX XX.X%  XXX XX.X%  Analgesia and sedation  XXX XX.X%  XXX XX.XX  XXX XX.XX  XXX XX XX.XX  XXX XX XX XX XX XX  X	Tracheal Intubation Tracheotomy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Nasal Feeding  XXX XX.X%  XXX XX.X%  Urinary Catheter  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Other Invasive treatment  XXX XX.X%  XXX XX.X%  Other treatments:  Lower body temperature  XXX XX.X%  XXX XX.X%  XXX XX.X%  Analgesia and sedation  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Proton pump inhibitors  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Anti-epilepsy  XXX XX.X%	Mechanical Ventilation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Urinary Catheter  Other Invasive treatment  Other treatments:  Lower body temperature  xxx xx.x%  xxx xx.x%  xxx xx.x%  xxx xx.x%  xxx xx.x%  xxx xx.x%  Analgesia and sedation  xxx xx.x%  Diuretics  xxx xx.x%  xxx xx.x%  xxx xx.x%  xxx xx.x%  xxx xx.x%  xxx xx.x%  Anti-epilepsy  xxx xx.x%	Physical or drug hypothermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other Invasive treatment  XXX XX.X%  XXX XX.X%  XXX XX.X%  Other treatments:  Lower body temperature  XXX XX.X%  Analgesia and sedation  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Proton pump inhibitors  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Anti-epilepsy  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  XXX XX.X%  Anti-epilepsy  XXX XX.X%  Anticoagulation reversal  XXX XX.X%	Nasal Feeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other Invasive treatments:         Lower body temperature       xxx xx.x%       xxx xx.x%       xxx xx.x%         Analgesia and sedation       xxx xx.x%       xxx xx.x%       xxx xx.x%         Proton pump inhibitors       xxx xx.x%       xxx xx.x%       xxx xx.x%         Diuretics       xxx xx.x%       xxx xx.x%       xxx xx.x%         Anti-epilepsy       xxx xx.x%       xxx xx.x%       xxx xx.x%         Dehydration       xxx xx.x%       xxx xx.x%       xxx xx.x%         BP control       xxx xx.x%       xxx xx.x%       xxx xx.x%         Glucose control       xxx xx.x%       xxx xx.x%       xxx xx.x%         BP elevating       xxx xx.x%       xxx xx.x%       xxx xx.x%         Anticoagulation reversal       xxx xx.x%       xxx xx.x%       xxx xx.x%	Urinary Catheter	xxx xx.x%	xxx xx.x%	xxx xx.x%
Lower body temperature	Other Invasive treatment	xxx xx.x%	xxx xx.x%	xxx xx.x%
Analgesia and sedation	Other treatments:			
Proton pump inhibitors  xxx xx.x%	Lower body temperature	xxx xx.x%	xxx xx.x%	xxx xx.x%
Diuretics xxx xx.x% xxx xx	Analgesia and sedation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anti-epilepsy xxx xx.x% xxx.x% xxx xx.x% xxx x	Proton pump inhibitors	xxx xx.x%	xxx xx.x%	xxx xx.x%
Dehydrationxxx xx.x%xxx xx.x%xxx xx.x%BP controlxxx xx.x%xxx xx.x%xxx xx.x%Glucose controlxxx xx.x%xxx xx.x%xxx xx.x%BP elevatingxxx xx.x%xxx xx.x%xxx xx.x%Anticoagulation reversalxxx xx.x%xxx xx.x%xxx xx.x%	Diuretics	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP control xxx xx.x% xxx xx.x% xxx xx.x%  Glucose control xxx xx.x% xxx xx.x% xxx xx.x%  BP elevating xxx xx.x% xxx xx.x% xxx xx.x%  Anticoagulation reversal xxx xx.x% xxx xx.x% xxx xx.x%	Anti-epilepsy	xxx xx.x%	xxx xx.x%	xxx xx.x%
Glucose control xxx xx.x% xxx xx.x% xxx xx.x% xxx xx.x%  BP elevating xxx xx.x% xxx xx.x% xxx xx.x% xxx xx.x%  Anticoagulation reversal xxx xx.x% xxx xx.x% xxx xx.x%	Dehydration	xxx xx.x%	xxx xx.x%	xxx xx.x%
BP elevating xxx xx.x% xxx xx.x% xxx xx.x%  Anticoagulation reversal xxx xx.x% xxx xx.x% xxx xx.x%	BP control	xxx xx.x%	xxx xx.x%	xxx xx.x%
Anticoagulation reversal xxx xx.x% xxx xx.x% xxx xx.x%	Glucose control	xxx xx.x%	xxx xx.x%	xxx xx.x%
	BP elevating	xxx xx.x%	xxx xx.x%	xxx xx.x%
Rehabilitation xxx xx.x% xxx xx.x% xxx xx.x%	Anticoagulation reversal	xxx xx.x%	xxx xx.x%	xxx xx.x%
	Rehabilitation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Acupuncture xxx xx.x% xxx xx.x% xxx xx.x%	Acupuncture	xxx xx.x%	xxx xx.x%	xxx xx.x%

Table 3. Reported stroke complications by visits

Complications Visits	Active drug (N = )	Placebo drug (N = )	Total (N = )
Baseline	xxx	xxx	xxx
Infection (respiratory)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (urinary)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (digest)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (other)	xxx xx.x%	xxx xx.x%	xxx xx.x%
AKI	xxx xx.x%	xxx xx.x%	xxx xx.x%
Gastrointestinal bleeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hypertonic coma	xxx xx.x%	xxx xx.x%	xxx xx.x%
Pulmonary embolism	xxx xx.x%	xxx xx.x%	xxx xx.x%
Intracerebral hypertension/herniation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hydrocephalus	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hyperthermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other	xxx xx.x%	xxx xx.x%	xxx xx.x%
24h (± 3h)	xxx	xxx	xxx
Infection (respiratory)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (urinary)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (digest)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (other)	xxx xx.x%	xxx xx.x%	xxx xx.x%
AKI	xxx xx.x%	xxx xx.x%	xxx xx.x%
Gastrointestinal bleeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hypertonic coma	xxx xx.x%	xxx xx.x%	xxx xx.x%
Pulmonary embolism	xxx xx.x%	xxx xx.x%	xxx xx.x%
Intracerebral hypertension/herniation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hydrocephalus	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hyperthermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other	xxx xx.x%	xxx xx.x%	xxx xx.x%
Day7 (± 1day)	xxx	xxx	xxx
Infection (respiratory)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (urinary)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (digest)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (other)	xxx xx.x%	xxx xx.x%	xxx xx.x%
AKI	xxx xx.x%	xxx xx.x%	xxx xx.x%
Gastrointestinal bleeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hypertonic coma	xxx xx.x%	xxx xx.x%	xxx xx.x%
Pulmonary embolism	xxx xx.x%	xxx xx.x%	xxx xx.x%
Intracerebral hypertension/herniation	xxx xx.x%	xxx xx.x%	xxx xx.x%

Hydrocephalus	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hyperthermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other	xxx xx.x%	xxx xx.x%	xxx xx.x%
Day 14 (± 2days)	xxx	xxx	xxx
Infection (respiratory)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (urinary)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (digest)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (other)	xxx xx.x%	xxx xx.x%	xxx xx.x%
AKI	xxx xx.x%	xxx xx.x%	xxx xx.x%
Gastrointestinal bleeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hypertonic coma	xxx xx.x%	xxx xx.x%	xxx xx.x%
Pulmonary embolism	xxx xx.x%	xxx xx.x%	xxx xx.x%
Intracerebral hypertension/herniation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hydrocephalus	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hyperthermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other	xxx xx.x%	xxx xx.x%	xxx xx.x%
Day28 (± 3days)	xxx	xxx	xxx
Infection (respiratory)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (urinary)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (digest)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (other)	xxx xx.x%	xxx xx.x%	xxx xx.x%
AKI	xxx xx.x%	xxx xx.x%	xxx xx.x%
Gastrointestinal bleeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hypertonic coma	xxx xx.x%	xxx xx.x%	xxx xx.x%
Pulmonary embolism	xxx xx.x%	xxx xx.x%	xxx xx.x%
Intracerebral hypertension/herniation	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hydrocephalus	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hyperthermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other	xxx xx.x%	xxx xx.x%	xxx xx.x%
Any reported after hospital arrival*	xxx	xxx	xxx
Infection (respiratory)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (urinary)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (digest)	xxx xx.x%	xxx xx.x%	xxx xx.x%
Infection (other)	xxx xx.x%	xxx xx.x%	xxx xx.x%
AKI	xxx xx.x%	xxx xx.x%	xxx xx.x%
Gastrointestinal bleeding	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hypertonic coma	xxx xx.x%	xxx xx.x%	xxx xx.x%
Pulmonary embolism	xxx xx.x%	xxx xx.x%	xxx xx.x%
Intracerebral hypertension/herniation	xxx xx.x%	xxx xx.x%	xxx xx.x%

Hydrocephalus	xxx xx.x%	xxx xx.x%	xxx xx.x%
Hyperthermia	xxx xx.x%	xxx xx.x%	xxx xx.x%
Other	xxx xx.x%	xxx xx.x%	xxx xx.x%

### Note:

<sup>\*</sup> including baseline up to 28 day follow-up visit.

Table 4. Study drug compliance

Study Medication <sup>1</sup>	Active drug	Placebo drug	Total
Duration of study treatment (days) <sup>2</sup>	(N = )	(N = ) xxx	(N = ) xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Duration of study treatment by category <sup>2</sup>	xxxx	xxxx	xxxx
1 – 7 days	xxx xx.x%	xxx xx.x%	xxx xx.x%
8 - 14 days	xxx xx.x%	xxx xx.x%	xxx xx.x%
15 - 21 days	xxx xx.x%	xxx xx.x%	xxx xx.x%
22 + days	xxx xx.x%	xxx xx.x%	xxx xx.x%
Bottles completed	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Complete >=80% of medication	xxx/xxx xx.x%	xxx/xxx xx.x%	xxx/xxx xx.x%
Complete all medication	xxx/xxx xx.x%	xxx/xxx xx.x%	xxx/xxx xx.x%

#### Note:

<sup>1</sup> Only patients who completed study medication and have sufficient treatment information are included.

<sup>2</sup> Duration >40 days is considered an error and not included

Table 5. Clinical assessment of outcomes over time

Variable Visits	Active drug (N = )	Placebo drug (N = )	Total (N = )
NIHSS	(14-7)	(14 – 7	(14 – )
Baseline	XXX	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Follow up 1 : 24h (± 3h)	xxx	XXX	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
5.11			
Follow up 2 : Day 7 (± 1day)	XXX	XXX	XXX
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Follow up 3 : Day 14 (± 2days)	xxx	XXX	XXX
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Follow up 4 : Day 28 (± 3days)	xxx	XXX	XXX
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
GCS			
Baseline	XXX	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
F-II			
Follow up 1 : 24h (± 3h)	XXX	xxx	XXX
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx

Variable Visits	Active drug (N = )	Placebo drug (N = )	Total (N = )
Follow up 2 : Day 7 (± 1day)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Follow up 3 : Day 14 (± 2days)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Follow up 4 : Day 28 (± 3days)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
mRS			
Baseline	xxx	xxx	xxx
0: No symptoms	xxx xx.x%	xxx xx.x%	xxx xx.x%
1: No significant disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
2: Slight disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
3: Moderate disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
4: Moderately severe disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
5: Severe disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
6: Dead	xxx xx.x%	xxx xx.x%	xxx xx.x%
Follow up 4 : Day 28 (± 3days)	xxx	xxx	xxx
0: No symptoms	xxx xx.x%	xxx xx.x%	xxx xx.x%
1: No significant disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
2: Slight disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
3: Moderate disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
4: Moderately severe disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
5: Severe disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
6: Dead	xxx xx.x%	xxx xx.x%	xxx xx.x%
Follow up 5 : Day 90 (± 7days)	xxx	xxx	xxx
0: No symptoms	xxx xx.x%	xxx xx.x%	xxx xx.x%
1: No significant disability	xxx xx.x%	xxx xx.x%	xxx xx.x%

Variable	Active drug	Placebo drug	Total
Visits 2: Slight disability	(N = ) xxx xx.x%	(N = ) xxx xx.x%	(N = ) xxx xx.x%
3: Moderate disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
4: Moderately severe disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
5: Severe disability	xxx xx.x%	xxx xx.x%	xxx xx.x%
6: Dead		·	·
6. Dead	xxx xx.x%	xxx xx.x%	xxx xx.x%
Barthel Index (BI)			
Follow up 4 : Day 28 (± 3days)	XXX	XXX	XXX
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
THE THUS	AAA to AAA	AAA CO AAA	AAA CO AAA
Follow up 5 : Day 90 (± 7days)	XXX	XXX	XXX
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
EQ-5D-5L VAS			
Follow up 4 : Day 28 (± 3days)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Follow up 5 : Day 90 (± 7days)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
EQ-5D-5L utility score (for survivors)			
Follow up 4 : Day 28 (± 3days)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Follow up 5 : Day 90 (± 7days)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx

Variable Visits	Active drug (N = )	Placebo drug (N = )	Total (N = )
EQ-5D-5L utility score (imputed death=0 score)			
Follow up 4 : Day 28 (± 3days)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Follow up 5 : Day 90 (± 7days)	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Clinical Pulmonary Infection Score (CPIS)			
Baseline	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Day 3	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Day 7	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx

Table 6. Descriptive table of primary outcome and other secondary outcomes

Variable	Active drug (N = )	Placebo drug (N = )	Total (N = )
UW-mRS at day 90	xxx	xxx	xxx
Mean (SD)	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xxx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Secondary outcomes			
Death or disability at day 28 <sup>1</sup>	xxx xx.x%	xxx xx.x%	xxx xx.x%
Death or disability at day 90 <sup>1</sup>	xxx xx.x%	xxx xx.x%	xxx xx.x%
Death at day 28	xxx xx.x%	xxx xx.x%	xxx xx.x%
Death at day 90	xxx xx.x%	xxx xx.x%	xxx xx.x%
Disability at day 28 <sup>1</sup>	xxx xx.x%	xxx xx.x%	xxx xx.x%
Disability at day 90 <sup>1</sup>	xxx xx.x%	xxx xx.x%	xxx xx.x%
Any Stroke Associated Pneumonia (SAP) <sup>2</sup>	xxx xx.x%	xxx xx.x%	xxx xx.x%

#### Note:

- 1 Death or disability, defined as mRS scores 4-6; Disability defined as mRS score 4-5.
- 2 SAP diagnosis standard: CPIS score>=6 from any visits of day 0, 3 and 7.

Table 7. Image results (reported)

Time from onset to CT (hours)  Mean (SD)	x/xxx xx.x%  xxx  xx.x (xxx.x)  xx (xxx; xxx)  xxx to xxx  xxx  xxx	xxx/xxx xx.x% xxx xxx.x (xxx.x) xxx (xxx; xxx) xxx to xxx	xxx/xxx xx.x% xxx xxx.x (xxx.x) xxx (xxx; xxx) xxx to xxx
Time from onset to CT (hours)  Mean (SD)	xxx (xxx.x) (xxx; xxx) (xxx; xxx;	xxx xxx.x (xxx.x) xxx (xxx; xxx) xxx to xxx	xxx xxx.x (xxx.x) xxx (xxx; xxx) xxx to xxx
Median (Q1; Q3)  min max  Intracranial hematoma volume (ml)  Mean (SD)  Median (Q1; Q3)  min max  Intraventricular hematoma (Y/N)  xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	xx.x (xxx.x) xx (xxx; xxx) xxx to xxx xxx	xxx.x (xxx.x) xxx (xxx; xxx) xxx to xxx	xxx.x (xxx.x) xxx (xxx; xxx) xxx to xxx
Median (Q1; Q3)  min max  Intracranial hematoma volume (ml)  Mean (SD)  Median (Q1; Q3)  min max  Intraventricular hematoma (Y/N)  xx	xx (xxx; xxx) xxx to xxx xxx	xxx (xxx; xxx) xxx to xxx	xxx (xxx; xxx) xxx to xxx
min max  Intracranial hematoma volume (ml)  Mean (SD)  Median (Q1; Q3)  min max  Intraventricular hematoma (Y/N)  xx	xxx to xxx	xxx to xxx	xxx to xxx
Intracranial hematoma volume (ml)  Mean (SD)  Median (Q1; Q3)  min max  Intraventricular hematoma (Y/N)  xx	XXX		
Mean (SD) x  Median (Q1; Q3) x  min max  Intraventricular hematoma (Y/N) xx		xxx	
Median (Q1; Q3) xx min max  Intraventricular hematoma (Y/N) xx	xx.x (xxx.x)		XXX
min max  Intraventricular hematoma (Y/N) xx		xxx.x (xxx.x)	xxx.x (xxx.x)
Intraventricular hematoma (Y/N) xx	xx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
	xxx to xxx	xxx to xxx	xxx to xxx
Intraventricular hematoma volume (ml)	x/xxx xx.x%	xxx/xxx xx.x%	xxx/xxx xx.x%
	xxx	xxx	xxx
Mean (SD) x	xx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Edema (Y/N) xx	x/xxx xx.x%	xxx/xxx xx.x%	xxx/xxx xx.x%
Edema volume (ml)	xxx	xxx	xxx
Mean (SD) x	xx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median (Q1; Q3)	xx (xxx; xxx)	xxx (xxx; xxx)	xxx (xxx; xxx)
min max	xxx to xxx	xxx to xxx	xxx to xxx
Any hydrocephalus (Y/N) xx	x/xxx xx.x%	xxx/xxx xx.x%	xxx/xxx xx.x%
Any surgical history (Y/N) xx	x/xxx xx.x%	xxx/xxx xx.x%	xxx/xxx xx.x%

Table 8. Descriptive analysis of EQ-5D-5L at day 90

Day 90	Visits	Active drug	Placebo drug	Total
Mobility         N=xxxx         N=xxxx         N=xxxx           1: I have no problems in walking about         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           2: I have slight problems with walking around         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           3: I have moderate problems with walking around         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           5: I am unable to walk around         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           5: I am unable to walk around         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           6: I am unable to walk around         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           8: I have no problems with washing or dressing myself         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           3: I have moderate problems with washing or dressing myself         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           4: I have severe problems with washing or dressing myself         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           5: I am unable to wash or dress myself         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)         xx (xx,x%)           Usual activities         N=xxx         N=xxx		(N = )	(N = )	(N = )
1: I have no problems in walking about		N-vvv	N-vvv	N-vvv
2: I have slight problems with walking around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           3: I have moderate problems with walking around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           4: I have severe problems with walking around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           5: I am unable to walk around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           Self-care         N=xxx         N=xxx         N=xxx           1: I have no problems with washing or dressing myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           2: I have slight problems with washing or dressing myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           3: I have moderate problems with washing or dressing myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           4: I have severe problems with washing or dressing myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           5: I am unable to wash or dress myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           Usual activities         N=xxx         N=xxxx         N=xxxx         N=xxxx           1: I have no problems doing my usual activities         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           2: I have slight				
3: I have moderate problems with walking around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           4: I have severe problems with walking around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           5: I am unable to walk around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           5: I am unable to walk around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           5: I am unable to walk around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           8: I am unable to walk around         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           1: I have no problems with washing or dressing myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           2: I have moderate problems with washing or dressing myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           4: I have severe problems with washing or dressing myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           5: I am unable to wash or dress myself         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           Usual activities         N=xxx         N=xxx         N=xxx           1: I have no problems doing my usual activities         xx (xx.x%)         xx (xx.x%)         xx (xx.x%)           2: I have slight problems doing my usual activities         xx (xx.x%)         xx (xx.x%)<	<u> </u>			
4: I have severe problems with walking around		i i		
Self-care  N=xxx N			· ·	
Self-care  N=xxx N=xxx N=xxx 1: I have no problems with washing or dressing myself xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3: I have moderate problems with washing or dressing myself xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3: I have moderate problems with washing or dressing myself xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3: I have severe problems with washing or dressing myself xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 5: I am unable to wash or dress myself xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  Usual activities N=xxx N=xxxx N=xxx N				
1: I have no problems with washing or dressing myself 2: I have slight problems with washing or dressing myself 3: I have moderate problems with washing or dressing myself 3: I have moderate problems with washing or dressing myself 4: I have severe problems with washing or dressing myself 4: I have severe problems with washing or dressing myself 5: I am unable to wash or dress myself  Wax (xx.x%)  Xx (xx.x%) Xx (xx	5 : I am unable to walk around	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
1: I have no problems with washing or dressing myself 2: I have slight problems with washing or dressing myself 3: I have moderate problems with washing or dressing myself 3: I have moderate problems with washing or dressing myself 4: I have severe problems with washing or dressing myself 4: I have severe problems with washing or dressing myself 5: I am unable to wash or dress myself  Wax (xx.x%)  Xx (xx.x%) Xx (xx				
2:I have slight problems with washing or dressing myself 3:I have moderate problems with washing or dressing myself 4:I have severe problems with washing or dressing myself 5:I am unable to wash or dress myself  Wsx (xx.x%)  Usual activities  N=xxx N=xxx N=xxx 1:I have no problems doing my usual activities 2:I have slight problems doing my usual activities 3:I have moderate problems doing my usual activities 4:I have severe problems doing my usual activities 5:I am unable to do my usual activities 7:I have no pain or discomfort 7:I have no pain or discomfort 8:I have moderate pain or discomfort 9:I have severe pain or discomfort 9:I have severe pain or discomfort 1:I have no pain or discomfort 1:I have no pain or discomfort 1:I have severe pain or discomfort 1:I have severe pain or discomfort 1:I have no	Self-care			
3:I have moderate problems with washing or dressing myself	1: I have no problems with washing or dressing myself	i i		` '
4:I have severe problems with washing or dressing myself  5:I am unable to wash or dress myself  Wx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  Usual activities  N=xxx N=xxx N=xxx  1:I have no problems doing my usual activities  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  3:I have moderate problems doing my usual activities  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  4:I have severe problems doing my usual activities  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  5:I am unable to do my usual activities  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  5:I am unable to do my usual activities  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  5:I am unable to do my usual activities  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  1:I have no pain or discomfort  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  3:I have moderate pain or discomfort  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  3:I have moderate pain or discomfort  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  5:I have extreme pain or discomfort  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  4:I have severe pain or discomfort  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  5:I have extreme pain or discomfort  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  1:I am not anxious or depressed  xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  xx (xx	2 : I have slight problems with washing or dressing myself		· ·	
5:I am unable to wash or dress myself  XX (XX.X%) XX (XX.X%) XX (XX.X%)  Usual activities  N=XXX N=XXX N=XXX  1:I have no problems doing my usual activities  XX (XX.X%) XX (XX.X%) XX (XX.X%)  3:I have moderate problems doing my usual activities  XX (XX.X%) XX (XX.X%) XX (XX.X%)  3:I have moderate problems doing my usual activities  XX (XX.X%) XX (XX.X%) XX (XX.X%)  4:I have severe problems doing my usual activities  XX (XX.X%) XX (XX.X%) XX (XX.X%)  5:I am unable to do my usual activities  XX (XX.X%) XX (XX.X%) XX (XX.X%)  1:I have no pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  3:I have moderate pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  3:I have extreme pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  5:I have extreme pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  5:I have extreme pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  5:I have extreme pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  5:I have actreme pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  XX (XX.X%)  5:I have extreme pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  XX (XX.X%)  5:I have actreme pain or discomfort  XX (XX.X%) XX (XX.X%) XX (XX.X%)  XX (XX.X%)  XX (XX.X%) XX (XX.	3: I have moderate problems with washing or dressing myself	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Usual activities  N=xxx N=xxx N=xxx 1:I have no problems doing my usual activities xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3:I have moderate problems doing my usual activities xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3:I have moderate problems doing my usual activities xx (xx.x%) xx (xx.x%) xx (xx.x%) 4:I have severe problems doing my usual activities xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 5:I am unable to do my usual activities xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)  Pain / discomfort N=xxx N=xxx N=xxx 1:I have no pain or discomfort xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3:I have moderate pain or discomfort xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3:I have moderate pain or discomfort xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 4:I have severe pain or discomfort xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 5:I have extreme pain or discomfort xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 1:I am not anxious or depressed xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3:I am moderately anxious or depressed xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) 3:I am severely anxious or depressed xx (xx.x%)	4: I have severe problems with washing or dressing myself	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
1: I have no problems doing my usual activities	5 : I am unable to wash or dress myself	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
1: I have no problems doing my usual activities				
2:I have slight problems doing my usual activities	Usual activities	N=xxx	N=xxx	N=xxx
3:I have moderate problems doing my usual activities	1: I have no problems doing my usual activities	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
4:I have severe problems doing my usual activities	2: I have slight problems doing my usual activities	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
5: I am unable to do my usual activities    XX (XX.X%)   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     Pain / discomfort   N=XXX   N=XXX     1: I have no pain or discomfort   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     2: I have slight pain or discomfort   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     3: I have moderate pain or discomfort   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     4: I have severe pain or discomfort   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     5: I have extreme pain or discomfort   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     4: I am not anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     2: I am slightly anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     3: I am moderately anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     4: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     4: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     4: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     4: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     5: I have extreme pain or discomfort   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     6: I am not anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     6: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     6: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     7: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     7: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     7: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     7: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     7: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     7: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)     7: I am severely anxious or depressed   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)   XX (XX.X%)   XX (	3 : I have moderate problems doing my usual activities	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Pain / discomfort  N=xxx  N=xxx  1: I have no pain or discomfort  xx (xx.x%)	4 : I have severe problems doing my usual activities	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
1: I have no pain or discomfort  2: I have slight pain or discomfort  3: I have moderate pain or discomfort  4: I have severe pain or discomfort  4: I have severe pain or discomfort  5: I have extreme pain or discomfort  4: I have extreme pain or discomfort  5: I have extreme pain or discomfort  7: I am not anxious or depressed  7: I am slightly anxious or depressed  7: I am moderately anxious or depressed  7: I am severely anxious or depressed	5 : I am unable to do my usual activities	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
1: I have no pain or discomfort  2: I have slight pain or discomfort  3: I have moderate pain or discomfort  4: I have severe pain or discomfort  4: I have severe pain or discomfort  5: I have extreme pain or discomfort  4: I have extreme pain or discomfort  5: I have extreme pain or discomfort  7: I am not anxious or depressed  7: I am slightly anxious or depressed  7: I am moderately anxious or depressed  7: I am severely anxious or depressed				
2: I have slight pain or discomfort  xx (xx.x%)	Pain / discomfort	N=xxx	N=xxx	N=xxx
3: I have moderate pain or discomfort  XX (XX.X%)	1 : I have no pain or discomfort	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
4: I have severe pain or discomfort  xx (xx.x%)	2 : I have slight pain or discomfort	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
5: I have extreme pain or discomfort  XX (XX.X%)	3 : I have moderate pain or discomfort	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Anxiety / depression  N=xxx  N=xxx  1: I am not anxious or depressed  xx (xx.x%)	4 : I have severe pain or discomfort	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
1: I am not anxious or depressed  2: I am slightly anxious or depressed  3: I am moderately anxious or depressed  4: I am severely anxious or depressed  2xx (xx.x%)  3xx (xx.x%)	5 : I have extreme pain or discomfort	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
1: I am not anxious or depressed  2: I am slightly anxious or depressed  3: I am moderately anxious or depressed  4: I am severely anxious or depressed  2xx (xx.x%)  3xx (xx.x%)				
2: I am slightly anxious or depressed  3: I am moderately anxious or depressed  4: I am severely anxious or depressed  xx (xx.x%)	Anxiety / depression	N=xxx	N=xxx	N=xxx
2: I am slightly anxious or depressed  xx (xx.x%)	1: I am not anxious or depressed	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
3: I am moderately anxious or depressed  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
4: I am severely anxious or depressed		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
		xx (xx.x%)	xx (xx.x%)	xx (xx.x%)

VAS (/100)	N=xxx	N=xxx	N=xxx
Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Median (Q1 – Q2)	xx (xx – xx)	xx (xx – xx)	xx (xx – xx)
Min - Max	xx – xx	xx – xx	xx – xx

CHAIN Statistical Analysis Plan

Version: 1.0 – Date: 11 January 2024

Table 9. Clinical outcomes: model results

		Primary model <sup>1</sup>			Adjusted model <sup>2</sup>	
Outcome / analysis method	N	OR/MD (95% CI)	P-value	N	OR/MD (95% CI)	P-value
UW-mRS at Day 90 (continuous)						
Main, non-imputed model	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Sensitivity analyses						
Multiple imputations one (MAR) <sup>3</sup>	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Additional sensitivity analysis one <sup>4</sup>	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Additional sensitivity analysis two <sup>4</sup>	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Additional sensitivity analysis three <sup>4</sup>	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Secondary outcomes						
Utility-weighted mRS at day 180 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Ordered mRS at day 28 (ordinal)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Ordered mRS at day 90 (ordinal)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Poor outcome [mRS 4-6] at Day 28 (binary)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Poor outcome [mRS 4-6] at Day 90 (binary)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Death at Day 28 [mRS 6] (binary)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Death at Day 90 [mRS 6] (binary)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Dependency at Day 28 [mRS 4-5] (binary)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Dependency at Day 90 [mRS 4-5] (binary)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
NIHSS at Day 1 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
NIHSS at Day 7 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Barthel index at Day 28 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Barthel index at Day 90 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
HRQoL measurements (survivors only)						

CHAIN Statistical Analysis Plan Version: 1.0 – Date: 11 January 2024

EQ-5D-5L visual analog scale at Day 28 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	XXXX	xx.xx (xx.xx to xx.xx)	0.xxx
EQ-5D-5L utility score at Day 28 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
EQ-5D-5L visual analog scale at Day 90 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
EQ-5D-5L utility score at Day 90 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
HRQoL measurements (impute death=0)						
EQ-5D-5L visual analog scale at Day 28 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
EQ-5D-5L utility score at Day 28 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
EQ-5D-5L visual analog scale at Day 90 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
EQ-5D-5L utility score at Day 90 (continuous)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx
Any stroke-associated pneumonia (binary)	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx	xxxx	xx.xx (xx.xx to xx.xx)	0.xxx

<sup>(1)</sup> For ordinal, continuous and binary outcomes, the primary model consists in a generalised linear model with the appropriate distribution and link function. Unadjusted models include following fixed effects: randomised group, regions, hematoma location and NIHSS at admission.

- (2) Adjusted models include the following additional baseline covariates: Age (continuous), mRS before stroke (categorical), sex (male vs female), time to randomisation (<12 vs ≥12 hours).
- (3) Referring to section 5.4.4
- (4) Referring to section 5.4.6

#### Programming notes:

- add/edit footnotes as appropriate
- for the analysis of dependency alone, restrict denominator to subjects who are alive (mRS 0-5) at corresponding timepoints.

CHAIN Statistical Analysis Plan

Version: 1.0 – Date: 11 January 2024

Table 10. Multiplicity adjustment

Secondary outcomes	P-value from the model	number of comparisons remain	adjusted significance level (Holm-Sidak)	Conclusion *
Ordered mRS at day 90 (ordinal)	xxx	8	0.0064	XXX
Poor outcome [mRS 4-6] at Day 90 (binary)	xxx	7	0.0073	XXX
Death at Day 90 [mRS 6] (binary)	xxx	6	0.0085	XXX
Dependency at Day 90 [mRS 4-5] (binary)	xxx	5	0.0102	XXX
NIHSS at Day 7 (continuous)	xxx	4	0.0127	XXX
Barthel index at Day 90 (continuous)	xxx	3	0.0170	XXX
EQ-5D-5L utility score at Day 90 (continuous)	xxx	2	0.0253	XXX
Any stroke-associated pneumonia (binary)	xxx	1	0.05	xxx

## Note:

<sup>\*</sup> Conclusion includes Remain significant, Change to non-significant, Remain non-significant

**Table 11. Adverse events** 

Event	Active drug (N = )	Placebo drug (N = )	P-value
Number of adverse events (AE)	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	0.xx
Relation to Treatment			
Definitely related	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Possibly related	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Probably not relevant	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Definitely irrelevant	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Unable to determine	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Number of serious adverse events (SAE)	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	0.xx
Relation to Treatment			
Definitely related	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Possibly related	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Probably not relevant	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Definitely irrelevant	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Unable to determine	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Number of AE of special interest (AESI)	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	0.хх
Type of AESI			
Hematoma enlargement (>6mL or 33%)	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	0.хх
New intracranial hematoma	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	0.хх
Diarrhea	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	0.хх
Abnormal laboratory test result	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	0.хх
Relation to Treatment			
Definitely related	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Possibly related	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Probably not relevant	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Definitely irrelevant	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	
Unable to determine	nEVT nPT(xx.x%)	nEVT nPT(xx.x%)	

#### Programming note:

SAEs will be summarised as the number (nPT) and proportion of patients experiencing at least one event. In addition, the total number of events (nEVT) will be reported. P-value from logistic regression. Conducted in ITT population and repeat in PP population.

> 37 307

Version: 1.0 – Date: 11 January 2024

Table 12. Causes of death (if available)

Cause	Active drug (N = )	Placebo drug (N = )
All patients		
Primary cause of death	N=XXX	N=XXX
Most common cause #1	nnn xx%	nnn xx%
Most common cause #2	nnn xx%	nnn xx%
Etc.		
Most common cause #10	nnn xx%	nnn xx%
All other causes	nnn xx%	nnn xx%
Underlying causes of death	N=XXX	N=XXX
Most common cause #1	nnn xx%	nnn xx%
Most common cause #2	nnn xx%	nnn xx%
Etc.		
Most common cause #10	nnn xx%	nnn xx%
All other causes	nnn xx%	nnn xx%

#### Programming notes:

- Order causes of death by descending frequency.
- Do not list categories with 0 deaths.
- Use number who died
- Depending on the distribution of deaths, we may choose to only report the x (e.g. 10) most common in the publication; however, the original table should include all causes with at least one patient.
- Conducted in ITT population

Cause	Active drug (N = )	Placebo drug (N = )
Eligibility violations	N=XXX	N=XXX
Age <18 years	nnn xx%	nnn xx%
Final diagnosis was not spontaneous ICH	nnn xx%	nnn xx%
Randomised >48 hours after stroke onset	nnn xx%	nnn xx%
NIHSS <8 and GCS 15	nnn xx%	nnn xx%
Etc.	nnn xx%	nnn xx%
Non-compliance with intervention	N=XXX	N=XXX
Patients who were found later in the trial to have received incorrect treatment or incorrect dose of the allocated study drug after confirmation by local investigators.	nnn xx%	nnn xx%
Other major protocol violations which have been adjudicated, for example concomitant TCM contains same components of FYTF-919.	nnn xx%	nnn xx%
Etc.	nnn xx%	nnn xx%
Primary outcome	N=XXX	N=XXX
Missing outcome assessment	nnn xx%	nnn xx%
Lost to follow-up	nnn xx%	nnn xx%
Etc.	nnn xx%	nnn xx%


#### Programming notes:

• Reasons for non-compliance and missing outcome will be defined while blinded.

Version: 1.0 – Date: 11 January 2024

### a. Figures

Figure 1: Consort flowchart



### Figure 2. Grotta bar charts of mRS

Programming note: Stacked bar chart with 2 bars (active vs placebo) per visit. Each bar to be of the same high (100%). Show the proportion in each category using labels on the bars.

## Figure 3. Boxplot of NIHSS by follow-up assessment

### Figure 4. Forest plot for subgroup analysis of UW-mRS at 90 days

Programming note: add number of subjects, estimated mean difference, SE, and P value for interaction.

## b. Listings

# Listing 1. Protocol deviations (if available)

Site ID	Patient ID	Date	Type of deviation	Description	Corrective action taken
	15	_	deviation		taken

## Listing 2. Serious adverse events

Site ID	Patient ID	Date	Event description	Event code	Relationship with treatment	Outcome